

09/773,736

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1839

L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047 OR 2046

L2 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09773736.str

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2

=> d l4

L4 HAS NO ANSWERS

L1 SCR 1839

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047 OR 2046

L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L4 QUE L3 AND L1 NOT L2

=> s l4 sss sam

SAMPLE SEARCH INITIATED 17:25:00 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 24486 TO ITERATE

4.1% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

19 ANSWERS

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 480386 TO 499054

PROJECTED ANSWERS: 8010 TO 10598

L5 19 SEA SSS SAM L3 AND L1 NOT L2

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047 OR 2046 OR 1841

L6 SCREEN CREATED

09/773,736

```
=>
Uploading C:\STNEXP4\QUERIES\09773736.str

L7      STRUCTURE UPLOADED

=> que L7 NOT L6

L8      QUE L7 NOT L6

=> d l8
L8 HAS NO ANSWERS
L6              SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047 OR 2046 O
R 1841
L7              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L8              QUE L7 NOT L6

=> s l8 sss sam
SAMPLE SEARCH INITIATED 17:27:22 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13124 TO ITERATE

    7.6% PROCESSED      1000 ITERATIONS                      16 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:   255628 TO 269332
PROJECTED ANSWERS:      3330 TO   5068

L9              16 SEA SSS SAM L7 NOT L6

=>
Uploading 09773736(species).str

L10     STRUCTURE UPLOADED

=> d l10
L10 HAS NO ANSWERS
L10              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l10 sss sam
SAMPLE SEARCH INITIATED 17:30:53 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 945909 TO ITERATE

    0.1% PROCESSED      1000 ITERATIONS                      0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

09/773,736

FULL FILE PROJECTIONS: ONLINE **INCOMPLETE**
BATCH **INCOMPLETE**
PROJECTED ITERATIONS: EXCEEDS 1000000
PROJECTED ANSWERS: EXCEEDS 0

L11 0 SEA SSS SAM L10

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 2046 OR 2047

L12 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09773736(species).str

L13 STRUCTURE UPLOADED

=> que L13 NOT L12

L14 QUE L13 NOT L12

=> d l14

L14 HAS NO ANSWERS

L12 SCR 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 2046 O
R 2047

L13 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L14 QUE L13 NOT L12

=> s l14 sss sam

SAMPLE SEARCH INITIATED 17:33:05 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 13095 TO ITERATE

7.6% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

11 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 255056 TO 268744
PROJECTED ANSWERS: 2160 TO 3600

L15 11 SEA SSS SAM L13 NOT L12

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 2046 OR 2047

09/773,736

L16 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09773736(species).str

L17 STRUCTURE UPLOADED

=> que L17 NOT L16

L18 QUE L17 NOT L16

=> d l18

L18 HAS NO ANSWERS

L16 SCR 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 2046 O
R 2047

L17 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

L18 QUE L17 NOT L16

=> s l18 sss sam

SAMPLE SEARCH INITIATED 17:35:28 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 13095 TO ITERATE

7.6% PROCESSED 1000 ITERATIONS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

5 ANSWERS

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 255056 TO 268744

PROJECTED ANSWERS: 824 TO 1794

L19 5 SEA SSS SAM L17 NOT L16

=>Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 2046 OR 2047

L20 SCREEN CREATED

=>

Uploading C:\STNEXP4\QUERIES\09773736(species).str

L21 STRUCTURE UPLOADED

=> que L21 NOT L20

L22 QUE L21 NOT L20

=> d l22

09/773,736

L22 HAS NO ANSWERS
L20 SCR 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 2046 O
R 2047
L21 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.
L22 QUE L21 NOT L20

=> s l22 sss sam
SAMPLE SEARCH INITIATED 17:37:33 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 13065 TO ITERATE

7.7% PROCESSED 1000 ITERATIONS 4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 254463 TO 268137
PROJECTED ANSWERS: 612 TO 1478

L23 4 SEA SSS SAM L21 NOT L20

=> s l22 sss ful
FULL SEARCH INITIATED 17:38:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 260551 TO ITERATE

100.0% PROCESSED 260551 ITERATIONS 1205 ANSWERS
SEARCH TIME: 00.00.05


L24 1205 SEA SSS FUL L21 NOT L20

=>
Uploading 09773736 (sub).str

L25 STRUCTURE UPLOADED

=> d l25
L25 HAS NO ANSWERS
L25 STR

09/773,736



G1
G2
G3
G4 C,O,N
G5 Cy,Ak

Structure attributes must be viewed using STN Express query preparation.

```
=> s 13 sub=l24 sss sam
SAMPLE SUBSET SEARCH INITIATED 17:40:04 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -      59 TO ITERATE
```

```
100.0% PROCESSED      59 ITERATIONS                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01
```

```
PROJECTIONS (WITHIN SPECIFIED SUBSET):      ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):      720 TO      1640
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):      720 TO      1640
```

L26 50 SEA SUB=L24 SSS SAM L3

```
=> s 13 sub=l24 sss ful
FULL SUBSET SEARCH INITIATED 17:40:12 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -    1205 TO ITERATE
```

```
100.0% PROCESSED    1205 ITERATIONS                1205 ANSWERS
SEARCH TIME: 00.00.01
```

L27 1205 SEA SUB=L24 SSS FUL L3

```
=> s 125 sub=l24 sss sam
SAMPLE SUBSET SEARCH INITIATED 17:40:38 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -      59 TO ITERATE
```

09/773,736

100.0% PROCESSED 59 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET): ONLINE **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 720 TO 1640
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET): 8 TO 329

L28 8 SEA SUB=L24 SSS SAM L25

=> s l25 sub=l24 sss ful
FULL SUBSET SEARCH INITIATED 17:40:44 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 1205 TO ITERATE

100.0% PROCESSED 1205 ITERATIONS 170 ANSWERS
SEARCH TIME: 00.00.01

L29 170 SEA SUB=L24 SSS FUL L25

=> s l24 not l29
L30 1035 L24 NOT L29

=> d his

(FILE 'HOME' ENTERED AT 17:24:09 ON 15 SEP 2002)

FILE 'REGISTRY' ENTERED AT 17:24:16 ON 15 SEP 2002

L1 SCREEN 1839
L2 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047 OR 20
L3 STRUCTURE UPLOADED
L4 QUE L3 AND L1 NOT L2
L5 19 S L4 SSS SAM
L6 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047 OR 20
L7 STRUCTURE UPLOADED
L8 QUE L7 NOT L6
L9 16 S L8 SSS SAM
L10 STRUCTURE UPLOADED
L11 0 S L10 SSS SAM
L12 SCREEN 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 20
L13 STRUCTURE UPLOADED
L14 QUE L13 NOT L12
L15 11 S L14 SSS SAM
L16 SCREEN 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 20
L17 STRUCTURE UPLOADED
L18 QUE L17 NOT L16
L19 5 S L18 SSS SAM
L20 SCREEN 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 20
L21 STRUCTURE UPLOADED
L22 QUE L21 NOT L20
L23 4 S L22 SSS SAM
L24 1205 S L22 SSS FUL
L25 STRUCTURE UPLOADED
L26 50 S L3 SSS SAM SUB=L24
L27 1205 S L3 SSS FUL SUB=L24
L28 8 S L25 SSS SAM SUB=L24
L29 170 S L25 SSS FUL SUB=L24
L30 1035 S L24 NOT L29

FILE 'CAPLUS' ENTERED AT 17:41:05 ON 15 SEP 2002

09/773,736

L31 136 S L30

=> s l31 1-50 bib,ab,hitstr

MISSING OPERATOR L31 1-50

The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> d l31 1-50 bib,ab,hitstr

09/773,736

L31 ANSWER 1 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2002:638277 CAPLUS
DN 137:155147
TI Preparation 6-O-carbamoyl ketolide derivatives of erythromycin useful as
antibacterials
IN Henninger, Todd C.; Xu, Xiaodong
PA USA
SO U.S. Pat. Appl. Publ., 62 pp., Cont.-in-part of Ser. No. US 2001-773,788.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002115620	A1	20020822	US 2001-11937	20011205
PRAI	US 2000-251547P	P	20001206		
	US 2001-773788	A2	20010201		

AB 6-O-carbamoyl ketolide derivs. of erythromycin antibacterials of the
formula I: wherein R1 and R2 are independently H, alkyl, alkenyl, alkynyl,
cycloalkyl, cycloalkenyl, provided that R1 and R2 are not both H; R1R2
together are N atom to which they are attached, form an optionally
substituted N-contg. heterocycle; R3 is H, alkylamine, alkyl, alkoxy,
alkenylamine, alkenyl, acyl, alkynylamine R4 is H, halogen, OH; R5 is a H,
hydroxy protecting group; R6 is H, alkyl, alkenyl, alkynyl, aryl,
heteroaryl, heterocyclo, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl,
cycloalkenyl, alkoxyalkyl, alkylthioalkyl; X and Y are together with the
carbon atom to which they are attached, form CO, imine, oxyimine; Y and Y1
are together with the carbon atom to which they are attached, form CO,
CHOH, imine, oxyimine; were prepd. These compds. are useful as
antibacterial agents. Thus, carbamic acid [(2E)-3-[4-(2-
pyrimidinyl)phenyl]-2-propenyl]-(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-
ethyltetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-
[[3,4,6-trideoxy-3-(dimethylamino)beta-D-xylo-hexopyranosyl]oxy]-2H-
oxacyclotetradecino[4,3-d]oxazol-11-yl ester was prepd. and tested in
vitro against E. coli, S. aureus, S. epidermidis, S. pneumoniae, S.
pyogenes, Enterococci, Moraxella catarrhalis, and H. influenzae MIC values
range from 0.03 to > 16 .mu.g/mL. These compds. are particularly useful
in the treatment of community-acquired pneumonia, upper and lower
respiratory tract infections, skin and soft tissue infections, meningitis,
hospital-acquired lung infections, and bone and joint infections.


IT 433921-07-4P 433921-08-5P 433921-11-0P
433921-20-1P 433921-27-8P 433921-30-3P
433921-31-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. carbamoyl ketolide derivs. of erythromycin useful as
antibacterials)


RN 433921-07-4 CAPLUS

CN 2-Propenal, 3-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 433921-08-5 CAPLUS
CN 2-Propenal, 3-[3-methoxy-4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 433921-11-0 CAPLUS
CN 2-Propenal, 3-[4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 433921-20-1 CAPLUS
CN 2-Propenal, 3-[3-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 433921-27-8 CAPLUS
CN 2-Propenal, 3-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 433921-30-3 CAPLUS


09/773,736

CN 2,4-Pentadienal, 5-[4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 433921-31-4 CAPLUS

CN 2-Propenal, 3-[4-(4-methyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 2 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2002:595509 CAPLUS
DN 137:135106
TI Combination of a 5-HT3 receptor antagonist with a serotonin reuptake inhibitor for the treatment of depression
IN Howard, Harry R.
PA USA
SO U.S. Pat. Appl. Publ., 20 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002107244	A1	20020808	US 2001-2303	20011102
	EP 1230921	A1	20020814	EP 2002-2250541	20020128
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRAI US 2001-266340P P 20010202

OS MARPAT 137:135106


AB The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a 5-HT3 receptor antagonist in combination with a serotonin reuptake inhibitor (SRI) antidepressant agent with improvement in sexual function and/or redn. in gastro-intestinal side effects. It also relates to pharmaceutical compns. contg. a pharmaceutically acceptable carrier, a 5-HT3 receptor antagonist and an SRI antidepressant. The ratio of the 5-HT3 receptor antagonist and the SRI antidepressant agent is between 0.001 to 1 and 1000 to 1, and esp. between 0.01 to 1 and 100 to 1 (no data).

IT **334980-54-0**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of 5-HT3 receptor antagonist with serotonin reuptake inhibitor for treatment of depression)

RN 334980-54-0 CAPLUS

CN 1H-Pyrazol-3-amine, 1-[4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 3 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 2002:592074 CAPLUS

DN 137:141964

TI Aqueous jet ink compositions with good weather resistance and fastness of their printed images

IN Naruse, Hideaki

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 16 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002220556	A2	20020809	JP 2001-17019	20010125
AB	The compns. comprise colorants dissolved or dispersed in aq. solvents and .gtoreq.1 host compds. for inclusion with the colorants. Thus, an ink comprising a water-sol. dye, solvents, and calix[4]arene-p-sulfonic acid tetrasodium salt showed good light fastness and ozone resistance.				
IT	445040-16-4				
RL:	TEM (Technical or engineered material use); USES (Uses)				
	(dye; aq. jet inks contg. hosts for dye inclusion compds. with good weather resistance and fastness)				
RN	445040-16-4 CAPLUS				
CN	Hexanamide, N-[4-[5-[[2-(acetylamino)-4-(diethylamino)phenyl]azo]-4-cyano-3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]-2-ethyl- (9CI)				
	(CA INDEX NAME)				




L31 ANSWER 4 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 2002:556113 CAPLUS
 DN 137:119694
 TI Sodium-hydrogen exchanger type 1 inhibitor combination with another agent
 for reduction of ischemia-associated tissue damage
 IN Tracey, Wayne R.; Hill, Roger J.
 PA Pfizer Inc., USA
 SO U.S. Pat. Appl. Publ., 20 pp.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002099075	A1	20020725	US 2002-52320	20020117
	US 6423705	B2	20020723		
	EP 1226830	A2	20020731	EP 2002-2250403	20020121
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRAI	US 2001-264173P	P	20010125		
OS	MARPAT 137:119694				
AB	<p>The invention provides methods of reducing tissue damage resulting from ischemia which comprise administering to a mammal in need of such redn. an effective amt. of a combination, or a pharmaceutical compn. comprising such combination, of a sodium-hydrogen exchanger type 1 (NHE-1) inhibitor and a second compd. selected from the group consisting of: (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and (e) an enzyme/protein modulator. The invention further provides kits comprising an amt. of a sodium-hydrogen exchanger type-1 inhibitor, and a pharmaceutically acceptable carrier, vehicle, or diluent in a first unit dosage form; an amt. of a second compd. selected from the group consisting of (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and (e) an enzyme/protein modulator selected from the group consisting of a protein kinase C activator, an endothelin converting enzyme inhibitor, a tissue-activated fibrinolytic inhibitor (TAFI), a Na⁺/Ca²⁺ exchanger isoform-1 (NCX-1) inhibitor, and a poly(ADP ribose) synthetase (PARS/PARP) inhibitor, and a pharmaceutically acceptable carrier, vehicle, or diluent in a second unit dosage form; and a container.</p>				
IT	<p>241802-10-8 241802-10-8D, prodrug derivs. 241802-17-5 241802-17-5D, prodrug derivs. RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (sodium-hydrogen exchanger type 1 inhibitor combination with another agent for redn. of ischemia-assocd. tissue damage)</p>				
RN	241802-10-8 CAPLUS				
CN	1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-4-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)				

09/773,736




RN 241802-10-8 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-4-
[(methylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)




RN 241802-17-5 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-5-
[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)

09/773,736



RN 241802-17-5 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-5-
[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 5 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2002:522631 CAPLUS
DN 137:93747
TI Preparation of pyrazolecarboxamides as inhibitors of factor Xa
IN Zhu, Bing-yan; Jia, Zhaozhong Jon; Huang, Wenrong; Song, Yonghong; Kanter, James; Scarborough, Robert M.
PA USA
SO U.S. Pat. Appl. Publ., 303 pp., Cont.-in-part of U.S. Ser. No. 662,807.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002091116	A1	20020711	US 2001-794214	20010228
PRAI	US 1999-154332P	P	19990917		
	US 2000-662807	A2	20000915		
OS	MARPAT 137:93747				
AB	The title compds. AQDEGJX [A = alkyl, cycloalkyl, (un)substituted Ph, naphthyl, etc.; Q = a direct link, divalent alkyl, alkenyl, etc.; D = a direct link, (un)substituted Ph, 5-10 membered (non)arom. heterocyclyl; E = a direct link, (CH ₂) _q CO, CO(CH ₂) _x , etc.; q, x = 0-2; G = (un)substituted Ph, 5-6 membered heteroaryl; J = a direct link, SO ₂ , CO, etc.; X = (un)substituted Ph, naphthyl, 6-membered heteroaryl, etc.] having activity against mammalian factor Xa, and useful in vitro or in vivo for preventing or treating coagulation disorders, were prepd. E.g., a 3-step synthesis of the pyrazolecarboxamide I was given.				


IT 330803-36-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrazolecarboxamides as inhibitors of factor Xa)

RN 330803-36-6 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-(5-bromo-2-pyridinyl)-1-[4-[(dimethylamino)iminomethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



IT 330803-89-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of pyrazolecarboxamides as inhibitors of factor Xa)

RN 330803-89-9 CAPLUS

09/773,736

CN 1H-Pyrazole-5-carboxylic acid, 1-[5-[[[(1,1-dimethylethyl)amino]carbonyl]-2-(methylsulfonyl)phenyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 6 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2002:449692 CAPLUS
DN 137:20548
TI Preparation 6-O-carbamoyl ketolide derivatives of erythromycin useful as
antibacterials
IN Henninger, Todd C.; Xu, Xiaodong C.
PA Ortho-McNeil Pharmaceutical, Inc., USA
SO PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002046204	A1	20020613	WO 2001-US47530	20011205
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRAI	US 2000-251547P	P	20001206		
	US 2001-773788	A	20010201		
OS	MARPAT 137:20548				
AB	6-O-carbamoyl ketolide derivs. of erythromycin antibacterials of the formula I: wherein R1 and R2 are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, provided that R1 and R2 are not both H; R1R2 together are N atom to which they are attached, form an optionally substituted N-contg. heterocycle; R3 is H, alkylamine, alkyl, alkoxy, alkenylamine, alkenyl, acyl, alkynylamine R4 is H, halogen, OH; R5 is a H, hydroxy protecting group; R6 is H, alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclo, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkenyl, alkoxyalkyl, alkylthioalkyl; X and X1 are together with the carbon atom to which they are attached, form CO, imine, oxyimine; Y, and Y1 are together with the carbon atom to which they are attached, form CO, CHOH, imine, oxyimine; were prepd. These compds. are useful as antibacterial agents. Thus, carbamic acid [(2E)-3-[4-(2-pyrimidinyl)phenyl]-2-propenyl]-(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-ethyltetradecahydro-3a,7,9,11,13,15-hexamethyl-2,6,8,14-tetraoxo-10-[[3,4,6-trideoxy-3-(dimethylamino)beta-D-xylo-hexopyranosyl]oxy]-2H-oxacyclotetradecino[4,3-d]oxazol-11-yl ester was prepd. and tested in vitro against E. coli, S. aureus, S. epidermidis, S. pneumoniae, S. pyogenes, Enterococci, Moraxella catarrhalis, and H. influenzae MIC values range from 0.03 to > 16 .mu.g/mL. These compds. are particularly useful in the treatment of community-acquired pneumonia, upper and lower respiratory tract infections, skin and soft tissue infections, meningitis, hospital-acquired lung infections, and bone and joint infections.				
IT	433921-07-4P 433921-08-5P 433921-11-0P 433921-20-1P 433921-27-8P 433921-30-3P 433921-31-4P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. carbamoyl ketolide derivs. of erythromycin useful as antibacterials)				
RN	433921-07-4	CAPLUS			


09/773,736

CN 2-Propenal, 3-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 433921-08-5 CAPLUS

CN 2-Propenal, 3-[3-methoxy-4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 433921-11-0 CAPLUS

CN 2-Propenal, 3-[4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 433921-20-1 CAPLUS

CN 2-Propenal, 3-[3-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 433921-27-8 CAPLUS


CN 2-Propenal, 3-[3-fluoro-4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



09/773,736


RN 433921-30-3 CAPLUS

CN 2,4-Pentadienal, 5-[4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 433921-31-4 CAPLUS

CN 2-Propenal, 3-[4-(4-methyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 7 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2002:436723 CAPLUS
DN 137:21600
TI Jet-printing ink compositions with good fastness and water resistance and
image-forming method
IN Omatsu, Tadashi; Noro, Masaki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 56 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2002167531	A2	20020611	JP 2000-363201	20001129
	US 2002096082	A1	20020725	US 2001-995761	20011129
PRAI	JP 2000-363201	A	20001129		

OS MAREPAT 137:21600

AB The compns. include NR101R102R103 (R101, R102 = H, aliph., arom., and heterocyclic groups, etc.; R103 = aliph., arom., and aliph. thioxy groups, etc.) and oil-sol. azo dyes I [R1, R2 = (substituted) alkyl, alkenyl, cycloalkyl, aralkyl; R3-R6 = H, halo, alkyl, etc.; X = electron-withdrawing group having Hammett .sigma.p const. of .gtoreq.0.20; Y = secondary or tertiary alkyl, (substituted) aryl; A = nonmetal at. groups forming 5-8-membered rings] dissolved in org. solvents having high m.ps. and dispersed in aq. media. Thus, II and Na dioctylsulfosuccinate were dissolved in a mixt. comprising (MeC6H5)3P:O, (Me2CHCCH2CHMeCH2O)3P:O, and Et acetate and dispersed in water to give an aq. emulsion. Image formed with ink contg. the emulsion and Me2NN(CH2CH2CO2C8H17)2 showed no blur after soaking in water for 10 s and good light and heat fastness.


IT 377777-01-0

RL: TEM (Technical or engineered material use); USES (Uses)
(dyes; jet-printing ink compns. with good fastness and water resistance)

RN 377777-01-0 CAPLUS

CN Hexanamide, N-[4-[5-[[2-(acetylamino)-4-(dioctylamino)phenyl]azo]-4-cyano-3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]-2-ethyl- (9CI)
(CA INDEX NAME)

09/773,736



09/773,736

L31 ANSWER 8 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 2002:107327 CAPLUS

DN 136:167394

TI Preparation of carboxamide compounds and their use as antagonists of a human 11CBY receptor

IN Johnson, Christopher Norbert; Jones, Martin; O'Toole, Catherine Anne; Stemp, Geoffrey; Thewlis, Kevin Michael; Witty, David

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 77 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002010146	A1	20020207	WO 2001-EP8637	20010726
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRAI GB 2000-18758 A 20000731

GB 2001-12544 A 20010523

OS MARPAT 136:167394

AB Title compds. [I; A = H, C1-6alkyl optionally substituted by hydroxyl, C1-6alkoxy, C1-6alkenyl, C1-6 acyl, halogeno, OH, CN, CF₃; R₃ = H, CH₃, CH₃CH₂; R₄ = arom. carbocycle, heterocycle; Z = O, S, NH, CH₂, single bond, at the 3 or 4 position of R₄ relative to the carbonyl group; R₅ = arom. carbocycle, heterocycle; Q = XYNR₁R₂; X = O, S; Y = C2-4 alkylene, C5-6 cycloalkylene; R₁, R₂ independently = C1-6 alkyl, phenyl-C1-6 alkyl; R₁R₂ = 5-, 6-, 7-membered ring optionally contg. one or more heteroatom selected from O, S, N; etc.], pharmaceutically acceptable salts, and solvate are prepd. and as antagonists of a human 11CBY receptor. Title compds. and pharmaceutical compn. are useful in the treatment and/or prophylaxis of one or more of the disorder, such as, major depression, manic depression, anxiety, etc. Thus, the title compd. II was prepd. from 2'-methyl-biphenyl-4-carboxylic acid and 4-(2-diisopropylamino-ethoxy)-3-methoxy-phenylamine in DMF in the presence of 1-(3-dimethylaminopropyl)-3-Et carbodiimide hydrochloride and 1-hydroxy-7-azabenzotriazole.

IT 395677-18-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of carboxamide compds. as antagonists of human 11CBY receptor)

RN 395677-18-6 CAPLUS

CN Benzamide, N-[4-[2-[bis(1-methylethyl)amino]ethoxy]-3-methoxyphenyl]-4-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)

09/773,736



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 9 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2002:72059 CAPLUS
DN 136:118464
TI Herbicidal heterocyclic substituted sulfonic acid anilides
IN Schallner, Otto; Andree, Roland; Schwarz, Hans-Georg; Linker, Karl-Heinz;
Drewes, Mark Wilhelm; Dahmen, Peter; Feucht, Dieter; Pontzen, Rolf
PA Bayer Aktiengesellschaft, Germany
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002006244	A1	20020124	WO 2001-EP7664	20010705
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	DE 10034803	A1	20020131	DE 2000-10034803	20000718


PRAI DE 2000-10034803 A 20000718
OS MARPAT 136:118464

AB Sulfonanilides I [R1 = OH, NO2, CN, CONH2, CSNH2, halogen, R3, Q1R3, Q1CQ2R3; R2, R3 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heterocyclylalkyl; X = H, CN, halogen; Z = nitrogen heterocyclic; Q1, Q2 = O, S] were prepd. for use as herbicides. Thus, the sulfonamide II [R4 = SCFC12] was obtained in 53% yield by treating II [R4 = H] with Cl2FCSCl.

IT **391277-20-6P**
RL: AGR (Agricultural use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of herbicidal N-(heterocyclylaryl)sulfonamides)

RN 391277-20-6 CAPLUS

CN Methanesulfonamide, N-[5-(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl)-2-cyano-4-fluorophenyl]-N-[(1,1-dimethylethyl)thio]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 10 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2002:51416 CAPLUS
DN 136:102196
TI Biphenylcarboxylic acid amides as inhibitors of microsomal triglyceride transfer protein
IN Priepke, Henning; Huel, Norbert; Thomas, Leo; Mark, Michael; Dahmann, Georg
PA Boehringer Ingelheim Pharma K.-G., Germany
SO PCT Int. Appl., 122 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002004403	A1	20020117	WO 2001-EP7627	20010704
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	DE 10033337	A1	20020117	DE 2000-10033337	20000708
	AU 2001067583	A5	20020121	AU 2001-67583	20010704
	US 2002032238	A1	20020314	US 2001-899884	20010706
PRAI	DE 2000-10033337	A	20000708		
	US 2000-220115P	P	20000724		
	WO 2001-EP7627	W	20010704		

OS MARPAT 136:102196

AB Biphenylcarboxamides I [R1, R2, R3 = H, F, Cl, Br, alkyl, fluoroalkyl, OH, alkoxy, (un)substituted NH2; R1R2 = 2,2'-CO; R4, R5 = H, alkyl; R6 = H, alkyl, (un)substituted NH2; NR5R6 = heterocyclic; R7 = H, F, Cl, Br, I, alkyl, alkoxy, NO2, amino] were prepd. for use as inhibitors of the microsomal triglyceride transfer protein with IC50 .ltoreq. 100.mu.M. Thus, the amide II was prepd. from 2-(4-MeC6H4)C6H4CONHC6H4COCl-3 and the pyrazolylbenzylamine. The latter compd. was obtained by reaction of 4-NCC6H4NHNH2 with PhCOCH2COMe and redn. of the cyano group. The acid chloride was obtained by treating 3-H2NC6H4CO2Et with 2-(4-MeC6H4)C6H4COCl, ester hydrolysis and conversion to the chloride.


IT 389602-85-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of biphenylcarboxylamides as inhibitors of microsomal triglyceride transfer protein)

RN 389602-85-1 CAPLUS

CN Benzamide, 3-amino-N-[[4-(3,5-dimethyl-4-propyl-1H-pyrazol-1-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)

09/773,736



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736


L31 ANSWER 11 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2002:39605 CAPLUS
DN 136:102380
TI Preparation of novel guanidine mimics as factor Xa inhibitors
IN Lam, Patrick Y.; Clark, Charles G.; Dominguez, Celia; Fevig, John M.; Han, Qi; Li, Renhua; Pinto, Donald J. P.; Pruitt, James R.; Quan, Mimi L.
PA Dupont Pharmaceuticals Company, USA
SO U.S., 117 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6339099	B1	20020115	US 1998-99358	19980618
	US 2002025963	A1	20020228	US 2001-924381	20010808
PRAI	US 1997-50265P	P	19970620		
	US 1998-99358	A3	19980618		
OS	MARPAT 136:102380				

AB The title compds. [I; ring D = 5-membered arom. system contg. from 1-2 heteroatoms selected from N, O, S; ring D is substituted with 0-2 R groups; ring E contains 0-2 N atom and is substituted by 0-1 R groups; R = Cl, F, Br, I, OH, alkoxy, amino(alkyl), (alkyl)amino; Z = bond, alkylene, (CH₂)_rO(CH₂)_r, (CH₂)_rNR₃(CH₂)_r, (CH₂)_rC(O)(CH₂)_r, (CH₂)_rC(O)O(CH₂)_r, (CH₂)_rOC(O)(CH₂)_r, (CH₂)_rC(O)NR₃(CH₂)_r, etc. provided that Z does not form a N-N, N-O, N-S, NCH₂N, NCH₂O, or NCH₂S bond with ring M or group A; R1a-1b = H, alk(en)yl, aminoalkyl, alkoxy, alternatively, R1a-1b, when attached to adjacent carbon atoms, together with the atoms to which they are attached form a 5-8 membered (un)satd. ring (un)substituted and which contains from 0-2 heteroatoms selected from the group consisting of N, O, and S; alternatively, when Z is C(O)NH and R1a is attached to a ring carbon adjacent to Z, then R1a is a C(O) which replaces the amide hydrogen of Z to form a cyclic imide; R₃ = H, alkyl, phenyl; A = (un)substituted carbocyclic, 5-10 membered heterocyclic system contg. 1-4 heteroatoms selected from N, O, S; B = H, Y, X-Y; X = sulfonylalkyl, alkylsulfonyl, sulfonamide, etc.; Y = alkylamino, provided that X-Y does not form a N-N, O-N or S-N bond, carbocyclic group, 5-10 membered heterocyclic r = 0-3], inhibitors of factor Xa which are useful in treating and preventing a thromboembolic disorder, were prepd. and formulated. Thus, a multi-step synthesis of the title compd. II, starting with 7-aminoisoquinoline, was described. A no. of compds. I were found to exhibit a K_i of .ltoreq. 15 .mu.M against factor Xa.


IT **218301-51-0P 218301-52-1P 218301-53-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of novel guanidine mimics as factor Xa inhibitors)
RN 218301-51-0 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 1-[3-(aminocarbonyl)-4-(2-phenylethenyl)phenyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 218301-52-1 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-cyano-4-(2-phenylethenyl)phenyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 218301-53-2 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-cyano-4-(2-phenylethenyl)phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 12 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 2002:5006 CAPLUS
 DN 136:241309
 TI Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds
 AU Trevillyan, James M.; Chiou, X. Grace; Chen, Yung-Wu; Ballaron, Stephen J.; Sheets, Michael P.; Smith, Morey L.; Wiedeman, Paul E.; Warrior, Usha; Wilkins, Julie; Gubbins, Earl J.; Gagne, Gerard D.; Fagerland, Jane; Carter, George W.; Luly, Jay R.; Mollison, Karl W.; Djuric, Stevan W.
 CS Global Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, IL, 60064, USA
 SO Journal of Biological Chemistry (2001), 276(51), 48118-48126
 CODEN: JBCHA3; ISSN: 0021-9258
 PB American Society for Biochemistry and Molecular Biology
 DT Journal
 LA English
 AB NFAT (nuclear factor of activated T cell) proteins are expressed in most immune system cells and regulate the transcription of cytokine genes crit. for the immune response. The activity of NFAT proteins is tightly regulated by the Ca²⁺/calmodulin-dependent protein phosphatase 2B/calcineurin (CaN). Dephosphorylation of NFAT by CaN is required for NFAT nuclear localization. Current immunosuppressive drugs such as cyclosporin A and FK506 block CaN activity thus inhibiting nuclear translocation of NFAT and consequent cytokine gene transcription. The inhibition of CaN in cells outside of the immune system may contribute to the toxicities assocd. with cyclosporin A therapy. In a search for safer immunosuppressive drugs, we identified a series of 3,5-bistrifluoromethyl pyrazole (BTP) derivs. that block Th1 and Th2 cytokine gene transcription. The BTP compds. block the activation-dependent nuclear localization of NFAT as detd. by electrophoretic mobility shift assays. Confocal microscopy of cells expressing fluorescent-tagged NFAT confirmed that the BTP compds. block calcium-induced movement of NFAT from the cytosol to the nucleus. Inhibition of NFAT was selective because the BTP compds. did not affect the activation of NF- κ B and AP-1 transcription factors. Treatment of intact T cells with the BTP compds. prior to calcium ionophore-induced activation of CaN caused NFAT to remain in a highly phosphorylated state. However, the BTP compds. did not directly inhibit the dephosphorylation of NFAT by CaN in vitro, nor did the drugs block the dephosphorylation of other CaN substrates including the type II regulatory subunit of protein kinase A and the transcription factor Elk-1. The data suggest that the BTP compds. cause NFAT to be maintained in the cytosol in a phosphorylated state and block the nuclear import of NFAT and, hence, NFAT-dependent cytokine gene transcription by a mechanism other than direct inhibition of CaN phosphatase activity. The novel inhibitors described herein will be useful in better defining the cellular regulation of NFAT activation and may lead to identification of new therapeutic targets for the treatment of autoimmune disease and transplant rejection.
 IT 223499-22-7 223499-30-7 245747-10-8
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (inhibition of NFAT activation and T cell cytokine prodn. by pyrazoles)
 RN 223499-22-7 CAPLUS
 CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)


Good hits
 Date
 no
 Good.

09/773,736




RN 223499-30-7 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 245747-10-8 CAPLUS

CN 4-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 13 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2001:936092 CAPLUS
DN 136:53752
TI Synthesis and use of mono-, di- and triethanolamine salts of zopolrestat alone and in combination with (e.g.) NHE-1 inhibitors
IN Mylari, Banavara L.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001056095	A1	20011227	US 2001-782798	20010213
PRAI	US 2000-183004P	P	20000216		

AB Mono-, di- and triethanolamine salts of [4-Oxo-(5-trifluoromethylbenzothiazol-2-ylmethyl)-3,4-dihydrophthalazin-1-yl]acetic acid (zopolrestat; I) were prepd. E.g., a soln. of I in acetone was added to ethanolamine (10 mol equiv, room temp., 1 h) which afforded, after purifn., the ethanolamine salt in 95% yield, m.p. 119 - 121.degree.C. Ethanolamine salts of I are used alone or with NHE-1 inhibitors (e.g. II), selective serotonin reuptake inhibitors (SSRIs, e.g. fluoxetine), glycogen phosphorylase inhibitors (GPIs), sorbitol dehydrogenase inhibitors (SDIs) and antihypertensive agents for treating diabetic complications.


IT **241802-10-8**, [1-(2-Chloro-4-methylaminosulfonylphenyl)-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine **241802-17-5**, [1-(2-Chloro-5-dimethylaminosulfonylphenyl)-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combination pharmaceutical; synthesis and use of mono-, di- and triethanolamine salts of zopolrestat alone and in combination with (e.g.) NHE-1 inhibitors)


RN 241802-10-8 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-4-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)



09/773,736

CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-5-
[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 14 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2001:873311 CAPLUS
DN 136:20957
TI Azo dyes, thir manufacture, their ink-jet inks and printing method
therewith
IN Fujiwara, Toshiki; Tateishi, Keiichi; Yamada, Masato
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 58 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001335714	A2	20011204	JP 2000-220649	20000721
PRAI	JP 2000-80733	A	20000322		

OS CASREACT 136:20957; MARPAT 136:20957

AB The lightfast azo dyes with good color hue show a structure I [R1, R2 = (substituted) alkyl, alkenyl, cycloalkyl or aralkyl; R3-R6 = H, halogen, (cyclo)alkyl, alkenyl, aralkyl, aryl, heterocyclo(loxy), CN, OH, NO2, NH2, alkoxy, alkylamino, arylamino, aryloxy, amido, ureido, sulfamoylamino, alkylthio, arylthio, alkoxycarbonylamino, sulfoamido, (alkoxy) carbamoyl, sulfamoyl, sulfonyl, azo, acyl(oxy), carbamoyloxy, silyloxy, aryloxycarbonyl(amino), imido, heterothio, sulfinyl, phosphoryl, hydrophilic ionic group or R1-R2, R1-R3, R2-R5 formed into ring structure; A = nonmetal group for forming C5-8 membered ring; X = electron-withdrawing group having Hammett's substituent const. σ value of ≥ 0.20 ; Y = secondary or tertiary alkyl, (substituted) aryl]. The II was prepd. from 5-amino-3-tert-butyl-4-cyanopyrazole, 3-methylcarbonylamino-N-ethyl-N-sulfonatobutylaniline, 3,5-dichloro-4-iodo-nitrobenzene, and 3-chlorosulfonylbenzoyl chloride and showed good light fastness.


IT 377776-93-7P

RL: IMF (Industrial manufacture); PRP (Properties); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(manuf. of lightfast azo dyes for aq. ink-jet inks)

RN 377776-93-7 CAPLUS

CN Hexanamide, N-[4-[5-[[2-(acetylamino)-4-[bis(1-methylethyl)amino]phenyl]azo]-4-cyano-3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]-2-ethyl- (9CI) (CA INDEX NAME)

09/773,736




IT 377777-01-0

RL: PRP (Properties); TEM (Technical or engineered material use); USES (Uses)

(manuf. of lightfast azo dyes for aq. ink-jet inks)



RN 377777-01-0 CAPLUS

CN Hexanamide, N-[4-[5-[[2-(acetylamino)-4-(diethylamino)phenyl]azo]-4-cyano-3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]-3,5-dichlorophenyl]-2-ethyl- (9CI)
(CA INDEX NAME)



09/773,736

L31 ANSWER 15 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2001:869722 CAPLUS
DN 137:170998
TI Synthesis and electronic absorption properties of some pyrazoles
functionalized with tricyanovinyl and tricyano-P-quinodimethane
chromophores
AU Asiri, Abdullah Mohamed
CS Chemistry Department, Faculty of Science, King Abdul-Aziz University,
Jeddah, 21589, Saudi Arabia
SO Journal of Saudi Chemical Society (2001), 5(2), 193-203
CODEN: JSCSFO; ISSN: 1319-6103
PB Saudi Chemical Society
DT Journal
LA English
AB The reaction between tetracyanoethylene and 7,7,8,8-
tetracyanoquinodimethane with pyrazoles I (R1 = R2 = Me, Ph; R1 = Ph, R2 =
Me; R1 = 2-C4H3S, R2 = CF3) gave 1-(4'-tricyanovinyl) and
1-(4'-tricyanoquinodimethane)phenyl-3,5-disubstituted pyrazoles II, III
and IV resp. The new pyrazole dyes showed absorption bands in the visible
and near IR region of the spectrum. The dyes showed remarkable
solvatochromism.
IT **446825-31-6P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and electronic absorption properties of pyrazoles
functionalized with tricyanovinyl and tricyano-P-quinodimethane
chromophores)
RN 446825-31-6 CAPLUS
CN Ethenetricarbonitrile, [4-[5-(2-thienyl)-3-(trifluoromethyl)-1H-pyrazol-1-
yl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 16 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 2001:851793 CAPLUS

DN 136:5986

TI Preparation of azole inhibitors of cytokine production

IN Bamaung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.; Gubbins, Earl J.; Luly, Jay R.; Tu, Noah P.; Madar, David J.; Warrior, Usha; Wiedeman, Paul E.; Zhou, Xun; Sciotti, Richard J.; Wagenaar, Frank L.

PA USA

SO U.S. Pat. Appl. Publ., 124 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001044445	A1	20011122	US 1999-289155	19990408

OS MARPAT 136:5986

AB The title compds. [I; R1, R3 = H, aryl, perfluoroalkyl, etc.; Z = N, C; R2 is absent or = H, alkyl, cycloalkyl, etc.; Q = (hetero)aryl (when Q = Ph, the Ph is 2-, 3-, or 4-substituted by E relative to the position of attachment of the pyrazole or 1,2,4-triazole ring to the Ph ring); R4, R5 = H, alkyl, haloalkyl, etc.; E = NO2, NH2, etc.], useful for inhibiting cytokine (Interleukin-2, Interleukin-4, or Interleukin-5) prodn. and cellular proliferation in stimulated human T cell lines or human peripheral blood mononuclear cells (biol. data given) and therefore have utility in the treatment of diseases that are prevented by or ameliorated with cytokine inhibitors, were prepd. General procedures for prepn. of compds. I were described. Thus, the title compd. II was prepd.

IT **223499-27-2P**, N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chlorobenzamide **223500-14-9P 245745-24-8P**

245745-44-2P 245745-76-0P 245745-83-9P

245745-87-3P 245745-89-5P 245745-90-8P


245745-92-0P 245746-66-1P 245746-91-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of azole inhibitors of cytokine prodn.)

RN 223499-27-2 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 223500-14-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


09/773,736




RN 245745-24-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 245745-44-2 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)




RN 245745-76-0 CAPLUS
CN Benzoic acid, 3-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




09/773,736


RN 245745-83-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-nitro-
(9CI) (CA INDEX NAME)



RN 245745-87-3 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-nitro-
(9CI) (CA INDEX NAME)




RN 245745-89-5 CAPLUS
CN Benzoic acid, 4-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 245745-90-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-92-0 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 245746-66-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-bromo-4-methoxy- (9CI) (CA INDEX NAME)



RN 245746-91-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 223499-30-7P 223499-41-0P 223499-45-4P,
 N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-
 pyridinecarboxamide 223499-46-5P 223499-47-6P
 245744-54-1P, N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-
 yl]phenyl]cyclopropanecarboxamide 245744-55-2P,
 N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,2,3,3-
 tetramethylcyclopropanecarboxamide 245744-56-3P,
 N-[4-[3,5-Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,2-dichloro-1-
 methylcyclopropanecarboxamide 245744-57-4P, N-[4-[3,5-
 Bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-oxo-6-pentyl-2H-pyran-3-
 carboxamide 245744-58-5P 245744-59-6P
 245744-60-9P 245744-62-1P 245744-63-2P
 245744-64-3P 245744-65-4P 245744-67-6P
 245744-68-7P 245744-70-1P 245744-71-2P
 245744-74-5P 245744-77-8P 245744-78-9P
 245744-80-3P 245744-81-4P 245744-82-5P
 245744-83-6P 245744-88-1P 245744-97-2P
 245745-04-4P 245745-05-5P 245745-06-6P
 245745-07-7P 245745-08-8P 245745-09-9P
 245745-11-3P 245745-12-4P 245745-14-6P
 245745-16-8P 245745-17-9P 245745-18-0P
 245745-20-4P 245745-22-6P 245745-23-7P
 245745-25-9P 245745-26-0P 245745-27-1P
 245745-28-2P 245745-29-3P 245745-31-7P
 245745-33-9P 245745-34-0P 245745-35-1P
 245745-36-2P 245745-37-3P 245745-38-4P
 245745-39-5P 245745-40-8P 245745-41-9P
 245745-42-0P 245745-43-1P 245745-45-3P
 245745-46-4P 245745-47-5P 245745-49-7P
 245745-50-0P 245745-51-1P 245745-52-2P
 245745-53-3P 245745-54-4P 245745-55-5P
 245745-56-6P 245745-57-7P 245745-58-8P
 245745-59-9P 245745-60-2P 245745-61-3P
 245745-62-4P 245745-63-5P 245745-64-6P
 245745-65-7P 245745-66-8P 245745-68-0P
 245745-69-1P 245745-70-4P 245745-71-5P
 245745-72-6P 245745-73-7P 245745-74-8P
 245745-75-9P 245745-77-1P 245745-78-2P
 245745-79-3P 245745-80-6P 245745-81-7P
 245745-82-8P 245745-84-0P 245745-85-1P
 245745-86-2P 245745-88-4P 245745-91-9P
 245745-93-1P 245745-94-2P 245745-96-4P
 245745-97-5P 245745-98-6P 245745-99-7P
 245746-02-5P 245746-03-6P 245746-04-7P

09/773,736


245746-05-8P 245746-06-9P 245746-07-0P
245746-08-1P 245746-09-2P 245746-10-5P
245746-11-6P 245746-12-7P 245746-13-8P
245746-14-9P 245746-15-0P 245746-16-1P
245746-18-3P 245746-19-4P 245746-20-7P
245746-21-8P 245746-22-9P 245746-24-1P
245746-25-2P 245746-26-3P 245746-27-4P
245746-28-5P 245746-29-6P 245746-30-9P
245746-31-0P 245746-32-1P 245746-33-2P
245746-35-4P 245746-36-5P 245746-37-6P
245746-38-7P 245746-39-8P 245746-40-1P
245746-41-2P 245746-42-3P 245746-43-4P
245746-44-5P 245746-45-6P 245746-46-7P
245746-47-8P 245746-48-9P 245746-49-0P
245746-50-3P 245746-51-4P 245746-52-5P
245746-53-6P 245746-54-7P 245746-55-8P
245746-56-9P 245746-57-0P 245746-58-1P
245746-59-2P 245746-60-5P 245746-61-6P
245746-62-7P 245746-63-8P 245746-64-9P
245746-65-0P 245746-67-2P 245746-68-3P
245746-69-4P 245746-70-7P 245746-71-8P
245746-72-9P 245746-73-0P 245746-74-1P
245746-75-2P 245746-76-3P 245746-77-4P
245746-78-5P 245746-79-6P 245746-80-9P
245746-81-0P 245746-82-1P 245746-83-2P
245746-84-3P 245746-85-4P 245746-86-5P
245746-87-6P 245746-88-7P 245746-89-8P
245746-90-1P 245746-92-3P 245746-93-4P
245746-94-5P 245746-95-6P 245746-96-7P
245746-97-8P 245746-98-9P 245746-99-0P
245747-00-6P 245747-02-8P 245747-03-9P
245747-07-3P 245747-08-4P 245747-09-5P
245747-10-8P 245747-11-9P 245747-12-0P
245747-13-1P 245747-14-2P 245747-15-3P
245747-16-4P 245747-18-6P 245747-19-7P
245747-20-0P 245747-21-1P 245747-22-2P
245747-23-3P 245747-24-4P 245747-25-5P
245747-26-6P 245747-27-7P 245747-28-8P
245747-29-9P 245747-30-2P 245747-31-3P
245747-32-4P 245747-34-6P 245747-35-7P
245747-37-9P 245747-38-0P 245747-39-1P
245747-40-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azole inhibitors of cytokine prodn.)


RN 223499-30-7 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)


09/773,736




RN 223499-41-0 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 223499-45-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 223499-46-5 CAPLUS
CN Pyrazinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 223499-47-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736

yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 245744-54-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245744-55-2 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,2,3,3-tetramethyl- (9CI) (CA INDEX NAME)



RN 245744-56-3 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,2-dichloro-1-methyl- (9CI) (CA INDEX NAME)



RN 245744-57-4 CAPLUS


CN 2H-Pyran-3-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-oxo-6-pentyl- (9CI) (CA INDEX NAME)

09/773,736




RN 245744-58-5 CAPLUS

CN Benzenesulfonamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 245744-59-6 CAPLUS


CN 1-Cyclohexene-1-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245744-60-9 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)

09/773,736




RN 245744-62-1 CAPLUS

CN 2-Cyclohexene-1-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 245744-63-2 CAPLUS

CN 1-Cyclopentene-1-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245744-64-3 CAPLUS

CN Cyclohexanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 245744-65-4 CAPLUS

CN 2-Butynamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-


09/773,736

(9CI) (CA INDEX NAME)




RN 245744-67-6 CAPLUS

CN 3-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
(9CI) (CA INDEX NAME)




RN 245744-68-7 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl-
3-nitro- (9CI) (CA INDEX NAME)




RN 245744-70-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-hydroxy- (9CI) (CA INDEX NAME)




09/773,736

RN 245744-71-2 CAPLUS
CN Cycloheptanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245744-74-5 CAPLUS
CN 2-Propenamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(2-chlorophenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 245744-77-8 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 245744-78-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-iodo- (9CI) (CA INDEX NAME)


09/773,736



RN 245744-80-3 CAPLUS
CN Cyclohexanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 245744-81-4 CAPLUS
CN Carbamic acid, [1-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 245744-82-5 CAPLUS
CN 3-Cyclohexene-1-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 245744-83-6 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-fluorophenyl)-
(9CI) (CA INDEX NAME)




RN 245744-88-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 245744-97-2 CAPLUS


CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 245745-04-4 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(hydroxymethyl)- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-05-5 CAPLUS
CN Acetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-cyano-
(9CI) (CA INDEX NAME)



RN 245745-06-6 CAPLUS
CN 2-Cyclohexene-1-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-07-7 CAPLUS
CN Cyclohexanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




09/773,736


RN 245745-08-8 CAPLUS
CN Benzeneacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
.alpha.-methoxy-.alpha.-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 245745-09-9 CAPLUS
CN Heptanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI)
(CA INDEX NAME)




RN 245745-11-3 CAPLUS
CN Benzamide, 3-amino-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
(9CI) (CA INDEX NAME)




RN 245745-12-4 CAPLUS
CN Benzamide, 4-amino-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
(9CI) (CA INDEX NAME)

09/773,736




RN 245745-14-6 CAPLUS
CN 2-Thiopheneacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-16-8 CAPLUS
CN L-Asparagine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 245745-17-9 CAPLUS
CN Carbamic acid, [7-[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]-7-oxoheptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


09/773,736




RN 245745-18-0 CAPLUS
CN Propanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(methylthio)- (9CI) (CA INDEX NAME)



RN 245745-20-4 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-cyano- (9CI) (CA INDEX NAME)




RN 245745-22-6 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-iodo- (9CI) (CA INDEX NAME)




09/773,736


RN 245745-23-7 CAPLUS
CN Propanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro- (9CI) (CA INDEX NAME)



RN 245745-25-9 CAPLUS
CN Hexanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 245745-26-0 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 245745-27-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(hexyloxy)- (9CI) (CA INDEX NAME)

09/773,736




RN 245745-28-2 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methyl-
(9CI) (CA INDEX NAME)




RN 245745-29-3 CAPLUS

CN Benzamide, 2-(acetyloxy)-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
(9CI) (CA INDEX NAME)



RN 245745-31-7 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4,6-
trimethyl- (9CI) (CA INDEX NAME)



RN 245745-33-9 CAPLUS


09/773,736

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-N-methyl- (9CI) (CA INDEX NAME)




RN 245745-34-0 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-N-methyl-4-nitro- (9CI) (CA INDEX NAME)




RN 245745-35-1 CAPLUS

CN Benzenemethanamine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)



RN 245745-36-2 CAPLUS


CN 1H-Pyrazole-4-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl-5-nitro- (9CI) (CA INDEX NAME)



RN 245745-37-3 CAPLUS


09/773,736

CN Benzenemethanamine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 245745-38-4 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-bromo- (9CI) (CA INDEX NAME)




RN 245745-39-5 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




RN 245745-40-8 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)




09/773,736


RN 245745-41-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 245745-42-0 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 245745-43-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-45-3 CAPLUS
CN Benzenemethanamine, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-46-4 CAPLUS
CN Benzonitrile, 3-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 245745-47-5 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 245745-49-7 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,4-dimethoxy- (9CI) (CA INDEX NAME)



RN 245745-50-0 CAPLUS
CN Cyclopentanepropanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-


09/773,736

yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-51-1 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 245745-52-2 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 245745-53-3 CAPLUS


CN 2-Butenamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)

09/773,736




RN 245745-54-4 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 245745-55-5 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-hydroxy- (9CI) (CA INDEX NAME)



RN 245745-56-6 CAPLUS


CN 5-Thiazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 245745-57-7 CAPLUS


09/773,736

CN Benamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 245745-58-8 CAPLUS

CN Benzenemethanamine, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)



RN 245745-59-9 CAPLUS


CN Benamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 245745-60-2 CAPLUS


CN Benamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-iodo- (9CI) (CA INDEX NAME)

09/773,736




RN 245745-61-3 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-heptyl-
(9CI) (CA INDEX NAME)




RN 245745-62-4 CAPLUS

CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
(9CI) (CA INDEX NAME)



RN 245745-63-5 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro-
(9CI) (CA INDEX NAME)




RN 245745-64-6 CAPLUS

CN 1,2-Benzenedicarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-


09/773,736

yl]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 245745-65-7 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245745-66-8 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro-2-nitro- (9CI) (CA INDEX NAME)




RN 245745-68-0 CAPLUS

CN Benzamide, 4-acetyl-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-69-1 CAPLUS
CN 2-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245745-70-4 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)




RN 245745-71-5 CAPLUS
CN Cyclopentanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245745-72-6 CAPLUS


09/773,736

CN Cyclohexanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-73-7 CAPLUS

CN 4-Piperidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-74-8 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 245745-75-9 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




09/773,736

RN 245745-77-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro-
(9CI) (CA INDEX NAME)




RN 245745-78-2 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-79-3 CAPLUS
CN Benzonitrile, 3-[(1E)-2-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 245745-80-6 CAPLUS
CN 1,4-Benzenedicarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736



RN 245745-81-7 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dinitro- (9CI) (CA INDEX NAME)




RN 245745-82-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 245745-84-0 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-cyano- (9CI) (CA INDEX NAME)

09/773,736




RN 245745-85-1 CAPLUS
CN 1,3-Benzenedicarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-86-2 CAPLUS
CN Benzonitrile, 3-[(1Z)-2-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 245745-88-4 CAPLUS
CN Benzonitrile, 3-[(1Z)-2-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-91-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-bromo-
(9CI) (CA INDEX NAME)



RN 245745-93-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro-
(9CI) (CA INDEX NAME)




RN 245745-94-2 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-bromo-
(9CI) (CA INDEX NAME)



RN 245745-96-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-


09/773,736

yl]phenyl]-2,6-dichloro- (9CI) (CA INDEX NAME)




RN 245745-97-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)



RN 245745-98-6 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-6-methyl- (9CI) (CA INDEX NAME)



RN 245745-99-7 CAPLUS

CN Benzenebutanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro-.gamma.-oxo- (9CI) (CA INDEX NAME)


09/773,736



RN 245746-02-5 CAPLUS


CN 1H-Pyrazole, 1-[4-[(1E)-2-(2-chlorophenyl)ethenyl]phenyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 245746-03-6 CAPLUS


CN Propanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(4-chlorophenoxy)-2-methyl- (9CI) (CA INDEX NAME)




RN 245746-04-7 CAPLUS

CN Acetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-05-8 CAPLUS
CN Benzoic acid, 4-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 245746-06-9 CAPLUS
CN Carbamic acid, [4-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]-4-oxobutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 245746-07-0 CAPLUS
CN Benzoic acid, 3-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 245746-08-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-


09/773,736

difluoro- (9CI) (CA INDEX NAME)




RN 245746-09-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-bromo- (9CI) (CA INDEX NAME)



RN 245746-10-5 CAPLUS


CN Benzamide, 2-amino-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245746-11-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-12-7 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 245746-13-8 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245746-14-9 CAPLUS
CN 2-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,6-dichloro- (9CI) (CA INDEX NAME)



09/773,736


RN 245746-15-0 CAPLUS

CN Acetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(2-nitrophenoxy)- (9CI) (CA INDEX NAME)



RN 245746-16-1 CAPLUS


CN Benzeneacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)



RN 245746-18-3 CAPLUS

CN 2-Propenamamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(2-thienyl)-, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 245746-19-4 CAPLUS


CN Carbamic acid, [4-[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 245746-20-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-acetyl-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245746-21-8 CAPLUS


CN Butanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245746-22-9 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro-2-methoxy- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-24-1 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methoxy-4-(methylthio)- (9CI) (CA INDEX NAME)



RN 245746-25-2 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-hydroxy-3-nitro- (9CI) (CA INDEX NAME)




RN 245746-26-3 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,4-dihydroxy- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-27-4 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-hydroxy-6-methoxy- (9CI) (CA INDEX NAME)



RN 245746-28-5 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 245746-29-6 CAPLUS
CN 4-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)



09/773,736


RN 245746-30-9 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2-chlorophenyl)-
(9CI) (CA INDEX NAME)




RN 245746-31-0 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(3-cyanophenyl)-
(9CI) (CA INDEX NAME)



RN 245746-32-1 CAPLUS


CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,4-difluorophenyl)-
(9CI) (CA INDEX NAME)



RN 245746-33-2 CAPLUS


CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2-cyanophenyl)-
(9CI) (CA INDEX NAME)

09/773,736




RN 245746-35-4 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2-nitrophenyl)-
(9CI) (CA INDEX NAME)




RN 245746-36-5 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,6-difluorophenyl)-
(9CI) (CA INDEX NAME)



RN 245746-37-6 CAPLUS


CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2-bromophenyl)-
(9CI) (CA INDEX NAME)



RN 245746-38-7 CAPLUS


09/773,736

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-cyanophenyl)-
(9CI) (CA INDEX NAME)




RN 245746-39-8 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-4-pyridinyl-
(9CI) (CA INDEX NAME)



RN 245746-40-1 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro-
3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 245746-41-2 CAPLUS

CN Benzamide, N-[2-(aminocarbonyl)phenyl]-4-[3,5-bis(trifluoromethyl)-1H-
pyrazol-1-yl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-42-3 CAPLUS
CN Benzeneacetamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)



RN 245746-43-4 CAPLUS
CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3-dichloro- (9CI) (CA INDEX NAME)




RN 245746-44-5 CAPLUS
CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-5-nitro- (9CI) (CA INDEX NAME)



RN 245746-45-6 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro-


09/773,736

3-nitro- (9CI) (CA INDEX NAME)




RN 245746-46-7 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 245746-47-8 CAPLUS

CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 245746-48-9 CAPLUS


CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-difluoro- (9CI) (CA INDEX NAME)



09/773,736


RN 245746-49-0 CAPLUS

CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-cyano-
(9CI) (CA INDEX NAME)




RN 245746-50-3 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-bromo-
3-nitro- (9CI) (CA INDEX NAME)



RN 245746-51-4 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-
4-fluoro- (9CI) (CA INDEX NAME)



RN 245746-52-5 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-
4-(methylsulfonyl)- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-53-6 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dichloro- (9CI) (CA INDEX NAME)



RN 245746-54-7 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3-difluoro- (9CI) (CA INDEX NAME)



RN 245746-55-8 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro-4-fluoro- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-56-9 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-difluoro- (9CI) (CA INDEX NAME)



RN 245746-57-0 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-6-fluoro- (9CI) (CA INDEX NAME)



RN 245746-58-1 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-59-2 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro-2-fluoro- (9CI) (CA INDEX NAME)




RN 245746-60-5 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-4-methoxy- (9CI) (CA INDEX NAME)



RN 245746-61-6 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-dichloro-3-nitro- (9CI) (CA INDEX NAME)



09/773,736


RN 245746-62-7 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-bromo-2-chloro- (9CI) (CA INDEX NAME)




RN 245746-63-8 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,4-difluoro- (9CI) (CA INDEX NAME)



RN 245746-64-9 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-bromo-5-methoxy- (9CI) (CA INDEX NAME)



RN 245746-65-0 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro-2-hydroxy- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-67-2 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-bromo-4-hydroxy- (9CI) (CA INDEX NAME)




RN 245746-68-3 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-4,5-difluoro- (9CI) (CA INDEX NAME)



RN 245746-69-4 CAPLUS


CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)



09/773,736


RN 245746-70-7 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro-2,5-difluoro- (9CI) (CA INDEX NAME)




RN 245746-71-8 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3,4-trifluoro- (9CI) (CA INDEX NAME)



RN 245746-72-9 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,4,5-trifluoro- (9CI) (CA INDEX NAME)




RN 245746-73-0 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4,5-trifluoro- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-74-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4,6-trifluoro- (9CI) (CA INDEX NAME)



RN 245746-75-2 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-difluoro-3-nitro- (9CI) (CA INDEX NAME)




RN 245746-76-3 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3,5-trifluoro- (9CI) (CA INDEX NAME)



09/773,736


RN 245746-77-4 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-dichloro-6-fluoro- (9CI) (CA INDEX NAME)




RN 245746-78-5 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-dichloro-3,5-dinitro- (9CI) (CA INDEX NAME)



RN 245746-79-6 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3,5,6-tetrafluoro- (9CI) (CA INDEX NAME)



RN 245746-80-9 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3,4,5-tetrafluoro- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-81-0 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-bromo-2,3,5,6-tetrafluoro- (9CI) (CA INDEX NAME)




RN 245746-82-1 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methyl-2-nitro- (9CI) (CA INDEX NAME)



RN 245746-83-2 CAPLUS


CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-cyano- (9CI) (CA INDEX NAME)



09/773,736


RN 245746-84-3 CAPLUS

CN 3-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245746-85-4 CAPLUS

CN 5-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245746-86-5 CAPLUS


CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 245746-87-6 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-88-7 CAPLUS

CN 3-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 245746-89-8 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245746-90-1 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 245746-92-3 CAPLUS

CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736

5-nitro- (9CI) (CA INDEX NAME)




RN 245746-93-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-chloro- (9CI) (CA INDEX NAME)




RN 245746-94-5 CAPLUS

CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)



RN 245746-95-6 CAPLUS


CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 245746-96-7 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-chloro- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-97-8 CAPLUS
CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]tetrahydro-5-oxo- (9CI) (CA INDEX NAME)



RN 245746-98-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-oxo- (9CI) (CA INDEX NAME)




RN 245746-99-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)




RN 245747-00-6 CAPLUS
CN 3-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-nitro- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-02-8 CAPLUS
CN 3-Thiazolidinecarboxylic acid, 4-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 245747-03-9 CAPLUS
CN 3-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methoxy- (9CI) (CA INDEX NAME)




RN 245747-07-3 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4,5-dibromo- (9CI) (CA INDEX NAME)



RN 245747-08-4 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-


09/773,736

yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 245747-09-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 245747-10-8 CAPLUS

CN 4-Isioxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 245747-11-9 CAPLUS


CN 3-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-chloro-4-methoxy- (9CI) (CA INDEX NAME)




RN 245747-12-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5,6-dichloro- (9CI) (CA INDEX NAME)


09/773,736



RN 245747-13-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-dichloro- (9CI) (CA INDEX NAME)




RN 245747-14-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dichloro- (9CI) (CA INDEX NAME)




RN 245747-15-3 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]-4-chloro- (9CI) (CA INDEX NAME)

09/773,736




RN 245747-16-4 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-2-fluorophenyl]-2,4-difluoro- (9CI) (CA INDEX NAME)



RN 245747-18-6 CAPLUS


CN Benzoic acid, 2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-5-[(5-bromo-2-chlorobenzoyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 245747-19-7 CAPLUS

CN 4-Isioxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-20-0 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 245747-21-1 CAPLUS
CN 4-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3-chlorophenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 245747-22-2 CAPLUS
CN 4-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-2-(trifluoromethyl)phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



09/773,736


RN 245747-23-3 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-2-methylphenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 245747-24-4 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-2-methoxyphenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 245747-25-5 CAPLUS


CN Benzamide, 4-chloro-N-[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-26-6 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, 4-methyl-N-[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-27-7 CAPLUS
CN 4-Isoxazolecarboxamide, 3,5-dimethyl-N-[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-28-8 CAPLUS
CN Benzamide, 4-chloro-N-[4-(5-methyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 245747-29-9 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, 4-methyl-N-[4-(5-methyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 245747-30-2 CAPLUS
CN 4-Isoxazolecarboxamide, 3,5-dimethyl-N-[4-(5-methyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-31-3 CAPLUS
CN 4-Isoxazolecarboxamide, 3,5-dimethyl-N-[4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-32-4 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[5-hydroxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 245747-34-6 CAPLUS
CN 4-Pyridinecarboxamide, 3-amino-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-35-7 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro-5-methoxy- (9CI) (CA INDEX NAME)

09/773,736




RN 245747-37-9 CAPLUS

CN Benzoic acid, 2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-5-[(2-fluorobenzoyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 245747-38-0 CAPLUS

CN Benzamide, 4-(aminomethyl)-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 245747-39-1 CAPLUS

CN 2-Propenamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



09/773,736


RN 245747-40-4 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro-
2-fluoro- (9CI) (CA INDEX NAME)



IT 245747-42-6P 245747-43-7P 245747-44-8P
245747-46-0P 245747-47-1P 245747-48-2P
245747-49-3P 245747-50-6P 245747-51-7P
245747-53-9P 245747-56-2P 245747-57-3P
245747-58-4P 245747-59-5P 245747-60-8P
245747-61-9P 245747-63-1P 245747-64-2P
245747-65-3P 245747-66-4P 245747-67-5P
245747-68-6P 245747-69-7P 245747-70-0P
245747-71-1P 245747-72-2P 245747-76-6P
245747-77-7P 245747-79-9P 245747-89-1P
245747-91-5P 245747-92-6P 245747-93-7P
245747-94-8P 245747-95-9P 245747-96-0P
245747-97-1P 245749-06-8P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of azole inhibitors of cytokine prodn.)

RN 245747-42-6 CAPLUS
CN Benzamide, N-[3-amino-4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
2-fluoro- (9CI) (CA INDEX NAME)




RN 245747-43-7 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3-cyanophenyl]-
2-fluoro- (9CI) (CA INDEX NAME)

09/773,736




RN 245747-44-8 CAPLUS

CN Benzamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 245747-46-0 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 245747-47-1 CAPLUS


CN 4-Pyridinecarboxamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-48-2 CAPLUS


CN 4-Pyridinecarboxamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)

09/773,736




RN 245747-49-3 CAPLUS

CN Benzamide, N-[4-[5-acetyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 245747-50-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 245747-51-7 CAPLUS

CN Benzamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3,5-trifluoro- (9CI) (CA INDEX NAME)




RN 245747-53-9 CAPLUS

CN Benzamide, 2-fluoro-N-[4-[5-(methylthio)-3-(trifluoromethyl)-1H-pyrazol-1-


09/773,736

yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-56-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-57-3 CAPLUS

CN Benzamide, 2-fluoro-N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-58-4 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 245747-59-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-acetyl-3-(trifluoromethyl)-1H-pyrazol-1-


09/773,736

yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 245747-60-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-fluoro-N-[4-[5-(methylthio)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-61-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-fluoro-N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-63-1 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-[5-ethoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



09/773,736


RN 245747-64-2 CAPLUS

CN 4-Pyridinecarboxamide, 3-fluoro-N-[4-[5-(methylthio)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-65-3 CAPLUS

CN 4-Pyridinecarboxamide, 3-fluoro-N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-66-4 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-67-5 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




09/773,736


RN 245747-68-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 245747-69-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 245747-70-0 CAPLUS
CN Benzamide, 2-fluoro-N-[4-[5-nitro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-71-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-72-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 245747-76-6 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 245747-77-7 CAPLUS
CN 4-Pyridinecarboxamide, 3-fluoro-N-[4-[5-nitro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-79-9 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[5-bromo-3-(trifluoromethyl)-1H-


09/773,736

pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 245747-89-1 CAPLUS

CN 4-Pyridinecarboxamide, 3-chloro-N-[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-91-5 CAPLUS

CN Benzamide, N-[4-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3-difluoro- (9CI) (CA INDEX NAME)



RN 245747-92-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 245747-93-7 CAPLUS

CN Benzamide, 2-chloro-N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-


09/773,736

yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-94-8 CAPLUS

CN 4-Pyridinecarboxamide, 3-chloro-N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-95-9 CAPLUS

CN Benzamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 245747-96-0 CAPLUS


CN Benzamide, 2-chloro-N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



09/773,736

RN 245747-97-1 CAPLUS


CN Benzamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3-difluoro- (9CI) (CA INDEX NAME)



RN 245749-06-8 CAPLUS

CN Carbamic acid, [(1R)-1-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 258518-62-6 374814-46-7 374814-48-9

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of azole inhibitors of cytokine prodn.)

RN 258518-62-6 CAPLUS


CN Benzoic acid, 2-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 374814-46-7 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-4-nitro- (9CI) (CA INDEX NAME)


09/773,736



RN 374814-48-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy-3-nitro- (9CI) (CA INDEX NAME)




IT 245748-04-3P 245748-09-8P 245748-43-0P
374814-24-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azole inhibitors of cytokine prodn.)
RN 245748-04-3 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 245748-09-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-4-cyano- (9CI) (CA INDEX NAME)

09/773,736




RN 245748-43-0 CAPLUS

CN Carbamic acid, [1-[4-[(2-fluorobenzoyl)amino]phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 374814-24-1 CAPLUS

CN Carbamic acid, [1-[4-[(4-pyridinylcarbonyl)amino]phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



FAN.CNT 1					
	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001279123	A2	20011010	JP 2000-91621	20000329
OS	MARPAT 135:290296				

IT **365245-24-5**
 RL: PRP (Properties); TEM (Technical or engineered material use); USES
 (Uses)
 (oil-sol. azomethine dyes for water-thinned ink-jet inks with good
 light and water resistance)

CCCCCCCCCCCCCS(=O)(=O)Nc1ccc(cc1)N2C(=N3C(=CN(C3)C#N)C2=C)C(=N4C(=CC(=CC4)C)N(C)CCNCCS(=O)(=O)C

09/773,736

L31 ANSWER 18 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2001:730683 CAPLUS
DN 135:288572
TI Preparation of diphenyl ether compounds as serotonin re-uptake inhibitors
IN Andrews, Mark David; Hepworth, David; Middleton, Donald Stuart; Stobie, Alan
PA Pfizer Limited, UK; Pfizer Inc.
SO PCT Int. Appl., 158 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001072687	A1	20011004	WO 2001-IB428	20010319
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 2002052395	A1	20020502	US 2001-810378	20010316
	US 6448293	B2	20020910		
PRAI	GB 2000-7884	A	20000331		
	US 2000-197127P	P	20000414		

OS MARPAT 135:288572


AB Title compds. I [wherein R₁ and R₂ = independently H or (cycloalkyl)alkyl; or R₁ and R₂ together with the N to which they are attached form an azetidine ring; R₃ = independently CF₃, OCF₃, alkylthio, or alkoxy; n = 1-3; R₄ and R₅ = independently AX; A = CH:CH or (CH₂)_p; p = 0-2; X = H, halo, OH, alkoxy, NO₂, CN, CHO, alkylthio, alkylsulfinyl, alkylsulfonyl, or (un)substituted carbamoyl, sulfamoyl, amino, carboxy, etc.; or pharmaceutically acceptable salts, solvates, or polymorphs thereof] were prepd. as monoamine re-uptake inhibitors, particularly as selective serotonin re-uptake inhibitors. For example, 4-(methylmercapto)phenol was coupled with 2-fluorobenzaldehyde using K₂CO₃ in DMF to give 2-[4-(methylsulfanyl)phenoxy]benzaldehyde (100%). The aldehyde was dissolved in THF, DCM, Me₂NH.bul.HCl, and TEA, treated with NaBH(OAc)₃, and converted to the salt with 1M HCl in Et₂O to afford N,N-dimethyl-N-[2-[4-(methylsulfanyl)phenoxy]benzyl]amine.bul.HCl (84%). Coupling the salt with ClSO₃H in CH₂Cl₂ at 0.degree. to 5.degree.C, followed by stepwise addn. of MeCN with POCl₃ and ammonia, produced the desired sulfonamide (II) in 61% yield. The latter showed serotonin re-uptake inhibition (SRI) activity with IC₅₀ .ltoreq. 50 nM and was > 100-fold as potent in the inhibition of serotonin re-uptake than in the inhibition of dopamine and noradrenaline re-uptake. I are useful in the treatment of disorders such as depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder, substance abuse disorders, and sexual dysfunction, including premature ejaculation (no data).

IT **364323-63-7P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)

09/773,736


RN 364323-63-7 CAPLUS
CN Formamide, N-[[5-(3-amino-1H-pyrazol-1-yl)-2-[4-(methylthio)phenoxy]phenyl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



IT **364323-46-6P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)
RN 364323-46-6 CAPLUS
CN 1H-Pyrazol-3-amine, 1-[3-[(methylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



IT **364323-47-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of di-Ph ether compds. as serotonin re-uptake inhibitors)
RN 364323-47-7 CAPLUS
CN 1H-Pyrazol-3-amine, 1-[3-[(dimethylamino)methyl]-4-[4-(methylthio)phenoxy]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 19 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2001:713292 CAPLUS
DN 135:272754
TI Preparation of insecticidal anthranilamides
IN Lahm, George P.; Myers, Brian J.; Selby, Thomas P.; Stevenson, Thomas M.
PA E.I. Du Pont de Nemours and Company, USA
SO PCT Int. Appl., 211 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

Not publ

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001070671	A2	20010927	WO 2001-US9338	20010320
	WO 2001070671	A3	20020214		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

Compds are
good hits

PRAI US 2000-191242P P 20000322
US 2000-220232P P 20000724
US 2000-254635P P 20001211
US 2001-262015P P 20010117

Not
No
Good

OS MARPAT 135:272754

AB The title compds. [I; A, B = O, S; J = substituted Ph, naphthyl,
(un)substituted 5-6 membered heteroarom., arom. 8-10 membered fused
heterobicyclic ring; n = 1-4; R1 = H, alkyl, alkenyl, etc.; R2 = H, alkyl,
alkoxy, etc.; R3 = H, alkyl, cycloalkyl, etc.; R4 = H, alkyl, halo, etc.],
useful for controlling arthropods, were prepd. E.g., a multi-step
synthesis of II which showed excellent level of plant protection (10% or
less feeding damage) in test with diamondback moth (DBM), was given.


IT 362635-34-5P 362635-36-7P 362635-37-8P
362635-39-0P 362635-42-5P 362635-43-6P
362635-45-8P 362635-46-9P 362635-49-2P
362635-51-6P 362635-52-7P 362635-54-9P
362635-60-7P 362635-61-8P 362635-72-1P
362635-73-2P 362635-92-5P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except
adverse); BSU (Biological study, unclassified); SPN (Synthetic
preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of insecticidal anthranilamides)

RN 362635-34-5 CAPLUS


CN Benzamide, 3-methyl-N-(1-methylethyl)-2-[[4-(trifluoromethyl)-2-[3-
(trifluoromethyl)-1H-pyrazol-1-yl]benzoyl]amino]- (9CI) (CA INDEX NAME)

09/773,736




RN 362635-36-7 CAPLUS

CN Benzamide, 2-[[2-(3-bromo-1H-pyrazol-1-yl)-4-(trifluoromethyl)benzoyl]amino]-3-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 362635-37-8 CAPLUS


CN Benzamide, 2-[[2-(3-cyano-1H-pyrazol-1-yl)-4-(trifluoromethyl)benzoyl]amino]-3-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 362635-39-0 CAPLUS

CN Benzamide, 3-methyl-N-(1-methylethyl)-2-[[2-(3-methyl-1H-pyrazol-1-yl)-4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)


09/773,736



RN 362635-42-5 CAPLUS
CN Benzamide, 3-methyl-N-(1-methylethyl)-2-[[2-(1H-pyrazol-1-yl)-4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 362635-43-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[2-[[[2-methyl-6-[(1-methylethyl)amino]carbonyl]phenyl]amino]carbonyl]-5-(trifluoromethyl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 362635-45-8 CAPLUS
CN Benzamide, 3-methyl-N-(1-methylethyl)-2-[[2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)


09/773,736



RN 362635-46-9 CAPLUS
CN Benzamide, 2-[[2-(3,5-dimethyl-1H-pyrazol-1-yl)-4-(trifluoromethyl)benzoyl]amino]-3-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 362635-49-2 CAPLUS
CN Benzamide, 3-chloro-N-(1-methylethyl)-2-[[4-(trifluoromethyl)-2-[3-(trifluoromethyl)-1H-pyrazol-1-yl]benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 362635-51-6 CAPLUS
CN Benzamide, 2-[[2-(3-bromo-1H-pyrazol-1-yl)-4-(trifluoromethyl)benzoyl]amino]-3-chloro-N-(1-methylethyl)- (9CI) (CA INDEX NAME)


09/773,736



RN 362635-52-7 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[2-[[[2-chloro-6-[[1-methylethyl]amino]carbonyl]phenyl]amino]carbonyl]-5-(trifluoromethyl)phenyl]-5-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 362635-54-9 CAPLUS
CN Benzamide, 3-chloro-2-[[2-(3-cyano-1H-pyrazol-1-yl)-4-(trifluoromethyl)benzoyl]amino]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 362635-60-7 CAPLUS
CN Benzamide, 2-[[2-[3-(1,1-dimethylethyl)-1H-pyrazol-1-yl]-4-(trifluoromethyl)benzoyl]amino]-3-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)


09/773,736



RN 362635-61-8 CAPLUS
CN Benzamide, 3-methyl-N-(1-methylethyl)-2-[[2-[3-(1-methylpropyl)-1H-pyrazol-1-yl]-4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 362635-72-1 CAPLUS
CN Benzamide, 3-chloro-N-(1-methylethyl)-2-[[2-(4-methyl-1H-pyrazol-1-yl)-4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)




RN 362635-73-2 CAPLUS
CN Benzamide, 3-methyl-N-(1-methylethyl)-2-[[2-(4-methyl-1H-pyrazol-1-yl)-4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)

09/773,736



RN 362635-92-5 CAPLUS

CN Benzamide, 3-chloro-N-(1-methylethyl)-2-[[2-(1H-pyrazol-1-yl)-4-(trifluoromethyl)benzoyl]amino]- (9CI) (CA INDEX NAME)



L31 ANSWER 20 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:676565 CAPLUS
 DN 135:247001
 TI Oxidation dyeing composition for keratinous fibers and dyeing method using same
 IN Lang, Gerard
 PA L'Oreal, Fr.
 SO PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001066072	A1	20010913	WO 2001-FR663	20010306
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2805738	A1	20010907	FR 2000-2858	20000306
EP 1181004	A1	20020227	EP 2001-913934	20010306
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2001005561	A	20020319	BR 2001-5561	20010306
PRAI FR 2000-2858	A	20000306		
WO 2001-FR663	W	20010306		

OS MARPAT 135:247001

AB The invention concerns a ready-to-use oxidn. dyeing compn. for keratinous fibers, and in particular human keratinous fibers such as hair comprising, in a suitable dyeing medium, at least an oxidn. base selected among certain substituted paraphenylenediamine derivs. and their addn. salts with an acid, at least a second selected oxidn. base, and the dyeing method using said compn. A hair dye compn. contained 1-(4'-amino-3'-methylphenyl)-4-hydroxy-2-methyl-pyrrolidine dihydrochloride 2x10⁻³, 2-methyl-5-aminophenol 3x10⁻³, 4-amino-3-methylphenol 10⁻³ mole, and water q.s. 100 g. Equal amt. of above compn. is mixed with 20 vol. hydrogen peroxide and applied on the hair for 30 min, the hair is then rinsed, washed with a shampoo, rinsed, and dried to obtain a purple red color.

IT **359840-75-8**


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(oxidative hair dye prepn. contg. paraphenylenediamine derivs.)

RN 359840-75-8 CAPLUS

CN 1,2-Butanediol, 4,4'-[[4-amino-3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]imino]bis- (9CI) (CA INDEX NAME)

09/773,736



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 21 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:676564 CAPLUS
 DN 135:247000
 TI Oxidation dyeing composition for keratinous fibers comprising
 paraphenylenediamine derivatives and coupling agents
 IN Lang, Gerard
 PA L'Oreal, Fr.
 SO PCT Int. Appl., 56 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001066071	A1	20010913	WO 2001-FR660	20010306
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2805737	A1	20010907	FR 2000-2857	20000306
EP 1181005	A1	20020227	EP 2001-915449	20010306
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2001005562	A	20020319	BR 2001-5562	20010306
PRAI FR 2000-2857	A	20000306		
WO 2001-FR660	W	20010306		

OS MARPAT 135:247000

AB The invention concerns a ready-to-use oxidn. dyeing compn. for keratinous fibers, and in particular human keratinous fibers such as hair comprising, in a suitable dyeing medium, at least an oxidn. base selected among certain substituted paraphenylenediamine derivs. and their addn. salts with an acid, at least a selected coupling agent, and the dyeing method using said compn. A hair dye compn. contained 1-(4'-amino-3'-methylphenyl)-4-hydroxy-2-methyl-pyrrolidine dihydrochloride 3x10⁻³, 2,4-diamino-1-(.beta.-hydroxyethyloxy)benzene 3x10⁻³, excipients and water q.s. 100 g. Equal amt. of above compn. is mixed with 20 vol. hydrogen peroxide and applied on the hair for 30 min, the hair is then rinsed, washed with a shampoo, rinsed, and dried to obtain a blue color.

IT 359840-75-8


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(oxidn. dyeing compn. for keratinous fibers comprising paraphenylenediamine derivs. and coupling agents)

RN 359840-75-8 CAPLUS

CN 1,2-Butanediol, 4,4'-[[4-amino-3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]imino]bis- (9CI) (CA INDEX NAME)

09/773,736



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 22 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2001:676563 CAPLUS
DN 135:246999
TI Oxidation dyeing composition for keratinous fibers containing
paraphenylenediamine derivatives and oxidants
IN Lang, Gerard
PA L'Oreal, Fr.
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001066070	A1	20010913	WO 2001-FR646	20010305
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	FR 2805739	A1	20010907	FR 2000-2860	20000306
PRAI	FR 2000-2860	A	20000306		

OS MARPAT 135:246999

AB The invention concerns a ready-to-use oxidn. dyeing compn. for keratinous fibers, and in particular human keratinous fibers such as hair comprising, in a suitable dyeing medium, at least an oxidn. base selected among certain substituted paraphenylenediamine derivs. and their addn. salts with an acid, at least an alk. agent and hydrogen peroxide, and the dyeing method using said compn. A hair dye compn. contained 1-(4'-amino-3'-methylphenyl)-4-hydroxy-2-methyl-pyrrolidine dihydrochloride 0.837, 2,4-diamino-1-(.beta.-hydroxyethoxy)-benzene 0.723, Oramix DG110 3.24, ethanol 18, polyethylene glycol-400 2.7, Dissoluine D40 0.43, sodium metabisulfite 0.205, 20.5% ammonia 10, and water q.s. 100 g. Equal amt. of above compn. is mixed with 20 vol. hydrogen peroxide and applied on the hair for 30 min, the hair is then rinsed, washed with a shampoo, rinsed, and dried to obtain a blue color.

IT. **359840-75-8**


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(oxidn. dyeing compn. for keratinous fibers contg. paraphenylenediamine derivs. and oxidants)

RN 359840-75-8 CAPLUS

CN 1,2-Butanediol, 4,4'-[[4-amino-3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]imino]bis- (9CI) (CA INDEX NAME)

09/773,736



RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 23 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:676562 CAPLUS
 DN 135:246998
 TI Oxidation dyeing composition for keratinous fibers comprising substituted
 paraphenylenediamine derivatives and polymers
 IN Lang, Gerard
 PA L'Oreal, Fr.
 SO PCT Int. Appl., 71 pp.
 CODEN: PIXXD2
 DT Patent
 LA French
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066069	A1	20010913	WO 2001-FR645	20010305
W:	AE, AG, AL, AM, AT, AU, AZ,		BA, BB, BG, BR, BY, BZ, CA, CH, CN,	
	CO, CR, CU, CZ, DE, DK, DM,		DZ, EE, ES, FI, GB, GD, GE, GH, GM,	
	HR, HU, ID, IL, IN, IS, JP,		KE, KG, KP, KR, KZ, LC, LK, LR, LS,	
	LT, LU, LV, MA, MD, MG, MK,		MN, MW, MX, MZ, NO, NZ, PL, PT, RO,	
	RU, SD, SE, SG, SI, SK, SL,		TJ, TM, TR, TT, TZ, UA, UG, US, UZ,	
	VN, YU, ZA, ZW, AM, AZ, BY,		KG, KZ, MD, RU, TJ, TM	
RW:	GH, GM, KE, LS, MW, MZ, SD,		SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,	
	DE, DK, ES, FI, FR, GB, GR,		IE, IT, LU, MC, NL, PT, SE, TR, BF,	
	BJ, CF, CG, CI, CM, GA, GN,		GW, ML, MR, NE, SN, TD, TG	
FR 2805740	A1	20010907	FR 2000-2861	20000306
PRAI FR 2000-2861	A	20000306		

OS MARPAT 135:246998

AB The invention concerns an oxidn. dyeing compn. for keratinous fibers, and in particular human keratinous fibers such as hair comprising, in a suitable dyeing medium, at least an oxidn. base selected among certain substituted paraphenylenediamine derivs. and their addn. salts with an acid, at least a polymer selected among amphoteric polymers, cationic polymers with specific repeat structural units, or amphiphilic polymers comprising at least a fatty chain, and the dyeing method using said compn. A hair dye compn. contained 1-(4'-amino-3'-methylphenyl)-4-hydroxy-2-methyl-pyrrolidine dihydrochloride 0.837, 2,4-diamino-1-(.beta.-hydroxyethyloxy)-benzene 0.723, Miranol A15 1, and water and excipients q.s. 100 g. Equal amt. of the compn. is mixed with 20 vol. hydrogen peroxide and applied on the hair for 30 min, the hair is then rinsed, washed with a shampoo, and rinsed with water and dried to obtain a blue color.

IT **359840-75-8**


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(oxidative hair dyes comprising substituted paraphenylenediamine derivs. and polymers)

RN 359840-75-8 CAPLUS

CN 1,2-Butanediol, 4,4'-[[4-amino-3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]imino]bis- (9CI) (CA INDEX NAME)

09/773,736



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 24 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2001:676561 CAPLUS
DN 135:246997
TI Oxidation dyeing composition for keratinous fibers with a particular
paraphenylenediamine derivative and a particular direct dyeing agent
IN Lang, Gerard
PA L'Oreal, Fr.
SO PCT Int. Appl., 49 pp.
CODEN: PIXXD2
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066068	A1	20010913	WO 2001-FR644	20010305
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2805741	A1	20010907	FR 2000-2862	20000306
PRAI FR 2000-2862	A	20000306		

OS MARPAT 135:246997

AB The invention concerns an oxidn. dyeing compn. for keratinous fibers, and in particular human keratinous fibers such as hair comprising, in a medium suitable for dyeing, at least an oxidn. base selected among certain substituted paraphenylenediamine derivs. and their addn. salts with an acid, and at least a synthetic direct dyeing agent selected among the azo, quinoid, triarylmethane, indoamino, azine dyes and/ or a natural dye. The invention also concerns a dyeing method using said compn. A hair dye compn. contained 1-(4'-amino-3'-methylphenyl)-4-hydroxy-2-methyl-pyrrolidine dihydrochloride 0.837, 2,4-diamino-1-(.beta.-hydroxyethyloxy)-benzene 0.723, Miranol A15 1, and water and excipients q.s. 100 g. Equal amt. of above compn. is mixed with 20 vol. hydrogen peroxide and applied on the hair for 30 min, the hair is then rinsed, washed with a shampoo, rinsed and dried to obtain a blue color.

IT **359840-75-8**


RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(oxidative hair dyes contg. paraphenylenediamine derivs. direct dyes)

RN 359840-75-8 CAPLUS

CN 1,2-Butanediol, 4,4'-[[4-amino-3-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]imino]bis- (9CI) (CA INDEX NAME)

09/773,736



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 25 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 2001:663733 CAPLUS

DN 135:228324

TI Dispersions of color fine granules and jet printing inks and jet printing methods

IN Yamanouchi, Junichi; Fujiwara, Yoshinori; Ishizuka, Takahiro; Sano, Kazue

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 23 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001247787	A2	20010911	JP 2000-62369	20000307
OS	MARPAT 135:228324				


AB Inks contain .gtoreq.1 polymer selected from polyurethanes, polyesters, polyamides, polyureas, and polycarbonates having 0.01-3.0 mmols/g disson. groups (carboxy and/or sulfonic acid groups) and oil-sol. azo dyes. Thus, an aq. dispersion contained 2,2-bis(hydroxymethyl)propionic acid-4,4'-diphenylmethane diisocyanate-ethylene glycol-hexamethylene diisocyanate-tetraethylene glycol copolymer Na salt, I, and solvents.

IT 359714-17-3

RL: TEM (Technical or engineered material use); USES (Uses)
(dispersions of color fine granules and jet printing inks and jet printing methods)

RN 359714-17-3 CAPLUS

CN Propanamide, N-[3-chloro-5-[[4-cyano-1-{2,6-dichloro-4-[[1-ethylpentyl)amino]sulfonyl]phenyl]-1H-pyrazol-5-yl]azo]-2-hydroxyphenyl]-2-methyl- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 26 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2001:481961 CAPLUS
DN 135:78350
TI Colored fine particle dispersions, their ink-jet inks and printing method therewith
IN Ishizuka, Takahiro; Fujiwara, Yoshinori; Yamada, Masato; Sano, Kazue
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 27 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2001181548	A2	20010703	JP 1999-365189	19991222
OS	MARPAT 135:78350				


AB Title aq. dispersions contain colored particles consisting of oil-sol. polymers and oil-sol. dyes I [R1-R4 = H, halogen, (cyclo)alkyl, aralkyl, aryl, heterocyclo(oxy) group, CN, OH, NO2, NH2, alkylamino, alkoxy, aryloxy, amido, arylamino, ureido, sulfamoyl(amino), alkylthio, arylthio, alkoxycarbonyl(amino), sulfonamido, carbamoyl, sulfonyl, azo, acyl(oxy), carbamoyloxy, silyloxy, aryloxycarbonyl(amino), imido, heterocyclothio, sulfinyl, phosphoryl, carboxyl, sulfo, or R3-R4 formed into heterocyclo or arom. group; R5 = heterocyclo group; M = H, ionized inorg. salt, or amine]. An aq. dispersion contg. alcs., NaOH soln., acrylic acid-Bu methacrylate-1H,1H,2H,2H-perfluorodecyl acrylate copolymer, and II was used to prep. an aq. ink, which gave sharp prints on various paper and showed good light and water resistance.

IT **347367-79-7**

RL: TEM (Technical or engineered material use); USES (Uses)
(aq. dispersion of azo dyes for ink-jet inks with light and water resistance)

RN 347367-79-7 CAPLUS

CN Propanamide, N-[5-[[4-cyano-1-[2,5-dichloro-4-[[[1-(ethylpentyl)amino]sulfonyl]phenyl]-1H-pyrazol-5-yl]azo]-2-hydroxy-3-methylphenyl]-2-methyl- (9CI) (CA INDEX NAME)




09/773,736

Date No Good.

L31 ANSWER 27 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:472697 CAPLUS
 DN 135:61329
 TI Preparation of pyrazoles as cAMP-specific phosphodiesterase inhibitors for pharmaceutical use as anti-inflammatory agents
 IN Martins, Timothy J.; Fowler, Kerry W.; Hertel, Carmen C.; Oliver, Amy
 PA Icos Corp., USA
 SO PCT Int. Appl., 123 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001046172	A1	20010628	WO 2000-US41435	20001023
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRAI US 1999-172067P	P	19991223		
OS MARPAT 135:61329				
AB Pyrazoles, such as I [Y = O, NOH; Z = O, NH; R1 = alkyl, cycloalkyl, aryl, heteroaryl, etc.; R2 = H, Me, alkyl, aryl, heteroaryl, etc.; R3, R4 = H, alkyl, haloalkyl, aryl], were prepd. as potent and selective inhibitors of PDE4 for use in the treatment of inflammatory diseases and other diseases involving elevated levels of cytokines, as well as central nervous system (CNS) disorders. Thus, pyrazole II (R1 = C6H4-4-Br) was prepd. by cyclocondensation of (4-bromophenyl)hydrazine hydrochloride with (MeCO)2CHCO2Et in pyridine and ethanol. The prepd. pyrazoles were tested for PDE4 and TNF.alpha. inhibiting activity.				
IT 257863-09-5 257863-14-2				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (prepn. of pyrazoles as cAMP-specific phosphodiesterase inhibitors for pharmaceutical use as anti-inflammatory agents)				
RN 257863-09-5 CAPLUS				
CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[(2,2-dimethyl-1-oxopropyl)amino]phenyl]-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)				



09/773,736

RN 257863-14-2 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[[4-methoxyphenyl)sulfonyl]amino]phenyl]-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 28 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2001:396661 CAPLUS
DN 135:19547
TI Preparation of sulfonamides and sulfinamides as NPY Y5 antagonists
IN Kawanishi, Yasuyuki; Takenaka, Hideyuki; Hanasaki, Kohji; Okada, Tetsuo
PA Shionogi + Co., Ltd., Japan
SO PCT Int. Appl., 273 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001037826	A1	20010531	WO 2000-JP8197	20001121
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
PRAI	JP 1999-336469	A	19991126		
	JP 1999-353786	A	19991214		

OS MARPAT 135:19547

AB The title compds. R1S(O)nN(R2)XYZ [R1 represents lower alkyl, cycloalkyl, etc.; R2 represents hydrogen, lower alkyl, etc.; n is 1 or 2; X represents lower alkylene, lower alkenylene, arylene, cycloalkylene, etc.; Y represents CONR7, CSNR7, NR7CO, NR7CS, etc. (wherein R7 represents hydrogen or lower alkyl); and Z represents lower alkyl, an optionally substituted hydrocarbon ring, an optionally substituted heterocycle, etc.] are prepd. In an in vitro test for affinity for the neuropeptide Y5 receptors, the title compd. I showed the IC50 value of 0.4 nM. Formulations are given.


IT **342574-52-1P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sulfonamides and sulfinamides as NPY Y5 antagonists)

RN 342574-52-1 CAPLUS

CN Cyclohexanecarboxamide, 4-[[[(1,1-dimethylethyl)sulfonyl]amino]-N-[4-(1H-pyrazol-1-yl)phenyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




09/773,736

L31 ANSWER 29 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2001:300687 CAPLUS
DN 134:311206
TI Preparation of 1,3,5-trisubstituted pyrazoles for pharmaceutical use as
factor Xa inhibitors
IN Zhou, Jiacheng; Oh, Lynette May; Confalone, Pasquale N.; Li, Hui-yin; Ma,
Philip
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 103 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001029006	A1	20010426	WO 2000-US29031	20001020
	W:	AU, BR, CA, CN, CZ, EE, HU, IL, IN, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, TR, UA, VN, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
	US 6329527	B1	20011211	US 2000-685127	20001010
	EP 1222172	A1	20020717	EP 2000-972292	20001020
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY			
	US 2002055641	A1	20020509	US 2001-5938	20011203
PRAI	US 1999-161666P	P	19991021		
	US 2000-685127	A3	20001010		
	WO 2000-US29031	W	20001020		


OS MARPAT 134:311206
AB 1,3,5-Trisubstituted pyrazoles, such as I [R = Me, NH₂; R₃ = CN, CH₂NH₂; R₄ = H, F], were prepd. for pharmaceutical use as factor Xa inhibitors (no biol. testing data presented). Thus, I (R = Me, R₃ = CN, R₄ = H) was prepd. via cyclization of F₃C CONHNHC₆H₄-3-CN with H₂C:CHCONHC₆H₃(-2-F)-4-C₆H₄-2-SO₂Me and subsequent dehydrogenation of the resulting pyrazoline using N-chlorosuccinimide.
IT **335275-80-4P 335275-89-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1,3,5-trisubstituted pyrazoles for pharmaceutical use as factor Xa inhibitors)
RN 335275-80-4 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 335275-89-3 CAPLUS

09/773,736

CN Carbamic acid, [[3-[5-[[[4-bromo-2-fluorophenyl]amino]carbonyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)




RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 30 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2001:283913 CAPLUS
DN 134:310974
TI Preparation of biaryl ether derivatives as monoamine reuptake inhibitors
IN Howard, Harry Ralph, Jr.; Adam, Mavis Diane
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001027068	A1	20010419	WO 2000-IB1373	20000927
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	BR 2000014733	A	20020611	BR 2000-14733	20000927
	EP 1220831	A1	20020710	EP 2000-960916	20000927
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	US 6410736	B1	20020625	US 2000-692335	20001019
	NO 2002001659	A	20020408	NO 2002-1659	20020408
PRAI	US 1999-159276P	P	19991013		
	US 1999-167761P	P	19991129		
	WO 2000-IB1373	W	20000927		
OS	MARPAT 134:310974				
AB	The title compds. [I; rings A and B can be replaced by naphthyl group; n, m = 1-3; R1, R2 = H, alkyl, alkenyl, etc.; NR1R2 = 4-8 membered satd. (un)substituted ring contg. 1-2 heteroatoms, including N atom to which R1 and R2 are attached; R3, R4 = H, alkyl optionally substituted with 1-3 F atoms; CR3R4 = 4-8 membered satd. (un)substituted carbocyclic ring; NR2CR3 = 4-8 membered satd. (un)substituted ring contg. 1-2 heteroatoms, including N atom to which R2 is attached; X = (un)substituted Ph, heteroaryl, heterocyclyl; Y = H, halo, alkyl optionally substituted with 1-3 F atoms, etc.; Z = H, halo, alkoxy, etc.] and their pharmaceutically acceptable salts which exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders, were prepd. E.g., a 3-step synthesis of I [R1 = Me; R2-R4 = H; X = 5-Ph; Z = H; Y = 3,4-Cl2] was given. All exemplified compds. I showed IC50 of .ltoreq. 250 nM for serotonin reuptake inhibition, and IC50 of .ltoreq. 1000 nM for dopamine and for norepinephrine reuptake inhibition.				
IT	334980-35-7P 334980-54-0P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of biaryl ether derivs. as monoamine reuptake inhibitors)				
RN	334980-35-7 CAPLUS				
CN	1H-Pyrazol-3-amine, 1-[4-(3,4-dichlorophenoxy)-3-[(methylamino)methyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)				


09/773,736



● 2 HCl

RN 334980-54-0 CAPLUS

CN 1H-Pyrazol-3-amine, 1-[4-(3,4-dichlorophenoxy)-3-
[(methylamino)methyl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 31 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:247348 CAPLUS
 DN 134:266520
 TI Preparation of nucleosides as adenosine receptors, antidiabetics, enzyme inhibitors, and for the treatment of ischemia
 IN Masamune, Hiroko; Deninno, Michael Paul; Scott, Robert William
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 194 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001023399	A1	20010405	WO 2000-IB1353	20000922
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW:				
	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1216257	A1	20020626	EP 2000-958949	20000922
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	BR 2000014384	A	20020702	BR 2000-14384	20000922
	NO 2002001474	A	20020522	NO 2002-1474	20020325
PRAI	US 1999-156828P	P	19990930		
	WO 2000-IB1353	W	20000922		

OS MARPAT 134:266520

AB Nucleosides I were prepd. as adenosine receptors, antidiabetics, enzyme inhibitors, and for the treatment of ischemia, wherein X is oxy, methylene or thio; Y is CH or N; Z is H, alkyl, alkyloxy, trifluoromethyl or halo; R1 is hydroxymethyl, alkoxy, cycloalkoxy, carboxy, alkoxy, cycloalkoxy, 1,1-aminoiminomethyl, 1,1-(mono-N- or di-N,N-alkylamino)iminomethyl, 1,1-(mono-N- or di-N,N-cycloalkylamino)iminomethyl, carbamoyl, mono-N- or di-N,N-alkylaminocarbonyl, mono-N- or di-N,N-cycloalkylaminocarbonyl or N-alkyl-N-cycloalkylaminocarbonyl; R2 is H, alkyl or cycloalkyl; R3 is halo, trifluoromethyl, cyano, alkyl, alkyloxy, ethenyl or ethynyl; D is oxy, thio, NH, alkyloxy, alkylthio or alkylamino; G is a partially satd., fully satd. or fully unsatd. five to eight membered ring optionally having one to three heteroatoms selected independently from oxygen, sulfur and nitrogen, or, a bicyclic ring consisting of two fused partially satd., fully satd. or fully unsatd. three to six membered rings, taken independently, optionally having one to four heteroatoms selected independently from nitrogen, sulfur and oxygen; wherein said G is optionally mono, di- or trisubstituted independently with halo, alkyl, trifluoromethyl, trifluoromethoxy, nitro, cyano, cycloalkyl, hydroxy or alkoxy or G is cyano, alkoxy, cycloalkoxy, amide, thioamide, alkylamine, cycloalkylamine. A3 agonists, methods of using such A3 agonists and pharmaceutical compns. contg. such A3 agonists. The A3 agonists are useful for the redn. of tissue damage resulting from tissue ischemia or hypoxia. Thus, [1-(8-bromoquinolin-5-yl)-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine was prepd. for the treatment of ischemia.

IT 241802-10-8P 241802-17-5P


09/773,736

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nucleosides as adenosine receptors antidiabetics enzyme inhibitors and for the treatment of ischemia)


RN 241802-10-8 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-4-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)



RN 241802-17-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-5-[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)




RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 32 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 2001:208248 CAPLUS
 DN 134:252334
 TI Preparation of 1-naphthyl-3-methyl-1H-pyrazole-5-carboxamides as
 inhibitors of factor Xa
 IN Zhu, Bing-Yan; Jia, Zhaozhong Jon; Huang, Wenrong; Song, Yonghong; Kanter,
 James; Scarborough, Robert M.
 PA Cor Therapeutics Inc., USA
 SO PCT Int. Appl., 314 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019798	A2	20010322	WO 2000-US25195	20000915
	WO 2001019798	A3	20011025		
	W:		AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	EP 1216231	A2	20020626	EP 2000-963451	20000915
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL		
	NO 2002001230	A	20020521	NO 2002-1230	20020312
PRAI	US 1999-154332P	P	19990917		
	WO 2000-US25195	W	20000915		
OS	MARPAT 134:252334				
AB	The title compds. AQDEGJX [A = alkyl, cycloalkyl, (un)substituted Ph; Q = a direct link, alkylene, CO, etc.; D = a direct link, (un)phenylene, etc.; E = a direct link, (CH ₂) _q CO, SO ₂ , etc.; q = 0-2; G = (un)substituted Ph, (un)substituted 5-6 membered (non)arom. heterocyclic a ring contg. 1-4 heteroatoms selected from N, O and S; J = a direct link, SO ₂ , CO, etc.; X = (un)substituted Ph, naphthyl, heteroaryl] having activity against mammalian factor Xa, and therefore useful in vitro or in vivo for preventing or treating coagulation disorders, were prepd. E.g., a 3-step synthesis of the pyrazolecarboxamide I was described.				
IT	330803-36-6P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of 1-naphthyl-3-methyl-1H-pyrazole-5-carboxamides as inhibitors of factor Xa)				
RN	330803-36-6 CAPLUS				
CN	1H-Pyrazole-5-carboxamide, N-(5-bromo-2-pyridinyl)-1-[4- [(dimethylamino)iminomethyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)				

09/773,736




IT 330803-89-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of 1-naphthyl-3-methyl-1H-pyrazole-5-carboxamides as inhibitors of factor Xa)

RN 330803-89-9 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[5-[[[(1,1-dimethylethyl)amino]carbonyl]-2-(methylsulfonyl)phenyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 33 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2000:658115 CAPLUS
DN 133:238010
TI Preparation of pyrazole derivatives as blockers of calcium
release-activated calcium channel (CRACC)
IN Kubota, Koichi; Yoshimura, Noriko; Okamoto, Yoshinori; Yonetoku, Yasuhiro;
Naito, Makoto; Ishikawa, Atsushi; Takeuchi, Makoto
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 22 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

(not published)
Common
inventions

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000256358	A2	20000919	JP 1999-62900	19990310
OS	MARPAT 133:238010				

AB The title compds. (I; ring D = pyrazolyl optionally substituted with 1-3 substituents selected from lower alkyl, alkenyl, alkynyl, or haloalkyl, lower alkylene-cycloalkyl, lower alkylene-O-lower alkyl, cycloalkyl, O-lower alkyl, CO₂H, lower alkoxy carbonyl, and halo; ring B = phenylene or optionally lower-substituted bivalent monocyclic arom. heterocyclic ring; X = NR₁CO, CONR₁, NR₁SO₂, SO₂NR₁; wherein R₁ = H, OH, lower alkyl, O-lower alkyl, lower alkyl-carbonyl; Y = bond, CO, lower alkylene, or lower alkenylene; ring A = Ph having at least one substituent selected from HO, O-lower alkyl, and F, or optionally substituent mono-, bi-, or tricyclic condensed heteroaryl; provided that when Y is a bond, ring A represents a group other than heteroaryl selected from thienyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, thiadiazolyl, pyridyl, pyrazinyl, and isoquinolyl) and pharmaceutically acceptable salts thereof are prepd. These compds. exhibit the inhibitory activity against CRACC and the prodn. of interleukin-2 and are useful for the prevention or treatment of allergies, inflammations, and autoimmune diseases. Thus, 2,1,3-benzoxadiazole-5-carbonyl chloride and Et₃N were successively added to a mixt. of 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]aniline and CH₂Cl₂ and stirred at room temp. for 8.5 h to give N-[(2,1,3-benzoxadiazol-5-yl)carbonyl]-4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]aniline. Preferred compds. I inhibited thapsigargin-stimulated increase in calcium concn. with IC₅₀ of .ltoreq.1 .mu.M and the prodn. of interleukin-2 with IC₅₀ of .ltoreq.0.1 .mu.M in Jurkat cell.

IT 245744-67-6P 245744-97-2P 245745-14-6P
245745-36-2P 245745-54-4P 245745-56-6P
245745-62-4P 245745-63-5P 245745-78-2P
245745-97-5P 245745-98-6P 245746-13-8P
245746-29-6P 245746-84-3P 245746-85-4P
245746-90-1P 245746-92-3P 245746-93-4P
245746-94-5P 245746-99-0P 245747-10-8P
245747-13-1P 251656-00-5P 292610-05-0P
292610-06-1P 292610-07-2P 292610-09-4P
292610-10-7P 292610-12-9P 292610-14-1P
292610-16-3P 292610-17-4P 292610-18-5P
292610-21-0P 292610-24-3P 292610-27-6P
292610-28-7P 292610-30-1P 292610-32-3P
292610-33-4P 292610-36-7P 292610-37-8P
292610-39-0P 292610-40-3P 292610-46-9P
292610-52-7P 292610-55-0P 292610-61-8P
292610-62-9P 292610-65-2P 292610-67-4P
292610-74-3P 292610-75-4P 292610-76-5P


09/773,736

292610-77-6P 292610-79-8P 292610-80-1P
292610-83-4P 292610-88-9P 292610-89-0P
292610-90-3P 292610-93-6P 292610-95-8P
292610-96-9P 292611-01-9P 292611-02-0P
292611-03-1P 292611-07-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of pyrazole derivs. as blockers of calcium release-activated calcium channel and inhibitors of interleukin-2 prodn.)


RN 245744-67-6 CAPLUS

CN 3-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
(9CI) (CA INDEX NAME)




RN 245744-97-2 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 245745-14-6 CAPLUS


CN 2-Thiopheneacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245745-36-2 CAPLUS


CN 1H-Pyrazole-4-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl-5-nitro- (9CI) (CA INDEX NAME)

09/773,736




RN 245745-54-4 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 245745-56-6 CAPLUS

CN 5-Thiazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 245745-62-4 CAPLUS


CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-63-5 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-78-2 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245745-97-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 245745-98-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-6-methyl- (9CI) (CA INDEX NAME)



09/773,736


RN 245746-13-8 CAPLUS

CN 1H-Pyrrole-2-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245746-29-6 CAPLUS

CN 4-Isioxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 245746-84-3 CAPLUS

CN 3-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245746-85-4 CAPLUS

CN 5-Isioxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 245746-90-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 245746-92-3 CAPLUS
CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-nitro- (9CI) (CA INDEX NAME)



RN 245746-93-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-chloro- (9CI) (CA INDEX NAME)




RN 245746-94-5 CAPLUS
CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)



RN 245746-99-0 CAPLUS


09/773,736

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)




RN 245747-10-8 CAPLUS

CN 4-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 245747-13-1 CAPLUS


CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-dichloro- (9CI) (CA INDEX NAME)




RN 251656-00-5 CAPLUS

CN 4-Pyridineacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 292610-05-0 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 292610-06-1 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 292610-07-2 CAPLUS
CN 3-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methyl-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




09/773,736


RN 292610-09-4 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 292610-10-7 CAPLUS
CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4,5-dibromo- (9CI) (CA INDEX NAME)




RN 292610-12-9 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1,2-dihydro-2-thioxo- (9CI) (CA INDEX NAME)




RN 292610-14-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(methylthio)- (9CI) (CA INDEX NAME)


09/773,736




RN 292610-16-3 CAPLUS
CN 1,2,3-Thiadiazole-4-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 292610-17-4 CAPLUS
CN 2H-Pyran-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)




RN 292610-18-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



09/773,736


RN 292610-21-0 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro-4-hydroxy- (9CI) (CA INDEX NAME)




RN 292610-24-3 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)




RN 292610-27-6 CAPLUS

CN 2-Thiophenecarboxamide, 5-acetyl-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 292610-28-7 CAPLUS

CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




09/773,736


RN 292610-30-1 CAPLUS
CN 1H-Pyrrole-3-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 292610-32-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1,2-dihydro-2-oxo- (9CI) (CA INDEX NAME)




RN 292610-33-4 CAPLUS
CN 2-Pyridineacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 292610-36-7 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)


09/773,736




RN 292610-37-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-nitro- (9CI) (CA INDEX NAME)



RN 292610-39-0 CAPLUS
CN 3-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 292610-40-3 CAPLUS
CN Pyrazinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 292610-46-9 CAPLUS
CN 3-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-(1,1-dimethylethyl)-2-methyl- (9CI) (CA INDEX NAME)

09/773,736




RN 292610-52-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-hydroxy- (9CI) (CA INDEX NAME)



RN 292610-55-0 CAPLUS


CN 1H-Pyrazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(1,1-dimethylethyl)-1,4-dimethyl- (9CI) (CA INDEX NAME)




RN 292610-61-8 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1,2,3,4-tetrahydro-4-oxo-2-thioxo- (9CI) (CA INDEX NAME)


09/773,736




RN 292610-62-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-hydroxy-4,6-dimethoxy- (9CI) (CA INDEX NAME)



RN 292610-65-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(butylmethylamino)- (9CI) (CA INDEX NAME)




RN 292610-67-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-[[2-(diethylamino)ethyl]ethylamino]- (9CI) (CA INDEX NAME)




09/773,736


RN 292610-74-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(methylthio)- (9CI) (CA INDEX NAME)



RN 292610-75-4 CAPLUS
CN 2-Propenamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 292610-76-5 CAPLUS
CN 2-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-chloro- (9CI) (CA INDEX NAME)




RN 292610-77-6 CAPLUS
CN 2-Furanacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-.alpha.-oxo- (9CI) (CA INDEX NAME)


09/773,736



RN 292610-79-8 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-chloro-2-(methylthio)- (9CI) (CA INDEX NAME)




RN 292610-80-1 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 292610-83-4 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-6-methoxy- (9CI) (CA INDEX NAME)


09/773,736




RN 292610-88-9 CAPLUS
CN 2-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1,6-dihydro-6-oxo- (9CI) (CA INDEX NAME)



RN 292610-89-0 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 292610-90-3 CAPLUS
CN 2-Thiopheneacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-.alpha.-oxo- (9CI) (CA INDEX NAME)



RN 292610-93-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-


09/773,736

yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 292610-95-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-(diethylamino)- (9CI) (CA INDEX NAME)



RN 292610-96-9 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(butylethylamino)- (9CI) (CA INDEX NAME)




RN 292611-01-9 CAPLUS

CN 1H-Pyrazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1,3-dimethyl- (9CI) (CA INDEX NAME)


09/773,736



RN 292611-02-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(diethylamino)- (9CI) (CA INDEX NAME)




RN 292611-03-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-[[2-(diethylamino)ethyl]ethylamino]- (9CI) (CA INDEX NAME)




RN 292611-07-5 CAPLUS
CN 3-Isothiazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4,5-dichloro- (9CI) (CA INDEX NAME)

09/773,736



09/773,736

L31 ANSWER 34 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2000:619239 CAPLUS
DN 133:344173
TI 1-Phenyl-5-pyrazolyl ureas: potent and selective p38 kinase inhibitors
AU Dumas, J.; Hatoum-Mokdad, H.; Sibley, R.; Riedl, B.; Scott, W. J.;
Monahan, M. K.; Lowinger, T. B.; Brennan, C.; Natero, R.; Turner, T.;
Johnson, J. S.; Schoenleber, R.; Bhargava, A.; Wilhelm, S. M.; Housley, T.
J.; Ranges, G. E.; Shrikhande, A.
CS Department of Chemistry Research, Bayer Research Center, West Haven, CT,
06516, USA
SO Bioorganic & Medicinal Chemistry Letters (2000), 10(18), 2051-2054
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science Ltd.
DT Journal
LA English
AB Inhibitors of the MAP kinase p38 are potentially useful for the treatment
of arthritis and osteoporosis. Several 2,3-dichlorophenyl ureas were
identified as small-mol. inhibitors of p38 by a combinatorial chem.
effort. Optimization for cellular potency led to the discovery of a new
class of potent and selective p38 kinase inhibitors, exemplified by the
1-phenyl-5-pyrazolyl urea 7 (IC50=13 nM).
IT **306818-00-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)
(1-Phenyl-5-pyrazolyl ureas: prepn. and inhibition of p38 kinase in
relation to structure)
RN 306818-00-8 CAPLUS
CN Acetamide, N-[3-[5-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]-3-(1,1-
dimethylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 35 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 2000:542317 CAPLUS
 DN 133:120327
 TI Preparation and herbicidal activity of 1-phenylpyrazole derivatives
 IN Ueno, Ryohei; Takabe, Fumiaki; Abe, Tetsuya; Izuki, Yoshinori; Miyazaki, Masahiro; Yamaji, Michihiro; Kawasaki, Hiroshi
 PA Kumiai Chemical Industry Co., Ltd., Japan; Ihara Chemical Industry Co., Ltd.
 SO Jpn. Kokai Tokkyo Koho, 90 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000219679	A2	20000808	JP 1999-172169	19990618
PRAI	JP 1998-189617	A	19980622		
OS	MARPAT 133:120327				


AB Title compds. I (Q = substituted Ph, benzofuranyl, benzoxazinyl, etc.; R1 = H, haloalkyl; R2 = OH, haloalkoxy; R3 = cyano, aminocarbonyl, etc.), useful as herbicides, are prepd. Thus, reaction of Me 2-[N-(4-chloro-2-fluorophenyl)-N-cyanomethylhydrazono]propionate with t-BuOK in MeOH at room temp. for 3 h gave, after treatment with aq. HCl, 86% 1-(4-chloro-2-fluorophenyl)-4-hydroxy-3-methylpyrazole-5-carbonitrile. I (R1 = H, R2 = F2CHO, R3 = cyano, Q = 2-fluoro-4-chloro-5-cyclopentyloxy) showed herbicidal activity at 10 g/are.

IT **285989-95-9P 285990-82-1P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prepn. and herbicidal activity of 1-phenylpyrazole derivs.)

RN 285989-95-9 CAPLUS


CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 285990-82-1 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-3-(hydroxymethyl)-4-(trifluoromethyl)-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)

09/773,736




IT 285989-69-7P 285989-70-0P 285989-86-8P
285989-87-9P 285989-88-0P 285989-89-1P
285989-90-4P 285989-91-5P 285989-92-6P
285989-93-7P 285989-94-8P 285989-96-0P
285989-97-1P 285990-00-3P 285990-02-5P
285990-03-6P 285990-04-7P 285990-10-5P
285990-11-6P 285990-15-0P 285990-16-1P
285990-27-4P 285990-28-5P 285990-33-2P
285990-34-3P 285990-39-8P 285990-48-9P
285990-49-0P 285990-54-7P 285990-57-0P
285990-58-1P 285990-61-6P 285990-62-7P
285990-67-2P 285990-68-3P 285990-73-0P
285990-74-1P 285990-76-3P 285990-77-4P
285990-78-5P 285990-80-9P 285990-81-0P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. and herbicidal activity of 1-phenylpyrazole derivs.)

RN 285989-69-7 CAPLUS


CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 285989-70-0 CAPLUS


CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-1H-pyrazol-1-yl]-4-fluorophenyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

09/773,736




RN 285989-86-8 CAPLUS

CN Acetamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 285989-87-9 CAPLUS


CN Acetamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)




RN 285989-88-0 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)


09/773,736



RN 285989-89-1 CAPLUS
CN Ethanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 285989-90-4 CAPLUS
CN Methanesulfonamide, 1-chloro-N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 285989-91-5 CAPLUS
CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]-1,1-difluoro- (9CI) (CA INDEX NAME)

09/773,736




RN 285989-92-6 CAPLUS

CN Benzenesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 285989-93-7 CAPLUS


CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 285989-94-8 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]-N-ethyl-1,1,1-trifluoro- (9CI) (CA INDEX NAME)


09/773,736



RN 285989-96-0 CAPLUS
CN Ethanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]-N-(ethylsulfonyl)- (9CI) (CA INDEX NAME)




RN 285989-97-1 CAPLUS
CN Methanesulfonamide, 1-chloro-N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]-N-[(chloromethyl)sulfonyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 285990-00-3 CAPLUS
CN Methanesulfonamide, N-[2-cyano-5-[5-cyano-4-(difluoromethoxy)-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 285990-02-5 CAPLUS
CN Methanesulfonamide, N-[2-cyano-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 285990-03-6 CAPLUS
CN 1H-Pyrazole-5-carbonitrile, 1-[4-cyano-2-fluoro-5-(2-propynylamino)phenyl]-4-(difluoromethoxy)-3-methyl- (9CI) (CA INDEX NAME)




RN 285990-04-7 CAPLUS
CN 1H-Pyrazole-5-carbonitrile, 1-[4-cyano-2-fluoro-5-(methylpropylamino)phenyl]-4-(difluoromethoxy)-3-methyl- (9CI) (CA INDEX NAME)


09/773,736



RN 285990-10-5 CAPLUS
CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-(1-methylethyl)-1H-pyrazol-1-yl]-4-fluorophenyl]-N-(methanesulfonyl)- (9CI)
(CA INDEX NAME)




RN 285990-11-6 CAPLUS
CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-(1-methylethyl)-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 285990-15-0 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[5-[bis(methylsulfonyl)amino]-4-chloro-2-fluorophenyl]-5-cyano-4-(difluoromethoxy)-, ethyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 285990-16-1 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-chloro-2-fluoro-5-[(methanesulfonyl)amino]phenyl]-5-cyano-4-(difluoromethoxy)-, ethyl ester (9CI) (CA INDEX NAME)




RN 285990-27-4 CAPLUS
CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-3-methyl-4-(trifluoromethoxy)-1H-pyrazol-1-yl]-4-fluorophenyl]-N-(methanesulfonyl)- (9CI) (CA INDEX NAME)

09/773,736




RN 285990-28-5 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-3-methyl-4-(trifluoromethoxy)-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 285990-33-2 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-[4-(chlorodifluoromethoxy)-5-cyano-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]-N-(methanesulfonyl)- (9CI) (CA INDEX NAME)




09/773,736


RN 285990-34-3 CAPLUS
CN Methanesulfonamide, N-[2-chloro-5-[4-(chlorodifluoromethoxy)-5-cyano-3-methyl-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 285990-39-8 CAPLUS
CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-3-methyl-4-(2,2,2-trifluoroethoxy)-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 285990-48-9 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[4-chloro-2-fluoro-5-[(methylsulfonyl)amino]phenyl]-4-(difluoromethoxy)-3-methyl- (9CI) (CA INDEX NAME)




RN 285990-49-0 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[5-[bis(methylsulfonyl)amino]-4-chloro-2-fluorophenyl]-4-(difluoromethoxy)-3-methyl- (9CI) (CA INDEX NAME)

09/773,736



RN 285990-54-7 CAPLUS


CN Methanesulfonamide, N-[5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]-2,4-difluorophenyl]- (9CI) (CA INDEX NAME)




RN 285990-57-0 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]phenyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)


09/773,736



RN 285990-58-1 CAPLUS
CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 285990-61-6 CAPLUS
CN Methanesulfonamide, N-[2,4-dichloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 285990-62-7 CAPLUS
CN Methanesulfonamide, N-[2,4-dichloro-5-[5-cyano-4-(difluoromethoxy)-3-methyl-1H-pyrazol-1-yl]phenyl]-N-(methanesulfonyl)- (9CI) (CA INDEX NAME)


09/773,736



RN 285990-67-2 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[2,4-dichloro-5-[(methylsulfonyl)amino]phenyl]-4-(difluoromethoxy)-3-methyl- (9CI) (CA INDEX NAME)




RN 285990-68-3 CAPLUS
CN 1H-Pyrazole-5-carboxamide, 1-[5-[(methylsulfonyl)amino]-2,4-dichlorophenyl]-4-(difluoromethoxy)-3-methyl- (9CI) (CA INDEX NAME)



09/773,736


RN 285990-73-0 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(trifluoromethyl)-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 285990-74-1 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-4-(trifluoromethyl)-1H-pyrazol-1-yl]-4-fluorophenyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)




RN 285990-76-3 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-3-methyl-4-(trifluoromethyl)-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 285990-77-4 CAPLUS
CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-3-methyl-4-(trifluoromethyl)-1H-pyrazol-1-yl]-4-fluorophenyl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 285990-78-5 CAPLUS
CN Methanesulfonamide, N-[2-cyano-5-[5-cyano-4-(trifluoromethyl)-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)




RN 285990-80-9 CAPLUS
CN Methanesulfonamide, N-[2,4-dichloro-5-[5-cyano-4-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 285990-81-0 CAPLUS
CN Methanesulfonamide, N-[2-chloro-5-[3-(chloromethyl)-5-cyano-4-(trifluoromethyl)-1H-pyrazol-1-yl]-4-fluorophenyl]- (9CI) (CA INDEX NAME)



IT 285991-02-8 285991-03-9 285991-04-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. and herbicidal activity of 1-phenylpyrazole derivs.)
RN 285991-02-8 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-chloro-2-fluoro-5-[(methylsulfonyl)amino]phenyl]-5-cyano-4-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 285991-03-9 CAPLUS
CN Methanesulfonamide, N-[5-[3-(bromomethyl)-5-cyano-4-(trifluoromethyl)-1H-pyrazol-1-yl]-2-chloro-4-fluorophenyl]- (9CI) (CA INDEX NAME)



09/773,736

RN 285991-04-0 CAPLUS
CN Methanesulfonamide, N-[2-chloro-5-[5-cyano-3-methyl-4-(2,2,2-trifluoroethoxy)-1H-pyrazol-1-yl]-4-fluorophenyl]-N-(methanesulfonyl)-
(9CI) (CA INDEX NAME)




09/773,736

Date No Good


L31 ANSWER 36 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2000:500185 CAPLUS
DN 133:202593
TI 3,5-Bis(trifluoromethyl)pyrazoles: A Novel Class of NFAT Transcription
Factor Regulator
AU Djuric, Stevan W.; BaMaung, Nwe Y.; Basha, Anwer; Liu, Huaqing; Luly, Jay
R.; Madar, David J.; Sciotti, Richard J.; Tu, Noah P.; Wagenaar, Frank L.;
Wiedeman, Paul E.; Zhou, Xun; Ballaron, Stephen; Bauch, Joy; Chen,
Yung-Wu; Chiou, X. Grace; Fey, Thomas; Gauvin, Donna; Gubbins, Earl;
Hsieh, Gin C.; Marsh, Kennan C.; Mollison, Karl W.; Pong, Melissa;
Shaughnessy, Thomas K.; Sheets, Michael P.; Smith, Morey; Trevillyan,
James M.; Warrior, Usha; Wegner, Craig D.; Carter, George W.
CS Immunological Diseases Research, Abbott Laboratories, Abbott Park, IL,
60064-6217, USA
SO Journal of Medicinal Chemistry (2000), 43(16), 2975-2981
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB The authors describe the identification and characterization of a novel
series of NFAT regulators that exert their biol. effects via a mechanism
that does not involve inhibition of the Ca-dependent phosphatase
calcineurin. A series of bis(trifluoromethyl)pyrazoles (BTPs) has been a
novel inhibitor of cytokine prodn. Identified initially as inhibitors of
IL-2 synthesis, the BTPs have been optimized in this regard and even
inhibit IL-2 prodn. with a 10-fold enhancement over cyclosporine in an ex
vivo assay. Addnl., the BTPs show inhibition of IL-4, IL-5, IL-8, and
eotaxin prodn. Unlike the IL-2 inhibitors, cyclosporine and FK506, the
BTPs do not directly inhibit the dephosphorylation of NFAT by calcineurin.
Structure-activity relations are briefly discussed. Pharmacokinetic data
showed that the BTPs are extensively protein bound.
IT 223499-22-7P 223499-27-2P 223499-30-7P
245745-63-5P 245745-65-7P 245746-54-7P
245746-76-3P 245747-08-4P 245747-10-8P
245747-44-8P 245747-48-2P 245747-49-3P
245747-57-3P 245747-64-2P 245747-65-3P
245747-71-1P 245747-72-2P 245747-76-6P
245747-77-7P 290814-63-0P 290814-64-1P
RL: BAC (Biological activity or effector, except adverse); BPR (Biological
process); BSU (Biological study, unclassified); SPN (Synthetic
preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(fluoromethyl)pyrazoles as novel class of NFAT transcription factor
regulator that inhibit cytokine prodn. in relation to structure and
pharmacokinetics)
RN 223499-22-7 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro-
(9CI) (CA INDEX NAME)

09/773,736




RN 223499-27-2 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-
(9CI) (CA INDEX NAME)




RN 223499-30-7 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 245745-63-5 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro-
(9CI) (CA INDEX NAME)



RN 245745-65-7 CAPLUS


09/773,736

CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245746-54-7 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3-difluoro- (9CI) (CA INDEX NAME)




RN 245746-76-3 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3,5-trifluoro- (9CI) (CA INDEX NAME)




RN 245747-08-4 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




09/773,736


RN 245747-10-8 CAPLUS
CN 4-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 245747-44-8 CAPLUS
CN Benzamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 245747-48-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 245747-49-3 CAPLUS
CN Benzamide, N-[4-[5-acetyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-57-3 CAPLUS
CN Benzamide, 2-fluoro-N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-64-2 CAPLUS
CN 4-Pyridinecarboxamide, 3-fluoro-N-[4-[5-(methylthio)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-65-3 CAPLUS
CN 4-Pyridinecarboxamide, 3-fluoro-N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-71-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-


09/773,736

pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 245747-72-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 245747-76-6 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 245747-77-7 CAPLUS

CN 4-Pyridinecarboxamide, 3-fluoro-N-[4-[5-nitro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




09/773,736

RN 290814-63-0 CAPLUS
CN Acetic acid ethyl ester, compd. with N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-difluorobenzamide (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 245746-56-9
CMF C18 H9 F8 N3 O




CM 2

CRN 141-78-6
CMF C4 H8 O2

Et-O-Ac

RN 290814-64-1 CAPLUS
CN 4-Pyridinecarboxamide, 3-fluoro-N-[4-[5-hydroxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 37 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2000:412214 CAPLUS
DN 133:30728
TI Preparation of 1-phenylpyrazole-3-carboxamides as fungicides
IN Okada, Itaru; Tomita, Hirofumi; Shiga, Yasushi
PA Mitsubishi Chemical Industries Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000169453	A2	20000620	JP 1999-254112	19990908
	KR 2000023547	A	20000425	KR 1999-41921	19990930
PRAI	JP 1998-277585	A	19980930		
OS	MARPAT 133:30728				


AB Title compds. I (R1 = H, alkyl, alkoxy; R2 = H, halo, alkyl; R3 = amino, alkylamino; X = halo, alkyl, allyl), useful as fungicides, are prepd. Thus, reaction of 4-chlorophenylhydrazine hydrochloride with di-Et oxalylpropionate in EtOAc in the presence of NaOH gave Et 1-(4-chlorophenyl)-5-hydroxy-4-methylpyrazole-3-carboxylate, which was converted in several steps to 1-(4-chlorophenyl)-5-methoxy-4-methyl-N-propylpyrazole-3-carboxamide (II). II at 500 ppm showed fungicidal activity against Magnaporthe grisea.

IT **274253-64-4P 274253-65-5P 274253-66-6P**
274253-70-2P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of 1-phenylpyrazole-3-carboxamides as fungicides)

RN 274253-64-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 4-chloro-1-[4-[(dimethylamino)sulfonyl]phenyl]-5-methoxy-N-propyl- (9CI) (CA INDEX NAME)




RN 274253-65-5 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-chloro-1-[4-[(dimethylamino)sulfonyl]phenyl]-N-(1,1-dimethylethyl)-5-methoxy- (9CI) (CA INDEX NAME)


09/773,736



RN 274253-66-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-1-[4-[(dimethylamino)sulfonyl]phenyl]-
N-ethyl-5-methoxy- (9CI) (CA INDEX NAME)



RN 274253-70-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-chloro-5-methyl-1-[4-
[(methylamino)sulfonyl]phenyl]-N-propyl- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 38 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2000:166124 CAPLUS
DN 132:214726
TI Silver halide photographic material containing hydrazine derivative
developer and image formation
IN Honda, Mari; Kita, Hiroshi
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 68 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 2000075452	A2	20000314	JP 1998-245147	19980831

AB The title photog. material possesses, on a support, .gtoreq.1 photog. constitutive layers .gtoreq.1 of which contains a compd. R11NHNHXR12, R11NHNHXR13, R11NHNHXR14, R11NHNHXR15, R11NHNHXR16 or R11NHNHXR17 [R11 = aryl, heterocyclic group; X = SO2, CO, COCO, CO2, CONR1, COCO2, COCONR2, SO2NR3; R1-3 = alkyl, alkenyl, alkynyl, aryl, heterocyclic group (these groups may be substituted); R12 = photog. useful group, R13 = image stabilizer residue; R14 = UV absorbent residue; R15 = color stain inhibitor residue; R16 = formalin-capturing agent residue; R17 = brightening agent residue]. An imaging method is also claimed, in which the dye images formed by using the material are chelation-treated. The material contg. a novel hydrazine developing agent is applicable to rapid processing and provides high quality images with improved storage stability by dipping in a metal chelating bath after development.

IT **260800-05-3**
RL: DEV (Device component use); MOA (Modifier or additive use); USES (Uses)
(photog. film contg. hydrazine deriv. developer)


RN 260800-05-3 CAPLUS

CN Butanoic acid, 4-[[[3-(5-amino-3-methyl-1H-pyrazol-1-yl)-5-sulfonylphenyl]sulfonyl]amino]-, 1-[2-(5-cyano-2-furanyl)hydrazide] (9CI)
(CA INDEX NAME)




09/773,736

L31 ANSWER 39 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2000:149980 CAPLUS
DN 132:317623
TI Prediction of inhibition of the sodium ion-proton antiporter by
benzoylguanidine derivatives from molecular structure
AU Kauffman, Gregory W.; Jurs, Peter C.
CS Department of Chemistry, The Pennsylvania State University, University
Park, PA, 16802, USA
SO Journal of Chemical Information and Computer Sciences (2000), 40(3),
753-761
CODEN: JCISD8; ISSN: 0095-2338
PB American Chemical Society
DT Journal
LA English
AB The use of quant. structure-activity relationships to predict IC50 values
of 113 potential Na⁺/H⁺ antiporter inhibitors is reported. Multiple
linear regression and computational neural networks (CNNs) are used to
develop models using a set of information-rich descriptors. The
descriptors encode information about topol., geometry, electronics, and
combination hybrids. A five-descriptor CNN model with root-mean-square
(rms) errors of 0.278 log units for the training set and 0.377 log units
for the prediction set was developed. Examn. of data set subclasses
showed that systematic structural variations were also well-encoded
resulting in 100% accuracy of prediction trends. An expt. involving a
committee of five CNNs was also performed to examine the effect of network
output averaging. This showed improved results decreasing the training
and cross-validation set rms error to 0.228 log units and the prediction
set rms error to 0.296 log units.
IT **176644-28-3 190368-95-7**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological
study, unclassified); PRP (Properties); BIOL (Biological study)
(prediction of inhibition of the sodium ion-proton antiporter by
benzoylguanidine derivs. from mol. structure)
RN 176644-28-3 CAPLUS
CN Benzamide, N-(aminoiminomethyl)-2-methyl-5-(methylsulfonyl)-4-(1H-pyrazol-
1-yl)- (9CI) (CA INDEX NAME)



RN 190368-95-7 CAPLUS
CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(1H-pyrazol-1-yl)-
(9CI) (CA INDEX NAME)

09/773,736



RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 40 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 2000:83115 CAPLUS
DN 132:137392
TI Preparation of azoles as Factor Xa inhibitors.
IN Pinto, Donald Joseph Phillip; Pruitt, James Russell; Cacciola, Joseph;
Fevig, John Matthew; Han, Qi; Orwat, Michael James; Quan, Mimi Lifan;
Rossi, Karen Anita
PA Dupont Pharmaceuticals Co., USA
SO U.S., 152 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6020357	A	20000201	US 1997-995834	19971222
PRAI	US 1996-33437P	P	19961223		
	US 1997-50304P	P	19970620		

OS MARPAT 132:137392


AB Title compds. [I; ring M contains, in addn. to J, 0-3 N atoms; J = N, NH; D = CN, C(:NR8)NR7R9, C(O)NR7R8, etc.; E = (un)substituted Ph, pyridyl, pyrimidinyl, etc.; DEG = R-substituted pyridyl; R = H, halo, CF3, etc.; G = absent, NHCH2, OCH2, etc.; Z = C1-4 alkylene, (CH2)rO(CH2)r, etc.; R1a, R1b = absent, NMe, OMe, etc.; A = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic contg. from 1-4 heteroatoms selected from N, O, and S; B = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic contg. from 1-4 heteroatoms selected from N, O, and S, etc.; R7 = H, OH, C1-6 alkyl, etc.; R8, R9 = H, C1-6 alkyl, (CH2)nPh; n = 0-3; r = 0-3; s = 0-2; with provisos], useful as inhibitors of factor Xa, were prep'd. and formulated. Thus, treatment of 4-[o-(tert-BuSO2)phenyl]aniline with Me3Al/hexane in CH2Cl2 followed by the addn. of Me 1-(3-cyanophenyl)imidazol-2-ylcarboxylate (prepn. described), and the Pinner reaction of the resulting intermediate afforded 1-(3-amidinophenyl)-2-[(2'-aminosulfonyl-1,1'-biphen-4-yl)aminocarbonyl]imidazole. Several I showed Ki .ltoreq.10 .mu.M against Factor Xa and thrombin.

IT 209959-82-0P 209959-90-0P 209959-91-1P
209959-92-2P 209960-00-9P 209960-01-0P
209960-02-1P 209960-06-5P 209960-52-1P
209960-53-2P 256512-56-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of azoles as Factor Xa inhibitors)

RN 209959-82-0 CAPLUS


CN 1H-Pyrazole-5-carboxylic acid, 3-methyl-1-[3-[[[(phenylmethoxy)carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 209959-90-0 CAPLUS


09/773,736

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 209959-91-1 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]phenyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 209959-92-2 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 209960-00-9 CAPLUS

CN Carbamic acid, [1-[3-[5-(hydroxymethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




09/773,736


RN 209960-01-0 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[1-[(1,1-dimethylethoxy)carbonyl]amino]ethyl]phenyl]-3-(trifluoromethyl)- (9CI)
(CA INDEX NAME)



RN 209960-02-1 CAPLUS
CN Carbamic acid, [1-[3-[5-[(4-bromophenyl)amino]carbonyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 209960-06-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(phenylmethoxy)carbonyl]amino]methyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 209960-52-1 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-(methylthio)-, methyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 209960-53-2 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-(methylthio)- (9CI) (CA INDEX NAME)



RN 256512-56-8 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-methyl-1-[3-[[[(phenylmethoxy)carbonyl]amino]methyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 41 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1999:784082 CAPLUS
DN 132:22963
TI Preparation of N-(pyrazolylphenyl)alkanamides and analogs as IL-2
production inhibitors
IN Betageri, Rajashekhar; Cywin, Charles L.; Hargrave, Karl; Hoermann, Mary
Ann; Kirrane, Thomas M.; Parks, Thomas M.; Patel, Usha R.; Proudfoot, John
R.; Sharma, Rajiv; Sun, Sanxing; Wang, Xiao-Jun
PA Boehringer Ingelheim Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 130 pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

Patent No. KIND DATE APPLICATION NO. DATE

PI WO 9962885 A1 19991209 WO 1999-US12295 19990603

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
KP, KR, KZ, LC, LK, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO,
NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
UG, UZ, VN, YU, ZW

AU 9942299 A1 19991220 AU 1999-42299 19990603
JP 2002516909 T2 20020611 JP 2000-552097 19990603

PRAI US 1998-88154P P 19980605 →
WO 1999-US12295 W 19990603

OS MARPAT 132:22963
AB Title compds. [I; R = R4Z1Z; R1, R3 = halo, CF3, alkyl, alkoxy, etc.; R2 =
H, halo, Me; R4 = (cyclo)alkyl, alkoxy, alkylamino, etc.; Z =
1,4-phenylene; Z1 = CONH, CO2NH, NH, etc.] were prep'd. Thus, I [R =
4-(R5HN)C6H4, R1 = R3 = CF3, R2 = H] (II; R5 = H) was amidated by
cyclohexanecarboxylic acid to give II (R5 = cyclohexylcarbonyl). Data for
biol. activity of I were given.

IT 223499-27-2P 223499-45-4P 223499-46-5P
245745-24-8P 245745-28-2P 245745-40-8P
245745-43-1P 245745-47-5P 245745-51-1P
245745-59-9P 245745-65-7P 245745-69-1P
245745-72-6P 245745-74-8P 245745-77-1P
245745-78-2P 245745-84-0P 245745-90-8P
245745-92-0P 245745-97-5P 245746-04-7P
245746-16-1P 245746-53-6P 245746-90-1P
245746-93-4P 245747-25-5P 251655-34-2P
251655-39-7P 251655-40-0P 251655-41-1P
251655-42-2P 251655-43-3P 251655-75-1P
251655-76-2P 251655-77-3P 251655-78-4P
251655-79-5P 251655-81-9P 251655-82-0P
251655-83-1P 251655-85-3P 251655-86-4P
251655-87-5P 251655-88-6P 251655-90-0P
251655-91-1P 251655-92-2P 251655-93-3P
251655-95-5P 251655-96-6P 251655-98-8P
251655-99-9P 251656-00-5P 251656-01-6P
251656-03-8P 251656-05-0P 251656-07-2P
251656-09-4P 251656-11-8P 251656-14-1P
251656-17-4P 251656-19-6P 251656-25-4P
251656-26-5P 251656-29-8P 251656-36-7P
251656-37-8P 251656-38-9P 251656-43-6P
251656-44-7P 251656-46-9P 251656-50-5P
251656-51-6P 251656-52-7P 251656-53-8P


09/773,736

251656-56-1P 251656-57-2P 251656-58-3P
251656-59-4P 251656-60-7P 251656-62-9P
251656-74-3P 251656-76-5P 251656-93-6P
251656-98-1P 251657-09-7P 251657-11-1P
251657-17-7P 251657-23-5P 251657-30-4P
251657-36-0P 251657-37-1P 251657-39-3P
251657-40-6P 251657-41-7P 251657-42-8P
251657-43-9P 251657-45-1P 251657-46-2P
251657-47-3P 251657-49-5P 251657-52-0P
251657-53-1P 251657-54-2P 251657-57-5P
251657-59-7P 251657-60-0P 251657-63-3P
251657-67-7P 251658-13-6P 251658-24-9P
251658-25-0P 251658-27-2P 251658-28-3P
251658-29-4P 251658-31-8P 251658-40-9P
251658-41-0P 251942-23-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents)


RN 223499-27-2 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-
(9CI) (CA INDEX NAME)



RN 223499-45-4 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 223499-46-5 CAPLUS

CN Pyrazinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-24-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 245745-28-2 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 245745-40-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 245745-43-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI)


09/773,736

(CA INDEX NAME)




RN 245745-47-5 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl-
(9CI) (CA INDEX NAME)



RN 245745-51-1 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl-
(9CI) (CA INDEX NAME)



RN 245745-59-9 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-
(methylsulfonyl)- (9CI) (CA INDEX NAME)

09/773,736




RN 245745-65-7 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-69-1 CAPLUS

CN 2-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-72-6 CAPLUS

CN Cyclohexanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 245745-74-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 245745-77-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 245745-78-2 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-84-0 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-cyano- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-90-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 245745-92-0 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 245745-97-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 245746-04-7 CAPLUS

09/773,736


CN Acetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI)
(CA INDEX NAME)



RN 245746-16-1 CAPLUS
CN Benzeneacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 245746-53-6 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dichloro- (9CI) (CA INDEX NAME)




RN 245746-90-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-93-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-chloro- (9CI) (CA INDEX NAME)



RN 245747-25-5 CAPLUS
CN Benzamide, 4-chloro-N-[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251655-34-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251655-39-7 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-


09/773,736

yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251655-40-0 CAPLUS

CN 4-Isoxazolemethanamine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 251655-41-1 CAPLUS

CN Benzenamine, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-ethyl- (9CI) (CA INDEX NAME)



RN 251655-42-2 CAPLUS

CN 4-Pyridinemethanamine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251655-43-3 CAPLUS

CN Benzenemethanamine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736

.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 251655-75-1 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-dichloro- (9CI) (CA INDEX NAME)



RN 251655-76-2 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3-dichloro- (9CI) (CA INDEX NAME)




RN 251655-77-3 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-dichloro- (9CI) (CA INDEX NAME)


09/773,736



RN 251655-78-4 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,4-dichloro- (9CI) (CA INDEX NAME)




RN 251655-79-5 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dichloro- (9CI) (CA INDEX NAME)




RN 251655-81-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(methylthio)- (9CI) (CA INDEX NAME)

09/773,736




RN 251655-82-0 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(methylsulfinyl)- (9CI) (CA INDEX NAME)



RN 251655-83-1 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-[(dimethylamino)methyl]- (9CI) (CA INDEX NAME)




RN 251655-85-3 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

09/773,736




RN 251655-86-4 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 251655-87-5 CAPLUS
CN 3-Piperidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251655-88-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-dimethoxy- (9CI) (CA INDEX NAME)


09/773,736



RN 251655-90-0 CAPLUS


CN 2-Pyrrolidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 251655-91-1 CAPLUS


CN 3-Piperidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 251655-92-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-, 1-oxide (9CI) (CA INDEX NAME)


09/773,736




RN 251655-93-3 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-, 1-oxide (9CI) (CA INDEX NAME)



RN 251655-95-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo-2-chloro- (9CI) (CA INDEX NAME)




RN 251655-96-6 CAPLUS
CN Benzenepropanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)




09/773,736


RN 251655-98-8 CAPLUS
CN Hexanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI)
(CA INDEX NAME)



RN 251655-99-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 251656-00-5 CAPLUS
CN 4-Pyridineacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-01-6 CAPLUS
CN Acetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(phenylamino)- (9CI) (CA INDEX NAME)

09/773,736




RN 251656-03-8 CAPLUS

CN 1-Pyrrolidineacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 251656-05-0 CAPLUS


CN Butanediamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-07-2 CAPLUS


CN Acetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)

09/773,736




RN 251656-09-4 CAPLUS

CN Benzamide, N-[4-[3,5-bis(1,1-dimethylethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 251656-11-8 CAPLUS

CN Benzamide, 4-chloro-N-[4-[3-methyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-14-1 CAPLUS

CN Benzamide, 4-chloro-N-[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 251656-17-4 CAPLUS
CN Benzamide, 4-chloro-N-[4-[5-(1-methylethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-19-6 CAPLUS
CN Benzamide, 4-chloro-N-[4-[3-(1-methylethyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-25-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-ethyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-26-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 251656-29-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-36-7 CAPLUS

CN Benzamide, 4-chloro-N-[4-[3-(methoxymethyl)-5-methyl-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-37-8 CAPLUS


CN Benzamide, 4-chloro-N-[4-[3-ethoxy-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-38-9 CAPLUS


09/773,736

CN 3-Pyridinecarboxamide, N-[4-[3-ethoxy-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-43-6 CAPLUS

CN Benzamide, 4-(1,1-dimethylethyl)-N-[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-44-7 CAPLUS

CN Cyclopentanecarboxamide, N-[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-46-9 CAPLUS

CN Benzamide, 4-chloro-N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 251656-50-5 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3-ethyl-5-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-51-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-ethyl-5-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-52-7 CAPLUS
CN Benzamide, 4-chloro-N-[4-[3-(1,1-dimethylethyl)-5-methyl-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-53-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-(1,1-dimethylethyl)-5-methyl-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 251656-56-1 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[5-methyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-57-2 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3-methyl-5-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-58-3 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-(3,5-diethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 251656-59-4 CAPLUS
CN Benzamide, 4-chloro-N-[4-[3-(methoxymethyl)-5-(trifluoromethyl)-1H-pyrazol-


09/773,736

1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-60-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3-(methoxymethyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-62-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-ethyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251656-74-3 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3-propyl-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 251656-76-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[5-propyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251656-93-6 CAPLUS
CN 4-Pyridinecarboxamide, 2-chloro-N-[4-(3,5-diethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 251656-98-1 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[4-(3,5-diethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 251657-09-7 CAPLUS
CN Hexanamide, 6-nitro-N-[4-[3-(tetrahydro-2-furanyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 251657-11-1 CAPLUS
CN Benzamide, 4-chloro-N-[4-[3-[(dimethylamino)methyl]-5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 251657-17-7 CAPLUS
CN 3-Pyridinecarboxamide, 6-chloro-N-[4-[5-ethyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251657-23-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[5-ethenyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



09/773,736


RN 251657-30-4 CAPLUS

CN 1,4-Benzenedicarboxamide, N-methyl-N'-[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251657-36-0 CAPLUS

CN 4-Isioxazolecarboxamide, N-[4-[5-ethyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 251657-37-1 CAPLUS


CN 1H-Imidazole-5-carboxamide, N-[4-[5-ethyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]-1,4-dimethyl- (9CI) (CA INDEX NAME)



RN 251657-39-3 CAPLUS


CN Butanoic acid, 4-[4-[[[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 251657-40-6 CAPLUS

CN Butanoic acid, 4-[4-[[[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 251657-41-7 CAPLUS


CN Benzamide, N-[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-[4-[(2-hydroxyethyl)amino]-4-oxobutoxy]- (9CI) (CA INDEX NAME)



RN 251657-42-8 CAPLUS


CN Benzamide, 4-(4-amino-4-oxobutoxy)-N-[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 251657-43-9 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-(cyanomethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251657-45-1 CAPLUS

CN Benzamide, 4-(3-cyanopropoxy)-N-[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251657-46-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-(3-ethoxy-5-ethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 251657-47-3 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-ethyl-1-[4-[(3-pyridinylcarbonyl)amino]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 251657-49-5 CAPLUS
CN Benzamide, N-[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(4-hydroxybutoxy)- (9CI) (CA INDEX NAME)




RN 251657-52-0 CAPLUS
CN Benzamide, N-[4-[5-ethyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]-4-(methoxymethyl)- (9CI) (CA INDEX NAME)




RN 251657-53-1 CAPLUS
CN 4-Pyridinecarboxamide, 2-chloro-N-[4-[5-ethyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 251657-54-2 CAPLUS

CN 4-Pyridinecarboxamide, 2,6-dichloro-N-[4-[5-ethyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251657-57-5 CAPLUS

CN Benzamide, N-[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 251657-59-7 CAPLUS


CN Pyrazinecarboxamide, N-[4-[5-ethyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



09/773,736


RN 251657-60-0 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-ethyl-3-(1-hydroxy-1-methylethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 251657-63-3 CAPLUS

CN Benzeneacetamide, N-[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-.alpha.-oxo- (9CI) (CA INDEX NAME)



RN 251657-67-7 CAPLUS


CN Benzamide, N-[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-[4-(methylsulfonyl)butoxy]- (9CI) (CA INDEX NAME)




RN 251658-13-6 CAPLUS

CN 3-Pyridinemethanamine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 251658-24-9 CAPLUS
CN Benzeneacetonitrile, .alpha.-[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]- (9CI) (CA INDEX NAME)



RN 251658-25-0 CAPLUS
CN Benzenemethanamine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 251658-27-2 CAPLUS
CN 4-Isoxazolemethanamine, N-[4-[5-ethyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 251658-28-3 CAPLUS
CN Benzoic acid, 4-[[[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 251658-29-4 CAPLUS

CN 2-Thiophenemethanamine, N-[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 251658-31-8 CAPLUS

CN 2-Thiophenemethanamine, N-[4-[5-ethyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 251658-40-9 CAPLUS


CN Benzenamine, N-(2-ethylbutyl)-4-[5-ethyl-3-(3-pyridinyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 251658-41-0 CAPLUS

CN 1H-Pyrazole-5-carbonitrile, 1-[4-[(2-ethylbutyl)amino]phenyl]-3-(3-pyridinyl)- (9CI) (CA INDEX NAME)


09/773,736




RN 251942-23-1 CAPLUS
CN 2H-Pyran-3-carboxamide, N-[4-[5-ethyl-3-(1-methylethyl)-1H-pyrazol-1-yl]phenyl]dihydro-2-methyl- (9CI) (CA INDEX NAME)

CM 1

CRN 251942-22-0
CMF C21 H29 N3 O2



IT **245747-10-8**
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of 1-(4-aminophenyl)pyrazoles and their use as
anti-inflammatory agents)
RN 245747-10-8 CAPLUS
CN 4-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 42 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:708733 CAPLUS
 DN 131:322416
 TI Preparation of 3-arylphenyl sulfide derivatives as insecticides and acaricides
 IN Toriyabe, Keiji; Takefuji, Nobuo; Itou, Minoru; Hirade, Tetsuya; Nishiyama, Kiyotoshi; Asahida, Mitsuharu; Maeda, Yasunobu; Wada, Nobuhide; Fujisawa, Toyokazu; Yano, Hiroyuki; Komatsu, Masaaki; Tada, Osamu
 PA Kumiai Chemical Industry Co., Ltd., Japan; Ihara Chemical Industry Co., Ltd.
 SO PCT Int. Appl., 148 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9955668	A1	19991104	WO 1999-JP2212	19990426
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	JP 2000198768	A2	20000718	JP 1999-108903	19990416
	AU 9935366	A1	19991116	AU 1999-35366	19990426
	EP 1076053	A1	20010214	EP 1999-917160	19990426
	R:	CH, DE, FR, GB, IT, LI			
PRAI	JP 1998-132768	A	19980427		
	JP 1998-283539	A	19980918		
	JP 1998-309580	A	19981030		
	WO 1998-JP9902212	W	19990426		
	WO 1999-JP2212	W	19990426		
OS	MARPAT 131:322416				
AB	Title compds. I (R = C2-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R1-R4 = hydrogen, halogeno, cyano, Cl-4 haloalkyl, etc.; n = 0, 1, 2; Ar = Ph, thiophene or pyrazole ring, etc.), useful as insecticides and acaricides, are prepd. Thus, reaction of 2-mercapto-4-(4-trifluoromethylphenyl)benzonitrile with allyl bromide in DMF in the presence of t-BuOK gave 43.0% 2-(2-propenylthio)-4-(4-trifluoromethylphenyl)benzonitrile (II). II showed acaricidal activity at 500 ppm.				
IT	248269-17-2P RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of 3-arylphenyl sulfide derivs. as insecticides and acaricides)				
RN	248269-17-2 CAPLUS				
CN	Acetamide, N-[2-[(2,2,2-trifluoroethyl)thio]-4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)				

09/773,736



RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 43 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1999:659365 CAPLUS
DN 131:271873
TI Preparation of pyrazoles and triazoles as inhibitors of cytokine
production
IN Ba Maung, Nwe Y.; Basha, Anwer; Djuric, Stevan W.; Gubbins, Earl J.; Luly,
Jay R.; Tu, Noah P.; Madar, David J.; Warrior, Usha; Wiedeman, Paul E.;
Zhou, Xun; Wagenaar, Frank L.; Sciotti, Richard J.
PA Abbott Laboratories, USA
SO PCT Int. Appl., 319 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

Date no good.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9951580	A1	19991014	WO 1999-US7766	19990408
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2327185	AA	19991014	CA 1999-2327185	19990408
	AU 9933879	A1	19991025	AU 1999-33879	19990408
	EP 1068187	A1	20010117	EP 1999-915341	19990408
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	JP 2002510679	T2	20020409	JP 2000-542301	19990408
PRAI	US 1998-56996	A	19980408		
	WO 1999-US7766	W	19990408		

← no US appls pending

OS MARPAT 131:271873
AB Title compds. [I; R1 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, heterocyclyloxy, heterocyclylsulfonyl; R2 = H, alkyl, cycloalkyl, alkylcarbonyl, heterocyclyl; R3 = H, NH2, OCONH2, CN, NO2, OH, CO2H, F, Cl, Br, I, aryl, perfluoroalkyl, heterocyclyloxy, heterocyclylsulfonyl; R4 and R5 are independently selected from H, alkyl, alkoxy, halo, perfluoroalkyl, CN, heterocycle; E = LB; B = alkyl, alkenyl, alkynyl; L = N:N, N:CH, CH:N, ON:CH, O, CO, NH, NHCO, NHSO2, NHCH2, alkenylene; Q = benzene ring with 2, 3, or 4 substituted E, heterocycle; Z = C; R2Z = N], E, Z isomers, stereoisomers, pharmaceutical acceptable salts, and prodrugs are prepd. and tested as cytokine prodn. inhibitors and are useful for treating diseases that are prevented by or ameliorated with Interleukin-2, Interleukin-4, or Interleukin-5 prodn. inhibitors. Thus, the title compd. II was prepd.

IT 223499-27-2P 223499-30-7P 223499-41-0P
223499-45-4P 223499-46-5P 223499-47-6P
223500-14-9P 245744-54-1P 245744-55-2P
245744-56-3P 245744-57-4P 245744-58-5P
245744-59-6P 245744-60-9P 245744-62-1P
245744-63-2P 245744-64-3P 245744-65-4P
245744-67-6P 245744-68-7P 245744-70-1P
245744-71-2P 245744-74-5P 245744-77-8P
245744-78-9P 245744-80-3P 245744-81-4P
245744-82-5P 245744-83-6P 245744-88-1P
245744-97-2P 245745-04-4P 245745-05-5P

245745-06-6P 245745-07-7P 245745-08-8P
245745-09-9P 245745-11-3P 245745-12-4P
245745-14-6P 245745-16-8P 245745-17-9P
245745-18-0P 245745-20-4P 245745-22-6P
245745-23-7P 245745-24-8P 245745-25-9P
245745-26-0P 245745-27-1P 245745-28-2P
245745-29-3P 245745-31-7P 245745-33-9P
245745-34-0P 245745-35-1P 245745-36-2P
245745-37-3P 245745-38-4P 245745-39-5P
245745-40-8P 245745-41-9P 245745-42-0P
245745-43-1P 245745-44-2P 245745-45-3P
245745-46-4P 245745-47-5P 245745-49-7P
245745-50-0P 245745-51-1P 245745-52-2P
245745-53-3P 245745-54-4P 245745-55-5P
245745-56-6P 245745-57-7P 245745-58-8P
245745-59-9P 245745-60-2P 245745-61-3P
245745-62-4P 245745-63-5P 245745-64-6P
245745-65-7P 245745-66-8P 245745-68-0P
245745-69-1P 245745-70-4P 245745-71-5P
245745-72-6P 245745-73-7P 245745-74-8P
245745-75-9P 245745-76-0P 245745-77-1P
245745-78-2P 245745-79-3P 245745-80-6P
245745-81-7P 245745-82-8P 245745-83-9P
245745-84-0P 245745-85-1P 245745-86-2P
245745-87-3P 245745-88-4P 245745-89-5P
245745-90-8P 245745-91-9P 245745-92-0P
245745-93-1P 245745-94-2P 245745-96-4P
245745-97-5P 245745-98-6P 245745-99-7P
245746-02-5P 245746-03-6P 245746-04-7P
245746-05-8P 245746-06-9P 245746-07-0P
245746-08-1P 245746-09-2P 245746-10-5P
245746-11-6P 245746-12-7P 245746-13-8P
245746-14-9P 245746-15-0P 245746-16-1P
245746-18-3P 245746-19-4P 245746-20-7P
245746-21-8P 245746-22-9P 245746-24-1P
245746-25-2P 245746-26-3P 245746-27-4P
245746-28-5P 245746-29-6P 245746-30-9P
245746-31-0P 245746-32-1P 245746-33-2P
245746-35-4P 245746-36-5P 245746-37-6P
245746-38-7P 245746-39-8P 245746-40-1P
245746-41-2P 245746-42-3P 245746-43-4P
245746-44-5P 245746-45-6P 245746-46-7P
245746-47-8P 245746-48-9P 245746-49-0P
245746-50-3P 245746-51-4P 245746-52-5P
245746-53-6P 245746-54-7P 245746-55-8P
245746-56-9P 245746-57-0P 245746-58-1P
245746-59-2P 245746-60-5P 245746-61-6P
245746-62-7P 245746-63-8P 245746-64-9P
245746-65-0P 245746-66-1P 245746-67-2P
245746-68-3P 245746-69-4P 245746-70-7P
245746-71-8P 245746-72-9P 245746-73-0P
245746-74-1P 245746-75-2P 245746-76-3P
245746-77-4P 245746-78-5P 245746-79-6P
245746-80-9P 245746-81-0P 245746-82-1P
245746-83-2P 245746-84-3P 245746-85-4P
245746-86-5P 245746-87-6P 245746-88-7P
245746-89-8P 245746-90-1P 245746-91-2P
245746-92-3P 245746-93-4P 245746-94-5P

09/773,736


245746-95-6P 245746-96-7P 245746-97-8P
245746-98-9P 245746-99-0P 245747-00-6P
245747-02-8P 245747-03-9P 245747-07-3P
245747-08-4P 245747-09-5P 245747-10-8P
245747-11-9P 245747-12-0P 245747-13-1P
245747-14-2P 245747-15-3P 245747-16-4P
245747-18-6P 245747-19-7P 245747-20-0P
245747-21-1P 245747-22-2P 245747-23-3P
245747-24-4P 245747-25-5P 245747-26-6P
245747-27-7P 245747-28-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of pyrazoles and triazoles as inhibitors of cytokine prodn.)


RN 223499-27-2 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-
(9CI) (CA INDEX NAME)




RN 223499-30-7 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 223499-41-0 CAPLUS

CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




09/773,736


RN 223499-45-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 223499-46-5 CAPLUS
CN Pyrazinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 223499-47-6 CAPLUS
CN 1H-Pyrrole-2-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 223500-14-9 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


09/773,736




RN 245744-54-1 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245744-55-2 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,2,3,3-tetramethyl- (9CI) (CA INDEX NAME)




RN 245744-56-3 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,2-dichloro-1-methyl- (9CI) (CA INDEX NAME)



RN 245744-57-4 CAPLUS


09/773,736

CN 2H-Pyran-3-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-oxo-6-pentyl- (9CI) (CA INDEX NAME)




RN 245744-58-5 CAPLUS

CN Benzenesulfonamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-difluoro- (9CI) (CA INDEX NAME)



RN 245744-59-6 CAPLUS


CN 1-Cyclohexene-1-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245744-60-9 CAPLUS


CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)

09/773,736




RN 245744-62-1 CAPLUS

CN 2-Cyclohexene-1-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 245744-63-2 CAPLUS

CN 1-Cyclopentene-1-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245744-64-3 CAPLUS

CN Cyclohexanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




RN 245744-65-4 CAPLUS

CN 2-Butynamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736

(9CI) (CA INDEX NAME)




RN 245744-67-6 CAPLUS

CN 3-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
(9CI) (CA INDEX NAME)




RN 245744-68-7 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl-
3-nitro- (9CI) (CA INDEX NAME)




RN 245744-70-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-hydroxy-
(9CI) (CA INDEX NAME)




09/773,736

RN 245744-71-2 CAPLUS
CN Cycloheptanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245744-74-5 CAPLUS
CN 2-Propenamamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(2-chlorophenyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 245744-77-8 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 245744-78-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-iodo- (9CI) (CA INDEX NAME)

09/773,736




RN 245744-80-3 CAPLUS

CN Cyclohexanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)



RN 245744-81-4 CAPLUS


CN Carbamic acid, [1-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 245744-82-5 CAPLUS


CN 3-Cyclohexene-1-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 245744-83-6 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-fluorophenyl)-
(9CI) (CA INDEX NAME)




RN 245744-88-1 CAPLUS

CN Cyclopropanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 245744-97-2 CAPLUS


CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 245745-04-4 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(hydroxymethyl)- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-05-5 CAPLUS
CN Acetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-cyano-
(9CI) (CA INDEX NAME)



RN 245745-06-6 CAPLUS
CN 2-Cyclohexene-1-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-07-7 CAPLUS
CN Cyclohexanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



09/773,736


RN 245745-08-8 CAPLUS

CN Benzeneacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
.alpha.-methoxy-.alpha.-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 245745-09-9 CAPLUS

CN Heptanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI)
(CA INDEX NAME)



RN 245745-11-3 CAPLUS


CN Benzamide, 3-amino-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
(9CI) (CA INDEX NAME)




RN 245745-12-4 CAPLUS

CN Benzamide, 4-amino-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
(9CI) (CA INDEX NAME)

09/773,736




RN 245745-14-6 CAPLUS
CN 2-Thiopheneacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-16-8 CAPLUS
CN L-Asparagine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-N2-[(1,1-dimethylethoxy)carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 245745-17-9 CAPLUS
CN Carbamic acid, [7-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]-7-oxoheptyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


09/773,736




RN 245745-18-0 CAPLUS
CN Propanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(methylthio)- (9CI) (CA INDEX NAME)



RN 245745-20-4 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-cyano- (9CI) (CA INDEX NAME)




RN 245745-22-6 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-iodo- (9CI) (CA INDEX NAME)




09/773,736


RN 245745-23-7 CAPLUS
CN Propanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro- (9CI) (CA INDEX NAME)



RN 245745-24-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)




RN 245745-25-9 CAPLUS
CN Hexanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-ethyl- (9CI) (CA INDEX NAME)




RN 245745-26-0 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)

09/773,736




RN 245745-27-1 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(hexyloxy)- (9CI) (CA INDEX NAME)




RN 245745-28-2 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 245745-29-3 CAPLUS

CN Benzamide, 2-(acetyloxy)-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-31-7 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4,6-


09/773,736

trimethyl- (9CI) (CA INDEX NAME)




RN 245745-33-9 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-N-methyl- (9CI) (CA INDEX NAME)




RN 245745-34-0 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-N-methyl-4-nitro- (9CI) (CA INDEX NAME)



RN 245745-35-1 CAPLUS


CN Benzenemethanamine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)



09/773,736


RN 245745-36-2 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl-5-nitro- (9CI) (CA INDEX NAME)




RN 245745-37-3 CAPLUS

CN Benzenemethanamine, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 245745-38-4 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-bromo- (9CI) (CA INDEX NAME)




RN 245745-39-5 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(dimethylamino)- (9CI) (CA INDEX NAME)




09/773,736


RN 245745-40-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 245745-41-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 245745-42-0 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)




RN 245745-43-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-44-2 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-nitro-
(9CI) (CA INDEX NAME)



RN 245745-45-3 CAPLUS
CN Benzenemethanamine, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-
fluorophenyl)- (9CI) (CA INDEX NAME)




RN 245745-46-4 CAPLUS
CN Benzonitrile, 3-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-
yl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 245745-47-5 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl-
(9CI) (CA INDEX NAME)


09/773,736



RN 245745-49-7 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,4-dimethoxy- (9CI) (CA INDEX NAME)




RN 245745-50-0 CAPLUS
CN Cyclopentanepropanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-51-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-52-2 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 245745-53-3 CAPLUS
CN 2-Butenamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 245745-54-4 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-hydroxy- (9CI) (CA INDEX NAME)



09/773,736


RN 245745-55-5 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-hydroxy- (9CI) (CA INDEX NAME)




RN 245745-56-6 CAPLUS

CN 5-Thiazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 245745-57-7 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(hydroxymethyl)- (9CI) (CA INDEX NAME)




RN 245745-58-8 CAPLUS

CN Benzenemethanamine, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-59-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 245745-60-2 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-iodo- (9CI) (CA INDEX NAME)




RN 245745-61-3 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-heptyl- (9CI) (CA INDEX NAME)




09/773,736


RN 245745-62-4 CAPLUS
CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
(9CI) (CA INDEX NAME)



RN 245745-63-5 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro-
(9CI) (CA INDEX NAME)




RN 245745-64-6 CAPLUS
CN 1,2-Benzenedicarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 245745-65-7 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-66-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro-2-nitro- (9CI) (CA INDEX NAME)



RN 245745-68-0 CAPLUS
CN Benzamide, 4-acetyl-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-69-1 CAPLUS
CN 2-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 245745-70-4 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-(diethylamino)- (9CI) (CA INDEX NAME)



RN 245745-71-5 CAPLUS
CN Cyclopentanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-72-6 CAPLUS
CN Cyclohexanecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-73-7 CAPLUS
CN 4-Piperidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245745-74-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 245745-75-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 245745-76-0 CAPLUS
CN Benzoic acid, 3-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 245745-77-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro-

09/773,736

(9CI) (CA INDEX NAME)




RN 245745-78-2 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-79-3 CAPLUS
CN Benzonitrile, 3-[(1E)-2-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 245745-80-6 CAPLUS
CN 1,4-Benzenedicarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736



RN 245745-81-7 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dinitro- (9CI) (CA INDEX NAME)




RN 245745-82-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-difluoro- (9CI) (CA INDEX NAME)




RN 245745-83-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-nitro- (9CI) (CA INDEX NAME)


09/773,736



RN 245745-84-0 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-cyano-
(9CI) (CA INDEX NAME)




RN 245745-85-1 CAPLUS
CN 1,3-Benzenedicarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-86-2 CAPLUS
CN Benzonitrile, 3-[(1Z)-2-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethenyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.


09/773,736



RN 245745-87-3 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-nitro-
(9CI) (CA INDEX NAME)




RN 245745-88-4 CAPLUS
CN Benzamide, 3-(aminosulfonyl)-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245745-89-5 CAPLUS
CN Benzoic acid, 4-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 245745-90-8 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)




RN 245745-91-9 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-bromo- (9CI) (CA INDEX NAME)




RN 245745-92-0 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)




09/773,736


RN 245745-93-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro-
(9CI) (CA INDEX NAME)



RN 245745-94-2 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-bromo-
(9CI) (CA INDEX NAME)




RN 245745-96-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-dichloro- (9CI) (CA INDEX NAME)




RN 245745-97-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)


09/773,736



RN 245745-98-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-6-methyl- (9CI) (CA INDEX NAME)




RN 245745-99-7 CAPLUS
CN Benzenebutanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro-.gamma.-oxo- (9CI) (CA INDEX NAME)



RN 245746-02-5 CAPLUS
CN 1H-Pyrazole, 1-[4-[(1E)-2-(2-chlorophenyl)ethenyl]phenyl]-3,5-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.

09/773,736




RN 245746-03-6 CAPLUS

CN Propanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(4-chlorophenoxy)-2-methyl- (9CI) (CA INDEX NAME)




RN 245746-04-7 CAPLUS

CN Acetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245746-05-8 CAPLUS

CN Benzoic acid, 4-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 245746-06-9 CAPLUS
CN Carbamic acid, [4-[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]-4-oxobutyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 245746-07-0 CAPLUS
CN Benzoic acid, 3-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 245746-08-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 245746-09-2 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-bromo- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-10-5 CAPLUS
CN Benzamide, 2-amino-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
(9CI) (CA INDEX NAME)



RN 245746-11-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 245746-12-7 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 245746-13-8 CAPLUS


09/773,736

CN 1H-Pyrrole-2-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245746-14-9 CAPLUS

CN 2-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,6-dichloro- (9CI) (CA INDEX NAME)



RN 245746-15-0 CAPLUS


CN Acetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-(2-nitrophenoxy)- (9CI) (CA INDEX NAME)



RN 245746-16-1 CAPLUS

CN Benzeneacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)


09/773,736



RN 245746-18-3 CAPLUS


CN 2-Propenamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-(2-thienyl)-, (2E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 245746-19-4 CAPLUS


CN Carbamic acid, [4-[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]-4-oxobutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 245746-20-7 CAPLUS


CN 4-Piperidinecarboxamide, 1-acetyl-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-21-8 CAPLUS

CN Butanamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI)
(CA INDEX NAME)




RN 245746-22-9 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro-2-methoxy- (9CI) (CA INDEX NAME)



RN 245746-24-1 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methoxy-4-(methylthio)- (9CI) (CA INDEX NAME)



09/773,736


RN 245746-25-2 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-hydroxy-3-nitro- (9CI) (CA INDEX NAME)




RN 245746-26-3 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,4-dihydroxy- (9CI) (CA INDEX NAME)



RN 245746-27-4 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-hydroxy-6-methoxy- (9CI) (CA INDEX NAME)



RN 245746-28-5 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-29-6 CAPLUS

CN 4-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 245746-30-9 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 245746-31-0 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(3-cyanophenyl)- (9CI) (CA INDEX NAME)




RN 245746-32-1 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,4-


09/773,736

difluorophenyl)- (9CI) (CA INDEX NAME)




RN 245746-33-2 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2-cyanophenyl)-
(9CI) (CA INDEX NAME)




RN 245746-35-4 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2-nitrophenyl)-
(9CI) (CA INDEX NAME)




RN 245746-36-5 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2,6-difluorophenyl)-
(9CI) (CA INDEX NAME)




09/773,736


RN 245746-37-6 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(2-bromophenyl)-
(9CI) (CA INDEX NAME)



RN 245746-38-7 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-cyanophenyl)-
(9CI) (CA INDEX NAME)




RN 245746-39-8 CAPLUS
CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-4-pyridinyl-
(9CI) (CA INDEX NAME)




RN 245746-40-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro-
3-(trifluoromethyl)- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-41-2 CAPLUS
CN Benzamide, N-[2-(aminocarbonyl)phenyl]-4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]- (9CI) (CA INDEX NAME)



RN 245746-42-3 CAPLUS
CN Benzeneacetamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)




RN 245746-43-4 CAPLUS
CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3-dichloro- (9CI) (CA INDEX NAME)




09/773,736


RN 245746-44-5 CAPLUS
CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-5-nitro- (9CI) (CA INDEX NAME)



RN 245746-45-6 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro-3-nitro- (9CI) (CA INDEX NAME)




RN 245746-46-7 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro-2-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 245746-47-8 CAPLUS
CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-48-9 CAPLUS
CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-difluoro- (9CI) (CA INDEX NAME)



RN 245746-49-0 CAPLUS
CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-cyano- (9CI) (CA INDEX NAME)




RN 245746-50-3 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-bromo-3-nitro- (9CI) (CA INDEX NAME)




RN 245746-51-4 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-4-fluoro- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-52-5 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



RN 245746-53-6 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dichloro- (9CI) (CA INDEX NAME)




RN 245746-54-7 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3-difluoro- (9CI) (CA INDEX NAME)




09/773,736


RN 245746-55-8 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro-4-fluoro- (9CI) (CA INDEX NAME)



RN 245746-56-9 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-difluoro- (9CI) (CA INDEX NAME)




RN 245746-57-0 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-6-fluoro- (9CI) (CA INDEX NAME)




RN 245746-58-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-59-2 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro-2-fluoro- (9CI) (CA INDEX NAME)




RN 245746-60-5 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-4-methoxy- (9CI) (CA INDEX NAME)



RN 245746-61-6 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-dichloro-3-nitro- (9CI) (CA INDEX NAME)



09/773,736


RN 245746-62-7 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-bromo-2-chloro- (9CI) (CA INDEX NAME)




RN 245746-63-8 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,4-difluoro- (9CI) (CA INDEX NAME)



RN 245746-64-9 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-bromo-5-methoxy- (9CI) (CA INDEX NAME)



RN 245746-65-0 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro-2-hydroxy- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-66-1 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-bromo-4-methoxy- (9CI) (CA INDEX NAME)



RN 245746-67-2 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-bromo-4-hydroxy- (9CI) (CA INDEX NAME)



RN 245746-68-3 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-4,5-difluoro- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-69-4 CAPLUS

CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-difluoro- (9CI) (CA INDEX NAME)




RN 245746-70-7 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro-2,5-difluoro- (9CI) (CA INDEX NAME)



RN 245746-71-8 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3,4-trifluoro- (9CI) (CA INDEX NAME)




RN 245746-72-9 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,4,5-trifluoro- (9CI) (CA INDEX NAME)


09/773,736



RN 245746-73-0 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4,5-trifluoro- (9CI) (CA INDEX NAME)




RN 245746-74-1 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4,6-trifluoro- (9CI) (CA INDEX NAME)




RN 245746-75-2 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-difluoro-3-nitro- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-76-3 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3,5-trifluoro- (9CI) (CA INDEX NAME)




RN 245746-77-4 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-dichloro-6-fluoro- (9CI) (CA INDEX NAME)



RN 245746-78-5 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,4-dichloro-3,5-dinitro- (9CI) (CA INDEX NAME)



09/773,736


RN 245746-79-6 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3,5,6-tetrafluoro- (9CI) (CA INDEX NAME)




RN 245746-80-9 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3,4,5-tetrafluoro- (9CI) (CA INDEX NAME)



RN 245746-81-0 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-bromo-2,3,5,6-tetrafluoro- (9CI) (CA INDEX NAME)



RN 245746-82-1 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methyl-2-nitro- (9CI) (CA INDEX NAME)

09/773,736




RN 245746-83-2 CAPLUS

CN Benzamide, N-[3-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-cyano-
(9CI) (CA INDEX NAME)




RN 245746-84-3 CAPLUS

CN 3-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245746-85-4 CAPLUS


CN 5-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245746-86-5 CAPLUS


09/773,736

CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 245746-87-6 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245746-88-7 CAPLUS

CN 3-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)




RN 245746-89-8 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 245746-90-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)



RN 245746-91-2 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 245746-92-3 CAPLUS
CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 245746-93-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-6-chloro- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-94-5 CAPLUS
CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
5-bromo- (9CI) (CA INDEX NAME)



RN 245746-95-6 CAPLUS
CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-
3-methyl- (9CI) (CA INDEX NAME)




RN 245746-96-7 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-chloro- (9CI) (CA INDEX NAME)




RN 245746-97-8 CAPLUS
CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]tetrahydro-5-oxo- (9CI) (CA INDEX NAME)


09/773,736




RN 245746-98-9 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 245746-99-0 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-bromo- (9CI) (CA INDEX NAME)




RN 245747-00-6 CAPLUS
CN 3-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-nitro- (9CI) (CA INDEX NAME)




RN 245747-02-8 CAPLUS
CN 3-Thiazolidinecarboxylic acid, 4-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


09/773,736




RN 245747-03-9 CAPLUS
CN 3-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-methoxy- (9CI) (CA INDEX NAME)



RN 245747-07-3 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4,5-dibromo- (9CI) (CA INDEX NAME)




RN 245747-08-4 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



09/773,736


RN 245747-09-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 245747-10-8 CAPLUS

CN 4-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 245747-11-9 CAPLUS

CN 3-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5-chloro-4-methoxy- (9CI) (CA INDEX NAME)



RN 245747-12-0 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-5,6-dichloro- (9CI) (CA INDEX NAME)



RN 245747-13-1 CAPLUS


09/773,736

CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,6-dichloro- (9CI) (CA INDEX NAME)




RN 245747-14-2 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,5-dichloro- (9CI) (CA INDEX NAME)



RN 245747-15-3 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]-4-chloro- (9CI) (CA INDEX NAME)



RN 245747-16-4 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-2-fluorophenyl]-2,4-difluoro- (9CI) (CA INDEX NAME)

09/773,736




RN 245747-18-6 CAPLUS

CN Benzoic acid, 2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-5-[(5-bromo-2-chlorobenzoyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 245747-19-7 CAPLUS


CN 4-Isioxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 245747-20-0 CAPLUS


CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3-(trifluoromethyl)phenyl]-4-methyl- (9CI) (CA INDEX NAME)

09/773,736




RN 245747-21-1 CAPLUS

CN 4-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3-chlorophenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 245747-22-2 CAPLUS

CN 4-Isoxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-2-(trifluoromethyl)phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 245747-23-3 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-2-methylphenyl]-4-methyl- (9CI) (CA INDEX NAME)




09/773,736


RN 245747-24-4 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-2-methoxyphenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 245747-25-5 CAPLUS
CN Benzamide, 4-chloro-N-[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-26-6 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, 4-methyl-N-[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-27-7 CAPLUS
CN 4-Isoxazolecarboxamide, 3,5-dimethyl-N-[4-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



09/773,736


RN 245747-28-8 CAPLUS
CN Benzamide, 4-chloro-N-[4-(5-methyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



IT 245747-29-9P 245747-30-2P 245747-31-3P
245747-32-4P 245747-34-6P 245747-35-7P
245747-37-9P 245747-38-0P 245747-39-1P
245747-40-4P 245747-42-6P 245747-43-7P
245747-44-8P 245747-46-0P 245747-47-1P
245747-48-2P 245747-49-3P 245747-50-6P
245747-51-7P 245747-53-9P 245747-56-2P
245747-57-3P 245747-58-4P 245747-59-5P
245747-60-8P 245747-61-9P 245747-63-1P
245747-64-2P 245747-65-3P 245747-66-4P
245747-67-5P 245747-68-6P 245747-69-7P
245747-70-0P 245747-71-1P 245747-72-2P
245747-76-6P 245747-77-7P 245747-79-9P
245747-89-1P 245747-91-5P 245747-92-6P
245747-93-7P 245747-94-8P 245747-95-9P
245747-96-0P 245747-97-1P 245749-06-8P
245749-07-9P 245749-09-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. of pyrazoles and triazoles as inhibitors of cytokine prodn.)

RN 245747-29-9 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, 4-methyl-N-[4-(5-methyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 245747-30-2 CAPLUS
CN 4-Isoxazolecarboxamide, 3,5-dimethyl-N-[4-(5-methyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-31-3 CAPLUS
CN 4-Isoxazolecarboxamide, 3,5-dimethyl-N-[4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-32-4 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[5-hydroxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 245747-34-6 CAPLUS
CN 4-Pyridinecarboxamide, 3-amino-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-35-7 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro-5-methoxy- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-37-9 CAPLUS
CN Benzoic acid, 2-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-5-[(2-chlorobenzoyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 245747-38-0 CAPLUS
CN Benzamide, 4-(aminomethyl)-N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 245747-39-1 CAPLUS
CN 2-Propenamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-methyl- (9CI) (CA INDEX NAME)




09/773,736


RN 245747-40-4 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro-2-fluoro- (9CI) (CA INDEX NAME)



RN 245747-42-6 CAPLUS
CN Benzamide, N-[3-amino-4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 245747-43-7 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-3-cyanophenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 245747-44-8 CAPLUS
CN Benzamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-46-0 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 245747-47-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-48-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 245747-49-3 CAPLUS
CN Benzamide, N-[4-[5-acetyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-50-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 245747-51-7 CAPLUS
CN Benzamide, N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3,5-trifluoro- (9CI) (CA INDEX NAME)




RN 245747-53-9 CAPLUS
CN Benzamide, 2-fluoro-N-[4-[5-(methylthio)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-56-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736

yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-57-3 CAPLUS

CN Benzamide, 2-fluoro-N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-58-4 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 245747-59-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 245747-60-8 CAPLUS

CN 3-Pyridinecarboxamide, 2-fluoro-N-[4-[5-(methylthio)-3-(trifluoromethyl)-


09/773,736

1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-61-9 CAPLUS

CN 3-Pyridinecarboxamide, 2-fluoro-N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-63-1 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-ethoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 245747-64-2 CAPLUS


CN 4-Pyridinecarboxamide, 3-fluoro-N-[4-[5-(methylthio)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



09/773,736


RN 245747-65-3 CAPLUS

CN 4-Pyridinecarboxamide, 3-fluoro-N-[4-[5-methoxy-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-66-4 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-67-5 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 245747-68-6 CAPLUS

CN 3-Pyridinecarboxamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




09/773,736


RN 245747-69-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)



RN 245747-70-0 CAPLUS
CN Benzamide, 2-fluoro-N-[4-[5-nitro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-71-1 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)




RN 245747-72-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-76-6 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 245747-77-7 CAPLUS
CN 4-Pyridinecarboxamide, 3-fluoro-N-[4-[5-nitro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-79-9 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 245747-89-1 CAPLUS
CN 4-Pyridinecarboxamide, 3-chloro-N-[4-[5-chloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 245747-91-5 CAPLUS
CN Benzamide, N-[4-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3-difluoro- (9CI) (CA INDEX NAME)



RN 245747-92-6 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[5-bromo-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-chloro- (9CI) (CA INDEX NAME)




RN 245747-93-7 CAPLUS
CN Benzamide, 2-chloro-N-[4-[5-cyano-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-94-8 CAPLUS
CN 4-Pyridinecarboxamide, 3-chloro-N-[4-[5-cyano-3-(trifluoromethyl)-1H-


09/773,736

pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 245747-95-9 CAPLUS

CN Benzamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-fluoro- (9CI) (CA INDEX NAME)




RN 245747-96-0 CAPLUS

CN Benzamide, 2-chloro-N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 245747-97-1 CAPLUS


CN Benzamide, N-[4-[5-(difluoromethoxy)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2,3-difluoro- (9CI) (CA INDEX NAME)



09/773,736


RN 245749-06-8 CAPLUS
CN Carbamic acid, [(1R)-1-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]propyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 245749-07-9 CAPLUS
CN Benzeneacetamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-.alpha.-methoxy-.alpha.-(trifluoromethyl)-, (.alpha.R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 245749-09-1 CAPLUS
CN 2-Furancarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]tetrahydro-5-oxo-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/773,736


IT 245748-04-3P 245748-09-8P 245748-43-0P

245748-64-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of pyrazoles and triazoles as inhibitors of cytokine prodn.)


RN 245748-04-3 CAPLUS

CN 4-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-nitro- (9CI) (CA INDEX NAME)




RN 245748-09-8 CAPLUS

CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-4-cyano- (9CI) (CA INDEX NAME)



RN 245748-43-0 CAPLUS


CN Carbamic acid, [1-[4-[(2-fluorobenzoyl)amino]phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 245748-64-5 CAPLUS

CN Carbamic acid, [1-[4-[(3-fluoro-4-pyridinyl)carbonyl]amino]phenyl]-3-(trifluoromethyl)-1H-pyrazol-5-yl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

09/773,736



RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 44 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:566034 CAPLUS
 DN 131:199699
 TI N-[(Substituted five-membered di- or triaza diunsaturated
 ring)carbonyl]guanidine derivatives for the treatment of ischemia
 IN Hamanaka, Ernest S.; Guzman-Perez, Angel; Ruggeri, Roger B.; Wester,
 Ronald T.; Mularski, Christian J.
 PA Pfizer Products Inc., USA
 SO PCT Int. Appl., 246 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9943663	A1	19990902	WO 1999-IB206	19990205
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2321642	AA	19990902	CA 1999-2321642	19990205
	AU 9920706	A1	19990915	AU 1999-20706	19990205
	AU 739403	B2	20011011		
	BR 9908332	A	20001107	BR 1999-8332	19990205
	EP 1056729	A1	20001206	EP 1999-901083	19990205
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	JP 2002504546	T2	20020212	JP 2000-533420	19990205
	ZA 9901578	A	20000828	ZA 1999-1578	19990226
	NO 2000004192	A	20000822	NO 2000-4192	20000822
PRAI	US 1998-76362P	P	19980227	NO US appln.	
	WO 1999-IB206	W	19990205		

OS MARPAT 131:199699


AB Guanidine derivs. ZCON:C(NH2)2 [I; Z = certain (un)substituted, diunsatd., diazoles and triazoles] and their pharmaceutically acceptable salts and/or prodrugs are disclosed, for use as inhibitors of sodium-hydrogen exchanger type 1 (NHE-1). Also disclosed are methods of using I, and pharmaceutical compns. contg. them. I are useful for the redn. of tissue damage resulting from tissue ischemia (no data). A large no. of compds. I and their intermediates were prepd. and/or specifically claimed. For instance, guanidine-HCl was converted to the free base, taken up in THF-DMF mixt., and coupled with 5-methyl-2-(2-methoxyphenyl)-2H-1,2,3-triazole-4-carboxylic acid (pre-activated with carbonyldiimidazole), and the resultant guanidine deriv. was isolated and acidified with HCl in MeOH, to give title compd. II.HCl in 17% yield.

IT **241800-11-3P**, Ethyl 5-cyclopropyl-1-[2-chloro-5-[(dimethylamino)sulfonyl]phenyl]-1H-pyrazole-4-carboxylate
241800-14-6P, Ethyl 5-cyclopropyl-1-[2-chloro-5-(methylaminosulfonyl)phenyl]-1H-pyrazole-4-carboxylate
241800-15-7P, Ethyl 5-cyclopropyl-1-[2-chloro-4-[(dimethylamino)sulfonyl]phenyl]-1H-pyrazole-4-carboxylate
241800-16-8P, Ethyl 5-cyclopropyl-1-[2-chloro-4-[(methylamino)sulfonyl]phenyl]-1H-pyrazole-4-carboxylate

241800-20-4P, Ethyl 5-cyclopropyl-1-[2-
 [(methylamino)sulfonyl]phenyl]-1H-pyrazole-4-carboxylate
241800-21-5P, Ethyl 5-cyclopropyl-1-[2-
 [(dimethylamino)sulfonyl]phenyl]-1H-pyrazole-4-carboxylate
241800-22-6P, Ethyl 1-(2-chloro-5-methylaminocarbonylphenyl)-5-
 cyclopropyl-1H-pyrazole-4-carboxylate **241800-23-7P**, Ethyl
 1-(2-chloro-5-dimethylaminocarbonylphenyl)-5-cyclopropyl-1H-pyrazole-4-
 carboxylate **241800-47-5P**, 5-Cyclopropyl-1-[2-chloro-5-
 [(dimethylamino)sulfonyl]phenyl]-1H-pyrazole-4-carboxylic acid
241800-49-7P, 5-Cyclopropyl-1-[2-chloro-5-
 [(methylamino)sulfonyl]phenyl]-1H-pyrazole-4-carboxylic acid
241800-55-5P, 5-Cyclopropyl-1-[2-chloro-4-
 [(dimethylamino)sulfonyl]phenyl]-1H-pyrazole-4-carboxylic acid
241800-56-6P, 5-Cyclopropyl-1-[2-chloro-4-
 [(methylamino)sulfonyl]phenyl]-1H-pyrazole-4-carboxylic acid
241800-63-5P, 5-Cyclopropyl-1-(2-dimethylaminosulfonylphenyl)-1H-
 pyrazole-4-carboxylic acid **241800-65-7P**,
 5-Cyclopropyl-1-[2-[(methylamino)sulfonyl]phenyl]-1H-pyrazole-4-carboxylic
 acid **241800-84-0P**, 1-(2-Chloro-5-methylaminocarbonylphenyl)-5-
 cyclopropyl-1H-pyrazole-4-carboxylic acid **241800-88-4P**,
 1-(2-Chloro-5-dimethylaminocarbonylphenyl)-5-cyclopropyl-1H-pyrazole-4-
 carboxylic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; prepn. of diazole and triazole guanidine derivs. as
 NHE-1 inhibitors for treatment of ischemia)

RN 241800-11-3 CAPLUS


CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-5-[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 241800-14-6 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-5-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl-, ethyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 241800-15-7 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-4-[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 241800-16-8 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-4-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl-, ethyl ester (9CI) (CA INDEX NAME)


09/773,736



RN 241800-20-4 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-cyclopropyl-1-[2-[(methylamino)sulfonyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 241800-21-5 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-cyclopropyl-1-[2-[(dimethylamino)sulfonyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 241800-22-6 CAPLUS


09/773,736

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-5-[(methylamino)carbonyl]phenyl]-5-cyclopropyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 241800-23-7 CAPLUS


CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-5-[(dimethylamino)carbonyl]phenyl]-5-cyclopropyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 241800-47-5 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-5-[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)


09/773,736



RN 241800-49-7 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-5-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)




RN 241800-55-5 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-4-[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)




RN 241800-56-6 CAPLUS

09/773,736


CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-4-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)



RN 241800-63-5 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-cyclopropyl-1-[2-[(dimethylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 241800-65-7 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 5-cyclopropyl-1-[2-[(methylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 241800-84-0 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-5-[(methylamino)carbonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)

09/773,736



RN 241800-88-4 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[2-chloro-5-[(dimethylamino)carbonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)



IT **241801-34-3P**, [1-[2-[(Dimethylamino)sulfonyl]phenyl]-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine hydrochloride **241801-36-5P**, [1-[2-[(Methylamino)sulfonyl]phenyl]-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine hydrochloride **241801-48-9P**, [1-[2-Chloro-5-[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine hydrochloride **241801-50-3P**, [1-[2-Chloro-5-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine hydrochloride **241801-56-9P**, [1-[2-Chloro-4-[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine hydrochloride **241801-57-0P**, [1-[2-Chloro-4-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine hydrochloride **241801-71-8P**, [1-[2-Chloro-5-[(methylamino)carbonyl]phenyl]-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine hydrochloride **241801-75-2P**, [1-[2-Chloro-5-[(dimethylamino)carbonyl]phenyl]-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine hydrochloride **241802-10-8P**, [1-[2-Chloro-4-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine **241802-17-5P**, [1-[2-Chloro-5-[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl-1H-pyrazole-4-carbonyl]guanidine


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

09/773,736

BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compd.; prepn. of diazole and triazole guanidine derivs. as
NHE-1 inhibitors for treatment of ischemia)

RN 241801-34-3 CAPLUS


CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-5-cyclopropyl-1-[2-
[(dimethylamino)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX
NAME)



● HCl

RN 241801-36-5 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-5-cyclopropyl-1-[2-
[(methylamino)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 241801-48-9 CAPLUS


CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-5-
[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl-, monohydrochloride (9CI)
(CA INDEX NAME)

09/773,736



● HCl


RN 241801-50-3 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-5-
[(methylamino)sulfonyl]phenyl]-5-cyclopropyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 241801-56-9 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-4-
[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl-, monohydrochloride (9CI)
(CA INDEX NAME)

09/773,736



● HCl


RN 241801-57-0 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-4-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl-, monohydrochloride (9CI)
(CA INDEX NAME)



● HCl


RN 241801-71-8 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-5-[(methylamino)carbonyl]phenyl]-5-cyclopropyl-, monohydrochloride (9CI)
(CA INDEX NAME)

09/773,736



● HCl


RN 241801-75-2 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-5-[(dimethylamino)carbonyl]phenyl]-5-cyclopropyl-, monohydrochloride (9CI)
(CA INDEX NAME)




● HCl

RN 241802-10-8 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-4-[(methylamino)sulfonyl]phenyl]-5-cyclopropyl-, monohydrochloride (9CI)
(CA INDEX NAME)

09/773,736



RN 241802-17-5 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[2-chloro-5-
[(dimethylamino)sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 45 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1999:468343 CAPLUS

DN 131:87911

TI Preparation of 1-substituted-pyrazole-3-carboxamide derivatives as fungicides

IN Okada, Itaru; Tomita, Hirofumi; Shiga, Yasushi

PA Mitsubishi Chemical Industries Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 26 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11199566	A2	19990727	JP 1998-83320	19980330
PRAI	JP 1997-85124		19970403		
	JP 1997-314916		19971117		

OS MARPAT 131:87911


AB Title compds. I and II (R1 = alkyl, alkoxy; R2, R3, R4, R6, R7, R8 = H, halo, alkyl, CF3, NO2, cyano, alkoxy, haloalkoxy, alkoxy-carbonyl, etc.; X = halo; Y = O, S; R5 = amino, alkoxyamino, pyrrolidinyl, morpholino, etc.) were prepd. Thus, chlorination of 4-bromo-1-(4-chlorophenyl)-5-methylpyrazole-3-carboxylic acid with SOCl2 followed by amidation with PrNH2 gave N-propyl-4-bromo-1-(4-chlorophenyl)-5-methylpyrazole-3-carboxamide. N-propyl-4-chloro-1-(4-chlorophenyl)-5-ethylpyrazole-3-carboxamide at 500 ppm gave total prevention of Magnaporthe grisea infection in rice plant.

IT **229637-92-7P 229638-15-7P 229638-17-9P**
229638-52-2P 229638-55-5P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of pyrazole-3-carboxamides as fungicides)

RN 229637-92-7 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 4-chloro-5-methyl-N-propyl-1-[4-(propylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 229638-15-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-chloro-N-ethyl-1-[4-(ethylamino)carbonyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)


09/773,736




RN 229638-17-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-butyl-1-[4-[(butylamino)carbonyl]phenyl]-4-chloro-5-methyl- (9CI) (CA INDEX NAME)



RN 229638-52-2 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 1-[4-(acetylaminophenyl)-4-bromo-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 229638-55-5 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 4-bromo-5-methyl-1-[4-(methylsulfonylamino)phenyl]-N-propyl- (9CI) (CA INDEX NAME)



09/773,736


L31 ANSWER 46 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1999:421659 CAPLUS
DN 131:58820
TI Preparation of nitrogen heteroaromatics as blood coagulation factor Xa inhibitors
IN Galemme, Robert A., Jr.; Pinto, Donald J. P.; Bostrom, Lori L.; Rossi, Karen Anita
PA Du Pont Pharmaceuticals Company, USA
SO PCT Int. Appl., 237 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9932454	A1	19990701	WO 1998-US26427	19981211
	W:	AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE			
	CA 2314401	AA	19990701	CA 1998-2314401	19981211
	AU 9917244	A1	19990712	AU 1999-17244	19981211
	BR 9813835	A	20001010	BR 1998-13835	19981211
	EP 1042299	A1	20001011	EP 1998-962082	19981211
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
	JP 2001526268	T2	20011218	JP 2000-525391	19981211
	ZA 9811517	A	20000615	ZA 1998-11517	19981215
	US 6271237	B1	20010807	US 1998-217336	19981221
	US 2002016326	A1	20020207	US 2001-833302	20010412
PRAI	US 1997-68491P	P	19971222		
	US 1997-996447	A	19971222		
	US 1998-101075P	P	19980918		
	WO 1998-US26427	W	19981211		
	US 1998-217336	A3	19981221		
OS	MARPAT 131:58820				
AB	DEG(CH2)sMZAB [I; D = cyano, amino(alkyl), amidino, etc.; E = (un)substituted phenylene, -pyridinediyl, -pyrimidinediyl, etc.; G = bond, NHCH2, OCH2, SCH2; M = (un)substituted pyrrolylene, -di-, -tri-, or -tetrazolylene; Z = (heteroatom-interrupted)(oxo)alkylene, oxyalkylene, alkyleneoxy, etc.; A = (un)substituted carbocyclic residue (sic) or -heterocyclylene; B = amino(alkyl), amidino, ureido, (un)substituted carbocyclic residue, etc.; s = 0-2] were prepd. Thus, 2-hydrazino-5-methoxybenzoic acid was cyclocondensed with MeCOCH2C(:NOMe)CO2Et (prepn. each given) and the product converted in 3 steps to 3-methyl-1-(2-azidomethyl-4-methoxyphenyl)-1H-pyrazole-5-carboxylic acid which was amidated by 4-(H2N)C6H4C6H4(CO2NHCM3)-2 to give, in 2 addnl. steps, title compd. II. Data for biol. activity of I were given.				
IT	228259-34-5P 228259-35-6P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of nitrogen heteroaroms. as blood coagulation factor Xa inhibitors)				
RN	228259-34-5 CAPLUS				
CN	Carbamic acid, [[2-[5-(2-furanyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)				

09/773,736



RN 228259-35-6 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[2-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RE.CNT 4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

09/773,736

L31 ANSWER 47 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1999:409328 CAPLUS

DN 131:75076

TI Azo dye-containing ink-jet inks with light and water resistance

IN Kamio, Takayoshi; Arai, Itsumi

PA Fuji Photo Film Co., Ltd., Japan

SO Jpn. Kokai Tokkyo Koho, 22 pp.

CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 11172183	A2	19990629	JP 1997-363419	19971215
OS	MARPAT 131:75076				

AB Title inks contain azo dyes I (R1-R4 = H, halogen, (cyclo)alkyl, aralkyl, aryl, heterocyclo, CN, OH, NO₂, (alkyl)amino, alkoxy, aryloxy, amido, arylamino, ureido, sulfamoylamino, alkylthio, arylthio, alkoxycarbonylamino, sulfenamido, carbamoyl, sulfamoyl, sulfonyl, alkoxycarbonyl, heterocycloxy, azo, acyloxy, carbamoyloxy, silyloxy, aryloxy, carbonyl(amino), imido, heterocycloxythio, sulfinyl, phosphoryl, acyl, carboxyl, sulfoyl or R3-R4 formed arom. or heterocyclo ring; R5 = unsatd. heterocyclo]. An oil ink comprising I (R1, R3 = Cl, R2, R4 = H, R5 = II) 6, di-Bu adipate 20, and benzyl alc. 70 parts showed discharge stability and gave prints with good light resistance (room light, 3 mo) and no smudges after soaking in water for 10 min.


IT 228545-23-1

RL: TEM (Technical or engineered material use); USES (Uses)

(specific azo dye-contg. ink-jet inks with light and water resistance)

RN 228545-23-1 CAPLUS


CN Propanamide, N-[3-chloro-5-[[4-cyano-1-[2,5-dichloro-4-[[[1-ethylpentyl)amino]sulfonyl]phenyl]-1H-pyrazol-5-yl]azo]-2-hydroxyphenyl]-2-methyl- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 48 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1999:388169 CAPLUS
DN 131:44813
TI Preparation of 3-(pyrazol-1-yl)benzoic acid derivatives as agrochemical fungicides
IN Eicken, Karl; Rheinheimer, Joachim; Wetterich, Frank; Ammermann, Eberhard; Lorenz, Gisela; Speakman, John-Bryan; Strathmann, Siegfried
PA BASF Aktiengesellschaft, Germany
SO PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9929671	A1	19990617	WO 1998-EP7920	19981205
	W: CA, JP, MX, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRAI	DE 1997-19754301		19971208		
OS	MARPAT 131:44813				
AB	The title compds. [I; R1 = C1-4 alkyl, C1-4 alkoxy, halo; R2 = C1-4 (halo)alkyl, C1-4 alkoxy, C3-6 cycloalkyl, halo, (un)substituted aryl; R3 = C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, (un)substituted aryl, etc.; R4 = ZR5; R5 = H, C1-6 (halo)alkyl, C3-6 alkenyl, (un)substituted Ph, etc.; X = S, SO, SO2; Y = O, S; Z = O, S, etc.; l, m = 0-3] were prepd. For example, thioetherification of 2,3-Cl(O2N)C6H3CO2Me with NaSMe in DMF gave 2-MeS analog which was hydrogenated in the presence of Raney Ni to give 2,3-MeS(H2N)C6H3CO2Me. This was diazotized, the diazonium salt reduced with SnCl2 in aq. HCl at -5 to 0.degree. and the resulting hydrazo salt alkalinized with 2N NaOH (pH 11) to give 2,3-MeS(H2NNH)C6H3CO2Me. The free base was cyclocondensed with (MeO)2CH2(OMe)2 to give Me 2-methylthio-3-(pyrazol-1-yl)benzoate which was saponified with KOH in MeOH and the salt acidified to give a title deriv. I (l = m = 0, R3 = Me, R4 = OH, X = S, Y = O) which gave protection of cucumber seedlings against Colletotrichum lagenarium.				
IT	227466-49-1P RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of 3-(pyrazol-1-yl)benzoic acid derivs. as agrochem. fungicides)				
RN	227466-49-1 CAPLUS				
CN	Benzamide, 2-(methylthio)-N-(phenylmethyl)-3-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)				



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 49 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:311182 CAPLUS
 DN 130:338112
 TI Preparation of N-(heterocyclylphenyl)isothiourea and -isoureas having
 nitric oxide synthase (NOS) inhibitory activities
 IN Makino, Toshihiko
 PA Chugai Seiyaku Kabushiki Kaisha, Japan
 SO PCT Int. Appl., 49 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9923069	A1	19990514	WO 1998-JP4967	19981104
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
TW 460460	B	20011021	TW 1998-87118206	19981102
CA 2307581	AA	19990514	CA 1998-2307581	19981104
AU 9897614	A1	19990524	AU 1998-97614	19981104
AU 737967	B2	20010906		
EP 1043312	A1	20001011	EP 1998-951681	19981104
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
US 6414005	B1	20020702	US 2000-530752	20000504
PRAI JP 1997-339267	A	19971104		
JP 1998-146492	A	19980420		
WO 1998-JP4967	W	19981104		

OS MARPAT 130:338112

AB Compsds. represented by general formula [I; wherein R1 represents (un)substituted aminoalkyl; R2 represents hydrogen, lower alkyl, or halo; R3 represents SR4 OR4, or NR5R6; wherein R4 represents lower alkyl or (un)substituted lower alkyl; R5 and R6 represent hydrogen, lower alkyl, or NO2 or they are combined together to form a 3- to 6-membered ring; and Ar represents a (un)substituted 5- to 6-membered heteroaryl group] are prepd. having NOS inhibitory activities, and being useful as medicines such as a remedy for cerebrovascular disorder,. Also claimed are (a) therapeutics for brain vascular disorders such as cerebral hemorrhage, sub-arachnoid hemorrhage, cerebral infarction, atherothrombotic infarction, lacunar infarction, embolism, transient ischemic attack (TIA), cerebral edema, and cerebral trauma, spinal injury, Parkinson's disease, Alzheimer's disease, and morphine resistance and dependence, (b) anticonvulsants, and (c) analgesics for headache, migraine, tension-type headache, cluster headache, and chronic paroxysmal headache contg. I as the active ingredients. Thus, N-[3-[bis(tert-butoxycarbonyl)aminomethyl]-4-(pyrrol-1-yl)phenyl]thiourea was heated with Et iodide in acetone under reflux for 14 h followed by treatment with 4 N aq. HCl to give N-[3-aminomethyl-4-(pyrrol-1-yl)phenyl]-S-ethylisothiourea dihydrochloride (II). II showed IC50 of 3.7, 1,920, and 7,930 nM against NOS isoforms, i.e. nNOS (type 1), eNOS (type 2), and iNOS (type 3), resp.

IT 209899-30-9P 224185-10-8P 224185-11-9P
 224185-12-0P 224185-13-1P 224185-14-2P

09/773,736

224185-15-3P 224185-16-4P 224185-17-5P

224185-18-6P 224185-22-2P 224185-23-3P


224185-24-4P 224185-25-5P 224185-26-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N-(heterocyclylphenyl)isothiourea and -isoureas having nitric oxide synthase (NOS) inhibitory activities as therapeutics)


RN 209899-30-9 CAPLUS

CN Imidodicarbonic acid, [[5-nitro-2-(1H-pyrazol-1-yl)phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 224185-10-8 CAPLUS


CN Imidodicarbonic acid, [[5-amino-2-(1H-pyrazol-1-yl)phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 224185-11-9 CAPLUS


CN Imidodicarbonic acid, [[5-[(aminothioxomethyl)amino]-2-(1H-pyrazol-1-yl)phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

09/773,736




RN 224185-12-0 CAPLUS

CN Imidodicarbonic acid, [[5-[[[(ethylthio)iminomethyl]amino]-2-(1H-pyrazol-1-yl)phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 224185-13-1 CAPLUS


CN Carbamic acid, [[5-(cyanoamino)-2-(1H-pyrazol-1-yl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 224185-14-2 CAPLUS


CN Imidodicarbonic acid, [[2-(4-methyl-1H-pyrazol-1-yl)-5-nitrophenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

09/773,736




RN 224185-15-3 CAPLUS

CN Imidodicarbonic acid, [[5-amino-2-(4-methyl-1H-pyrazol-1-yl)phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 224185-16-4 CAPLUS


CN Imidodicarbonic acid, [[5-[(aminothioxomethyl)amino]-2-(4-methyl-1H-pyrazol-1-yl)phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 224185-17-5 CAPLUS

CN Imidodicarbonic acid, [[5-(cyanoamino)-2-(4-methyl-1H-pyrazol-1-yl)phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


09/773,736



RN 224185-18-6 CAPLUS
CN Imidodicarbonic acid, [[5-[[(ethylthio)iminomethyl]amino]-2-(4-methyl-1H-pyrazol-1-yl)phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)




RN 224185-22-2 CAPLUS
CN Carbamic acid, [[3-bromo-6-methyl-5-nitro-2-(1H-pyrazol-1-yl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 224185-23-3 CAPLUS
CN Carbamic acid, [[3-[(aminothioxomethyl)amino]-2-methyl-6-(1H-pyrazol-1-yl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 224185-24-4 CAPLUS

CN Carbamic acid, [[3-[(benzoylamino)thioxomethyl]amino]-2-methyl-6-(1H-pyrazol-1-yl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 224185-25-5 CAPLUS

CN Carbamic acid, [[3-[(ethylthio)iminomethyl]amino]-2-methyl-6-(1H-pyrazol-1-yl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 224185-26-6 CAPLUS

CN Carbamic acid, [[3-(cyanoamino)-2-methyl-6-(1H-pyrazol-1-yl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 50 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1999:271338 CAPLUS

DN 130:311815

TI Preparation of pyrazole derivatives as calcium release-dependent calcium channel inhibitors and inhibitors of interleukin-2 (IL-2) production

IN Kubota, Hirokazu; Yonetoku, Yasuhiro; Sugasawa, Keizou; Funatsu, Masashi; Kawazoe, Souichirou; Toyoshima, Akira; Okamoto, Yoshinori; Ishikawa, Jun; Takeuchi, Makoto

PA Yamanouchi Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9919303	A1	19990422	WO 1998-JP4583	19981012
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9887139	A1	19990429	AU 1998-87139	19980929
	BR 9803883	A	20000516	BR 1998-3883	19981006
	CA 2304979	AA	19990422	CA 1998-2304979	19981012
	AU 9894593	A1	19990503	AU 1998-94593	19981012
	EP 1024138	A1	20000802	EP 1998-947818	19981012
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI			
	CN 1218046	A	19990602	CN 1998-121354	19981013
	JP 11240832	A2	19990907	JP 1998-290734	19981013
Parent →	US 6348480	B1	20020219	US 2000-529131	20000407
	NO 2000001907	A	20000609	NO 2000-1907	20000412
	US 2001011090	A1	20010802	US 2001-773736	20010202
PRAI	JP 1997-279093	A	19971013		
	WO 1998-JP4583	W	19981012		
	US 2000-529131	A3	20000407		

OS MARPAT 130:311815

AB Pyrazole derivs. represented by general formula [I; ring D = pyrazolyl optionally substituted by 1-3 substituents selected from alkyl, lower alkenyl, lower alkynyl, lower haloalkyl, cycloalkylalkyl, alkoxyalkyl, cycloalkyl, alkoxy, CO₂H, alkoxycarbonyl, and halo; ring B = phenylene, a nitrogen-contg., divalent, satd. ring group, or an optionally alkylated, monocyclic, divalent heteroarom. ring group; X = -NR₁-CR₂R₃-, -CR₂R₃-NR₁-, -NR₁-SO₂-, -SO₂-NR₁- or -CR₄:CR₅-; wherein R₁ = H, OH, alkyl, alkoxy, alkylcarbonyl; R₂, R₃ = H or alkyl or R₂R₃ = O or S; R₄, R₅ = H, halo, lower haloalkyl; A = (1) Ph optionally having one or more substituents, (2) mono-, di- or tricyclic fused heteroaryl optionally having one or more substituents, (3) cycloalkyl optionally having one or more substituents, (4) a nitrogen-contg., satd. ring group optionally having one or more substituents, (5) lower alkenyl optionally having one or more substituents, (6) lower alkynyl optionally having one or more substituents, or (7) alkyl optionally having one or more substituents; or A and X are combined together to represent 1-pyrrolidinylcarbonyl, pyrazolidinylcarbonyl, piperidinocarbonyl, piperazinylcarbonyl, morpholinocarbonyl, 3,4-2H-1,4-benzoxazin-4-ylcarbonyl, or

09/773,736

indolylcarbonyl] are prepd. Also claimed are medicinal compns., in particular, calcium release-dependent calcium channel inhibitors, IL-2 prodn. inhibitors, and therapeutics or preventives for allergies, inflammations, or autoimmune diseases, bronchial asthma, or rheumatoid arthritis for contg. the above compds. I as the active ingredients. Thus, 4-methylthiazole-5-carboxylic acid was condensed with 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]aniline using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in 1,2-dichloroethane at room temp. overnight to give the title compd., 4'-pyrazolylthiazole-5-carboxanilide deriv. (II). II in vitro showed IC50 of .1 to req. 1 .mu.M .mu.g/mL for inhibiting the prodn. of IL-2 in Jurkat cells.


IT 223499-21-6P 223499-22-7P 223499-23-8P
223499-24-9P 223499-25-0P 223499-26-1P
223499-27-2P 223499-28-3P 223499-29-4P
223499-30-7P 223499-31-8P 223499-32-9P
223499-33-0P 223499-35-2P 223499-36-3P
223499-37-4P 223499-38-5P 223499-40-9P
223499-41-0P 223499-43-2P 223499-44-3P
223499-45-4P 223499-46-5P 223499-47-6P
223499-48-7P 223499-50-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrazole derivs. as calcium release-dependent calcium channel inhibitors and inhibitors of interleukin-2 prodn. for treatment and prevention of diseases)

RN 223499-21-6 CAPLUS


CN 5-Thiazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



Elected species.

RN 223499-22-7 CAPLUS


CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)



RN 223499-23-8 CAPLUS


09/773,736

CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[(4-chlorobenzoyl)amino]phenyl]-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 223499-24-9 CAPLUS


CN 4-Piperidinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 223499-25-0 CAPLUS


CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[(methylsulfonyl)amino]phenyl]-5-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 223499-26-1 CAPLUS

CN 1H-Imidazole-4-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 223499-27-2 CAPLUS
CN Benzamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-2-chloro-
(9CI) (CA INDEX NAME)



RN 223499-28-3 CAPLUS
CN 2-Thiazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 223499-29-4 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-N-hydroxy-4-methyl- (9CI) (CA INDEX NAME)



RN 223499-30-7 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-N-hydroxy-4-methyl- (9CI) (CA INDEX NAME)


09/773,736

1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 223499-31-8 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, N-[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 223499-32-9 CAPLUS

CN 1,2,3-Thiadiazole-5-carboxamide, 4-methyl-N-[4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 223499-33-0 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[(4-chlorobenzoyl)amino]phenyl]-5-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)




09/773,736


RN 223499-35-2 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[[4-methyl-1,2,3-thiadiazol-5-yl]carbonyl]amino]phenyl]-5-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 223499-36-3 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, 4-methyl-N-[4-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 223499-37-4 CAPLUS
CN 5-Thiazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 223499-38-5 CAPLUS
CN 1,2,3-Thiadiazole-5-carboxamide, 4-methyl-N-[4-[5-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736



RN 223499-40-9 CAPLUS
CN 5-Oxazolecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 223499-41-0 CAPLUS
CN 2-Thiophenecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)




RN 223499-43-2 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[(2,3-dimethyl-1-oxo-2-butenyl)amino]phenyl]-5-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 223499-44-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[(cyclopropylcarbonyl)amino]phenyl]-5-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 223499-45-4 CAPLUS


CN 3-Pyridinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 223499-46-5 CAPLUS


CN Pyrazinecarboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 223499-47-6 CAPLUS

CN 1H-Pyrazole-2-carboxamide, N-[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 223499-48-7 CAPLUS

CN Benzamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-(4-methyl-1,2,3-thiadiazol-5-yl)- (9CI) (CA INDEX NAME)



RN 223499-50-1 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[[3-(4-chlorophenyl)-1-oxo-2-propenyl]amino]phenyl]-5-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



09/773,736


IT 223500-14-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of pyrazole derivs. as calcium release-dependent calcium channel inhibitors and inhibitors of interleukin-2 prodn. for treatment and prevention of diseases)

RN 223500-14-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 51 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:271335 CAPLUS
 DN 130:311531
 TI Preparation of prostaglandin agonists and their use to treat bone disorders
 IN Cameron, Kimberly O'Keefe; Lefker, Bruce Allen; Rosati, Robert Louis
 PA Pfizer Inc., USA
 SO PCT Int. Appl., 255 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9919300	A1	19990422	WO 1998-IB1540	19981005
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2305548	AA	19990422	CA 1998-2305548	19981005
AU 9891815	A1	19990503	AU 1998-91815	19981005
AU 731509	B2	20010329		
EP 1021410	A1	20000726	EP 1998-944169	19981005
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO			
BR 9813028	A	20000815	BR 1998-13028	19981005
JP 2001519414	T2	20011023	JP 2000-515873	19981005
ZA 9809230	A	20000410	ZA 1998-9230	19981009
NO 2000001754	A	20000607	NO 2000-1754	20000405
PRAI US 1997-61727P	P	19971010		
WO 1998-IB1540	W	19981005		

OS MARPAT 130:311531

AB Title prostaglandin agonists GAB(KM)QZ [A is SO₂, CO; G is Ar, alkylene, ArCONHalkylene, amino, oxyalkylene, etc.; B is N, CH; Q is alkylene, alkyl, alkylene-W-alkylene, alkylene-W-X-alkylene; W is oxy, thio, sulfinio, sulfonyl, aminosulfonyl, etc.; X is aryl; K is a bond, alkylene, thioalkylene, alkylene-thioalkylene, etc.; M is Ar, ArSar, ArSOAr, ArSO₂Ar, ArOAr], prodrugs thereof and the pharmaceutically acceptable salts of said compds. and said prodrugs are prepd. as well as methods of using such prostaglandin agonists, pharmaceutical compns. contg. such prostaglandin agonists and kits contg. such prostaglandin agonists are discussed. The prostaglandin agonists are useful for the treatment of bone disorders including osteoporosis.


IT 223489-52-9P 223489-53-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of prostaglandin agonists and their use to treat bone disorders)


RN 223489-52-9 CAPLUS

CN Heptanoic acid, 7-[[[4-(1H-pyrazol-1-yl)phenyl]methyl](2-pyridinylsulfonyl)amino]- (9CI) (CA INDEX NAME)


09/773,736




RN 223489-53-0 CAPLUS
CN Heptanoic acid, 7-[[[4-(1H-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]- (9CI) (CA INDEX NAME)



IT 223490-94-6P 223490-95-7P 223490-96-8P
223490-97-9P 223491-44-9P 223491-82-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(prepn. of prostaglandin agonists and their use to treat bone disorders)
RN 223490-94-6 CAPLUS
CN Heptanoic acid, 7-[[[4-(1H-pyrazol-1-yl)phenyl]methyl]amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 223490-95-7 CAPLUS
CN Heptanoic acid, 7-[[[4-(1H-pyrazol-1-yl)phenyl]methyl](2-pyridinylsulfonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)



RN 223490-96-8 CAPLUS
CN Heptanoic acid, 7-[[[4-(1H-pyrazol-1-yl)phenyl]methyl](3-pyridinylsulfonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)


09/773,736

pyridinylsulfonyl)amino]-, methyl ester (9CI) (CA INDEX NAME)




RN 223490-97-9 CAPLUS

CN Benzenepropanoic acid, 3-[[[4-(1H-pyrazol-1-yl)phenyl]methyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 223491-44-9 CAPLUS

CN Benzenepropanoic acid, .alpha.-methyl-3-[[[4-(1H-pyrazol-1-yl)phenyl]methyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 223491-82-5 CAPLUS

CN Acetic acid, [3-[[[4-(1H-pyrazol-1-yl)phenyl]methyl]amino]methyl]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 52 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1999:186093 CAPLUS
 DN 130:318449
 TI Photodecomposition of Some Para-Substituted 2-Pyrazolylphenyl Azides.
 Substituents Affect the Phenylnitrene S-T Gap More Than the Barrier to
 Ring Expansion
 AU Albinì, Angelo; Bettinetti, Gianfranco; Minoli, Giovanna
 CS Dipartimento di Chimica Organica, Università di Pavia, Pavia, I-27100,
 Italy
 SO Journal of the American Chemical Society (1999), 121(13), 3104-3113
 CODEN: JACSAT; ISSN: 0002-7863
 PB American Chemical Society
 DT Journal
 LA English
 AB A series of para-substituted (H, Me, Cl, F, CF₃, OMe, NMe₂) Ph azides
 bearing a dimethylpyrazolyl group in position 2 allowing intramol.
 trapping of singlet nitrene have been photolyzed at both 295 and 90 K in
 ethanol. For three significant models (H, CF₃, NMe₂), the reaction has
 been further studied in the presence of diethylamine (DEA) and of oxygen.
 With all substituents but NMe₂, singlet nitrene (trapped intramolecularly
 to give pyrazolobenzotriazoles) and didehydroazepine (trapped with DEA to
 give 5H-azepines and then rearranging to 3H-azepines) are in equil. With
 the NMe₂ deriv., the nonelectrophilic singlet is not trapped, while DEA
 adds to the benzoazirine, the precursor of the didehydroazepine. Thus,
 electronic effects do not hinder the equil. between singlet nitrene and
 its cyclic isomers, while detg. which of the above intermediates decays to
 a stable end product. The electron-donating group NMe₂ has a second
 important effect, causing a drastic enhancement of the triplet nitrene
 energy and redn. of the S-T gap, so that triplet nitrene is also in equil.
 with the singlet and the benzoazirine. As for triplet nitrenes, these
 have been characterized in matrix at 90 K, and the competition between
 dimerization (to give azo compds., as typical of such stabilized species)
 and hydrogen abstraction from the solvent (involving a sizable barrier)
 has been studied. The energetic p-dimethylamino triplet undergoes
 hydrogen abstraction exclusively. When present, oxygen adds efficiently
 to all of the nitrenes, giving a nitroso oxide, likewise characterized in
 the matrix, which then converts to the nitroso and nitro derivs. in good
 yields. Photochem. excitation of the triplet in matrix leads to intramol.
 hydrogen abstraction.
 IT **223594-89-6P**, 1-[2-Amino-3-(diethylamino)-5-(dimethylaminophenyl)]-
 3,5-dimethylpyrazole
 RL: PEP (Physical, engineering or chemical process); SPN (Synthetic
 preparation); PREP (Preparation); PROC (Process)
 (photolysis of pyrazolylphenyl azides at different temps. and in
 presence of diethylamine nucleophile trap)
 RN 223594-89-6 CAPLUS
 CN 1,2,4-Benzenetriamine, 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N2,N2-diethyl-
 N4,N4-dimethyl- (9CI) (CA INDEX NAME)

09/773,736



RE.CNT 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


09/773,736

L31 ANSWER 53 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1999:9833 CAPLUS
DN 130:66494
TI Preparation of novel guanidine mimics as factor Xa inhibitors
IN Lam, Patrick Y.; Clark, Charles G.; Dominguez, Celia; Fevig, John Matthew;
Han, Qi; Li, Renhua; Pinto, Donald Joseph-Phillip; Pruitt, James Russell;
Quan, Mimi Lifan
PA The Du Pont Merck Pharmaceutical Company, USA
SO PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857951	A1	19981223	WO 1998-US12680	19980618
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9879768	A1	19990104	AU 1998-79768	19980618
EP 991638	A1	20000412	EP 1998-930361	19980618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9810137	A	20000808	BR 1998-10137	19980618
JP 2002505686	T2	20020219	JP 1999-504785	19980618
NO 9905965	A	19991203	NO 1999-5965	19991203
LV 12496	B	20010120	LV 1999-178	19991216
LT 4705	B	20000925	LT 1999-147	19991217
PRAI US 1997-878884	A	19970619	<i>Abn - no Cont. Appln.</i>	
WO 1998-US12680	W	19980618		


OS MARPAT 130:66494
AB The title compds. [I; rings D-E represent guanidine mimics; ring D = CH₂N:CH, CH₂CH₂N:CH, a 5-6 membered arom. system contg. 0-2 heteroatoms selected from the group N, O, and S; ring E is substituted with 0-2 R (substituents), provided that when ring D is unsubstituted, it contains at least one heteroatom; ring E contains 0-2 N atom and is substituted by 0-1 R; R = halo, OH, Cl-3 alkoxy, etc.; M = (un)substituted pyrazole, imidazole, tetrazole, etc.], inhibitors of factor Xa which are useful in treating and preventing a thromboembolic disorder, were prepd. and formulated. Thus, a multi-step synthesis of the title compd. II, starting with 7-aminoisoquinoline, was described. A no. of compds. I were found to exhibit a Ki of .ltoreq. 15 .mu.M against factor Xa.
IT **218301-51-0P 218301-52-1P 218301-53-2P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of novel guanidine mimics as factor Xa inhibitors)
RN 218301-51-0 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 1-[3-(aminocarbonyl)-4-(2-phenylethenyl)phenyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 218301-52-1 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-cyano-4-(2-phenylethenyl)phenyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 218301-53-2 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-cyano-4-(2-phenylethenyl)phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RE.CNT 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L31 ANSWER 54 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1998:479506 CAPLUS

DN 129:109090

TI Preparation of nitrogen-containing heteroaromatics as factor Xa inhibitors

IN Pinto, Donald Joseph Phillip; Pruitt, James Russell; Cacciola, Joseph;

Fevig, John Matthew; Han, Qi; Orwat, Michael James; Quan, Mimi Lifan;

Rossi, Karen Anita

PA The Dupont Merck Pharmaceutical Co., USA

SO PCT Int. Appl., 438 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9828269	A1	19980702	WO 1997-US22895	19971215
	W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9856020	A1	19980717	AU 1998-56020	19971215
	AU 730224	B2	20010301		
	EP 946508	A1	19991006	EP 1997-952409	19971215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1246847	A	20000308	CN 1997-181852	19971215
	BR 9714073	A	20000509	BR 1997-14073	19971215
	JP 2001509145	T2	20010710	JP 1998-528845	19971215
	ZA 9711586	A	19990701	ZA 1997-11586	19971223
	NO 9902633	A	19990820	NO 1999-2633	19990601
	LT 4673	B	20000725	LT 1999-76	19990622
	LV 12430	B	20000720	LV 1999-99	19990730
PRAI	US 1996-769859	A	19961223		
	US 1997-879944	A	19970620		
	WO 1997-US22895	W	19971215		

OS MARPAT 129:109090

AB The title compds. [I; ring M contains, in addn. to J, 0-3 N atoms; J = N, NH; D = CN, C(:NR8)NR7R9, C(O)NR7R8, etc.; E = (un)substituted Ph, pyridyl, pyrimidinyl, etc.; DEG = R-substituted pyridyl; R = H, halo, CF3, etc.; G = absent, NHCH2, OCH2, etc.; Z = C1-4 alkylene, (CH2)rO(CH2)r, etc.; R1a, R1b = absent, NMe, OMe, etc.; A = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic contg. from 1-4 heteroatoms selected from N, O, and S; B = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic contg. from 1-4 heteroatoms selected from N, O, and S, etc.; R7 = H, OH, C1-6 alkyl, etc.; R8, R9 = H, C1-6 alkyl, (CH2)nPh; n = 0-3; r = 0-3; s = 0-2], useful as inhibitors of factor Xa, were prepd. and formulated. Thus, treatment of 4-[o-(tert-BuSO2)phenyl]aniline with Me3Al/hexane in CH2Cl2 followed by the addn. of Me 1-(3-cyanophenyl)imidazol-2-ylcarboxylate (prepn. described), and the Pinner reaction of the resulting intermediate afforded the title compd. II. A no. of compds. I were found to exhibit a Ki of .ltoreq. 10 .mu.M against factor Xa. Some compds. I were evaluated and found to exhibit Ki of < 10 .mu.M against thrombin.

IT 209959-82-0P 209959-90-0P 209959-91-1P

209959-92-2P 209960-00-9P 209960-01-0P

209960-02-1P 209960-06-5P 209960-52-1P

209960-53-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

09/773,736

(prepn. of nitrogen-contg. heteroaroms. as factor Xa inhibitors)


RN 209959-82-0 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-methyl-1-[3-[[[(phenylmethoxy)carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 209959-90-0 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 209959-91-1 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]phenyl]-3-methyl-, ethyl ester (9CI) (CA INDEX NAME)



RN 209959-92-2 CAPLUS


CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(1,1-dimethylethoxy)carbonyl]methylamino]methyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



09/773,736


RN 209960-00-9 CAPLUS

CN Carbamic acid, [1-[3-[5-(hydroxymethyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 209960-01-0 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[1-[(1,1-dimethylethoxy)carbonyl]amino]ethyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 209960-02-1 CAPLUS


CN Carbamic acid, [1-[3-[5-[[4-bromophenyl]amino]carbonyl]-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 209960-06-5 CAPLUS


CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(phenylmethoxy)carbonyl]amino]methyl]phenyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

09/773,736




RN 209960-52-1 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-(methylthio)-, methyl ester (9CI) (CA INDEX NAME)



RN 209960-53-2 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 1-[3-[[[(1,1-dimethylethoxy)carbonyl]amino]methyl]phenyl]-3-(methylthio)- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 55 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1998:479495 CAPLUS
DN 129:108995
TI Preparation of aromatic and heterocyclic amine derivatives as NOS inhibitors
IN Esaki, Toru; Makino, Toshihiko; Nishimura, Yoshikazu; Nagafuji, Toshiaki
PA Chugai Seiyaku Kabushiki Kaisha, Japan
SO PCT Int. Appl., 165 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9828257	A1	19980702	WO 1997-JP4762	19971224
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GM, GW, HU, ID, IL, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9853394	A1	19980717	AU 1998-53394	19971224
	AU 742388	B2	20020103		
	JP 10237028	A2	19980908	JP 1997-366474	19971224
	EP 949242	A1	19991013	EP 1997-950368	19971224
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	CN 1240419	A	20000105	CN 1997-180594	19971224
	NO 9903109	A	19990824	NO 1999-3109	19990622
	US 6331553	B1	20011218	US 1999-331733	19990624
PRAI	JP 1996-359791	A	19961224		
	WO 1997-JP4762	W	19971224		

OS MARPAT 129:108995

AB The title compds. I [R1 and R2 represent each hydrogen, etc.; R3 and R4 represent each hydrogen, lower alkyl, etc.; R5 represents hydrogen, etc.; X1, X2, X3 and X4 represent each hydrogen, lower alkoxyl, etc.; A represents an optionally substituted pyridine ring, etc.; and m and n are each 0 or 1] are prepd. I are useful as pharmaceuticals for cerebrovascular disorders, etc. The title compd. II in vitro showed IC50 values of 22.6 nM and 916.7 nM against nNOS and iNOS, resp.


IT **209898-98-6P 209899-30-9P 209899-31-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arom. and heterocyclic amine derivs. as NOS inhibitors)


RN 209898-98-6 CAPLUS

CN Carbamic acid, [[5-[(4-methyl-2-pyridinyl)amino]-2-(1H-pyrazol-1-yl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


09/773,736



RN 209899-30-9 CAPLUS
CN Imidodicarbonic acid, [[5-nitro-2-(1H-pyrazol-1-yl)phenyl]methyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 209899-31-0 CAPLUS
CN Carbamic acid, [[5-amino-2-(1H-pyrazol-1-yl)phenyl]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 56 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1998:424227 CAPLUS
DN 129:95491
TI Preparation of N-[(substituted five-membered heteroaryl)carbonyl]guanidine derivatives as Na⁺/H⁺ exchanger inhibitors
IN Okazaki, Toshio; Kikuchi, Kazumi; Sugasawa, Keizo; Kaku, Hidetaka; Takanashi, Masahiro
PA Yamanouchi Pharmaceutical Co., Ltd., Japan; Merck Patent G.m.b.H.; Kikuchi, Kazumi; Sugasawa, Keizo; Kaku, Hidetaka; Takanashi, Masahiro
SO PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

not prior.

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9827061	A1	19980625	WO 1997-JP4605	19971215
	W:	AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	ZA 9711102	A	19980813	ZA 1997-11102	19971210
	AU 9854119	A1	19980715	AU 1998-54119	19971215
PRAI	JP 1996-335638		19961216		
	WO 1997-JP4605		19971215		

OS MARPAT 129:95491
AB N-[(Substituted five-membered heteroaryl)carbonyl]guanidine derivs. represented by general formula (I) or pharmacol. acceptable salts thereof [wherein the five-membered heteroaryl ring represents Q or Q1 (wherein X1 represents oxygen, sulfur, or NR₃; and X2 represents nitrogen or CR₄); R1 represents optionally substituted aryl or optionally substituted five- or six-membered monocyclic heteroaryl; R2 represents hydrogen, halogeno, optionally halogen-substituted lower alkyl, lower alkoxy, lower alkylthio, or optionally protected amino, provided that when the R1-substituted five-membered heteroaryl ring is Q2, R2 is neither hydrogen nor ethoxy; and R3 and R4 each represents hydrogen or optionally halogen-substituted lower alkyl] are prepd. They are useful as a drug, esp. an Na⁺/H⁺ exchanger inhibitor, for the prevention, treatment, or diagnosis of various diseases in which an Na⁺/H⁺ exchanger participates, such as hypertension, arrhythmia, angina pectoris, myocardial infarct, organ damages caused by ischemia or ischemic reperfusion, cell proliferative diseases (e.g. arteriosclerosis and cancer), and disorders caused by high blood sugar (e.g. complications of diabetes). Thus, imidazole was treated with NaH in DMF at room temp. for 30 min and then stirred with Et 2-[3-(2-bromoethoxy)phenyl]-4-methylthiazole-5-carboxylate at 70.degree. for 3 h followed by heating with guanidine hydrochloride in the presence of NaH at 80.degree. for 3 h to give the title compd., [(imidazolylmethoxy)phenyl]thiazolecarbonylguanidine deriv. (II). The tile compds. I in vitro inhibited Na⁺/H⁺ exchanger with Ki of from 10⁻⁶ to 10⁻⁸.

IT **209538-78-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

09/773,736

(prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine
derivs. as Na⁺/H⁺ exchanger inhibitors for treatment of diseases)


RN 209538-78-3 CAPLUS

CN 1H-Pyrazole-4-carboxamide, N-(aminoiminomethyl)-1-[3-
[[dimethylamino)acetyl]amino]phenyl]-5-methyl-, dimethanesulfonate (9CI)
(CA INDEX NAME)

CM 1


CRN 209538-77-2

CMF C16 H21 N7 O2



CRN 75-75-2

CMF C H4 O3 S




IT **209540-03-4P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(prepn. of N-[(substituted five-membered heteroaryl)carbonyl]guanidine
derivs. as Na⁺/H⁺ exchanger inhibitors for treatment of diseases)

RN 209540-03-4 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[3-[(bromoacetyl)amino]phenyl]-3,5-
dimethyl-, ethyl ester (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 57 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1998:351919 CAPLUS
DN 129:87956
TI Color diffusion transfer image-forming system and color image formation
IN Naruse, Hideaki; Nakamura, Takemare
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 82 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10142764	A2	19980529	JP 1996-317058	19961113
OS	MARPAT 129:87956				

AB In the title system using a photosensitive material contg. a photosensitive Ag halide, a binder, a compd. I (Z = carbamoyl, acyl, alkoxycarbonyl, aryloxycarbonyl, sulfonyl, sulfamoyl; Q = atoms required to form an unsatd. ring along with the C atom), and a compd. that reacts with an oxidized product of I to form or release a diffusive dye on a support and a dye-fixing material possessing .gtoreq.1 dye-fixing layer on which the dye formed by exposure and development of the photosensitive material is transferred, the dye-fixing layer and/or its adjacent layer contains .gtoreq.1 selected from phenol derivs., II and III [R10 = alkyl, alkenyl, aryl, aralkyl, heterocycle, R18CO, R19SO2, R20NHCO (R18-20 = substituent); R11, R12 = H, halo, alkyl, alkenyl, alkoxy, alkenoxy; R13-17 = H, alkyl, alkenyl, aryl; E = nonmetal atoms required to form a 5- to 7-membered ring along with the C and N atoms; R18 = H, alkyl, alkenyl, alkynyl, acyl, sulfonyl, sulfinyl, oxy radical, OH; R19-22 = H, alkyl]. The photosensitive material is imagewise exposed and laminated with the dye-fixing material followed by development to fix the diffusive dye from the photosensitive material on the dye-fixing material to form an image. Durable, high d. color images are obtained.

IT **193065-74-6 209247-53-0**
RL: TEM (Technical or engineered material use); USES (Uses)
(diffusion-transfer photog. material contg. hydrazine deriv. color developer)

RN 193065-74-6 CAPLUS
CN Hydrazinecarboxamide, N-[3-[2,4-bis(1,1-dimethylpropyl)phenoxy]propyl]-2-[3-methyl-4-(methylsulfonyl)-1-[3-[(methylsulfonyl)amino]phenyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)


09/773,736



RN 209247-53-0 CAPLUS

CN Benzoic acid, 2,4-dichloro-5-[[[2-[[[2-[4-cyano-1-[3-[(methylsulfonyl)amino]phenyl]-1H-pyrazol-5-yl]hydrazino]carbonyl]amino]ethyl]sulfonyl]amino]-, decyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

— (CH₂)₉—Me

09/773,736

L31 ANSWER 58 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1998:198072 CAPLUS
DN 128:277023
TI Silver halide photographic material containing polymethyne pyrazolone dye
IN Noro, Masaki
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 53 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 10083041	A2	19980331	JP 1996-255357	19960906
OS	MARPAT 128:277023				


AB Claimed photog. material contains a pyrazolone polymethyne dye I (L1-3 = methyne; R1 = H, substituent; R2 = substituent; m = 0-4; R3 = H, CHR3'X; R3' = H, substituent; X = electron-attractive group having Hamet' s .sigma.m of 0.3-1.5; R4 = CO2R1-, COR10, COR10, CONR11R12, CN; R5 = H, alkyl, aryl, heterocyclic group; R1- = alkyl, aryl; R11, R12 = H, alkyl, aryl; n = 1, 2). The dye is preferably incorporated in a polymer latex to dye a component layer, such as yellow filter layer, antihalation layer or interlayer, of the photog. material. It does not diffuse to adjacent layers, nevertheless, is easily washed off during processing, leaving little residual colored stain. Thus, in the prepn. of a multilayer color reversal film, the interlayer between red- and green-sensitive layer units was added by a solid dispersion of compd. I (L1-3 = -CH-; R1 = methyl; m = 0; R3 = 1-(acetyloxy)ethyl; R4 = CN; R5 = H; n = 1).

IT 205499-58-7

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, polymethyne pyrazolone dye from; for photog. materials)

RN 205499-58-7 CAPLUS

CN Hexanamide, N-[[4-[3-cyano-5-[[4-methylphenyl)sulfonyl]oxy]-1H-pyrazol-1-yl]phenyl)sulfonyl]-2-ethyl- (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 60 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1997:579703 CAPLUS
DN 127:205576
TI Preparation of sulfonylureidopyrazole derivatives as endothelin converter
enzyme inhibitors
IN Matsushita, Kayo; Hasegawa, Hirohiko; Kuribayashi, Yoshikazu; Ohashi,
Naohito
PA Sumitomo Pharmaceuticals Co., Ltd., Japan; Matsushita, Kayo; Hasegawa,
Hirohiko; Kuribayashi, Yoshikazu; Ohashi, Naohito
SO PCT Int. Appl., 260 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9730978	A1	19970828	WO 1997-JP532	19970225
	W: AU, CA, CN, KR, NZ, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	JP 10007658	A2	19980113	JP 1997-56883	19970224
	CA 2247286	AA	19970828	CA 1997-2247286	19970225
	AU 9717354	A1	19970910	AU 1997-17354	19970225
	EP 885890	A1	19981223	EP 1997-904634	19970225
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
PRAI	JP 1996-65498		19960226		
	WO 1997-JP532		19970225		
OS	MARPAT 127:205576				
AB	The title compds. (I and II; A = O, S; R1 = alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R2, R3 = H, aryl, alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R4, R6 = H, halo, NH2, NO2, alkyl, alkenyl, alkynyl, cycloalkyl, etc.; R5 = heterocyclyl, H, aryl, alkyl, alkenyl, alkynyl, cycloalkyl, etc.) are prepd. I and II, having inhibitory effects on endothelin converter enzyme (ECE), are useful in the prevention and treatment of various circulatory disease, bronchial contraction, nervous disorder, hyposecretion, vascular lesions, various ulcers, etc. Thus, 5-amino-4-cyano-1-phenyl-(1H)-pyrazole was reacted with 4-toluenesulfonyl isocyanate to give 84.1% I (R1 = 4-MeC6H4, R2 = R3 = R6 = H, R4 = CN, R5 = Ph), which showed IC50 of 4.6 .mu.M against ECE.				
IT	194542-20-6P RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of sulfonylureidopyrazole derivs. as endothelin converter enzyme inhibitors)				
RN	194542-20-6 CAPLUS				
CN	Acetamide, N-[4-[4-cyano-5-[[[(4-methylphenyl)sulfonyl]amino]carbonyl]amino]-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)				

09/773,736



09/773,736

L31 ANSWER 61 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1997:522450 CAPLUS
DN 127:142729
TI Color developer, silver halide photographic material, and image formation method
IN Nakamura, Takemare
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 80 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 09152704	A2	19970610	JP 1995-334305	19951130
OS	MARPAT 127:142729				


AB Color developers represented by general formula (Y2)mQCNHNHZ(Y1)n [Z = carbamoyl, etc.; Q = atoms which, together with C, form an unsatd. ring; Y1, Y2 = substituent having dissocn. group with pKa = 1 - 12; (Y2 is substituent on said unsatd. ring); n, m = 0 - 3; n+m .gtoreq. 1] are claimed. Also claimed is a silver halide photog. material comprising a support having one or more hydrophilic colloidal layers contg. one or more color developers represented by the above general formula. Also claimed is an image formation method in which an exposed silver halide photog. material is developed in the presence of a color developer represented by the above general formula. The use of the title method gives high quality images.

IT **193065-74-6P**

RL: NUU (Other use, unclassified); SPN (Synthetic preparation); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses) (color developer, silver halide photog. material, and image formation method)

RN 193065-74-6 CAPLUS

CN Hydrazinecarboxamide, N-[3-[2,4-bis(1,1-dimethylpropyl)phenoxy]propyl]-2-[3-methyl-4-(methylsulfonyl)-1-[3-[(methylsulfonyl)amino]phenyl]-1H-pyrazol-5-yl]- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 62 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1997:490980 CAPLUS
DN 127:191919
TI One-pot preparation of azo compounds having sulfonamide and carboxamide groups
IN Machiguchi, Kazuhiro; Ueda, Yuji
PA Sumitomo Chemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	JP 09188662	A2	19970722	JP 1996-2211	19960110
OS	CASREACT 127:191919				

AB The title compds. useful as dyes for color filters (no data) are prepd. by treatment of compds. having AN=N group [A = (un)substituted Ph or naphthyl], .gtoreq.1 SO₃H group per mol., and .gtoreq.1 CO₂H group per mol. with halogenation agents chosen from halosulfonic acids, sulfonyl halides, P halides, P oxyhalides, and thionylhalides in the presence of DMF and other org. solvents under heating, and successive treatment of the reaction mixts. with NH₃, primary amines, or secondary amines in the presence of bases. Anticorrosive reactors are not required in this process. Thus, Tartrazine NS (I, R = ONa) was treated with SOCl₂ at 70.degree. for 1 h in a 1,4-dioxane-DMF mixt., then treated with PrNH₂ and Et₃N at 25.degree. for 3 h to give 85% I (R = NHPr).


IT **194159-26-7P 194159-27-8P 194159-28-9P**
194159-29-0P 194159-30-3P 194159-31-4P
194159-32-5P 194159-33-6P 194159-34-7P
194159-43-8P

RL: IMF (Industrial manufacture); TEM (Technical or engineered material use); PREP (Preparation); USES (Uses)
(one-pot prepn. of azo dyes having sulfonamide and carboxamide groups for color filters)


RN 194159-26-7 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 5-hydroxy-N-propyl-1-[4-[(propylamino)sulfonyl]phenyl]-4-[[4-[(propylamino)sulfonyl]phenyl]azo]-(9CI) (CA INDEX NAME)

09/773,736




RN 194159-27-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-hexyl-1-[4-[(hexylamino)sulfonyl]phenyl]-4-[[4-[(hexylamino)sulfonyl]phenyl]azo]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 194159-28-9 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-dodecyl-1-[4-[(dodecylamino)sulfonyl]phenyl]-4-[[4-[(dodecylamino)sulfonyl]phenyl]azo]-5-hydroxy- (9CI) (CA INDEX NAME)

09/773,736




RN 194159-29-0 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(3-ethoxypropyl)-1-[4-[[(3-ethoxypropyl) amino] sulfonyl]phenyl]-4-[[4-[[(3-ethoxypropyl) amino] sulfonyl]phenyl]azo]-5-hydroxy- (9CI) (CA INDEX NAME)




RN 194159-30-3 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(1,3-dimethylbutyl)-1-[4-[[(1,3-dimethylbutyl) amino] sulfonyl]phenyl]-4-[[4-[[(1,3-dimethylbutyl) amino] sulfonyl]phenyl]azo]-5-hydroxy- (9CI) (CA INDEX NAME)

09/773,736



RN 194159-31-4 CAPLUS


CN 1H-Pyrazole-3-carboxamide, 5-hydroxy-N-(1,1,3,3-tetramethylbutyl)-1-[4-[[[(1,1,3,3-tetramethylbutyl)amino]sulfonyl]phenyl]-4-[[4-[[[(1,1,3,3-tetramethylbutyl)amino]sulfonyl]phenyl]azo]- (9CI) (CA INDEX NAME)



RN 194159-32-5 CAPLUS


CN 1H-Pyrazole-3-carboxamide, N-[2-(ethylamino)ethyl]-1-[4-[[[2-(ethylamino)ethyl]amino]sulfonyl]phenyl]-4-[[4-[[[2-(ethylamino)ethyl]amino]sulfonyl]phenyl]azo]-5-hydroxy- (9CI) (CA INDEX NAME)

09/773,736



RN 194159-33-6 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-hydroxy-N-[2-[(2-hydroxyethyl)amino]ethyl]-1-[4-[[[2-[(2-hydroxyethyl)amino]ethyl]amino]sulfonyl]phenyl]-4-[[4-[[[2-[(2-hydroxyethyl)amino]ethyl]amino]sulfonyl]phenyl]azo]- (9CI) (CA INDEX NAME)

PAGE 1-A




09/773,736

PAGE 1-B

—NH—CH₂—CH₂—OH

RN 194159-34-7 CAPLUS
CN 1H-Pyrazole-3-carboxamide, 5-hydroxy-N-[2-(2-hydroxyethoxy)ethyl]-1-[4-
[[[2-(2-hydroxyethoxy)ethyl]amino]sulfonyl]phenyl]-4-[[4-[[[2-(2-
hydroxyethoxy)ethyl]amino]sulfonyl]phenyl]azo]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—O—CH₂—CH₂—OH


RN 194159-43-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-(1,5-dimethylhexyl)-1-[4-[[[1,5-
dimethylhexyl]amino]sulfonyl]phenyl]-4-[[4-[[[1,5-
dimethylhexyl]amino]sulfonyl]phenyl]azo]-5-hydroxy- (9CI) (CA INDEX NAME)

09/773,736




L31 ANSWER 63 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:397187 CAPLUS
 DN 127:4719
 TI [2-Methyl-5-(methylsulfonyl)benzoyl]guanidine Na⁺/H⁺ Antiporter Inhibitors
 AU Baumgarth, Manfred; Beier, Norbert; Gericke, Rolf
 CS Preclinical Pharmaceutical Research, Merck KGaA, Darmstadt, 64271, Germany
 SO Journal of Medicinal Chemistry (1997), 40(13), 2017-2034
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 AB The inhibition of the Na⁺/H⁺ exchanger during cardiac ischemia and reperfusion has been shown to be beneficial for the preservation of cellular integrity and functional performance. The aim of the present investigation was to come up with potent and selective benzoylguanidines as NHE inhibitors for use as an adjunctive therapy in the treatment of acute myocardial infarction. During the course of our investigations it became clear that substitution ortho to the acylguanidine was of crucial importance for the potency of the compds. 4-Chloro- and 4-fluoro-2-methylbenzoic acids and were prepd. using the directed ortho metalation technique with the carboxylic acid as the directing group. With the LDA/methyl iodide system the 2-Me group could be extended to an Et group. 4-Alkyl groups were inserted by the palladium-catalyzed cross-coupling reaction into 4-bromo-2-methylbenzoic acid Me ester. Starting with benzoic acids, the methylsulfonyl group was introduced by a sequence of std. reactions (sulfochlorination, redn., and methylation). 4-Aryl derivs. were synthesized by the palladium-catalyzed Suzuki reaction. A large no. of nucleophilic displacement reactions in the 4-position were carried out with S-, O-, and N-nucleophiles as well as with the cyano and trifluoromethyl group. Using the ester method, acid chlorides, or Mukaiyama's procedure, the 5-(methylsulfonyl)benzoic acid derivs. were finally converted to the [5-(methylsulfonyl)benzoyl]guanidine s with excess guanidine. In some cases nucleophilic substitutions with pyridinols and piperidine derivs. were carried out at the end of the reaction sequence with the 4-halo-N-(diaminomethylene)-5-(methylsulfonyl)benzamides. Variations in the 4-position were most reasonable, but the vol. of the substituents was of crucial importance. Substitution in the 3- and particularly in the 6-position led to considerable worsening of the inhibitory effects of the Na⁺/H⁺ exchanger. The 2-Me compds., however, showed without exception higher in vitro activities than their demethyl counterparts, obviously caused by a conformational restriction of the acylguanidine chain. [2-Methyl-5-(methylsulfonyl)-4-pyrrolobenzoyl]guanidine methanesulfonate (I) is a NHE-1 subtype specific NHE inhibitor, being 27-fold more potent toward the NHE-1 than the NHE-2 isoform. I was found to act cardioprotectively not only when given before an exptl. induced ischemia, but also curatively after the onset of symptoms of acute myocardial infarction when given prior to the induction of reperfusion.
 IT **176644-28-3P 190368-95-7P**
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 ([2-methyl-5-(methylsulfonyl)benzoyl]guanidine Na⁺/H⁺ antiporter inhibitors)
 RN 176644-28-3 CAPLUS
 CN Benzamide, N-(aminoiminomethyl)-2-methyl-5-(methylsulfonyl)-4-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)

09/773,736



RN 190368-95-7 CAPLUS

CN Benzamide, N-(aminoiminomethyl)-3-(methylsulfonyl)-4-(1H-pyrazol-1-yl)-
(9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 64 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1996:713002 CAPLUS
DN 125:328721
TI Preparation of herbicidal heteroaryl-substituted anilides
IN Petersen, Wallace Christian; Pifferitti, Michael Anthony; Stevenson,
Thomas Martin; Tseng, Chi-Ping
PA E.I. Du Pont De Nemours and Company, USA
SO PCT Int. Appl., 178 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9631517	A1	19961010	WO 1996-US3803	19960320
	W: AL, AU, BB, BG, BR, CA, CN, CZ, EE, GE, HU, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9654262	A1	19961023	AU 1996-54262	19960320
PRAI	US 1995-416415		19950404		
	WO 1996-US3803		19960320		

OS MARPAT 125:328721

AB The title compds. [I; Q = II, III, IV; T = O, S; X = a single bond, O, S, (un)substituted NH; Y = O, S, CH:CH, etc.; Z, W = CH, N; V = CH, CMe, N; R1 = C1-5 alkyl, CH2(C3-4 cycloalkyl), C3-6 cycloalkyl, etc.; R2, R3 = H, halo, C1-2 alkyl, etc.; R4 = C1-4 haloalkyl, C1-4 haloalkoxy, CN, etc.; n = 0-1] and their oxides, and agriculturally-suitable salts which are useful for controlling undesired vegetation, were prepd. Thus, treatment of 5-(trifluoromethyl)-4H-1,2,4-triazole-3(2H)-thione with Na in MeOH followed by addn. of 1-(2-amino-5-methylphenyl)-2-chloroethanone, cyclization of the resulting intermediate V with concd. H2SO4 and reaction of benzamine VI with Me2CHCH2COCl in the presence of Et3N in Et2O afforded I [Q = II; T = O; X = a single bond; Y = S; Z, W = N; R1 = Me2CHCH2; R2 = Me; R3 = H; R4 = CF3] which showed 100% control in preemergence tests carried out on bedstraw, crabgrass, giant foxtail.

IT 183611-70-3P 183611-71-4P 183611-72-5P


183611-73-6P 183611-74-7P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of herbicidal heteroaryl-substituted anilides)

RN 183611-70-3 CAPLUS


CN Propanamide, 2-methyl-N-[4-methyl-2-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




2 Differences
- sign. position
- methyl sub. on
phenylene.

RN 183611-71-4 CAPLUS
CN Cyclopropanecarboxamide, N-[4-methyl-2-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 183611-72-5 CAPLUS
CN Butanamide, 3-methyl-N-[4-methyl-2-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 183611-73-6 CAPLUS
CN Cyclopropanecarboxamide, 2-methyl-N-[4-methyl-2-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 183611-74-7 CAPLUS
CN 2-Butenamide, 3-methyl-N-[4-methyl-2-[3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 65 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1996:455768 CAPLUS
DN 125:114322
TI Preparation of urea derivatives as cholesterol acyltransferase inhibitors
IN Terasawa, Takeshi; Tanaka, Akira; Chiba, Toshiyuki; Takasugi, Hisashi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 228 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9610559	A1	19960411	WO 1995-JP1982	19950929
	W: AU, CA, CN, HU, JP, KR, MX, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2200981	AA	19960411	CA 1995-2200981	19950929
	AU 9535779	A1	19960426	AU 1995-35779	19950929
	EP 784612	A1	19970723	EP 1995-932934	19950929
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 10510512	T2	19981013	JP 1995-511616	19950929
	ZA 9508365	A	19960508	ZA 1995-8365	19951004
PRAI	GB 1994-19970		19941004		
	GB 1995-6720		19950331		
	GB 1995-14021		19950710		
	WO 1995-JP1982		19950929		
OS	MARPAT 125:114322				
AB	R4YC6H4(CH2)nNR2CONHR3 [R2 = (ar)alkyl, heterocyclyl(alkyl), alkoxyalkyl, etc.; R3,R4 = (un)substituted aryl, heterocyclyl; Y = bond, alkylene, O, CO, CONH, etc.; n = 0 or 1] were prep. Thus, 1-cycloheptyl-1-(4-phenoxyphenylmethyl)-3-(2,4,6-trifluorophenyl)urea had IC50 of 1.1x10-8M against cholesterol acyltransferase in vitro.				
IT	179055-56-2P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of urea derivs. as cholesterol acyltransferase inhibitors)				
RN	179055-56-2 CAPLUS				
CN	Cycloheptanamine, N-[[4-(1H-pyrazol-1-yl)phenyl]methyl]- (9CI) (CA INDEX NAME)				



09/773,736

L31 ANSWER 66 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1996:303752 CAPLUS
DN 124:343303
TI Preparation of N-(heterocyclylbenzoyl)guanidines as hydrogen ion-sodium
antiporter inhibitors
IN Gericke, Rolf; Dorsch, Dieter; Baumgarth, Manfred; Minck, Klaus-Otto;
Beier, Norbert
PA Merck Patent Gmbh, Germany
SO Eur. Pat. Appl., 18 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 699666	A1	19960306	EP 1995-113307	19950824
	EP 699666	B1	19990107		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	DE 4430861	A1	19960307	DE 1994-4430861	19940831
	SK 281446	B6	20010312	SK 1995-1029	19950821
	AU 9530250	A1	19960314	AU 1995-30250	19950824
	AU 702258	B2	19990218		
	AT 175406	E	19990115	AT 1995-113307	19950824
	ES 2129716	T3	19990616	ES 1995-113307	19950824
	CA 2157146	AA	19960301	CA 1995-2157146	19950829
	CZ 286400	B6	20000412	CZ 1995-2202	19950829
	NO 9503404	A	19960301	NO 1995-3404	19950830
	ZA 9507284	A	19960402	ZA 1995-7284	19950830
	HU 73183	A2	19960628	HU 1995-2548	19950830
	CN 1126720	A	19960717	CN 1995-116901	19950830
	CN 1058004	B	20001101		
	US 5753680	A	19980519	US 1995-520780	19950830
	RU 2152390	C1	20000710	RU 1995-114847	19950830
	PL 183393	B1	20020628	PL 1995-310224	19950830
	JP 08073427	A2	19960319	JP 1995-245151	19950831
	BR 9503881	A	19960917	BR 1995-3881	19950831
PRAI	DE 1994-4430861	A	19940831		

OS MARPAT 124:343303

AB Title compds. (I; R = heterocyclyl, heteroaryl; R1 = fluoromethyl, halo, alkyl, alkoxy, etc.; R2,R3 = H, halo, alkyl, alkoxy, etc) were prepd. as hydrogen ion-sodium antiporter inhibitors (no data). Thus, 2-methyl-4-chloro-5-methylsulfonylbenzoic acid was aminated by imidazole and the Me ester amidated by guanidine to give title compd. II.


IT **176644-28-3P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-(heterocyclylbenzoyl)guanidines as hydrogen ion-sodium antiporter inhibitors)

RN 176644-28-3 CAPLUS


CN Benzamide, N-(aminoiminomethyl)-2-methyl-5-(methylsulfonyl)-4-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)

09/773,736




09/773,736

L31 ANSWER 67 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1996:116248 CAPLUS
DN 124:260919
TI Synthesis of 3,5-bis(trifluoromethyl)pyrazoles of possible herbicidal activity
AU Faïd-Allah, H. M.; Mokhtar, H. M.; Nassar, A. M. G.; Morsi, M.
CS Faculty Science, Alexandria University, Alexandria, Egypt
SO Bulletin of the Faculty of Science, Assiut University, B: Chemistry (1995), 24(1), 187-95
CODEN: BFSAE6; ISSN: 1010-2671
PB Assiut University
DT Journal
LA English
AB Seven series of p-(di- and trisubstituted pyrazol-1-yl)benzenesulfonylurea and -thiourea derivs. of possible herbicidal activity were prep'd. Cyclization of the benzenesulfonylthiourea derivs. with Et bromoacetate and Et .beta.-bromopropionate afforded the 2-iminothiazolidinone and the 2-iminothiazinone derivs., resp.
IT **175403-65-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(Synthesis of 3,5-bis(trifluoromethyl)pyrazoles of possible herbicidal activity)
RN 175403-65-3 CAPLUS
CN Benzenesulfonamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




IT **175403-66-4P 175403-67-5P 175403-68-6P**
175403-69-7P 175403-70-0P 175403-71-1P
175403-72-2P 175403-73-3P 175403-74-4P
175403-75-5P 175403-76-6P 175403-77-7P
175403-78-8P 175403-79-9P 175403-80-2P
175403-81-3P 175403-82-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and cyclization with bromoalkanoates)
RN 175403-66-4 CAPLUS
CN Benzenesulfonamide, N-[(butylamino)thioxomethyl]-4-(5-hydroxy-3-methyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)

09/773,736




RN 175403-67-5 CAPLUS

CN Benzenesulfonamide, N-[(cyclohexylamino)thioxomethyl]-4-(5-hydroxy-3-methyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 175403-68-6 CAPLUS

CN Benzenesulfonamide, 4-(5-hydroxy-3-methyl-1H-pyrazol-1-yl)-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 175403-69-7 CAPLUS


CN Benzenesulfonamide, 4-(5-hydroxy-3-methyl-1H-pyrazol-1-yl)-N-[[(phenylmethyl)amino]thioxomethyl]- (9CI) (CA INDEX NAME)



09/773,736


RN 175403-70-0 CAPLUS

CN Benzenesulfonamide, 4-(5-hydroxy-3,4-dimethyl-1H-pyrazol-1-yl)-N-[(propylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 175403-71-1 CAPLUS

CN Benzenesulfonamide, N-[(butylamino)thioxomethyl]-4-(5-hydroxy-3,4-dimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 175403-72-2 CAPLUS


CN Benzenesulfonamide, N-[(cyclohexylamino)thioxomethyl]-4-(5-hydroxy-3,4-dimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 175403-73-3 CAPLUS


CN Benzenesulfonamide, 4-(5-hydroxy-3,4-dimethyl-1H-pyrazol-1-yl)-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 175403-74-4 CAPLUS

CN Benzenesulfonamide, 4-(5-hydroxy-3,4-dimethyl-1H-pyrazol-1-yl)-N-
[[(phenylmethyl)amino]thioxomethyl]- (9CI) (CA INDEX NAME)



RN 175403-75-5 CAPLUS


CN Benzenesulfonamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-
[(butylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 175403-76-6 CAPLUS

CN Benzenesulfonamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-
[(propylamino)thioxomethyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 175403-77-7 CAPLUS
CN Benzenesulfonamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-[(cyclohexylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 175403-78-8 CAPLUS
CN Benzenesulfonamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 175403-79-9 CAPLUS
CN Benzenesulfonamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-[[(phenylmethyl)amino]thioxomethyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 175403-80-2 CAPLUS
CN Benzenesulfonamide, 4-[4-bromo-3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-
[(cyclohexylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 175403-81-3 CAPLUS
CN Benzenesulfonamide, 4-[4-bromo-3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-
[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 175403-82-4 CAPLUS
CN Benzenesulfonamide, 4-[4-bromo-3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-
[[(phenylmethyl) amino] thioxomethyl]- (9CI) (CA INDEX NAME)




IT 175403-55-1P 175403-56-2P 175403-57-3P
175403-58-4P 175403-59-5P 175403-60-8P
175403-61-9P 175403-62-0P 175403-63-1P
175403-64-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 175403-55-1 CAPLUS
CN Benzenesulfonamide, N-[(butylamino)carbonyl]-4-(5-hydroxy-3-methyl-1H-
pyrazol-1-yl)- (9CI) (CA INDEX NAME)

09/773,736




RN 175403-56-2 CAPLUS

CN Benzenesulfonamide, N-[(cyclohexylamino)carbonyl]-4-(5-hydroxy-3-methyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 175403-57-3 CAPLUS

CN Benzenesulfonamide, 4-(5-hydroxy-3-methyl-1H-pyrazol-1-yl)-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 175403-58-4 CAPLUS

CN Benzenesulfonamide, 4-(5-hydroxy-3,4-dimethyl-1H-pyrazol-1-yl)-N-[(propylamino)carbonyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 175403-59-5 CAPLUS
CN Benzenesulfonamide, N-[(butylamino)carbonyl]-4-(5-hydroxy-3,4-dimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 175403-60-8 CAPLUS
CN Benzenesulfonamide, N-[(cyclohexylamino)carbonyl]-4-(5-hydroxy-3,4-dimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 175403-61-9 CAPLUS
CN Benzenesulfonamide, 4-(5-hydroxy-3,4-dimethyl-1H-pyrazol-1-yl)-N-[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 175403-62-0 CAPLUS
CN Benzenesulfonamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-[(propylamino)carbonyl]- (9CI) (CA INDEX NAME)


09/773,736



RN 175403-63-1 CAPLUS
CN Benzenesulfonamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-[(butylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 175403-64-2 CAPLUS
CN Benzenesulfonamide, 4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]-N-[(cyclohexylamino)carbonyl]- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 68 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1995:884700 CAPLUS
DN 123:325369
TI Nonlinear optical material and triazole compound
IN Okazaki, Masaki
PA Fuji Photo Film Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 6 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07225401	A2	19950822	JP 1994-17622	19940214
OS	MARPAT 123:325369				

AB The material consists of a heterocyclic compd. I (Ar = electron-attractive group-contg. phenyl; Z = at. group forming pyrrole, pyrazole, imidazole, triazole, tetrazole, indazole). The triazole compd. is II (X = NO₂, cyano). The material is useful for wavelength converters, etc. The material shows high transmittance for blue light.


IT **170023-28-6**

RL: PRP (Properties); TEM (Technical or engineered material use); USES (Uses)

(heterocyclic compd. nonlinear optical material with high transmittance for blue light)

RN 170023-28-6 CAPLUS

CN Benzonitrile, 4-[2-[4-(1H-pyrazol-1-yl)phenyl]ethenyl]- (9CI) (CA INDEX NAME)




09/773,736


L31 ANSWER 69 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1995:835463 CAPLUS
DN 123:256771
TI Guanidine derivatives as inhibitors of Na⁺/H⁺ exchange in cells
IN Kuno, Atsushi; Inoue, Yoshikazu; Takasugi, Hisashi; Mizuno, Hiroaki;
Yamasaki, Kumi
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 212 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9426709	A1	19941124	WO 1994-JP786	19940512
	W: AU, CA, CN, HU, JP, KR, RU, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	TW 393487	B	20000611	TW 1994-83104223	19940510
	CA 2163004	AA	19941124	CA 1994-2163004	19940512
	AU 9466912	A1	19941212	AU 1994-66912	19940512
	AU 685457	B2	19980122		
	HU 70206	A2	19950928	HU 1994-3233	19940512
	EP 699185	A1	19960306	EP 1994-914623	19940512
	EP 699185	B1	20010905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	CN 1123545	A	19960529	CN 1994-192121	19940512
	CN 1080257	B	20020306		
	JP 08511243	T2	19961126	JP 1994-525245	19940512
	RU 2141946	C1	19991127	RU 1995-122558	19940512
	AT 205191	E	20010915	AT 1994-914623	19940512
	ES 2159558	T3	20011016	ES 1994-914623	19940512
	ZA 9403388	A	19950123	ZA 1994-3388	19940517
	US 5824691	A	19981020	US 1995-532804	19951109
PRAI	GB 1993-10074	A	19930517		
	GB 1993-25268	A	19931210		
	WO 1994-JP786	W	19940512		
OS	MARPAT 123:256771				
AB	The N-benzoylguanidine derivs. or N-(heteroaroyl)guanidine derivs. I (X, Y, Z = nitrogen, methine; R2 = H, aryl, etc.; R3 = H, alkoxy, hydroxy, etc.) and pharmaceutically acceptable salts thereof were disclosed as pharmaceuticals. I inhibit the sodium/hydrogen exchange in cells and are hence useful for the treatment of cardiovascular diseases, cerebrovascular diseases, renal diseases, arteriosclerosis or shock. A claimed example compd. is N-[3-(1H-pyrrol-1-yl)benzoyl]guanidine [i.e., N-(aminoiminomethyl)-3-(1H-pyrrol-1-yl)benzamide] (II).				
IT	168619-90-7P 168620-03-9P 168620-99-3P 168621-65-6P				
	RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)				
	(prepn. of N-(aroyl)guanidine derivs. as sodium exchange inhibitors)				
RN	168619-90-7 CAPLUS				
CN	Benzamide, N-(aminoiminomethyl)-3-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)				

09/773,736




RN 168620-03-9 CAPLUS
CN Benzamide, N-(aminoiminomethyl)-3-(1H-pyrazol-1-yl)-, monohydrochloride
(9CI) (CA INDEX NAME)




● HCl

RN 168620-99-3 CAPLUS
CN Benzamide, N-(aminoiminomethyl)-3-(5-amino-1H-pyrazol-1-yl)- (9CI) (CA
INDEX NAME)




RN 168621-65-6 CAPLUS
CN Benzamide, N-(aminoiminomethyl)-3-(5-amino-1H-pyrazol-1-yl)-,
dihydrochloride (9CI) (CA INDEX NAME)



2 HCl

L31 ANSWER 70 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1995:502774 CAPLUS
DN 123:228117
TI Synthesis of dimethylpyrazolo[1,2-a]benzotriazoles and
methylpyrazolo[1,2-a]quinoxalines by cyclization of 3,5-dimethyl-1-(2-
nitrenophenyl)pyrazoles
AU Albini, Angelo; Bettinetti, Gianfranco; Minoli, Giovanna
CS Dip. Chimica Organica, Universita, v. Taramelli, Pavia, 27100, Italy
SO Heterocycles (1995), 40(2), 597-605
CODEN: HTCYAM; ISSN: 0385-5414
PB Japan Institute of Heterocyclic Chemistry
DT Journal
LA English
AB The thermal and photochem. decompn. of a series of 1-(5-substituted
2-azidophenyl)-3,5-dimethylpyrazoles has been examd. under a homogeneous
set of conditions. Cyclization to pyrazolo[1,2-a]benzotriazole (via
singlet nitrene) is an efficient process except when the Ph substituent
induces intersystem crossing to the azide triplet or compensates for its
electrophilicity. On the contrary, cyclization to pyrazolo[1,2-
a]quinoxaline (via triplet nitrene) is not a preparatively useful process,
due to competition with dimerization to the azo derivs. and redn. to
aminophenylpyrazoles.
IT **168140-59-8P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(synthesis of dimethylpyrazolobenzotriazoles and
methylpyrazoloquinoxalines by cyclization of
dimethylnitrenophenylpyrazoles)
RN 168140-59-8 CAPLUS
CN Acetamide, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX
NAME)



09/773,736

L31 ANSWER 71 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1994:310964 CAPLUS
DN 120:310964
TI Nonlinear optical material and laser wavelength conversion method
IN Okazaki, Masaki
PA Fuji Photo Film Co Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 15 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 05323395	A2	19931207	JP 1992-131159	19920522
	JP 3035682	B2	20000424		

OS MARPAT 120:310964

AB The title material contains a nonlinear optical response compd. having a structure R1L1:L2COR2 (I) (R1-2 = pyrrole, pyrazole, imidazole, triazole, tetrazole; L1-2 = methine). The nonlinear optical response compd. is represented by the structure II, III, or IV (R3-4 = aryl; Z1-2 = pyrrole, pyrazole, imidazole, 1,2,4-triazole; n = 1-4). The optical material having no inversion symmetry is used in laser wavelength conversion. The optical material (with 2nd harmonic generation) shows high blue light-transmittance.


IT **154880-22-5P 154880-26-9P**

RL: PREP (Preparation)

(prepn. of, 2nd harmonic generator, for laser wavelength converters)


RN 154880-22-5 CAPLUS

CN 2-Propen-1-one, 1-phenyl-3-[4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 154880-26-9 CAPLUS

CN 2-Propen-1-one, 1-(4-bromophenyl)-3-[4-(1H-pyrazol-1-yl)phenyl]- (9CI)
(CA INDEX NAME)



09/773,736

L31 ANSWER 72 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1994:270383 CAPLUS
DN 120:270383
TI (Biphenylmethyl)pyrazole angiotensin II antagonists
IN Ashton, Wallace T.; Chang, Linda L.; Greenlee, William J.; Hutchins,
Steven M.
PA Merck and Co., Inc., USA
SO U.S., 30 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5262412	A	19931116	US 1993-28845	19930310
OS	MARPAT 120:270383				

AB The title compds. [I; R1 = SO₂NHCOR₂₃, SO₂NHCO₂R₂₄; R₂₃ = aryl, heteroaryl, (un)branched (un)substituted C1-6 alkyl, C3-6 alkenyl, etc.; R₂₄ = (un)branched (un)substituted C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, aryl, (un)substituted C3-7 cycloalkyl; R₂, R₃ = H, F, Cl, CF₃, C1-4 alkyl; R₄ = H, F; R₅ = H, F, Cl, CF₃, C1-4 alkyl; R₆ = C1-6 alkyl; R₈ = H, F, Cl, Br, iodo, OH, C1-4 alkoxy, (un)substituted NH₂, CN, etc.; V1 = CH₃, CF₃, Cl, iodo, F, OMe, NO₂, CN; V₂ = amine- or carbonyl- or S-based substituent at ring position 4 or 5], which are angiotensin II antagonists (no data), useful in the treatment of hypertension and related cardiovascular disorders (no data), are prep'd. and I-contg. formulations presented. Thus, Et 3-n-butyl-4-[[2'-[N-(2-chlorobenzoyl)sulfamoyl]biphenyl-4-yl]methyl]-1-[2-chloro-5-(valeryl-amino)phenyl]-1H-pyrazole-5-carboxylate was prep'd. from Et 2,4-dioxooctanoate in 10 steps.


IT 154057-06-4

RL: RCT (Reactant)

(prepn. as intermediate in prepn. of (biphenylmethyl)pyrazole angiotensin II antagonists)

RN 154057-06-4 CAPLUS

CN Propanamide, N-[3-[4-[(4-bromo-2-fluorophenyl)methyl]-3-butyl-5-cyano-1H-pyrazol-1-yl]-4-chlorophenyl]- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 73 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1994:107000 CAPLUS
 DN 120:107000
 TI Preparation of N-arylpyrazole derivatives as herbicides
 IN Schallner, Otto; Tiemann, Ralf; Luerksen, Klaus; Santel, Hans-Joachim;
 Schmidt, Robert R.; Vosswinkel, Renate
 PA Bayer A.-G., Germany
 SO Eur. Pat. Appl., 16 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 558999	A2	19930908	EP 1993-102464	19930217
	EP 558999	A3	19940413		
	R: BE, CH, DE, FR, GB, IT, LI, NL				
	DE 4206531	A1	19930909	DE 1992-4206531	19920302
	JP 06065206	A2	19940308	JP 1993-58060	19930224
	AU 9333845	A1	19930909	AU 1993-33845	19930226
PRAI	DE 1992-4206531		19920302		
OS	MARPAT 120:107000				


AB The title compds. I [R1 = H, alkyl, haloalkyl; R2 = H, halo, nitro, alkyl, haloalkyl; R1R2 = alkanediyl; R3 = H, halo, alkyl, haloalkyl; R4 = H, halo; R5 = H, alkyl; R6 = (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl] were prepd. as herbicides, defoliants, and desiccants. Thus, condensation of 1-(4-cyano-3-fluorophenyl)-5-chloro-3,4-tetramethylenepyrazole with benzenesulfonamide in the presence of K2CO3 in DMSO gave 98% title compd. I [R1R2 = (CH2)4, R3 = Cl, R4 = R5 = H, R6 = Ph]. Similarly prepd. compds., e.g. I [R1R2 = (CH2)4, R3 = Cl, R4 = F, R5 = H, R6 = Me], showed superior pre- and post-emergence activity and comparable selectivity to a known arylpyrazole.

IT 152604-85-8P 152604-86-9P 152604-89-2P
 152604-90-5P 152604-91-6P 152604-92-7P
 152604-93-8P 152604-94-9P 152604-95-0P
 152604-96-1P 152604-97-2P

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as herbicide)

RN 152604-85-8 CAPLUS


CN Methanesulfonamide, N-[2-cyano-4-fluoro-5-(3,4,5-trimethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



09/773,736


RN 152604-86-9 CAPLUS

CN 1-Butanesulfonamide, N-[2-cyano-4-fluoro-5-(3,4,5-trimethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 152604-89-2 CAPLUS

CN Methanesulfonamide, N-[2-cyano-5-(3,5-dimethyl-1H-pyrazol-1-yl)-4-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 152604-90-5 CAPLUS


CN 1-Butanesulfonamide, N-[2-cyano-5-(3,5-dimethyl-1H-pyrazol-1-yl)-4-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 152604-91-6 CAPLUS


CN Methanesulfonamide, N-[5-(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl)-2-cyano-4-fluorophenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 152604-92-7 CAPLUS

CN 1-Butanesulfonamide, N-[5-(4-chloro-3,5-dimethyl-1H-pyrazol-1-yl)-2-cyano-4-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 152604-93-8 CAPLUS


CN Methanesulfonamide, N-[2-cyano-4-fluoro-5-(4-nitro-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 152604-94-9 CAPLUS


CN 1-Butanesulfonamide, N-[2-cyano-4-fluoro-5-(4-nitro-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 152604-95-0 CAPLUS

CN Methanesulfonamide, N-[2-cyano-5-(3,5-dimethyl-4-nitro-1H-pyrazol-1-yl)-4-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 152604-96-1 CAPLUS


CN 1-Butanesulfonamide, N-[2-cyano-5-(3,5-dimethyl-4-nitro-1H-pyrazol-1-yl)-4-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 152604-97-2 CAPLUS

CN 1-Butanesulfonamide, N-[2-cyano-4-fluoro-5-(3,4,5-trimethyl-1H-pyrazol-1-yl)phenyl]-1,1,2,2,3,3,4,4,4-nonafluoro- (9CI) (CA INDEX NAME)


09/773,736



09/773,736

L31 ANSWER 74 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1994:66183 CAPLUS
DN 120:66183
TI Structure of dimethyl 2-[o-(3,5-dimethyl-1-pyrazolyl)anilino]-3-methoxymaleate
AU Sardone, N.; Oberti, R.
CS Cent. Studio Cristallochim. Cristallogr., CNR, Pavia, 27100, Italy
SO Acta Crystallographica, Section C: Crystal Structure Communications (1993), C49(11), 1976-8
CODEN: ACSCEE; ISSN: 0108-2701
DT Journal
LA English
AB In the title compd. the pyrazole and benzene rings form a dihedral angle of 64.5(1).degree.. Neither ring deviates significantly from planarity. There is an intramol. H bond between atom N12 and atom O23 [N12...O23 2.682(4) .ANG., N12-H12...O23 102.9(2).degree.]; all other bond distances and angles are within the expected ranges. Crystallog. data and at. coordinates are given.
IT **152335-72-3**
RL: PRP (Properties)
(crystal structure of)
RN 152335-72-3 CAPLUS
CN 2-Butenedioic acid, 2-[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]-3-methoxy-, dimethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



09/773,736


L31 ANSWER 75 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1993:13901 CAPLUS
DN 118:13901
TI Cyan dye-forming coupler and silver halide color photographic material
containing said coupler
IN Sato, Kozo; Ishii, Yoshio
PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 23 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 04188136	A2	19920706	JP 1990-315907	19901122

AB The title cyan coupler is represented by general structure I. For I, R =
substituent; Z1 = CO, SO2, etc.; Z2 = non-metallic atoms which, together
with NNHZ1, form a 5- or 6-membered ring; X = H, or group to be released
upon coupling reaction with an oxidized arom. primary amine developing
agent. Also claimed is a color photog. material contg. the title coupler.
The title photog. material gives excellent color reprodn.

IT **144896-28-6P**
RL: PREP (Preparation)
(prepn. of, as cyan coupler)

RN 144896-28-6 CAPLUS
CN Butanamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2-chloro-4-(2,3-
dihydro-3-oxo-1H-pyrazol-1-yl)-5-hydroxyphenyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 76 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1992:531127 CAPLUS

DN 117:131127

TI Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase

AU Artico, M.; Silvestri, R.; Stefancich, G.; Avigliano, L.; Di Giulio, A.; Maccarrone, M.; Agostinelli, E.; Mondovi, B.; Morpurgo, L.

CS Dip. Studi Farm., Univ. Roma 'La Sapienza', Rome, 00185, Italy

SO Eur. J. Med. Chem. (1992), 27(3), 219-28

CODEN: EJMCA5; ISSN: 0223-5234

DT Journal

LA English


AB New hydrazides were synthesized in search for specific inhibitors of bovine serum amine oxidase: a series of benzoic and phenylacetic acid hydrazides contg. the 1H-imidazol-1-yl or the 1H-imidazol-1-ylmethyl group as o-, m-, or p-substituent in the Ph ring; an analogous series of p-substituted phenylhydrazides with a 5 or 6-membered heterocyclic ring substituent, and a series of similar phenylpropionic hydrazides. The longer and more flexible phenylacetic hydrazides, and to a somewhat lesser extent the phenylpropionic ones, were better specific inhibitors of bovine serum amine oxidase than the benzoic hydrazides, which were also bound by the enzyme with high affinity, but at a slow rate. Derivs. with p- and m-substituents were more reactive than the o-substituted ones. The chem. nature of the substituent was less important than its position in the Ph ring and the presence of methylene spacers. These data point to the presence of a hydrophobic site at short distance from the protein carbonyl cofactor, so that simultaneous interaction of the 2 ends of the inhibitor mol. can occur at the 2 sites. The presence of the hydrophobic site was confirmed by the capability of some mols. deprived of the hydrazidic group to act as mild inhibitors. All hydrazides were less reactive by 2-3 orders of magnitude towards pig kidney diamine oxidase and FAD-dependent monoamine oxidase from rat brain mitochondria, while the other compds. showed similar inhibition power against all proteins. The specificity for the bovine enzyme seems therefore to be related to the concerted action of the 2 moieties of the inhibitor mol.

IT **143426-69-1P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and catalytic hydrogenation of)

RN 143426-69-1 CAPLUS

CN 2-Propenoic acid, 3-[4-(1H-pyrazol-1-yl)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT **140837-47-4P**

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)

RN 140837-47-4 CAPLUS

CN Benzoic acid, 4-(1H-pyrazol-1-yl)-, hydrazide (9CI) (CA INDEX NAME)

09/773,736



09/773,736

L31 ANSWER 77 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1992:210723 CAPLUS
DN 116:210723
TI Spectrophotometric analysis using peroxidase as label
IN Kamiyama, Mikio; Kawakatsu, Satoru; Kita, Hiroshi; Kaneko, Yutaka
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 18 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03254699	A2	19911113	JP 1990-51710	19900305
OS	MARPAT 116:210723				

AB A sensitive spectrophotometric method using peroxidase as a label and a chromogenic reagent comprised of primary arom. amines and I or II [R = substitutes; m = 0-4; Y = substitutes having 1.5>.sigma.p (Hammett's const.)>0.3; X = H, departing groups] are described. H2O2 from the peroxidase-catalyzed reaction oxidizes the primary arom. amines and the oxidn. products subsequently couple-react with I or II to generate dyes that are detectable in the 500.apprx.700 nM range. Detn. of glucose using a chromogenic compn. contg. N,N-diEt-3-Me-4-aminoaniline and II (R = H; Y = CN; X = H) was shown. The sensitivity was significantly higher than that of prior art.


IT **130875-04-6**

RL: ANST (Analytical study)

(substrate in peroxidase-mediated spectrophotometric anal.)

RN 130875-04-6 CAPLUS

CN 1-Dodecanesulfonamide, N-[2,5-bis(1,1-dimethylpropyl)-4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 78 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1992:184505 CAPLUS
DN 116:184505
TI Silver halide photographic material
IN Ohashi, Hirobumi; Kawashima, Yasuhiko; Kagawa, Nobuaki
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 28 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03204640	A2	19910906	JP 1990-386	19900108

AB The title material on a support has at least one layer contg. a dispersion of solid particles of a pyrazolone oxonol dye I (R1 = a substituent; R2 = H, alkyl, alkenyl, cycloalkyl, etc.; L1-L3 = a methine linkage; E = an acidic ring needed for forming an oxonol dye; n = 0-2). The title material shows excellent storage stability.

IT **140214-02-4**
RL: TEM (Technical or engineered material use); USES (Uses)
(silver halide photog. materials contg.)

RN 140214-02-4 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 4-(4,4-dicyano-1,3-butadienyl)-5-hydroxy-1-[4-[[[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]amino]sulfonyl]phenyl]- (9CI)
(CA INDEX NAME)


PAGE 1-A



PAGE 1-B

—CH2—CH2—OH

L31 ANSWER 79 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1992:123773 CAPLUS
 DN 116:123773
 TI Bovine serum amine oxidase: half-site reactivity with phenylhydrazine, semicarbazide, and aromatic hydrazides
 AU Morpurgo, Laura; Agostinelli, Enzo; Mondovi, Bruno; Avigliano, Luciana; Silvestri, Romano; Stefancich, Giorgio; Artico, Marino
 CS Cent. Biol. Mol., Univ. Roma La Sapienza, Rome, 00185, Italy
 SO Biochemistry (1992), 31(9), 2615-21
 CODEN: BICHAW; ISSN: 0006-2960
 DT Journal
 LA English
 AB Arom. hydrazides of the general formula $\text{NH}_2\text{NHCO}(\text{CH}_2)_n\text{C}_6\text{H}_4\text{R}$ were covalently bound by bovine serum amine oxidase (EC 1.4.3.6; BSAO), giving rise to optical and CD absorptions at 350-400 nm. Benzohydrazides ($n = 0$) reacted slowly, in the ratio of 1 per dimeric protein mol., like semicarbazide. Phenylacetohydrazides ($n = 1$) and phenylpropionic hydrazides ($n = 2$) reacted instead in the ratio of 2 per dimer, one mol. at a much faster rate than the other. The fast reaction correlated with the loss of enzymic activity. The contribution to the optical absorbance of either mol. was identical, but only the 1st one produced a CD band, the wavelength and sign of which were detd. by the no. n of methylene groups in the hydrazide. In $n = 1$ and $n = 2$ compds., the reaction was faster as the more hydrophobic R substituent became (triazolyl < imidazolyl < phenyl), suggesting interaction with the protein matrix. Phenylhydrazine was found to react with the native enzyme in the ratio of only 1 per protein dimer. However, 1 phenylhydrazine was also slowly bound by most 1:1 enzyme-hydrazide adducts, with the formation of ternary derivs. Phenylhydrazine formed the usual intense band at 447 nm with $n = 1$ and $n = 2$ hydrazide-BSAO adducts and a weaker, blue-shifted band with the adducts of semicarbazide and of some $n = 0$ hydrazides. In both cases, the hydrazide absorption band was unaffected. Competition was obsd. with other benzohydrazides and with the 2nd mol. of $n = 1$ compds. A half-site mechanism appears to be operative, the 2nd site being always less reactive than the 1st. Reactivity and adduct conformation were also affected by N,N -diethyldithiocarbamate, a powerful enzyme inhibitor that binds Cu.
 IT **140837-47-4**
 RL: BIOL (Biological study)
 (amine oxidase of blood serum binding of, stoichiometry of)
 RN 140837-47-4 CAPLUS
 CN Benzoic acid, 4-(1H-pyrazol-1-yl)-, hydrazide (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 80 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1991:558982 CAPLUS
DN 115:158982
TI Alkylenebisamides
IN Ao, Eiboku; Tanaka, Hiroshi; Nakao, Tatsu; Yamagami, Keiji; Fujii, Akihiro
PA Yoshitomi Pharmaceutical Industries, Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 9 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03077869	A2	19910403	JP 1989-212733	19890817
	JP 2867450	B2	19990308		

OS MARPAT 115:158982


AB Title compds. I and their acid salts [R1-4 = H, halo, lower alkyl, lower alkoxy, formyl, CO2R5, NR6R7, CONR8R9; R5-9 = H, lower alkyl, aralkyl; R6 and R7 or R8 and R9 may form a heterocycle with the adjacent N; X, Y = CH:CH, N:CH, O, S, NR10; R10 = H, lower alkyl; A = C2-30 alkylene, alkenylene, or alkynylene; A may contain .gtoreq.1 of O, S, and NR11 in the chain and lower alkyl, Ph, aralkyl, oxo, oxime (including alkoxime), or amine as pendant; R11 = H, lower alkyl, acyl; .gtoreq.1 of R1-4 is not H when X = Y = N:CH and A = C2-12 alkylene], useful as neoplasm inhibitors, are prepd. Thus, 1.8 g 6-chloronicotinoyl chloride was added in portions to a CHCl3 soln. of 1.7 g N-(8-aminooctyl)nicotinamide contg. Et3N with ice cooling, held at room temp., then refluxed, and recrystd. from EtOH/isopropyl ether to give 2.0 g N-(8-nicotinoylaminoctyl)-6-chloronicotinamide with m.p. 139-142.degree..

IT **135854-37-4P**

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as neoplasm inhibitor)

RN 135854-37-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[6-[[4-(3-methyl-1H-pyrazol-1-yl)benzoyl]amino]hexyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 82 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1991:471593 CAPLUS
 DN 115:71593
 TI Preparation of pyrazole derivatives having antiinflammatory, analgesic, and antithrombotic activities
 IN Matsuo, Masaaki; Tsuji, Kiyoshi; Konishi, Nobukiyo; Nakamura, Katsuya
 PA Fujisawa Pharmaceutical Co., Ltd., Japan
 SO Eur. Pat. Appl., 71 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 418845	A1	19910327	EP 1990-117983	19900919
	EP 418845	B1	19950809		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE			
	ZA 9007282	A	19910731	ZA 1990-7282	19900912
	IL 95675	A1	19960331	IL 1990-95675	19900913
	US 5134142	A	19920728	US 1990-582358	19900914
	CA 2025599	AA	19910323	CA 1990-2025599	19900918
	HU 57733	A2	19911230	HU 1990-5970	19900919
	HU 208122	B	19930830		
	ES 2088933	T3	19961001	ES 1990-117983	19900919
	JP 03141261	A2	19910617	JP 1990-252319	19900920
	JP 2586713	B2	19970305		
	NO 9004134	A	19910325	NO 1990-4134	19900921
	CN 1050382	A	19910403	CN 1990-107130	19900921
	CN 1046506	B	19991117		
	AU 9063072	A1	19910418	AU 1990-63072	19900921
	AU 637142	B2	19930520		
	RU 2021990	C1	19941030	RU 1990-4831230	19900921
	RU 2059622	C1	19960510	RU 1991-5010250	19911202
PRAI	GB 1989-21466		19890922		
	GB 1990-8399		19900412		

OS MARPAT 115:71593

AB The title compds. [I; R1 = heterocyclyl, (un)substituted aryl; R2 = H, CH2NH2, alkylaminomethyl, halomethyl, acyloxymethyl, acyl, acylamino, cyano, halo, alkylthio, alkylsulfinyl; R3 = (un)substituted aryl or heterocyclyl; provided that, e.g. when R2 = (esterified) CO2H, trihalomethyl, R3 = substituted aryl or heterocyclyl] are prep'd., e.g. by reaction of R3COCH2COR2, OHCCHR3COR2, or OHCCHR2COR3 with R1NHNH2. Thus, a mixt. of Et 4-(4-methylthiophenyl)-2,4-dioxobutanoate and 4-FC6H4NHNH2.HCl in EtOH-dioxane was refluxed 5 h to give Et 1-(4-fluorophenyl)-3-(4-methylthiophenyl)pyrazole-5-carboxylate. A total of approx. 250 I were prep'd. and 9 I at 3.2 or 10 mg/kg/day p.o. for 23 days inhibited 80.6-100% of mycobacterial adjuvant-induced secondary lesion in rat hind paws.


IT 134730-92-0P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as antiinflammatory, analgesic, and antithrombotic)

RN 134730-92-0 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 5-[5-(methylsulfonyl)-2-thienyl]-1-[4-[(2-oxoethyl)amino]phenyl]- (9CI) (CA INDEX NAME)

09/773,736



L31 ANSWER 84 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1991:81868 CAPLUS

DN 114:81868

TI Preparation of N-phenylsulfonyl-N'-pyrimidinylureas and analogs as herbicides

IN Arabori, Hideo; Yamazaki, Shiro; Arahira, Masato; Murakami, Aiko

PA Kureha Chemical Industry Co., Ltd., Japan

SO Eur. Pat. Appl., 34 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 382436	A1	19900816	EP 1990-301155	19900205
	EP 382436	B1	19950510		
	R: DE, FR, GB				
	JP 02207084	A2	19900816	JP 1989-27368	19890208
	JP 09012541	A2	19970114	JP 1996-186901	19890208
	US 5127937	A	19920707	US 1990-473809	19900202
	CA 2029347	AA	19920507	CA 1990-2029347	19901106
	CA 2029347	C	19971223		
	US 5242894	A	19930907	US 1992-871659	19920421
	US 5362885	A	19941108	US 1993-81945	19930625
PRAI	JP 1989-27368		19890208		
	US 1990-473809		19900202		
	US 1992-871659		19920421		

OS MARPAT 114:81868

AB The title compds. (I; R = pyrrolyl, 2,5-dimethylpyrrolyl, 3,4-dimethyl-2,5-dioxo-3-pyrrolinyl, 3,5-dimethylpyrazolyl; R1 = H, Cl, alkyl, alkoxy, carbonyl; X1 = alkyl, alkoxy, Cl; X2 = alkyl, alkoxy; Z = CH, N) were prepd. Thus, benzenesulfonamide II (R2 = H) (prepn. given) was stirred 15 h with N-pyrimidinylcarbamate QOPh in AcNMe2 contg. DBU to give title compd. II (R2 = Q) which gave 91-100% kill of 9 weeds, e.g., Amaranthus retroflexus, at 10 g/ha foliar spray.


IT **131969-99-8P 132013-78-6P**

RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as herbicide)

RN 131969-99-8 CAPLUS


CN Benzoic acid, 2-[[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]amino]sulfonyl]-4-(3,5-dimethyl-1H-pyrazol-1-yl)-, methyl ester (9CI) (CA INDEX NAME)

09/773,736



RN 132013-78-6 CAPLUS

CN Benzenesulfonamide, 2-chloro-N-[[4,6-dimethoxy-2-pyrimidinyl]amino]carbonyl]-5-(3,5-dimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 86 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1991:8227 CAPLUS
DN 114:8227
TI Polyamides with improved dyeability
IN Kaul, Bansil Lal; Vougioukas, Angelos Elie
PA Sandoz A.-G., Switz.; Sandoz-Patent-G.m.b.H.
SO Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 5

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 379470	A2	19900725	EP 1990-810040	19900117
	EP 379470	A3	19920318		
	EP 379470	B1	19960320		
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	DE 3901716	A1	19900726	DE 1989-3901716	19890121
	DE 3901717	A1	19900726	DE 1989-3901717	19890121
	DE 3930089	A1	19910321	DE 1989-3930089	19890909
	EP 618256	A2	19941005	EP 1994-109533	19900117
	EP 618256	A3	19950426		
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	US 5470921	A	19951128	US 1994-247132	19940520
PRAI	DE 1989-3901716	A	19890121		
	DE 1989-3901717	A	19890121		
	DE 1989-3930089	A	19890909		
	DE 1989-3932912	A	19891003		
	EP 1990-810040	A3	19900117		
	US 1991-727506	B1	19910709		
AB	The title polyamides are reaction products with hindered amines, trimesic amides, triazine triamines, dyes bearing OH or amino but no sulfo groups, or polyamides reactive with OH and/or amino groups. Fibers prepd. from nylon 6 contg. 2% 2,6-bis[(2,2,6,6-tetramethyl-4-piperidinyl)amino]-4-chlorotriazine (I) had better dyeability than without I.				
IT	131077-53-7DP , chromium complexes, reaction products with polyamides 131077-54-8DP , chromium complexes, reaction products with polyamides 131077-56-ODP , chromium complexes, reaction products with polyamides 131099-04-2DP , chromium complexes, reaction products with polyamides RL: PREP (Preparation) (manuf. of, with good dyeability)				
RN	131077-53-7 CAPLUS				
CN	2-Propenamide, N-[4-[4-[2-hydroxy-5-[(methylamino)sulfonyl]phenyl]azo]-3,5-dimethyl-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)				

09/773,736

PAGE 1-A




PAGE 2-A

||
O


RN 131077-54-8 CAPLUS
CN 2-Propenamide, N-[3-[4-[[2-hydroxy-5-[(methylamino)sulfonyl]phenyl]azo]-
3,5-dimethyl-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 131077-56-0 CAPLUS
CN 2-Propenamide, N-[4-[4-[[2-hydroxy-4-[(methylamino)sulfonyl]phenyl]azo]-3,5-dimethyl-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




09/773,736

PAGE 2-A



RN 131099-04-2 CAPLUS
CN 2-Propenamide, N-[3-[4-[[2-hydroxy-4-[(methylamino)sulfonyl]phenyl]azo]-3,5-dimethyl-1H-pyrazol-1-yl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



09/773,736

L31 ANSWER 87 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1990:641429 CAPLUS
 DN 113:241429
 TI Cyan photographic coupler
 IN Kita, Hiroshi; Kida, Shuji; Kaneko, Yutaka
 PA Konica Co., Japan
 SO Eur. Pat. Appl., 35 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 386931	A1	19900912	EP 1990-302133	19900228
	R: DE, GB				
	JP 02232650	A2	19900914	JP 1989-52267	19890304
	JP 02277049	A2	19901113	JP 1989-97456	19890419
	US 5223386	A	19930629	US 1991-753438	19910830
PRAI	JP 1989-52267		19890304		
	JP 1989-97456		19890419		
	US 1990-484710		19900226		

OS MARPAT 113:241429


AB A cyan photog. coupler producing cyan dye images having excellent fastness against heat, moisture, and light is an arom. compd. represented by the general formula I, II, III, IV, or V (R = an org. group preferably alkyl, aryl, carboxyl, oxycarboxyl, CN, OH alkoxy, aryloxy, amino, amido, halogen, or sulfonamido; Y = an org. group having a Hammett's substituent const. .sigma.p of 0.3-1.5 preferably CN, NO2, SO2, .beta.-carboxyvinyl, sulfinyl, .beta.,.beta.-dicyanovinyl, halogenated alkyl, formyl, carboxyl, CO, alkoxy carbonyl, aryloxy carbonyl, 1-tetrazolyl, 5-chlorotetrazolyl, carbamoyl, or sulfamoyl; Z = a group of atoms necessary to form a 5-7-membered N-contg. heterocyclic ring; X = H or a group capable of splitting off upon reacting with an oxidized photog. developing agent; l = 0-4; m = 0-5; n = 0-3).

IT **130875-04-6**

RL: TEM (Technical or engineered material use); USES (Uses)
 (cyan photog. coupler)

RN 130875-04-6 CAPLUS

CN 1-Dodecanesulfonamide, N-[2,5-bis(1,1-dimethylpropyl)-4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




L31 ANSWER 88 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1990:423909 CAPLUS
 DN 113:23909
 TI Preparation of butenoic or propenoic acid derivatives containing aryl and heterocyclyl groups having coronary vasodilating and heart rate lowering effect
 IN Minami, Norio; Ozaki, Fumihito; Ishibashi, Keiji; Kabasawa, Yasuhiro; Ikemori, Megumi; Ogawa, Toshiaki; Kawamura, Takanori
 PA Eisai Co., Ltd., Japan
 SO Eur. Pat. Appl., 152 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 344577	A2	19891206	EP 1989-109228	19890523
	EP 344577	A3	19920325		
	EP 344577	B1	19961009		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	FI 8902362	A	19891202	FI 1989-2362	19890517
	US 5047417	A	19910910	US 1989-354306	19890519
	AT 143949	E	19961015	AT 1989-109228	19890523
	NO 8902170	A	19891204	NO 1989-2170	19890530
	AU 8935822	A1	19891207	AU 1989-35822	19890530
	AU 616014	B2	19911017		
	HU 50319	A2	19900129	HU 1989-2734	19890530
	HU 210932	B	19950928		
	ZA 8904102	A	19900328	ZA 1989-4102	19890530
	DD 287496	A5	19910228	DD 1989-329059	19890530
	DK 8902649	A	19891202	DK 1989-2649	19890531
	CN 1040366	A	19900314	CN 1989-103717	19890531
	CA 1318667	A1	19930601	CA 1989-601297	19890531
	SU 1833371	A3	19930807	SU 1989-4614354	19890601
	US 5177089	A	19930105	US 1990-557713	19900725
	RU 2041871	C1	19950820	RU 1992-5010978	19920302
	US 5382595	A	19950117	US 1992-959654	19921013
	US 5607953	A	19970304	US 1994-347099	19941123
PRAI	JP 1988-134892		19880601		
	US 1989-354306		19890519		
	US 1990-557713		19900725		
	US 1992-959654		19921013		
OS	MARPAT 113:23909				
AB	Title compds. GCH:CHCH2CONR2ANR3(CH2)nJ (G = substituted Ph, naphthyl, (heteroaryl)phenyl, (heteroaryl)heterocyclyl; R2, R3 = H, alkyl, allyl, cycloalkyl; R2R3N = 5-7-membered satd. heterocyclyl; R3N = 5-7-membered heterocyclyl having N or N and O together with A; A = substituted Cl-3-, -Cl-6 alkylene; J = (un)substituted Ph, -pyridyl; n = 1-6) and a pharmacol. acceptable salt thereof, are prepd. (E)-4-[4-(1-Imidazol-1-yl)phenyl]-3-butenic acid in aq. MeCN was treated with DCC/N-hydroxybenzotriazole, the mixt. was stirred 4 h, 3,5-(MeO)2C6H3CH2CH2NMe(CH2)3NH2 in MeCN was added, and the mixt. was stirred 3 d to give butenamide I. I in dogs at 0.3 mg/kg i.v. lowered heart rate by 11-20% and increased coronary blood flow 201-300%.				
IT	127406-60-4P RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as intermediate for cardiovascular agent)				
RN	127406-60-4 CAPLUS				

09/773,736

CN 3-Butenoic acid, 4-[4-(1H-pyrazol-1-yl)phenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 127404-56-2P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for lowering heart rate and as coronary vasodilator)

RN 127404-56-2 CAPLUS

CN 3-Butenamide, N-[3-[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-4-[4-(1H-pyrazol-1-yl)phenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



09/773,736


L31 ANSWER 81 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1991:492267 CAPLUS
DN 115:92267
TI Preparation of (imidazolylphenyl)butenamide derivatives as cardiovascular agents
IN Minami, Norio; Ozaki, Fumihiro; Ishibashi, Keiji; Kabasawa, Yasuhiro; Ikemori, Megumi; Ogawa, Toshiaki; Kawamura, Takanori
PA Eisai Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 47 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 03095157	A2	19910419	JP 1989-139896	19890601
	JP 2905219	B2	19990614		
PRAI	JP 1989-126176		19890519		

OS MARPAT 115:92267
AB Butenamide derivs. [I; X = O, S, CH:CH, N:CH; R1 = heteroaryl, e.g., imidazolyl; R2, R3 = H, alkyl, cycloalkyl, aryl, etc.; A = C1-6 alkylene, R3N may form heterocycle with groups on either side of N; J = (substituted) Ph; n = 1-6] are prepd. A mixt. of acid II, N-hydroxybenzotriazole, DCC, and diamine III in 50% aq. MeCN was stirred under cooling and at room temp. to give 52% amide IV, which reduced the heart rate by 21-30% and increased the coronary blood flow by 1-100% at 0.3 mg/kg i.v. in dogs.

IT **127406-60-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, in prepn. of cardiovascular agent)
RN 127406-60-4 CAPLUS
CN 3-Butenoic acid, 4-[4-(1H-pyrazol-1-yl)phenyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



IT **127404-56-2P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of, as cardiovascular agent)
RN 127404-56-2 CAPLUS
CN 3-Butenamide, N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-4-[4-(1H-pyrazol-1-yl)phenyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

09/773,736



09/773,736

L31 ANSWER 89 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1990:188900 CAPLUS
DN 112:188900
TI Silver halide photographic material containing oxonol dye
IN Kagawa, Nobuaki; Kawashima, Yasuhiko; Tanaka, Mari
PA Konica Co., Japan
SO Jpn. Kokai Tokkyo Koho, 20 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1



	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01224749	A2	19890907	JP 1988-50789	19880304

AB In the title photog. material, .gtoreq.1 of photog. constitutional layers contains an oxonol dye (I) [R = cyano, R1CO, SO2R1 (R1 = alkyl, aryl, heterocyclyl); J = divalent org. group; Z = CONR2, NR2CO, SO2NR2, NR2SO2, CO2, OCO, SO2, SO2O, OSO2, NR2CONR3, O(CpH2qO)n, NR2CO2, OCONR2, NR2, SO, (R2, R3 = H, alkyl, aryl, heterocyclyl; p, q = 2-4; n .gtoreq. 1); sol = water-sol. functional group, or org. moiety with .gtoreq.1 of water-sol. functional groups; E = acid nucleus necessary to form an oxonol dye; L1-L5 = methine group; i, j, m = 0-1]. The dye is useful as filter dye, or in halation prevention or irradsn. prevention.

IT **126323-31-7**
RL: USES (Uses)
(photog. antihalation dye)


RN 126323-31-7 CAPLUS

CN Poly(oxy-1,2-ethanediyl), .alpha.-[2-[[[4-[3-cyano-4-(4,4-dicyano-1,3-butadienyl)-5-hydroxy-1H-pyrazol-1-yl]phenyl]sulfonyl]amino]ethyl]-.omega.-hydroxy- (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 91 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1989:553451 CAPLUS
Correction of: 1987:423132
DN 111:153451
Correction of: 107:23132
TI Synthesis and antibacterial activity of novel pyrazolinone penicillins
AU Basker, Michael J.; Cook, Richard T.; Lowther, John; Taylor, Andrew W.
CS Res. Div., Beecham Pharm., Betchworth/Surrey, RH3 7AJ, UK
SO J. Antibiot. (1986), 39(3), 479-82
CODEN: JANTAJ; ISSN: 0021-8820
DT Journal
LA English
AB Penicillins I (R = H, 4-NO₂, 3-NO₂, 4-Br, 4-SO₂Me, 4-OMe, 4-OH, 3-NH₂, 4-NH₂, 3-acylamino, 4-acylamino) (25 compds.) were prepd. by acylating ampicillin. Some I (R = acylamino) had better bactericidal activity than piperacillin. The other I were less active than piperacillin.
IT 105432-71-1 105432-82-4 105432-87-9
105432-93-7 105433-03-2 105433-21-4
105433-27-0 105433-30-5 105652-01-5
105652-02-6 105674-32-6
RL: RCT (Reactant)
(chlorination of)
RN 105432-71-1 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[4-(acetylamino)phenyl]-2,3-dihydro-3-oxo-
(9CI) (CA INDEX NAME)




RN 105432-82-4 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[4-(benzoylamino)phenyl]-2,3-dihydro-3-oxo-
(9CI) (CA INDEX NAME)




RN 105432-87-9 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 2,3-dihydro-3-oxo-1-[4-[(1-oxobutyl)amino]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 105432-93-7 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[[4-(aminosulfonyl)benzoyl]amino]phenyl]-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 105433-03-2 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 2,3-dihydro-3-oxo-1-[4-[[2,4,6-tris(acetyloxy)benzoyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 105433-21-4 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 2,3-dihydro-3-oxo-1-[4-[(phenylacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 105433-27-0 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 2,3-dihydro-3-oxo-1-[4-[(1-oxopropyl)amino]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 105433-30-5 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[(3,5-dihydroxybenzoyl)amino]phenyl]-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 105652-01-5 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 2,3-dihydro-3-oxo-1-[3-[(1-oxobutyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 105652-02-6 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[(3,4-dihydroxybenzoyl)amino]phenyl]-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 105674-32-6 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[[2-(acetamido)-1-oxopropyl]amino]phenyl]-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)

09/773,736




IT 105674-03-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acetylation of)

RN 105674-03-1 CAPLUS

CN Benzeneacetic acid, .alpha.-[[[2,3-dihydro-3-oxo-1-[4-[(1-oxobutyl)amino]phenyl]-1H-pyrazol-4-yl]carbonyl]amino]-3,4-dihydroxy-,
(R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 105458-13-7P 105651-86-3P 105651-87-4P

105651-98-7P 105651-99-8P 105674-21-3P


105674-22-4P 105674-23-5P 105674-29-1P

105674-30-4P 105674-31-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and silylation of)


RN 105458-13-7 CAPLUS

CN 1H-Pyrazole-4-carbonyl chloride, 1-[4-(benzoylamino)phenyl]-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)




09/773,736


RN 105651-86-3 CAPLUS
CN 1H-Pyrazole-4-carbonyl chloride, 1-[4-[(3,5-dihydroxybenzoyl)amino]phenyl]-
2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 105651-87-4 CAPLUS
CN 1H-Pyrazole-4-carbonyl chloride, 1-[4-[[2-(acetylamino)-1-oxopropyl]amino]phenyl]-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)




RN 105651-98-7 CAPLUS
CN 1H-Pyrazole-4-carbonyl chloride, 2,3-dihydro-3-oxo-1-[4-[(1-oxobutyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 105651-99-8 CAPLUS
CN 1H-Pyrazole-4-carbonyl chloride, 2,3-dihydro-3-oxo-1-[4-[(1-oxopropyl)amino]phenyl]- (9CI) (CA INDEX NAME)

09/773,736




RN 105674-21-3 CAPLUS

CN 1H-Pyrazole-4-carbonyl chloride, 1-[4-[[4-(aminosulfonyl)benzoyl]amino]phenyl]-2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)




RN 105674-22-4 CAPLUS

CN 1H-Pyrazole-4-carbonyl chloride, 2,3-dihydro-3-oxo-1-[3-[(1-oxobutyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 105674-23-5 CAPLUS

CN 1H-Pyrazole-4-carbonyl chloride, 2,3-dihydro-3-oxo-1-[4-[[2,4,6-tris(acetyloxy)benzoyl]amino]phenyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 105674-29-1 CAPLUS
CN 1H-Pyrazole-4-carbonyl chloride, 2,3-dihydro-3-oxo-1-[4-
[(phenylacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 105674-30-4 CAPLUS
CN 1H-Pyrazole-4-carbonyl chloride, 1-[4-[(3,4-dihydroxybenzoyl)amino]phenyl]-
2,3-dihydro-3-oxo- (9CI) (CA INDEX NAME)



RN 105674-31-5 CAPLUS
CN 1H-Pyrazole-4-carbonyl chloride, 1-[4-(acetylamino)phenyl]-2,3-dihydro-3-
oxo- (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 92 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1989:114754 CAPLUS
DN 110:114754
TI 2(1H)-Quinolinones with cardiac stimulant activity. 2. Synthesis and biological activities of 6-(N-linked, five-membered heteroaryl) derivatives
AU Alabaster, Colin T.; Bell, Andrew S.; Campbell, Simon F.; Ellis, Peter; Henderson, Christopher G.; Morris, David S.; Roberts, David A.; Ruddock, Keith S.; Samuels, Gillian M. R.; Stefaniak, Mark H.
CS Dep. Discovery Biol. Discovery Chem., Pfizer Cent. Res., Sandwich/Kent, UK
SO J. Med. Chem. (1989), 32(3), 575-83
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 110:114754
AB A series of 6-(N-linked, five-membered heteroaryl)-2(1H)-quinolinones, e.g., I (R, R1, R2 = H, Me), were synthesized and evaluated for cardiotonic activity. Most compds. were prepd. by H2SO4-catalyzed cyclization of an N-(4-heteroarylphenyl)-3-ethoxypropenamide or by condensation of a (2-amino-5-heteroaryl)benzaldehyde or -acetophenone deriv. with the ylide derived from tri-Et phosphonoacetate. In anesthetized dogs, I (R = R1 = R2 = H) (25 .mu.g/kg) produced a greater increase in cardiac contractility (percentage increase in dP/dt max) than alternative 6-(five-membered heteroaryl, e.g., tetrazol-1-yl)-substituted analogs. Introduction of 4-Me or 2,4-di-Me substituents into the imidazole ring of I produced a marked increase in inotropic activity, and these compds. were some 5 and 10 times more potent than milrinone. Most I also displayed pos. inotropic effects (decrease in QZ interval) in conscious dogs after oral administration (0.0625-1 mg/kg) and in many cases there was little difference in activities at both the 1- and 3-h time points. I (R = R1 = Me, R2 = H) (II) (62.5, 125, 250 .mu.g/kg) demonstrated dose-related cardiac stimulant activity which, in contrast to milrinone, was maintained over the whole 7-h test period. No changes in heart rate were detected at any dose level and I (R, R1 = H, Me; R2 = H) also displayed high selectivity for the stimulation of cardiac contractile force rather than heart rate in the Starling dog heart-lung prepn. Increases in dP/dt max of approx. 50% were accompanied by heart rate changes of less than 10 beats/min. Physicochem. measurements gave a log P of 1.64 for II with pKa values of 7.13 +/- 0.04 and 11.5 +/- 0.2 for the imidazole and quinolinone moieties, resp. X-ray structural anal. of II showed the imidazole and quinolinone rings at 52.degree. to one another in close agreement with the min.-energy conformation (30.degree.) suggested by PCILO calcns. II is currently undergoing phase II clin. evaluation in congestive heart failure patients.
IT **102791-99-1P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and cyclization of, quinolinone deriv. from)
RN 102791-99-1 CAPLUS
CN 2-Propenamide, 3-ethoxy-N-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-, (E)-(9CI) (CA INDEX NAME)

Double bond geometry as shown.


same as #93

09/773,736




09/773,736

L31 ANSWER 94 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1987:477715 CAPLUS
DN 107:77715
TI Synthesis, reactions and biological activity of 3-[p-(N-methyl/ethyl-N-phenylcarbamoyl)]phenylsydnones
AU Badachikar, S. V.; Tikare, R. K.; Puranik, G. S.
CS Dep. Stud. Chem., Karnatak Univ., Dharwad, 580 003, India
SO Indian J. Chem., Sect. B (1986), 25B(10), 1079-80
CODEN: IJSBDB; ISSN: 0376-4699
DT Journal
LA English
OS CASREACT 107:77715
AB The title sydnones I (R = Me, Et) have been prepd. from p-aminobenzanilides and converted into pyrazolyl derivs. II (R1 = OMe, Ph). These compds. exhibit antibacterial activity comparable to that of std. compds. (sulfanilamide and phenol) at different concns.
IT **109547-41-3P 109573-01-5P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. and antibacterial activity of)
RN 109547-41-3 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[4-[(methylphenylamino)carbonyl]phenyl]-, dimethyl ester (9CI) (CA INDEX NAME)



Same as #104

RN 109573-01-5 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[4-[(ethylphenylamino)carbonyl]phenyl]-, dimethyl ester (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 95 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1987:477005 CAPLUS

DN 107:77005

TI Method for converting ether groups to hydroxyl groups and ester groups to acid groups

IN King, Patrick F.

PA Polaroid Corp. , USA

SO U.S., 8 pp. Cont.-in-part of U.S. Ser. No. 490,773, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4652635	A	19870324	US 1984-621060	19840615
PRAI	US 1983-490773		19830502		

AB A process for dealkylation of alkyl or aryl ethers and hydrolysis of alkyl or aryl esters by treating them successively with a 2-halo-1,3,2-benzodioxaborole and H₂O is described. A mixt. of Me 1-naphthaleneacetate and 2-bromo-1,3,2-benzodioxaborole in CH₂Cl₂ was stirred for 24 h at room temp. and subsequently treated with H₂O to give 60% 1-naphthaleneacetic acid. The method was used to deblock a variety of protected dye developers.


IT **109547-23-1**

RL: RCT (Reactant)

(hydrolysis of, by treatment with bromobenzodioxaborole and water)

RN 109547-23-1 CAPLUS

CN Benzoic acid, 2-[[3-methyl-1-[4-[(methyloctadecylamino)sulfonyl]phenyl]-1H-pyrazol-4-yl]azo]-, methyl ester (9CI) (CA INDEX NAME)



IT **109547-24-2P**


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. of, by hydrolysis of ester deriv. with bromobenzodioxaborole and water)

09/773,736

RN 109547-24-2 CAPLUS

CN Benzoic acid, 2-[[3-methyl-1-[4-[(methyloctadecylamino)sulfonyl]phenyl]-1H-pyrazol-4-yl]azo]- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 96 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1986:626551 CAPLUS
 DN 105:226551
 TI (Sulfonamidophenyl)pyrazoles and their use as herbicides
 IN Yanagi, Mikio; Kawada, Shuji; Futatsuya, Fumio; Kobayashi, Kenji
 PA Nippon Kayaku Co., Ltd., Japan
 SO Eur. Pat. Appl., 39 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 191303	A1	19860820	EP 1986-100385	19860114
	R: CH, DE, FR, GB, IT, LI				
	JP 61165374	A2	19860726	JP 1985-3957	19850116
	JP 62033155	A2	19870213	JP 1985-171793	19850806
	US 4666507	A	19870519	US 1985-814395	19851230
	BR 8600123	A	19860923	BR 1986-123	19860115
	NL 8601766	A	19870302	NL 1986-1766	19860707
	BE 905091	A1	19870112	BE 1986-216907	19860711
	ES 2000669	A6	19880316	ES 1986-302	19860715
PRAI	JP 1985-3957		19850116		
	JP 1985-171793		19850806		

OS CASREACT 105:226551


AB The title compds. [I; R1 = H, halo, Me; R2 = H, halo, alkyl; R3 = PhCH2, (substituted) lower alkyl, Ph; R4 = H, alkenyl, alkynyl, (substituted) alkyl, (halo-substituted) MeSO2, Ph; R5 = halo; R6, R7 = Me, Et; R6R7 = (CH2)3, (CH2)4] (.apprx.64 compds.) were prepd. as herbicides. Thus, benzopyrazole II (R8 = NO2) was reduced to the amine which was treated with (F3CSO2)2O to give 50% II (R8 = NHSO2CF3) (III). At 0.8 g/are, III gave complete control of barnyardgrass, broadleaf weeds, and bulrush, without damage to preemegent rice in flooded fields. The title compds. also controlled weeds in soybeans, cotton, corn, wheat, and sunflowers without damage to crops.

IT 105289-27-8P 105289-33-6P 105289-35-8P
 105289-36-9P 105289-43-8P 105289-46-1P
 105289-47-2P 105289-71-2P 105313-85-7P
 105313-86-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as selective herbicide)

RN 105289-27-8 CAPLUS


CN Methanesulfonamide, N-[2-chloro-5-(5-chloro-3,4-dimethyl-1H-pyrazol-1-yl)-4-fluorophenyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



09/773,736


RN 105289-33-6 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-(5-chloro-3-methyl-1H-pyrazol-1-yl)-4-fluorophenyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)




RN 105289-35-8 CAPLUS

CN Ethanesulfonamide, N-[2-chloro-5-(4,5-dichloro-3-methyl-1H-pyrazol-1-yl)-4-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 105289-36-9 CAPLUS


CN Ethanesulfonamide, N-[2-chloro-5-(4,5-dichloro-3-methyl-1H-pyrazol-1-yl)-4-fluorophenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 105289-43-8 CAPLUS


CN Methanesulfonamide, N-[2-chloro-5-(4,5-dichloro-3-methyl-1H-pyrazol-1-yl)-4-fluorophenyl]-N-methyl- (9CI) (CA INDEX NAME)

09/773,736




RN 105289-46-1 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-(4,5-dichloro-3-methyl-1H-pyrazol-1-yl)-4-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 105289-47-2 CAPLUS


CN Benzenesulfonamide, N-[5-(4-bromo-5-chloro-3-methyl-1H-pyrazol-1-yl)-2-chloro-4-fluorophenyl]-4-nitro- (9CI) (CA INDEX NAME)



RN 105289-71-2 CAPLUS


CN Methanesulfonamide, N-[2-chloro-5-(4,5-dichloro-3-methyl-1H-pyrazol-1-yl)-4-fluorophenyl]-N-methyl-1-(methylsulfonyl)- (9CI) (CA INDEX NAME)

09/773,736




RN 105313-85-7 CAPLUS

CN Methanesulfonamide, N-[5-(4-bromo-5-chloro-3-methyl-1H-pyrazol-1-yl)-2-chloro-4-fluorophenyl]-1,1,1-trifluoro- (9CI) (CA INDEX NAME)



RN 105313-86-8 CAPLUS

CN Methanesulfonamide, N-[2-chloro-5-(4,5-dichloro-3-methyl-1H-pyrazol-1-yl)-4-fluorophenyl]-N-(methanesulfonyl)- (9CI) (CA INDEX NAME)



09/773,736


L31 ANSWER 98 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1986:515061 CAPLUS
DN 105:115061
TI Heteroarylquinolone inotropic agents
IN Roberts, David Anthony; Campbell, Simon Fraser
PA Pfizer Ltd., UK; Pfizer Corp.
SO Eur. Pat. Appl., 108 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

Same as #93

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	EP 166533	A1	19860102	EP 1985-303766	19850529
	EP 166533	B1	19900411		
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	ES 543514	A1	19860901	ES 1985-543514	19850527
	ZA 8503992	A	19870128	ZA 1985-3992	19850527
	CA 1292234	A1	19911119	CA 1985-482424	19850527
	FI 8502123	A	19851130	FI 1985-2123	19850528
	DK 8502360	A	19851130	DK 1985-2360	19850528
	NO 8502124	A	19851202	NO 1985-2124	19850528
	NO 163186	C	19900418		
	AU 8543032	A1	19851205	AU 1985-43032	19850528
	AU 562081	B2	19870528		
	DD 237509	A5	19860716	DD 1985-276727	19850528
	HU 40642	A2	19870128	HU 1985-2033	19850528
	HU 195961	B	19880829		
	IL 75326	A1	19880930	IL 1985-75326	19850528
	SU 1433411	A3	19881023	SU 1985-3901004	19850528
	JP 61000082	A2	19860106	JP 1985-116316	19850529
	JP 02055431	B4	19901127		
	PL 145325	B1	19880930	PL 1985-253689	19850529
	AT 51868	E	19900415	AT 1985-303766	19850529
	ES 552107	A1	19880216	ES 1986-552107	19860217
PRAI	GB 1984-13685		19840529		
	GB 1984-27167		19841026		
	EP 1985-303766		19850529		
AB	The title compds. [I; R = H, alkyl, alkoxy, OH, CF ₃ , halo, cyano, HOCH ₂ ; R ₁ = N-contg. heteroaryl; R ₂ = R ₃ = H; R ₂ R ₃ = bond] were prepd. as inotropic agents (no data). Thus, 4.325 g 1-(4-amino-3-methylphenyl)imidazole was acylated with trans-EtOCH:CHCOCl to give 2.75 g trans-1-[4-(3-ethoxypropenamido)-3-methylphenyl]imidazole. This (2.7 g) was cyclized with H ₂ SO ₄ to give 1.71 g imidazolylquinolone II.				
IT	102791-85-5P 102791-99-1P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and cyclization of, by sulfamic acid)				
RN	102791-85-5 CAPLUS				
CN	2-Propenamide, 3-ethoxy-N-[4-(1H-pyrazol-1-yl)phenyl]-, (E)- (9CI) (CA INDEX NAME)				


Double bond geometry as shown.

09/773,736



RN 102791-99-1 CAPLUS
CN 2-Propenamide, 3-ethoxy-N-[2-methyl-4-(1H-pyrazol-1-yl)phenyl]-, (E)-
(9CI) (CA INDEX NAME)

Double bond geometry as shown.




09/773,736


L31 ANSWER 99 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1986:34096 CAPLUS
 DN 104:34096
 TI Substituted 4,5-dihydro-6-vinyl-3(2H)-pyridazinones and
 6-vinyl-3(2H)-pyridazinones
 IN Hilboll, Gerd; Prop, Gerrit; Borbe, Harald O.; Uhlenndorf, Joachim
 PA Nattermann, A., und Cie. G.m.b.H., Fed. Rep. Ger.
 SO Ger. Offen., 58 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 3401911	A1	19850801	DE 1984-3401911	19840120
	EP 150463	A1	19850807	EP 1984-116018	19841220
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	DK 8500253	A	19850721	DK 1985-253	19850118
	JP 60161982	A2	19850823	JP 1985-6022	19850118
	ZA 8500443	A	19850925	ZA 1985-443	19850118
	ES 539673	A1	19851116	ES 1985-539673	19850118
PRAI	DE 1984-3401911		19840120		

OS CASREACT 104:34096
 AB Antihypertensive and antithrombotic (no data) title compds. I [R =
 (un)substituted Ph, heteroaryl; R1, R2 = H, alkyl; R3 = H, alkyl, Ph;
 dotted line = optional double bond] were prepd. Thus, 50 g 4-AcNHC6H4CHO
 was refluxed with 35.8 g MeCOCH2CH2CO2H in PhMe contg. piperidine to give
 48.3 g 4-AcNHC6H4CH:CHCOCH2CH2CO2H. This (5.2 g) was refluxed in MeOH
 with N2H4.H2O to give 1.3 g dihydropyridazinone II.
 IT **99662-30-3P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and cyclocondensation of, with hydrazine)
 RN 99662-30-3 CAPLUS
 CN 5-Hexenoic acid, 4-oxo-6-[4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX
 NAME)



IT **99662-18-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as antihypertensive and antithrombotic)
 RN 99662-18-7 CAPLUS
 CN 3(2H)-Pyridazinone, 4,5-dihydro-6-[2-[4-(1H-pyrazol-1-yl)phenyl]ethenyl]-
 (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 100 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1985:596075 CAPLUS
 DN 103:196075
 TI Herbicidal pyrazole derivatives
 IN Yanagi, Mikio; Yamada, Osamu; Futatsuya, Fumio; Shida, Atsuhiko
 PA Nippon Kayaku Co., Ltd. , Japan
 SO Eur. Pat. Appl., 93 pp.
 CODEN: EPXXDW
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 138527	A2	19850424	EP 1984-306807	19841005
	EP 138527	A3	19870603		
	R: AT, BE, CH, DE, FR, GB, IT, LI, NL				
	JP 60081169	A2	19850509	JP 1983-188939	19831008
	JP 61060658	A2	19860328	JP 1984-180365	19840831
	DK 8404792	A	19850409	DK 1984-4792	19841005
	BR 8405055	A	19850820	BR 1984-5055	19841005
PRAI	JP 1983-188939		19831008		
	JP 1984-180365		19840831		

OS CASREACT 103:196075

AB Arylpyrazoles I [R = alkyl; R1 = H, halogen, alkyl, alkylthio, alkylsulfonyl; RR1 = (un)substituted (CH2)n; R2 = halo, Me, alkoxy, R6S(O)m; R3 = H, halo, Me; R4 = H, halo, NO2, Me, cyano, CO2H, alkoxy, alkoxycarbonyl; R5 = CO2H, modified CO2H; R6 = alkyl; n = 3,4; m = 0-2] were prepd. Thus, 4,3-Cl(Me2CHO2C)C6H3NHNH2 and 2-carbethoxycyclohexanone were cyclocondensed to give 59.3% indazolone II, which was chlorinated by POCl3 to give 87.4% indazole III. Preemergent application of III to flooded paddy rice at 1.5 g/are gave 100% control of Echinochloa crus-galli without crop damage.


IT 98114-15-9P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and herbicidal activity of)

RN 98114-15-9 CAPLUS


CN L-Alanine, N-[5-(4-bromo-5-chloro-3-methyl-1H-pyrazol-1-yl)-2-chloro-4-fluorobenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



09/773,736

L31 ANSWER 101 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1985:596030 CAPLUS
DN 103:196030
TI Synthesis of 3,5-dimethyl-4-(substituted sulfonamidobenzeneazo,
4-sulfophenyl- and 4-sulfonaphthylazo)-1(H)-(heterosubstituted)pyrazoles
and evaluation of their antibacterial properties
AU Fernandes, P. S.; Desai, Dhimant; Gawri, Neelam; Pandey, Sudhanshu; Patel,
Himat
CS Nadkarny-Sacasa Res. Lab., St. Xavier's Coll., Bombay, 400 001, India
SO J. Indian Chem. Soc. (1984), 61(9), 818-19
CODEN: JICSAH; ISSN: 0019-4522
DT Journal
LA English
OS CASREACT 103:196030
AB The pyrazole derivs. I (R = Q, Q1, Q2, Q3; R1 = Ph, p-O2NC6H4, HO2CCH2)
and II (R = Q, Q1, Q2, Q3; R2 = p-HO3SC6H4, 4-sulfo-1-naphthyl) were
prepd. by treating (MeCO)2CHN:NC6H4(SO2NHR1)-p and (MeCO)2CHN:NR2 with
RNHNH2 (R = Q, Q1, Q2, Q3) to give the corresponding hydrazones, which
were cyclized by HOAc. Some I and II showed bactericidal activity.
IT **98191-33-4P 98191-44-7P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and intramol. cyclization of, pyrazole deriv. from)
RN 98191-33-4 CAPLUS
CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, [2-[[4-
[[(carboxymethyl) amino]sulfonyl]phenyl]azo]-1-methyl-3-
oxobutylidene]hydrazide (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

— CO₂H

RN 98191-44-7 CAPLUS
CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, [1-methyl-3-oxo-2-[(4-
sulfophenyl)azo]butylidene]hydrazide (9CI) (CA INDEX NAME)




IT **67138-88-9**

RL: RCT (Reactant)

(reaction of, with azopentanedione deriv.)


RN 67138-88-9 CAPLUS

CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, hydrazide (9CI) (CA
INDEX NAME)




L31 ANSWER 102 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1984:530632 CAPLUS
 DN 101:130632
 TI Heteropentalenes. The thermal addition of pyrazolo- and triazolobenzotriazoles to dimethyl acetylenedicarboxylate
 AU Albini, Angelo; Bettinetti, Gianfranco; Minoli, Giovanna
 CS Dip. Chim. Org., Univ. Pavia, Pavia, 27100, Italy
 SO J. Org. Chem. (1984), 49(15), 2670-6
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA English
 OS CASREACT 101:130632
 AB Pyrazolobenzotriazole [I; X = X1 = CH (II)] and triazolobenzotriazoles [I; X = N, X1 = CH (III), X = CH, X1 = N (IV)] undergo electrophilic attack by MeO2CC.tplbond.CC(=O)OMe (V) to form diradical or zwitterionic intermediates, which evolve along different pathways. Thus, initial attack at position 5 of the heteropentalene results in formal cycloaddn., yielding the pyrazolopyrazolobenzotriazole VI (R = H) from II and the triazolopyrazolobenzotriazole VII from III. VII decomps. to pyrazolobenzotriazoledicarboxylate VIII, in turn capable of further cycloaddn. with V to give VI (R = CO2Me). Protic media trap the intermediate to give, e.g., cis-2-R1C6H4NHC(CO2Me):C(OMe)CO2Me (R1 = 1H-pyrazol-1-yl, 2H-1,2,3-triazol-2-yl). Attack at position 1 or 3 gives stable products only when H is present at these positions; then a H intermol. shift ensues to form pyrazolo- or triazolobenzotriazolylmaleates or fumarates (e.g., IX). In the case of IV the initial adduct transfers a H and rearranges to the stable pyridazinobenzotriazine radical X.
 IT **90460-16-5P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn., IR, and NMR spectra of)
 RN 90460-16-5 CAPLUS
 CN 2-Butenedioic acid, 2-methoxy-3-[[2-(1H-pyrazol-1-yl)phenyl]amino]-, dimethyl ester, (Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




09/773,736

L31 ANSWER 103 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1984:68233 CAPLUS
DN 100:68233
TI Heteropentalenes. The thermal addition of 1,3-dimethylpyrazolo[1,2-a]benzotriazole to dimethyl acetylenedicarboxylate
AU Albini, Angelo; Bettinetti, Gianfranco; Minoli, Giovanna
CS Dip. Chim. Org., Univ. Pavia, Pavia, 27100, Italy
SO J. Chem. Soc., Perkin Trans. 1 (1983), (10), 2491-4
CODEN: JCPRB4; ISSN: 0300-922X
DT Journal
LA English
OS CASREACT 100:68233
AB The heteropentalene I with (MeO₂CC.tplbond.)₂ in anhyd. CCl₄ for 20 h gave the tetracyclic compd. II, quant. The zwitterionic reaction intermediate was trapped by MeOH or H₂O, giving 65% 2-RC₆H₄NHC(CO₂Me):C(OMe)CO₂Me and 10% [2-RC₆H₄NHC(CO₂Me):C(CO₂Me)]₂O (R = 3,5-dimethylpyrazol-1-yl), resp. II undergoes spontaneous retrocycloaddn. to pyrazolobenzotriazole III and radical cleavage to give, unexpectedly, Me 4,5-dihydro-2-methyl-4-oxopyrazolo[2,3-a]quinoxaline-3-carboxylate as the main product together with small amts. of 2 benzotriazolylpentenones.
IT **88609-14-7P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 88609-14-7 CAPLUS
CN 2-Butenedioic acid, 2-[[2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]-3-methoxy-, dimethyl ester (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 104 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1984:68227 CAPLUS
DN 100:68227
TI Synthesis, reactions and biological activity of 3-p-
(sulfonamido)phenylsydnone and its derivatives
AU Tikare, Ravindra K.; Badami, Bharati V.; Puranik, Gurubasav S.
CS Dep. Chem., Karnatak Univ., Dharwad, 580 003, India
SO Indian J. Chem., Sect. B (1983), 22B(7), 673-7
CODEN: IJSBDB; ISSN: 0376-4699
DT Journal
LA English
OS CASREACT 100:68227
AB Some new sydnones I (R = NMePh, NEtPh, morpholino, piperidino,
pyrrolidino, NEt2, R1 = H) were prepd from 4-RSO2C6H4N(NO)CH2CO2H. On
treatment with Br, MeO2CC.tplbond.CCO2Me or PhCOC.tplbond.CCOPh give I (R1
= Br) and pyrazole II (R2 = R3 = CO2Me, Bz). Hydrazine hydrochlorides,
obtained by hydrolysis of I, react with cyclohexanone, NH3, and
acetylacetone to furnish tetrahydrocarbazoles III, 4-RSO2C6H4NHNH2 and
3,5-dimethylpyrazoles II (R1 = R3 = Me, R2 = H). Some I are active
against Escherichia coli, Staphylococcus aureus, Candida albicans and
Aspergillus niger.
IT **88323-66-4P 88323-67-5P 88323-71-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and fungicidal activity of)
RN 88323-66-4 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[4-[(methylphenylamino)sulfonyl]phenyl
1]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 88323-67-5 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[4-[(ethylphenylamino)sulfonyl]phenyl
1]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 88323-71-1 CAPLUS

09/773,736


CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[4-[(diethylamino)sulfonyl]phenyl]-, dimethyl ester (9CI) (CA INDEX NAME)



09/773,736


L31 ANSWER 105 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1984:68078 CAPLUS
DN 100:68078
TI Penicillins and compositions containing them
IN Taylor, Andrew William; Cook, Richard Thomas
PA Beecham Group PLC, UK
SO Eur. Pat. Appl., 84 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 90656	A1	19831005	EP 1983-301786	19830330
	R: BE, CH, DE, FR, GB, IT, LI, NL, SE				
	AU 8312943	A1	19831006	AU 1983-12943	19830329
	ZA 8302226	A	19840229	ZA 1983-2226	19830329
	US 4537886	A	19850827	US 1983-479953	19830329
	JP 58183692	A2	19831026	JP 1983-54989	19830330
	ES 521192	A1	19840601	ES 1983-521192	19830330
	ES 527711	A1	19860201	ES 1983-527711	19831201
PRAI	GB 1982-9426		19820331		
AB	Penicillins I (R = substituted pyrazolyl; R1 = Ph, substituted Ph, heterocyclic) and some related cephalosporins were prepd. Thus, ampicillin was acylated with QCO2H to give 20% I (R = Q, R1 = Ph) which had a min. inhibitory concn. against Escherichia coli NCTC 10418 of 5.0 .mu.g/mL.				
IT	88597-57-3				
	RL: RCT (Reactant) (hydrolysis of)				
RN	88597-57-3 CAPLUS				
CN	1H-Pyrazole-4-carboxylic acid, 2,3-dihydro-1-[4-[(4-hydroxybutyl)amino]phenyl]-3-oxo-, ethyl ester (9CI) (CA INDEX NAME)				




IT **88597-58-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and acylation of ampicillin by)
RN 88597-58-4 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 2,3-dihydro-1-[4-[(4-hydroxybutyl)amino]phenyl]-3-oxo- (9CI) (CA INDEX NAME)


09/773,736



L31 ANSWER 106 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1984:34459 CAPLUS
 DN 100:34459
 TI Synthesis and antidiabetic activity of some sulfonylurea derivatives of
 3,4,5-trisubstituted pyrazoles
 AU Soliman, Raafat; Mokhtar, Hassan; Mohamed, Hosny F.
 CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
 SO J. Pharm. Sci. (1983), 72(9), 1004-7
 CODEN: JPMSAE; ISSN: 0022-3549
 DT Journal
 LA English
 AB Sulfonylureas I and II (R = Et, Pr, Bu, cyclohexyl, Ph, allyl, CH₂Ph; R₁ =
 Me, Ph; R₂ = Et, H; R₃ = H, Br; X = O, S) were prepd. from the
 sulfonamides and RNCX. II (R = Ph, R₃ = H) had antidiabetic activity
 comparable to that of phenformin. Some I also had antidiabetic activity.
 IT **88281-50-9P 88281-51-0P**
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (prepn. and antidiabetic activity of)
 RN 88281-50-9 CAPLUS
 CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[[[(butylamino)carbonyl]amino]sulfonyl
]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




RN 88281-51-0 CAPLUS
 CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[[[(cyclohexylamino)carbonyl]amino]sul
 fonyl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




IT **88281-43-0P 88281-44-1P 88281-46-3P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and hydrolysis of)
 RN 88281-43-0 CAPLUS
 CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[[[(ethylamino)carbonyl]amino]sulfonyl
]phenyl]-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 88281-44-1 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 3,5-dimethyl-1-[4-
[[[(propylamino)carbonyl]amino]sulfonyl]phenyl]-, ethyl ester (9CI) (CA
INDEX NAME)



RN 88281-46-3 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




IT 88281-48-5P 88281-49-6P 88281-52-1P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 88281-48-5 CAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[[[(ethylamino)carbonyl]amino]sulfonyl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)




09/773,736


RN 88281-49-6 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3,5-dimethyl-1-[4-
[[[(propylamino)carbonyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 88281-52-1 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3,5-dimethyl-1-[4-
[[[(phenylamino)carbonyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




IT **88281-45-2P 88281-47-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn., hydrolysis, and antidiabetic activity of)
RN 88281-45-2 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-[4-[[[(butylamino)carbonyl]amino]sulfonyl]
phenyl]-3,5-dimethyl-, ethyl ester (9CI) (CA INDEX NAME)




RN 88281-47-4 CAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3,5-dimethyl-1-[4-
[[[(phenylamino)carbonyl]amino]sulfonyl]phenyl]-, ethyl ester (9CI) (CA
INDEX NAME)

09/773,736



09/773,736

L31 ANSWER 107 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1984:34458 CAPLUS
DN 100:34458
TI Synthesis and antidiabetic activity of some sulfonylurea derivatives of
3,5-disubstituted pyrazoles
AU Soliman, Raafat; Mokhtar, Hassan; Mohamed, Hosny F.
CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SO J. Pharm. Sci. (1983), 72(9), 999-1004
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English
AB The sulfonylureas I (R = Cl, OMe; R1 = H, Et; R2 = Et, Pr, Ph, cyclohexyl,
Bu, CH2Ph, 4-MeC6H4; X = O, S) were prepd. from 4-H2NSO2C6H4NHNH2,
4-RC6H4CH: CPhCOCH2COCO2Et, and R2NCX, followed by ester hydrolysis. I
have hypoglycemic activity which is lower than that of styryl and
.alpha.-alkylstyryl analogs.
IT **81750-29-0**
RL: RCT (Reactant)
(hydrolysis and antidiabetic activity of)
RN 81750-29-0 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(butylamino)carbonyl]amino]sulfonyl
phenyl]-5-(2-phenylethenyl)-, ethyl ester (9CI) (CA INDEX NAME)




09/773,736


L31 ANSWER 108 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1983:575812 CAPLUS
DN 99:175812
TI Herbicidal sulfonamides
IN Wolf, Anthony David; Rorer, Morris Padgett
PA du Pont de Nemours, E. I., and Co. , USA
SO Eur. Pat. Appl., 271 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 83975	A2	19830720	EP 1983-300073	19830106
	EP 83975	A3	19840801		
	EP 83975	B1	19871119		
	R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
	US 4465505	A	19840814	US 1982-428806	19821007
	US 4511392	A	19850416	US 1982-436631	19821029
	AT 30915	E	19871215	AT 1983-300073	19830106
	CA 1239929	A1	19880802	CA 1983-419031	19830106
	US 4606755	A	19860819	US 1984-685026	19841221
	US 4695311	A	19870922	US 1986-861260	19860509
	US 4810282	A	19890307	US 1987-60204	19870610
PRAI	US 1982-337932		19820107		
	US 1982-337934		19820107		
	US 1982-428806		19821007		
	US 1982-436631		19821029		
	EP 1983-300073		19830106		
	US 1984-685026		19841221		
	US 1986-861260		19860509		
OS	CASREACT 99:175812				
AB	Benzenesulfonamides I (R = azolyl, azinyl; R1 = H, F, Cl, Br, Me, CF3, OMe; R2 = H, Me; R3 = substituted pyrimidinyl, triazinyl; X = O, S) (67 compds.) were prep'd. Thus, 2-O2NC6H4COMe was treated with Me2NCH(OMe)2 to give 2-O2NC6H4COCH:CHNMe2, which was cyclized with NH2OH to the isoxazole II (R4 = NO2). Redn. of the nitro group, diazotization, and reaction with SO2-HCl gave II (R4 = SO2Cl), which was amidated and treated with BuNCO and COCl2 to give II (R4 = SO2NCO). Treatment of the isocyanate with 2-amino-4,6-dimethoxypyrimidine gave III which, at 0.05 kg/ha preemergence, gave total control of e.g., nutsedge.				
IT	87488-87-7P 87489-19-8P 87489-20-1P 87489-21-2P 87489-22-3P 87489-23-4P RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. and herbicidal activity of)				
RN	87488-87-7 CAPLUS				
CN	Benzenesulfonamide, N-[[[4-methoxy-6-methyl-2-pyrimidinyl)amino]carbonyl]-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)				


09/773,736



RN 87489-19-8 CAPLUS
CN Benzenesulfonamide, N-[[(4,6-dimethyl-2-pyrimidinyl)amino]carbonyl]-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 87489-20-1 CAPLUS
CN Benzenesulfonamide, N-[[(4,6-dimethoxy-2-pyrimidinyl)amino]carbonyl]-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 87489-21-2 CAPLUS
CN Benzenesulfonamide, N-[[(4,6-dimethoxy-1,3,5-triazin-2-yl)amino]carbonyl]-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)


09/773,736



RN 87489-22-3 CAPLUS
CN Benzenesulfonamide, N-[[4-methoxy-6-methyl-1,3,5-triazin-2-yl]amino]carbonyl]-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



RN 87489-23-4 CAPLUS
CN Benzenesulfonamide, N-[[4,6-dimethyl-1,3,5-triazin-2-yl]amino]carbonyl]-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 109 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1983:551722 CAPLUS

DN 99:151722

TI Antidiabetic activity of some 1-substituted 3,5-dimethylpyrazoles

AU Soliman, Raafat; Darwish, Suzan A. S.

CS Fac. Pharm., Univ. Alexandria, Egypt

SO J. Med. Chem. (1983), 26(11), 1659-63

CODEN: JMCMAR; ISSN: 0022-2623

DT Journal

LA English

OS CASREACT 99:151722

AB One title compd. (I, Y = CO) [50476-17-0] prepd. by heating ClCO₂Et [541-41-3] with 2 equiv. of 3,5-dimethylpyrazole (II) [67-51-6] in the presence of anhyd. K₂CO₃, another title compd. (I, Y = CH₂CO) [87013-78-3] prepd. either by heating 3,5-dimethylpyrazole-1-acetic acid hydrazide [64019-58-5] with an equiv. of MeCOCH₂COMe [123-54-6] at 110.degree., or by treating II with 1/2 its equiv. of ClCH₂COCl [79-04-9], and III (R = aroyl, substituted COCH₂, substituted carbonylphenylurea, substituted benzenesulfonylurea, etc., and R₁ = H or Br) prepd. mostly either by acylation or alkylation of II or by cyclization of acyl hydrazides with MeCOCH₂COMe, were tested for hypoglycemic activity with alloxan-diabetic female albino mice. III (R = substituted carbonylphenylurea or substituted carbamoylbenzenesulfonylurea, R₁ = H or Br) showed potent hypoglycemic activity. Structure activity relations are discussed.

IT 87014-12-8P 87014-13-9P 87014-14-0P


87014-15-1P 87014-16-2P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. and hypoglycemic activity of)


RN 87014-12-8 CAPLUS

CN Benzenesulfonamide, 4-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-N-[(ethylamino)carbonyl]- (9CI) (CA INDEX NAME)




RN 87014-13-9 CAPLUS

CN Benzenesulfonamide, 4-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-N-[(1-methylethylamino)carbonyl]- (9CI) (CA INDEX NAME)




09/773,736


RN 87014-14-0 CAPLUS
CN Benzenesulfonamide, 4-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-N-
[(butylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 87014-15-1 CAPLUS
CN Benzenesulfonamide, 4-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-N-
[(cyclohexylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 87014-16-2 CAPLUS
CN Benzenesulfonamide, 4-(4-bromo-3,5-dimethyl-1H-pyrazol-1-yl)-N-
[(phenylamino)carbonyl]- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 110 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1982:583951 CAPLUS

Correction of: 1982:53843

DN 97:183951

Correction of: 96:53843

TI 4-Heterocyclyl-4'-vinylstilbenes

IN Burdeska, Kurt; Kabas, Guglielmo; Weber, Kurt

PA Ciba-Geigy A.-G. , Switz.

SO Eur. Pat. Appl., 94 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 31796	A2	19810708	EP 1980-810393	19801215
	EP 31796	A3	19810930		
	EP 31796	B1	19850123		
	R: CH, DE, FR, GB, IT				
	BR 8008402	A	19810721	BR 1980-8402	19801219
	ES 498034	A1	19811116	ES 1980-498034	19801220
	JP 56098263	A2	19810807	JP 1980-180625	19801222
	JP 01060068	B4	19891220		
PRAI	CH 1979-11402		19791221		
	CH 1980-7008		19800918		

AB Compds. of general structure I are prepd., where R is a monocyclic 5- or 6-membered arom. heterocyclic group (optionally with 1 or 2 fused benzene rings), a bicyclic 9-membered arom. heterocyclic group, Ph, CN, carboxy, alkoxy, carbonyl, alkylsulfonyl, or arylsulfonyl; R1 = H or alkyl; R2 = H, alkyl, alkoxy, carbonyl, carbamoyl, sulfonamido, alkenyl, carboxy, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, CN, sulfo, or dialkoxylphosphinyl; R3 = H, alkyl, or alkenyl; and only one of R2 and R3 can be H. I are esp. useful as fluorescent whiteners for fibers and plastics. Over 100 addnl. I were prepd. by the same or similar methods. Thus, condensation of 2-[4-[(diethoxyphosphinyl)methyl]phenyl]-4,6-dimethoxypyrimidine [79382-97-1] with 4-HCOC6H4CH:CHCO2Me [7560-50-1] in DMF in the presence of NaOMe gave cryst. II [79381-32-1], a fluorescent whitener for polyester textiles.


IT 79381-57-0P 79381-58-1P

RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)

(manuf. of, as fluorescent brightener for fibers and plastics)

RN 79381-57-0 CAPLUS


CN 2-Propenoic acid, 3-[4-[2-[4-(3-methyl-1H-pyrazol-1-yl)phenyl]ethenyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 79381-58-1 CAPLUS

CN 2-Propenenitrile, 3-[4-[2-[4-(3-methyl-1H-pyrazol-1-yl)phenyl]ethenyl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736



L31 ANSWER 111 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1982:199576 CAPLUS
 DN 96:199576
 TI Synthesis and spectra of new 3-carbethoxypyrazole sulfonylurea derivatives
 AU Allah, Hassan M. Faïd; Mokhtar, Hassan M.; Soliman, R.
 CS Fac. Sci., Alexandria Univ., Alexandria, Egypt
 SO J. Heterocycl. Chem. (1981), 18(8), 1561-4
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 AB Treating pyrazoles I (R = H, Me, Ph; R1 = H) (II) with R2NCO and R2NCS (R2 = Et, Bu, cyclohexyl) gave I [R1 = CONHR2 (III), CSNHR2] resp. Brominating II gave 4-bromopyrazoles which were treated with R2NCS to give IV., also prepd. by brominating III. Alk. hydrolysis of III gave the corresponding acids.
 IT **81750-29-0P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and bromination of)
 RN 81750-29-0 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(butylamino)carbonyl]amino]sulfonyl]phenyl]-5-(2-phenylethenyl)-, ethyl ester (9CI) (CA INDEX NAME)




IT **81750-28-9P 81750-32-5P 81750-33-6P**
81750-40-5P 81750-41-6P 81750-42-7P
81750-50-7P
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
 RN 81750-28-9 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(ethylamino)carbonyl]amino]sulfonyl]phenyl]-5-(2-phenylethenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 81750-32-5 CAPLUS
 CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(ethylamino)carbonyl]amino]sulfonyl]phenyl]-5-(1-methyl-2-phenylethenyl)-, ethyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 81750-33-6 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(butylamino)carbonyl]amino]sulfonyl]phenyl]-5-(1-methyl-2-phenylethenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 81750-40-5 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(ethylamino)thioxomethyl]amino]sulfonyl]phenyl]-5-(2-phenylethenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 81750-41-6 CAPLUS


CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(ethylamino)thioxomethyl]amino]sulfonyl]phenyl]-5-(1-methyl-2-phenylethenyl)-, ethyl ester (9CI) (CA INDEX NAME)

09/773,736




RN 81750-42-7 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(butylamino)thioxomethyl]amino]sulfonyl]phenyl]-5-(1-methyl-2-phenylethenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 81750-50-7 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 4-bromo-1-[4-[[[(butylamino)carbonylamino]sulfonyl]phenyl]-5-(2-phenylethenyl)-, ethyl ester (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 112 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1982:53843 CAPLUS
 DN 96:53843
 TI 4-Heterocyclyl-4'-vinylstilbenes
 IN Burdeska, Kurt; Kabas, Guglielmo; Weber, Kurt
 PA Ciba-Geigy A.-G., Switz.
 SO Eur. Pat. Appl., 94 pp.
 CODEN: EPXXDW
 DT Patent
 LA German

Same as #110


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 31796 A2		19810708	EP 1980-810393	19801215
	R: CH, DE, FR, GB, IT				
PRAI	CH 1979-11402		19791221		
	CH 1980-7008		19800918		

AB Compds. of general structure I are prepd., where R is a monocyclic 5- or 6-membered arom. heterocyclic group (optionally with 1 or 2 fused benzene rings), a bicyclic 9-membered arom. heterocyclic group, Ph, CN, carboxy, alkoxycarbonyl, alkylsulfonyl, or arylsulfonyl; R1 = H or alkyl; R2 = H, alkyl, alkoxycarbonyl, carbonyl, sulfonyl, alkenyl, carboxy, alkylsulfonyl, arylsulfonyl, aralkylsulfonyl, CN, sulfo, or dialkoxyposphinyl; R3 = H, alkyl, or alkenyl; and only one of R2 and R3 can be H. I are esp. useful as fluorescent whiteners for fibers and plastics. Thus, condensation of 2-[4-[(diethoxyphosphinyl)methyl]phenyl]-4,6-dimethoxypyrimidine [79382-97-1] with 4-HCOC6H4CH:CHCO2Me [7560-50-1] in DMF in the presence of NaOMe gave cryst. II [79381-32-1], a fluorescent whitener for polyester textiles. Over 100 addnl. I were prepd. by the same or similar methods.

IT **79381-57-0P 79381-58-1P**
 RL: IMF (Industrial manufacture); MOA (Modifier or additive use); PREP (Preparation); USES (Uses)
 (manuf. of, as fluorescent brightener for fibers and plastics)


RN 79381-57-0 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-[4-(3-methyl-1H-pyrazol-1-yl)phenyl]ethenyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 79381-58-1 CAPLUS

CN 2-Propenenitrile, 3-[4-[2-[4-(3-methyl-1H-pyrazol-1-yl)phenyl]ethenyl]phenyl]- (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 113 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1981:550580 CAPLUS
DN 95:150580
TI Preparation and antidiabetic activity of cyclic sulfonylthiourea derivatives
AU Soliman, Raafat; Feid-Allah, Hassan M.; Mohamed, Hosny F.
CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SO J. Pharm. Sci. (1981), 70(8), 952-6
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English
AB 3-Substituted 5-methyl-1-[p-(3,5-dimethylpyrazol-1-yl)-, 5-methyl-1-[p-(5-methyl-3-carboxypyrazol-1-yl), 1-[p-(3-methyl-5-phenylpyrazol-3-yl)- and 1-[p-(3-methyl-4-bromo-5-phenylpyrazol-1-yl)benzenesulfonyl]-2-thiohydantoin and their 5-methyl-2-thiohydantoin and 5,6-dihydro-4(3H)-oxo-2(1H)-pyrimidinethione derivs. were prepd. Thiohydantoin I showed antidiabetic activity at 0.2 mmole/kg orally in mice.
IT 69180-77-4 69180-78-5 69180-80-9
69180-81-0 69180-85-4 69180-86-5
69180-87-6 79222-84-7
RL: RCT (Reactant)
(cyclocondensation of, with bromopropionate, thiohydantoin from)
RN 69180-77-4 CAPLUS
CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-[(2-propenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 69180-78-5 CAPLUS
CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-[(propylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 69180-80-9 CAPLUS
CN Benzenesulfonamide, N-[(cyclohexylamino)thioxomethyl]-4-(3,5-dimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)


09/773,736




RN 69180-81-0 CAPLUS
CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-
[[(phenylmethyl)amino]thioxomethyl]- (9CI) (CA INDEX NAME)



RN 69180-85-4 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[4-[[[(propylamino)thioxomethyl]
amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 69180-86-5 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(butylamino)thioxomethyl]amino]sulf
onyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 69180-87-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(cyclohexylamino)thioxomethyl]amino]
[sulfonyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)

09/773,736



RN 79222-84-7 CAPLUS
CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-[(4-methylphenyl)amino]thioxomethyl]- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 114 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1981:499273 CAPLUS
 DN 95:99273
 TI Finishing fibrous materials
 IN Springer, Hartmut
 PA Hoechst A.-G., Fed. Rep. Ger.
 SO Eur. Pat. Appl., 25 pp.
 CODEN: EPXXDW
 DT Patent
 LA German
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 24676	A2	19810311	EP 1980-104925	19800819
	EP 24676	A3	19810325		
	EP 24676	B1	19850130		
	R: BE, CH, DE, FR, GB, IT				
	DE 2934247	A1	19810409	DE 1979-2934247	19790824
	IN 154958	A	19841222	IN 1980-CA942	19800819
	AU 8061675	A1	19810305	AU 1980-61675	19800822
	AU 537205	B2	19840614		
	BR 8005344	A	19810310	BR 1980-5344	19800822
	JP 56037377	A2	19810411	JP 1980-114884	19800822
	JP 63065712	B4	19881216		
	CS 214719	P	19820528	CS 1980-5761	19800822
	CA 1164159	A1	19840327	CA 1980-358807	19800822
	US 4394129	A	19830719	US 1981-296469	19810826
PRAI	DE 1979-2934247		19790824		
	US 1980-179992		19800821		

AB Dyes, optical brighteners, and creaseproofing agents contg. groups with the formula ZNRCN (Z = SO₂ or CO; R = H, NH₄, or a mono-, di-, or trivalent metal are suitable for finishing all types of textiles. Thus, 20 parts Cu phthalocyanine dye [78547-49-6] with the formula CuPc[SO₂N(NH₄)CN]₄ was dissolved in 1000 parts water. A cotton fabric was dyed in the bath at 95.degree. using goods-liquor ratio 1:20, thermofixed 2 min at 210.degree., rinsed with cold and hot water, and treated with a boiling dil. soap soln. A turquoise blue shade with good washfastness and very good lightfastness was obtained.

IT **78508-51-7P**
 RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation)
 (prepn. and coupling of, with diazotized aminophenylsulfonylcyanamide)


RN 78508-51-7 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[(cyanoamino)sulfonyl]phenyl]-5-hydroxy- (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 115 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1981:497687 CAPLUS
DN 95:97687
TI Synthesis and central nervous system depression properties of
3-[(1'-pyrazolyl)phenyl]sydnones
AU Havanur, Shambhuling B.; Badami, Bharati V.; Puranik, Gurubasav S.
CS Dep. Chem., Karnatak Univ., Dharwad, 580003, India
SO Arch. Pharm. (Weinheim, Ger.) (1981), 314(6), 503-7
CODEN: ARPMAS; ISSN: 0365-6233
DT Journal
LA English
AB Sydnones I [R = R2 (R3 = H, Me); R1 = H, Me, Ph] were prepd. by the
reaction of 2-RC6H4NH2 and ClCHR1CO2Me and subsequent nitrosation and
cyclization of 2-RC6H4NHCHR1CO2H. I [R = R2 (R3 = H), R1 = H] had central
nervous system depressant activity and considerable toxicity.
IT **78786-56-8P 78786-57-9P 78786-59-1P**
78786-60-4P 78786-62-6P 78786-64-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and cyclization of)
RN 78786-56-8 CAPLUS
CN Glycine, N-nitroso-N-[2-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 78786-57-9 CAPLUS
CN Glycine, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-N-nitroso- (9CI) (CA
INDEX NAME)




RN 78786-59-1 CAPLUS
CN Alanine, N-nitroso-N-[2-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 78786-60-4 CAPLUS
CN Alanine, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-N-nitroso- (9CI) (CA INDEX NAME)



RN 78786-62-6 CAPLUS
CN Benzeneacetic acid, .alpha.-[nitroso[2-(1H-pyrazol-1-yl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 78786-64-8 CAPLUS
CN Benzeneacetic acid, .alpha.-[[2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]nitrosoamino]- (9CI) (CA INDEX NAME)




IT **78786-65-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)

09/773,736


(prepn. and deesterification of)
RN 78786-65-9 CAPLUS
CN Alanine, N-[2-(1H-pyrazol-1-yl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




IT 78786-55-7P 78786-58-0P 78786-61-5P
78786-63-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and nitrosation of)
RN 78786-55-7 CAPLUS
CN Glycine, N-[2-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 78786-58-0 CAPLUS
CN Alanine, N-[2-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 78786-61-5 CAPLUS
CN Alanine, N-[2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




09/773,736

RN 78786-63-7 CAPLUS
CN Benzeneacetic acid, .alpha.-[[2-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]- (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 116 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1981:84014 CAPLUS
DN 94:84014
TI Synthesis of 3-[p-(pyrazolyl)]phenylsydnones
AU Havanur, Shambhuling B.; Badami, Bharati V.; Puranik, Gurubasav S.
CS Dep. Chem., Karnatak Univ., Dharwad, 58003, India
SO J. Heterocycl. Chem. (1980), 17(5), 1049-51
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
AB Condensation of p-RC₆H₄NH₂ (R = 1-pyrazolyl, 3,5-dimethyl-1-pyrazolyl, 3,4,5-trimethyl-1-pyrazolyl) with R₁ClCHCO₂Me (R₁ = H, Me, Ph) gave 70-5% p-RC₆H₄NHCHR₁CO₂H which on treatment with NaNO₂ gave 75-80% p-RC₆H₄N(NO)CHR₁CO₂H. Cyclizing the last with Ac₂O gave 60-76% title compds. I.
IT **76458-01-0P 76458-02-1P 76458-03-2P**
76458-04-3P 76458-05-4P 76458-06-5P
76458-07-6P 76458-08-7P 76458-09-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and cyclization of)
RN 76458-01-0 CAPLUS
CN Glycine, N-nitroso-N-[4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 76458-02-1 CAPLUS
CN Alanine, N-nitroso-N-[4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 76458-03-2 CAPLUS
CN Benzeneacetic acid, .alpha.-[nitroso[4-(1H-pyrazol-1-yl)phenyl]amino]- (9CI) (CA INDEX NAME)


09/773,736




RN 76458-04-3 CAPLUS
CN Glycine, N-[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-N-nitroso- (9CI) (CA INDEX NAME)



RN 76458-05-4 CAPLUS
CN Alanine, N-[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-N-nitroso- (9CI) (CA INDEX NAME)




RN 76458-06-5 CAPLUS
CN Benzeneacetic acid, .alpha.-[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]nitrosoamino]- (9CI) (CA INDEX NAME)



RN 76458-07-6 CAPLUS
CN Glycine, N-nitroso-N-[4-(3,4,5-trimethyl-1H-pyrazol-1-yl)phenyl]- (9CI)


09/773,736

(CA INDEX NAME)




RN 76458-08-7 CAPLUS

CN Alanine, N-nitroso-N-[4-(3,4,5-trimethyl-1H-pyrazol-1-yl)phenyl]- (9CI)
(CA INDEX NAME)



RN 76458-09-8 CAPLUS

CN Benzeneacetic acid, .alpha.-[nitroso[4-(3,4,5-trimethyl-1H-pyrazol-1-yl)phenyl]amino]- (9CI) (CA INDEX NAME)



IT 76457-93-7P 76457-94-8P 76457-95-9P

76457-96-0P 76457-97-1P 76457-98-2P


76457-99-3P 76458-00-9P 76544-71-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and nitrosation of)


RN 76457-93-7 CAPLUS

CN Glycine, N-[4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 76457-94-8 CAPLUS
CN Alanine, N-[4-(1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 76457-95-9 CAPLUS
CN Benzeneacetic acid, .alpha.-[[4-(1H-pyrazol-1-yl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 76457-96-0 CAPLUS
CN Glycine, N-[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 76457-97-1 CAPLUS
CN Alanine, N-[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 76457-98-2 CAPLUS
CN Benzeneacetic acid, .alpha.-[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 76457-99-3 CAPLUS
CN Glycine, N-[4-(3,4,5-trimethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 76458-00-9 CAPLUS
CN Benzeneacetic acid, .alpha.-[[4-(3,4,5-trimethyl-1H-pyrazol-1-yl)phenyl]amino]- (9CI) (CA INDEX NAME)




RN 76544-71-3 CAPLUS
CN Alanine, N-[4-(3,4,5-trimethyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)

09/773,736



09/773,736


L31 ANSWER 117 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1980:146664 CAPLUS
DN 92:146664
TI Photochemistry of nitrogen heterocycles. V. Photosubstitution reactions in heterocyclic series. Case of 1-p-nitrophenylpyrazoles and -imidazoles
AU Bouchet, P.; Joncheray, G.; Jacquier, R.; Elguero, J.
CS Lab. Synth. Etude Physicochim. Heterocycles Azotes, Univ. Sci. Tech. Languedoc, Montpellier, 34060, Fr.
SO Tetrahedron (1979), 35(11), 1331-8
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA French
AB Photosubstitution reactions of 1-(p-nitrophenyl)pyrazoles and 1-(p-nitrophenyl)imidazoles bearing different substituents in the heterocyclic ring were studied. Pyrazoles only gave products with acetate, cyanate, and cyanide ions as nucleophile, the 4-formyl deriv. of the starting material being formed with the first two nucleophiles and the 4-cyano, 4-carboxamido, and several reduced products being formed with the third. (Nitrophenyl)imidazoles underwent photosubstitution with the cyanide ion forming cyano- and (hydroxymethylene)imidazoles.
IT **73225-22-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 73225-22-6 CAPLUS
CN Acetamide, N-[4-(4-cyano-3-methyl-1H-pyrazol-1-yl)phenyl]- (9CI) (CA INDEX NAME)



L31 ANSWER 118 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1979:97348 CAPLUS
 DN 90:97348
 TI Preparation and antidiabetic activity of some sulfonylurea derivatives of 3,5-disubstituted pyrazoles
 AU Soliman, Raafat
 CS Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
 SO J. Med. Chem. (1979), 22(3), 321-5
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 AB The title compds. I (R = Me, CO₂H; R₁ = substituted urea or substituted thiourea, substituted thiohydantoin or substituted 4-oxo-2-thiopyrimidine) were prepd. from 1-(p-sulfamylphenyl)-3,5-dimethylpyrazole [69181-13-1] and from the appropriate thiourea deriv. with Et bromoacetate and Et 3-bromopropionate [539-74-2]. Among the 53 I derivs. evaluated for hypoglycemic activity using alloxanized female albino mice, 1-cyclohexyl-3-[[p-(3,5-dimethylpyrazol-1-yl)phenyl]sulfonyl]urea [69180-65-0], 1-benzyl-3-[[p-(3,5-dimethylpyrazol-1-yl)phenyl]sulfonyl]-5,6-dihydro-4(3H)-oxo-2(1H)-pyrimidinethione [69180-66-1], and 1-benzyl-3-[[p-(3-carboxy-5-methylpyrazol-1-yl)phenyl]sulfonyl]-5,6-dihydro-4(3H)-oxo-2(1H)-pyrimidinethione [69180-67-2] were the most active. Structure-activity relations are discussed.


IT 69180-65-0P 69180-68-3P 69180-69-4P
 69180-70-7P 69180-71-8P 69180-72-9P
 69180-73-0P 69180-74-1P 69180-75-2P
 69180-76-3P 69180-77-4P 69180-78-5P
 69180-79-6P 69180-80-9P 69180-81-0P
 69180-82-1P 69180-83-2P 69180-84-3P
 69180-85-4P 69180-86-5P 69180-87-6P
 69180-88-7P 69180-89-8P 69203-75-4P
 69203-76-5P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. and antidiabetic activity of)

RN 69180-65-0 CAPLUS
 CN Benzenesulfonamide, N-[(cyclohexylamino)carbonyl]-4-(3,5-dimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 69180-68-3 CAPLUS
 CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-[(ethylamino)carbonyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 69180-69-4 CAPLUS
CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-
[(propylamino)carbonyl]- (9CI) (CA INDEX NAME)



RN 69180-70-7 CAPLUS
CN Benzenesulfonamide, N-[(butylamino)carbonyl]-4-(3,5-dimethyl-1H-pyrazol-1-
yl)- (9CI) (CA INDEX NAME)




RN 69180-71-8 CAPLUS
CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-
[[phenylmethyl]amino]carbonyl]- (9CI) (CA INDEX NAME)




RN 69180-72-9 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(ethylamino)carbonyl]amino]sulfonyl]
phenyl]-5-methyl- (9CI) (CA INDEX NAME)


09/773,736




RN 69180-73-0 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[4-[[[(propylamino)carbonyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 69180-74-1 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(butylamino)carbonyl]amino]sulfonyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 69180-75-2 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 69180-76-3 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[4-[[[(phenylmethyl)amino]carbonyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 69180-77-4 CAPLUS
CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-[(2-propenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)



RN 69180-78-5 CAPLUS
CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-[(propylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 69180-79-6 CAPLUS
CN Benzenesulfonamide, N-[(butylamino)thioxomethyl]-4-(3,5-dimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 69180-80-9 CAPLUS
CN Benzenesulfonamide, N-[(cyclohexylamino)thioxomethyl]-4-(3,5-dimethyl-1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)


09/773,736




RN 69180-81-0 CAPLUS
CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-
[[(phenylmethyl) amino] thioxomethyl]- (9CI) (CA INDEX NAME)



RN 69180-82-1 CAPLUS
CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-
[(phenylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 69180-83-2 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(ethylamino)thioxomethyl]amino]sulfonyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 69180-84-3 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[4-[[[(2-propenylamino)thioxomethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 69180-85-4 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[4-[[[(propylamino)thioxomethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 69180-86-5 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(butylamino)thioxomethyl]amino]sulfonyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 69180-87-6 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 1-[4-[[[(cyclohexylamino)thioxomethyl]amino]sulfonyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)




RN 69180-88-7 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[4-[[[(phenylmethyl)amino]thioxomethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


09/773,736




RN 69180-89-8 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-methyl-1-[4-[[[(phenylamino)thioxomethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 69203-75-4 CAPLUS
CN Benzenesulfonamide, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-N-[(ethylamino)thioxomethyl]- (9CI) (CA INDEX NAME)




RN 69203-76-5 CAPLUS
CN Hydrazinecarboxamide, 2-(aminoiminomethyl)-N-[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




IT **69181-15-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction. with amines)
RN 69181-15-3 CAPLUS
CN Carbamic acid, [[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)

09/773,736




09/773,736

L31 ANSWER 119 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1979:54876 CAPLUS
DN 90:54876
TI Synthesis of some substituted pyrazole-3-carboxylic acids with possible hypoglycemic and antimicrobial activity. Part 1
AU Mokhtar, Hassan; Soliman, Raafat
CS Fac. Sci., Univ. Alexandria, Alexandria, Egypt
SO Pharmazie (1978), 33(10), 649-51
CODEN: PHARAT; ISSN: 0031-7144
DT Journal
LA English
AB Condensation of PhCH:CR1COCH2COCO2Et (R1 = H, Me, Ph) with p-R2C6H4NHNH2 (R2 = CO2H, SO2NH2, 2-pyrimidinylsulfamoyl) or PhSO2NHNH2 gave 65-75% I and 65% II, resp. KMnO4 oxidn. of I gave 30-70% III, which were hydrolyzed to the resp. acids. Hydrolysis of I gave 80% corresponding acids which were successively converted to the acid chloride and amide.
IT **68962-62-9P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and hydrolysis of)
RN 68962-62-9 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-acetyl-1-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT **68962-65-2P**
RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)
RN 68962-65-2 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 5-acetyl-1-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 120 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1978:579914 CAPLUS
DN 89:179914
TI Synthesis and nucleophilic addition to conjugated imines of
1-(p-Aminophenyl)-3,5-dimethylpyrazole
AU Fernandes, P. S.; Joshi, N. N.; Menezes, A. J.; D'Souza, V.; Nadkarny, V.
CS Nadkarny-Sacasa Res. Lab., St. Xavier's Coll., Bombay, India
SO J. Indian Chem. Soc. (1977), 54(9), 923-4
CODEN: JICSAH; ISSN: 0019-4522
DT Journal
LA English
AB Schiff bases I (RR1 = bond, R2 = 2- or 4-OH, 4-MeO, 4-NO2) (II) were
prepd. by condensation of 1-(p-aminophenyl)-3,5-dimethylpyrazole with
R2C6H4CHO in EtOH/AcOH. II with HCN or NaBH4 gave I (R = H, R1 = CN or
H).
IT **67927-26-8P 67927-27-9P 67927-28-0P**
67927-29-1P 67927-30-4P 67927-31-5P
67927-32-6P 67927-33-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 67927-26-8 CAPLUS
CN Benzeneacetonitrile, .alpha.-[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)




RN 67927-27-9 CAPLUS
CN Benzeneacetonitrile, .alpha.-[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]-4-hydroxy- (9CI) (CA INDEX NAME)




RN 67927-28-0 CAPLUS
CN Benzeneacetonitrile, .alpha.-[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]-4-methoxy- (9CI) (CA INDEX NAME)

09/773,736




RN 67927-29-1 CAPLUS

CN Benzeneacetonitrile, .alpha.-[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]-4-nitro- (9CI) (CA INDEX NAME)




RN 67927-30-4 CAPLUS

CN Phenol, 2-[[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]methyl]- (9CI)
(CA INDEX NAME)



RN 67927-31-5 CAPLUS


CN Phenol, 4-[[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]amino]methyl]- (9CI)
(CA INDEX NAME)




RN 67927-32-6 CAPLUS

CN Benzenemethanamine, N-[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-4-methoxy- (9CI) (CA INDEX NAME)

09/773,736



RN 67927-33-7 CAPLUS
CN Benzenemethanamine, N-[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]-4-nitro-
(9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 121 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1978:509221 CAPLUS

DN 89:109221

TI The scope of the reactions of hydrazines and hydrazones. Part 4.
Trisubstituted pyrazoles of possible hypoglycemic and antibacterial activity

AU Soliman, R.; Mokhtar, H.; Elashry, E. S. H.

CS Dep. Pharm. Chem., Fac. Pharm., Alexandria, Egypt

SO Pharmazie (1978), 33(4), 184-5

CODEN: PHARAT; ISSN: 0031-7144

DT Journal

LA English


AB Condensation of PhCH:CHCOCH₂COCO₂Et (I) with RNHO₂SC₆H₄NHNH₂-p (R = H, 2-pyrimidinyl, 4-methyl-2-pyrimidinyl, 5-methoxy-2-pyrimidinyl) gave 50-70% pyrazoles II (R₁ = Et, R₂ = PhCH:CH) which were hydrolyzed to give 80% II (R₁ = H, R₂ = PhCH:CH) and oxidized by KMnO₄ to give 35% II (R = H, 2-pyrimidinyl, 5-methoxy-2-pyrimidinyl, R₁ = Et, R₂ = CO₂H). Addnl. obtained was 40% III.

IT **67419-93-6P 67419-94-7P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 67419-93-6 CAPLUS

CN 1H-Pyrazole-3,5-dicarboxylic acid, 1-[4-[(2-pyrimidinylamino)sulfonyl]phenyl]-, 3-ethyl ester (9CI) (CA INDEX NAME)



RN 67419-94-7 CAPLUS


CN 1H-Pyrazole-3,5-dicarboxylic acid, 1-[4-[[5-methoxy-2-pyrimidinyl]amino]sulfonyl]phenyl]-, 3-ethyl ester (9CI) (CA INDEX NAME)





09/773,736

CN 2-Butenamide, 3-amino-2-cyano-N-[3,5-dichloro-4-[4,5-dichloro-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-4,4,4-trifluoro- (9CI) (CA INDEX NAME)



L31 ANSWER 124 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1977:29705 CAPLUS

DN 86:29705

TI Synthesis of a few sulfonylhydrazides, acid hydrazides, and their derivatives and 1',2',4'-triazoles from 1-phenyl-3,5-dimethylpyrazole

AU Fernandes, P. S.; Coutinho, J. G.; Coelho, K. B.; Nadkarny, V. V.

CS Nadkarny-Sacasa Res. Lab., St. Xavier's Coll., Bombay, India

SO J. Indian Chem. Soc. (1976), 53(5), 498-501

CODEN: JICSAH

DT Journal

LA English

AB About 30 pyrazole derivs. I [R = NH₂, PhCH:N, p-HO₂CC₆H₄, m-PhCH:NNHCOC₆H₄, p-(p-MeC₆H₄NHCSNHNHCO)C₆H₄, etc.] and II were prepd. Thus, 3,5-dimethyl-1-phenylpyrazole was treated with ClSO₃H followed by H₂NNH₂ to give I (R = NH₂) which was condensed with PhCHO to give I (R = PhCH:N) (III). III inhibited growth of *Salmonella typhi* (no data).


IT 61320-25-0P 61320-45-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. and condensation with aldehydes and isothiocyanates)


RN 61320-25-0 CAPLUS

CN Benzoic acid, 4-[[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]sulfonyl]amino]-, hydrazide (9CI) (CA INDEX NAME)



RN 61320-45-4 CAPLUS

CN Benzoic acid, 3-[[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]sulfonyl]amino]-, hydrazide (9CI) (CA INDEX NAME)



IT 61320-46-5P


RL: SPN (Synthetic preparation); PREP (Preparation)

(prepn. and esterification, and reaction with hydrazine hydrate)

RN 61320-46-5 CAPLUS

CN Benzoic acid, 3-[[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

09/773,736




IT **61319-82-2P**

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)


RN 61319-82-2 CAPLUS

CN Benzoic acid, 4-[[[4-(3,5-dimethyl-1H-pyrazol-1-yl)phenyl]sulfonyl]amino]-
(9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 122 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1978:459859 CAPLUS
DN 89:59859
TI Synthesis of some substituted pyrazoles as possible antibacterial agents
AU Joshi, N. N.; Nadkarny, V. V.
CS Nadkarny-Sacasa Res. Lab., St. Xavier's Coll., Bombay, India
SO J. Indian Chem. Soc. (1977), 54(11), 1081-3
CODEN: JICSAH; ISSN: 0019-4522
DT Journal
LA English
AB 4-(3,5-Dimethyl-1-pyrazolyl)benzoyl hydrazide (I) was treated with R1CHO (R1 = Ph, substituted Ph, 2-furyl) to give the pyrazolylbenzoic acid hydrazides II. I and R2NCS (R2 = Ph, 4-MeC6H4, 4-ClC6H4) gave the thiosemicarbazides III, which were cyclized to give the pyrazolylphenyl-substituted heterocycles IV (X = R2N, R3 = SH; X = O, S, R3 = R2NH). At 0.5 mg/mL, III completely inhibited Staphylococcus aureus.
IT **67138-88-9**
RL: RCT (Reactant)
(condensation with aldehydes and isothiocyanates)
RN 67138-88-9 CAPLUS
CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, hydrazide (9CI) (CA INDEX NAME)




IT **67138-70-9P 67138-71-0P 67138-72-1P**
67138-73-2P 67138-74-3P 67138-75-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 67138-70-9 CAPLUS
CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, (phenylmethylene)hydrazide (9CI) (CA INDEX NAME)




RN 67138-71-0 CAPLUS
CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, [(2-hydroxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)


09/773,736




RN 67138-72-1 CAPLUS
CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, [(4-hydroxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 67138-73-2 CAPLUS
CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, [(4-methoxyphenyl)methylene]hydrazide (9CI) (CA INDEX NAME)




RN 67138-74-3 CAPLUS
CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, [(4-nitrophenyl)methylene]hydrazide (9CI) (CA INDEX NAME)



RN 67138-75-4 CAPLUS
CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, (2-furanylmethylene)hydrazide (9CI) (CA INDEX NAME)

09/773,736




IT 67138-76-5P 67138-77-6P 67138-78-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn., cyclization reaction, and bactericidal activity of)


RN 67138-76-5 CAPLUS

CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, 2-
[(phenylamino)thioxomethyl]hydrazide (9CI) (CA INDEX NAME)




RN 67138-77-6 CAPLUS

CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, 2-[[4-
methylphenyl]amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)




RN 67138-78-7 CAPLUS

CN Benzoic acid, 4-(3,5-dimethyl-1H-pyrazol-1-yl)-, 2-[[4-
chlorophenyl]amino]thioxomethyl]hydrazide (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 123 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1978:21721 CAPLUS
DN 88:21721
TI Electrochemical oxidation of 1-phenylpyrazolidin-3-one in acetonitrile
AU Adam, Harry H.; Baigrie, Brian D.; Joslin, Trevor A.
CS Res. Div., Kodak Ltd., Harrow, Engl.
SO J. Chem. Soc., Perkin Trans. 2 (1977), (10), 1287-93
CODEN: JCPKBH
DT Journal
LA English
AB In the title oxidn., 2 oxidn. waves were obsd. using cyclic voltammetry;
these were due to the oxidn. of the protonated and neutral compd.
Controlled potential electrolyses gave 75% 1-phenylpyrazolin-3-one and 20%
3-anilino-N-[4-(3-oxopyrazolin-1-yl)phenyl]propionamide. A mechanism for
the oxidn. is proposed in which a key role is played by
1-phenylpyrazolidin-3-one radical cation.
IT **65127-53-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 65127-53-9 CAPLUS
CN Propanamide, N-[4-(2,3-dihydro-3-oxo-1H-pyrazol-1-yl)phenyl]-3-
(phenylamino)- (9CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 126 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1975:578909 CAPLUS
DN 83:178909
TI Reactions of 1-alkylbenzimidazolium 3-imines with acetylenic compounds and benzaldehyde
AU Tamura, Yasumitsu; Hayashi, Hironori; Nishimura, Yoshiro; Ikeda, Masazumi
CS Fac. Pharm. Sci., Osaka Univ., Suita, Japan
SO J. Heterocycl. Chem. (1975), 12(2), 225-30
CODEN: JHTCAD
DT Journal
LA English
AB 1-Alkyl-3-aminobenzimidazolium salts I (R = Me, Et; R1 = H, Me) react with MeO2CC.tplbond.CCO2Et or PhCOC.tplbond.CCOPh in the presence of base gave 1:1 adducts, 1-(2-alkylaminophenyl)pyrazole derivs. II (R2 = Ph, MeO). Treatment of I with PhCHO in the presence of alkali gives benzaldehyde 2-(N,N-acylalkylamino)phenylhydrazones. The same hydrazones are obtained by alkaline treatment of 1-alkyl-3-benzaliminobenzimidazolium salts, which are prepd. from the 3-amino salts and PhCHO.
IT **57179-53-0P 57179-56-3P 57179-67-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 57179-53-0 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[2-(ethylamino)phenyl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 57179-56-3 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[2-(ethylamino)phenyl]-5-methyl-, dimethyl ester (9CI) (CA INDEX NAME)



RN 57179-67-6 CAPLUS
CN 1H-Pyrazole-3,4-dicarboxylic acid, 1-[2-(acetylmethylamino)phenyl]-, dimethyl ester (9CI) (CA INDEX NAME)


09/773,736




09/773,736

L31 ANSWER 127 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1974:493091 CAPLUS
 DN 81:93091
 TI 3-Phenyl-7-pyrazolylcoumarin derivatives
 IN Kobayashi, Eizo
 PA Showa Chemical Industries, Ltd.
 SO Japan., 8 pp.
 CODEN: JAXXAD
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 49000975	B4	19740110	JP 1970-43293	19700522
AB	3-Phenyl-7-pyrazolylcoumarins (I, R = H, Cl, Me; R1, R2 = H, Me, Ph), fluorescent whitening agents for polyamide and polyester fibers and PVC [9002-86-2], were prepd. by treating stilbene hydrazines (II, R5 = NHH2, R3 = carboxyl deriv., R4 = Me or Et), obtained by diazotization and redn. of II (R5 = NH2), with .beta.-diketones or their derivs. to give pyrazolylstilbenes, and then closing the coumarin ring. Thus, 4,2-O2N(MeO)C6H3Me was treated with S in refluxing 95% EtOH contg. Na2SO4 and NaOH, and condensed with PhCH2CN to give II (R = H, R3 = CN, R4 = Me, R5 = NH2) (III) [27280-72-4]. Similarly, II (R = p-Cl, R3 = CN, R4 = Et, R5 = NH2) [52258-78-3] was prepd. The hydrazine [52028-99-6] prepd. by diazotization and redn. of III was condensed with Ac2CH2 to give the dimethylpyrazolylstilbene deriv. [52258-79-4], which was cyclized with AlCl3 to I (R = H, R1 = R2 = Me) [22563-78-6]. By similar means, 11 addnl. I were prepd.				
IT	52258-68-1 52258-75-0 52258-77-2 52258-79-4 RL: RCT (Reactant) (ring closure of, to coumarin deriv.)				
RN	52258-68-1 CAPLUS				
CN	Benzeneacetonitrile, .alpha.-[[2-methoxy-4-(3-methyl-1H-pyrazol-1-yl)phenyl]methylene]- (9CI) (CA INDEX NAME)				




RN 52258-75-0 CAPLUS
 CN Benzeneacetonitrile, .alpha.-[[2-methoxy-4-(5-methyl-1H-pyrazol-1-yl)phenyl]methylene]- (9CI) (CA INDEX NAME)



09/773,736


RN 52258-77-2 CAPLUS

CN Benzeneacetonitrile, .alpha.-[[2-methoxy-4-(1H-pyrazol-1-yl)phenyl]methylene]- (9CI) (CA INDEX NAME)



RN 52258-79-4 CAPLUS

CN Benzeneacetonitrile, .alpha.-[[4-(3,5-dimethyl-1H-pyrazol-1-yl)-2-methoxyphenyl]methylene]- (9CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 128 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1974:38349 CAPLUS

DN 80:38349

TI Fiber-reactive azo dyes

IN De Montmollin, Rene; Schuetz, Hans U.

PA Ciba-Geigy A.-G.

SO Ger. Offen., 38 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2303601	A1	19730802	DE 1973-2303601	19730125
	DE 2303601	C2	19830929		
	CH 565225	A	19750815	CH 1972-1227	19720127
	US 3872314	A	19750318	US 1974-433792	19740116
PRAI	CH 1972-1227		19720127		
	GB 1973-2703		19730118		

AB The fiber-reactive dyes (I, R = BrCH₂CHBr or CH₂:CBr; R₁ = 2,5-Cl(HO₃S)C₆H₃ or 4-CH₂:CBrCONHC₆H₄, 4-BrCH₂CHBrCONHC₆H₄) were prep'd. and dyed wool wet- and lightfast yellow shades. Thus, diazotized 2,5-H₂N(BrCH₂CHBrCONH)C₆H₃SO₃H was coupled with the Na salt of 1-(2-chloro-5-sulfophenyl)-3-methylpyrazolin-5-one imine to give dye [R = BrCH₂CHBr, R₁ = 2,5-Cl(HO₃S)C₆H₃] [42788-73-8]. Three other I was prep'd. similarly. Reaction of the azo dye II with BrCH₂CHBrCOCl followed by treatment with 10N NaOH at 10-15.deg. for 15 min gave dye (I, R = CH₂:CBr, R₁ = p-CH₂:CBrCONHC₆H₄) [42863-70-7].

IT **42863-70-7P 43074-62-0P**


RL: IMF (Industrial manufacture); PREP (Preparation)
(prepn. of)

RN 42863-70-7 CAPLUS

CN Benzenesulfonic acid, 2-[[5-amino-1-[4-[(2-bromo-1-oxo-2-propenyl)amino]phenyl]-3-methyl-1H-pyrazol-4-yl]azo]-5-[(2-bromo-1-oxo-2-propenyl)amino]- (9CI) (CA INDEX NAME)

09/773,736

PAGE 1-A




PAGE 2-A

RN 43074-62-0 CAPLUS
CN Benzenesulfonic acid, 2-[[5-amino-1-[4-[(2,3-dibromo-1-oxopropyl)amino]phenyl]-3-methyl-1H-pyrazol-4-yl]azo]-5-[(2,3-dibromo-1-oxopropyl)amino]- (9CI) (CA INDEX NAME)

09/773,736

PAGE 1-A



PAGE 2-A

09/773,736

L31 ANSWER 129 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1972:142378 CAPLUS

DN 76:142378

TI Pyrazolylazo dyes

IN Ramanathan, Visvanathan

PA Ciba-Geigy A.-G.

SO Ger. Offen., 53 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2132837	A	19720120	DE 1971-2132837	19710701
	CH 535816	A	19730530	CH 1970-10308	19700708
	GB 1348688	A	19740320	GB 1971-28103	19710616
	US 3860571	A	19750114	US 1971-154168	19710617
	FR 2098230	A5	19720310	FR 1971-24337	19710702
	FR 2098230	B1	19760206		
	BE 769610	A1	19720107	BE 1971-105568	19710707
PRAI	CH 1970-10308		19700708		
	CH 1971-5941		19710423		

AB The title dyes [I, R = o-O2NC6H4, 4,2-O2N(NC)C6H3, 5-nitro-2-thiazolyl, or 2,4-Cl(O2N)C6H3; R1 = H2N or HO; R2 = m-Me2NCH2, p-Me2NCH2, p-(3-pyridiniopropyl).MeSO3- p-(3-piperidinopropyl), or p-Me3N+CH2.MeSO4-] were prepd. and used to dye polyacrylonitrile fibers fast yellow, orange, or red shades. Thus, diazotized 2,5-H2N(O2N)C6H3CN was added to 5-amino-1-[p-[(dimethylamino)methyl]phenyl]-3-methylpyrazole in EtOH at 0.5.deg. to give an azo dye [I, R = 4,2-O2N(NC)C6H3, R1 = H2N, R2 = p-Me2NCH2] (II) [34560-31-1], orange on polyacrylonitrile. Treatment of II with Me2SO4 gave the corresponding quaternized azo dye (I, R2 = p-Me3N+CH2.MeSO4-) [34560-32-2]. Similarly prepd. were 3 other I.


IT 34560-31-1P

RL: IMF (Industrial manufacture); PREP (Preparation)
(prepn. of)

RN 34560-31-1 CAPLUS


CN Benzonitrile, 2-[[5-amino-1-[4-[(dimethylamino)methyl]phenyl]-3-methyl-1H-pyrazol-4-yl]azo]-5-nitro- (9CI) (CA INDEX NAME)

09/773,736




09/773,736

L31 ANSWER 130 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1971:88641 CAPLUS
DN 74:88641
TI Analysis of some pyrazolone[azo] dyes
AU Hamano, Kiyoshi; Wakae, Masao
CS Ind. Res. Inst., Osaka, Japan
SO Yuki Gosei Kagaku Kyokai Shi (1970), 28(10), 1050-3
CODEN: YGKKAE
DT Journal
LA Japanese
AB Attempts to identify pyrazolone azo dye components (I) by reductive cleavage often lead to dimerization of the resulting aminopyrazolones (II) to rubazonic acids. Stable II compds. were obtained, except for 3-CO₂Et derivs., by replacement of the 5-OH group by Cl and subsequent hydrogenolysis. Attempted N-methylation failed. I (R = Me, R₁ = H) (5 g) was refluxed for 8 hr in 40 ml POCl₃ and the 5-Cl analog (5 g, m. 173-4.degree.) hydrogenated over 3 g Raney Ni in EtOH and 50 kg/cm² H at 90.degree. for 5 hr. Addn. of 5 ml concd. HCl deposited p-(H₂N)2C₆H₄.2-HCl. The filtrate was heated with Ac₂O-NaOAc to give 1-phenyl-3-methyl-4- acetamidopyrazole monohydrate, m. 67-8.degree.. Three other I were similarly cleaved.
IT **31825-35-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 31825-35-1 CAPLUS
CN Acetanilide, 4'-(4-acetamido-3-methylpyrazol-1-yl)- (8CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 131 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1970:466498 CAPLUS
DN 73:66498
TI Synthesis and pharmacological properties of pyrazoles. II. 1-Substituted
4-aminopyrazoles
AU Bianchi, Mario; Bonacina, F.; Osvaldo, A.; Pirola, C.
CS Lab. Ric. "Vister" S.p.A., Como, Italy
SO Farmaco, Ed. Sci. (1970), 25(8), 592-617
CODEN: FRPSAX
DT Journal
LA Italian
AB I (R = PhCH₂, PhC₂H₄, PhC₃H₆, a substituted phenyl, or a heterocycle, R₁ =
N:NPh, NO₂, benzenesulfonamido, or substituted amino) were prepd. and
their pharmacol. properties examd., none showed greater antipyretic,
analgesic, or antiinflammatory activity than 1-phenyl-4-
(dimethylamino)pyrazole.
IT **28466-50-4**
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmacol. activity of)
RN 28466-50-4 CAPLUS
CN Acetanilide, 4'-(4-aminopyrazol-1-yl)- (8CI) (CA INDEX NAME)



09/773,736

L31 ANSWER 132 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1967:465441 CAPLUS
DN 67:65441
TI Dye intermediates
IN Umberger, Jacob Q.
PA du Pont de Nemours, E. I., and Co.
SO U.S., 5 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3299013		19670117	US	19610529

AB Photographic color formers result from the addn. of vinyl ethers to maleic acid derivs. Thus, a mixt. of 257 g. 1,2-HOC10H6CONHCH2CH2OCH:CH2 (I), 98 g. maleic anhydride (II), and 3 l. thiophene-free C6H6 was refluxed with stirring for 5 min., cooled, 4.0 g. [Me2C(CN)N:]2 (III) added, the mixt. refluxed with stirring for 45 min., cooled to 60.degree., the slurry filtered, washed with 300 ml. CH2Cl2, the cake slurried twice with CH2Cl2, filtered, washed each time with CH2Cl2 and air-dried to const. wt. to give 288 g. 1:1 adduct (IV) (equiv. wt. 380) as a white powder. BuNH2 (8 g.) was added to a soln. of 14 g. IV in 200 ml. dry Me2CO, the mixt. refluxed for 3 hrs. on a steam bath, cooled, poured onto 250 g. ice and 100 ml. HCl, the ppt. filtered after 1 hr., washed with H2O, and air-dried overnight to give 13 g. 1:1 adduct of I and N-butylmaleamic acid (equiv. wt. 473). Other color formers were obtained by treating IV with Et2NH, n-C8H17NH2, BuOH, and H2NCH2CH2NH2. Similarly, other adducts were prepd. (reactants and shade given): 4-BzCH2CONHC6H4SO2NHCH2CH2OCH:CH2 (V), II, III, yellow; V, di-Et maleate, III, white; VI (R1 = ClSO2, R2 = BzO) (VII), H2NCH2CH2OCH:CH2 (VIII), II, III, magenta; VI (R1 = ClCO, R2 = EtO2CO), VIII, II, III, magenta. A mixt. of 132 g. 1,2-HOC10H6CO2Ph, 43.5 g. VIII, and 660 ml. abs. EtOH was refluxed 4 hrs., cooled to 0.degree. and the crystals filtered washed, with EtOH, and air-dried to give 59 g. I, m. 120.5-1.0.degree. (C6H6). The condensation of VIII with 4-BzCH2CONHC6H4SO2Cl in MeCN gave V, m. 116-17.degree. (MeOH). VI (R1 = HO3S, R2 = HO), KOH, K2CO3, and BzCl gave VI (R1 = KO3S, R2 = BzO), which with PCl5 gave VII, m. 151-2.degree. (CH2Cl2).

IT 30848-31-8P

RL: IMF (Industrial manufacture); PREP (Preparation)
(prepn. of)

RN 30848-31-8 CAPLUS


CN Maleic anhydride, polymer with p-(5-hydroxy-3-methylpyrazol-1-yl)-N-[2-(vinylloxy)ethyl]benzenesulfonamide benzoate (ester) (8CI) (CA INDEX NAME)

CM 1

CRN 4733-74-8

CMF C21 H21 N3 O5 S


09/773,736



CM 2

CRN 108-31-6

CMF C4 H2 O3




L31 ANSWER 133 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1966:20061 CAPLUS
 DN 64:20061
 OREF 64:3743e-h,3744a-b
 TI Copolymeric dye intermediates for color photography
 PA E. I. du Pont de Nemours & Co.
 SO 9 pp.
 DT Patent
 LA Unavailable
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 995363		19650616	GB	
PRAI	US		19610529		
AB	<p>Vinyl ether color formers of the general formula $\text{CH}_2\text{:CHOCH(Z)Q}$, where Z is H or Me and Q is an enol contg. a color-forming nucleus, are copolymerized with XCOCH:CHCOY to give the title copolymers. Thus, a soln. of 132 g. 1,2-HOC10H6CO2Ph and 43.5 g. $\text{CH}_2\text{:CH}_2\text{OCH}_2\text{CH}_2\text{NH}_2$ (I) in 660 ice. abs. alc. was refluxed 4 hrs., cooled to 0.degree., filtered, and washed with alc. to give 59 g. 1,2-HOC10H6CONHCH2CH2OCH:CH2 (II), m. 120.5-1.degree. (MeOH-C6H6), a cyan color former. A soln. of 169 g. p-BzCH2CONHC6H4SO2Cl in 845 ml. MeCN at 60.degree. was added to a soln. of 72 g. $\text{Na}_2\text{CO}_3 \cdot \text{H}_2\text{O}$ and 48 g. I in 845 ml. H_2O at 10.degree., stirred 90 min., poured into a mixt. of 2 kg. ice. and 500 ml. H_2O, and filtered to give 142 g. p-BzCH2CONHC6H4SO2NHCH2CH2OCH:CH2 (III), m. 116-7.degree. (MeOH), a yellow color former. H_2O (1 l.), 254 g. 1-(p-sulfophenyl)-3-methyl-5-pyrazolone, 60 g. KOH, and 138 g. anhyd. K_2CO_3 were added to a 5 l. flask, iced to 5.degree., and 155 g. BzCl was added over 1 hr., the temp. being kept below 10.degree.. The mixt. was stirred 14 hrs. as the temp. rose to 25.degree., treated with 50 g. KCl, stirred 30 min., filtered, washed with 3% KCl soln. and recryst. from 400 ml. H_2O to give 69.5% of the K salt of 1-(p-sulfophenyl)-3-methyl-5-benzoxypyrazole (IV). IV was treated with PCl_5 in POCl_3 as solvent at a low temp. to give the sulfonyl chloride (V), m. 151-2.degree. (CH_2Cl_2). V was condensed with I to give 1-[N-(beta.-vinylloxyethyl)benzenesulfonamide]-3-methyl-5-benzoxypyrazole, which was copolymerized with maleic anhydride (VI) to give a magenta color-forming copolymer. A mixt. of 257 g. II, 98 g. VI, and 3 l. C_6H_6 was refluxed 5 min., cooled, 4.0 g. $[\text{Me}_2\text{C}(\text{CN})\text{N}]_2$ (VII) was added and the mixt. refluxed 45 min., cooled to 60, and filtered. The ppt. was washed with 300 ml. CH_2Cl_2, twice slurried in 1500 ml. CH_2Cl_2, filtered, washed with 200 ml. CH_2Cl_2 and air dried to give 288 g. powd. white 1:1 copolymer (VIII), equiv. wt. 380 (by uv absorption). A soln. of 14 g. VIII and 8 g. BuNH_2 in 200 ml. dry acetone was refluxed 3 hrs., cooled, poured into a mixt. of 250 g. ice and 100 ml. concd. HCl, filtered, washed with H_2O, and air dried to give 13 g. 1:1 copolymer (IX) of II and $\text{HO}_2\text{CCH:CHCONHBu}$, equiv. wt. 473. Similarly, other IX were prepd. (X, Y and equiv. wt. given): OH, NEt_2, 424; OH, $\text{NH}(\text{CH}_2)_5\text{Me}$, 523; OH, OBu, 405. A soln. of 11.5 g. III in 20 ml. EtCO_2Et and 20 ml. C_6H_6 was refluxed 5 min. to expel O, 2.9 g. VI and 0.1 g. VII were added, the mixt. was refluxed 30 min., and 12 g. copolymer of III and VI was obtained. A soln. of 11.6 g. III in 30 ml. $(\text{:CHCOEt})_2$ (X) was held at 90-5.degree. under a stream of N for 5 min. to expel O, 0.1 g. VII was added. After 16 min., the mixt. was cooled to room temp. and 11.8 g. copolymer of III and X was obtained. 1-(p-Chloroformylphenyl)-3-methyl-5-pyrazolyl Et carbonate (U.S. 2,476,981) was condensed with I to give a magenta color former which was copolymerized with VI. The above copolymers were used in the color-sensitive layers of a multilayer color reversal film. The film was exposed to a color scene and processed by color reversal to give excellent</p>				


09/773,736

colors.
IT **4733-74-8**, Benzenesulfonamide, p-(5-hydroxy-3-methylpyrazol-1-yl)-
N-[2-(vinylloxy)ethyl], benzoate (ester)
(and polymers with maleic anhydride and maleamic acid derivs.)
RN 4733-74-8 CAPLUS
CN Benzenesulfonamide, p-(5-hydroxy-3-methylpyrazol-1-yl)-N-[2-
(vinylloxy)ethyl]-, benzoate (ester) (8CI) (CA INDEX NAME)




09/773,736

L31 ANSWER 134 OF 136 CAPLUS COPYRIGHT 2002 ACS
AN 1964:26157 CAPLUS
DN 60:26157
OREF 60:4653h,4654a
TI The antidiabetic activity of 3,5-dimethylpyrazoles
AU Wright, John B.; Dulin, William E.; Markillie, John H.
CS Upjohn Co., Kalamazoo, MI
SO J. Med. Chem. (1964), 7(1), 102-5
DT Journal
LA Unavailable
AB Forty-one pyrazoles were investigated for antidiabetic activity. A no. of those contg. Me groups in both the 3- and 5-positions were found to possess hypoglycemic activities as great as 100 times that of tolbutamide in glucose-primed, intact, fasted rats.
IT **91959-10-3**, Benzamide, p-(3,5-dimethylpyrazol-1-yl)-N-methyl-
92439-93-5, Benzamide, p-(3,5-dimethylpyrazol-1-yl)-N,N-dimethyl- (blood sugar lowering by)
RN 91959-10-3 CAPLUS
CN Benzamide, p-(3,5-dimethylpyrazol-1-yl)-N-methyl- (7CI) (CA INDEX NAME)



RN 92439-93-5 CAPLUS
CN Benzamide, p-(3,5-dimethylpyrazol-1-yl)-N,N-dimethyl- (7CI) (CA INDEX NAME)



L31 ANSWER 135 OF 136 CAPLUS COPYRIGHT 2002 ACS

AN 1963:475337 CAPLUS

DN 59:75337

OREF 59:13989d-h,13990a

TI Sulfamoylbenzo-1,2,3,4-thiatriazine 1,1-dioxides-a new class with oral diuretic activity

AU Lee, G. E.; Wragg, W. R.

SO J. Pharm. Pharmacol. (1963), 15(9), 589-95

DT Journal

LA Unavailable


AB The prepn. of some sulfamoylbenzo-1,2,3,4-thiatriazine 1,1-dioxides and their diuretic activity are described. 5-Chloro-2,4-bis(methylsulfamoyl)-aniline (3.13 g.) was dissolved in 40 ml. concd. sulfuric acid. Sodium nitrite (0.7 g.) in 20 ml. concd. sulfuric acid was added with cooling. After 2 hrs. stirring at 0-5.degree., the soln. was poured on 100 g. ice, dild. to 325 ml., and rapidly filtered. The filtrate was dild. to 500 ml. and the orange cryst. ppt. was filtered off and dried over silica-gel to give 2.53 g. 6-chloro-2-methyl-7-methylsulfamoylbenzo-1,2,3,4-thiatriazine 1,1-dioxide (Ia), (R = Cl, R1 = R2 = Me) (I), m. 165-7.degree.. By the same technique, taking similar wt. proportions of reagents, 17 g. Ia (R = Cl, R1 = Me, R2 = H) was obtained, m. 166-7.degree., from 31.6 g. 5-chloro-2-methylsulfamoyl-4-sulfamoylaniline; and 18 g. Ia (R = CF3, R1 = R2 = Me), m. 148-9.degree., was obtained from 20 g. 2,4-bis(methylsulfamoyl)-5-trifluoromethylaniline. 6-Chloro-3,4-dihydro-3-oxo-7-sulfamoyl-1,2,4-benzothiadiazine 1,1-dioxide (10 g.) was dissolved in 30 ml. dry dimethylformamide, and to this soln. 1.5 g. Nail in 50% oil suspension was added in portions. The soln. was heated to 70.degree. and 5.5 g. benzyl bromide was added. After 1 hr. at 70.degree., the soln. was cooled and poured in ice. The ethanol-water recrystd. material, m. 250-2.degree., was hydrolyzed with 20% NaOH to give 2-benzylsulfamoyl-5-chloro-4-sulfamoylaniline, m. 155-60.degree.. The latter compd. (18.3 g.) was dissolved in 490 ml. AcOH, 245 ml. water, and 61 ml. 2N sulfuric acid, and 3.42 g. NaNO2 in 49 ml. H2O added, and the mixt. dild. to ppt. yellow Ia (R = Cl, R1 = PhCH2, R2 = H), m. 1580 (decompn.) (MeOH). By heating I (20 g.) in 150 ml. concd. HCl over a steam bath, a pink cryst. ppt. of 1,5-dichloro-2,4-bis(methylsulfamoyl)benzene, m. 184-6.degree. (EtOH), was obtained. I (24.8 g.) in concd. HCl was reduced by 100 g. SnCl2 at room temp. for 48 hrs. to give 15.5 g. cryst. 5-chloro-2,4-bis(methylsulfamoyl)phenylhydrazine (II), m. 234-6.degree. (H2O). The latter compd. was N-acetylated by addg. to a cooled 2N HCl soln. of I (20.degree.) 15 ml. acetic anhydride, followed by 100 g. NaOAc in 100 ml. H2O to give 10 g. prisms, m. 197-8.degree. (H2O). To 0.92 g. II in 2 ml. 2N HCl and 20 ml. EtOH was added 1 ml. tetraethoxypropane and the mixt. refluxed 2.5 hrs. to give 5-chloro-2,4-bis(methylsulfamoyl)-1-pyrazol-1-ylbenzene, m. 203-5.degree. (EtOH). To 3.28 g. II in 200 ml. methyl alc. was added 1 ml. 4% NaOH and 0.75 ml. 40% HCHO. After refluxing 0.5 hr., the soln. was evapd. to dryness to give golden 7-chloro-2,3,4,5-tetrahydro-2-methyl-8-methylsulfamoylbenzo-1,2,4,5-thiatriazepine 1,1-dioxide, m. 210-12.degree. (H2O). The diuretic activity of the benzo-1,2,3,4-thiatriazine 1,1-dioxides, the unmethylated sulfonamide, and the trifluoromethyl compds. is similar to that of chlorothiazide. Replacement of Me in position 2 of the ring system by a benzyl group decreases the activity to 0.1 of the 2-methyl compd. The hydrazine compd. and its derivs. have no activity. The pyrazolyl deriv. is 0.25 as active as chlorothiazide.

IT 91552-30-6, m-Benzenedisulfonamide, 4-chloro-N,N'-dimethyl-6-pyrazol-1-yl-
(prepn. of)

09/773,736

RN 91552-30-6 CAPLUS

CN m-Benzenedisulfonamide, 4-chloro-N,N'-dimethyl-6-pyrazol-1-yl- (7CI) (CA
INDEX NAME)



09/773,736

L31 ANSWER 136 OF 136 CAPLUS COPYRIGHT 2002 ACS
 AN 1962:443299 CAPLUS
 DN 57:43299
 OREF 57:8698f-i
 TI Water-soluble quaternary ammonium salts of monazo dyes
 PA CIBA Ltd.
 SO 7 pp.
 DT Patent
 LA Unavailable


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 889471		19620214	GB	
PRAI	CH		19590129		

AB Azo dyes contg. a pyrazolone residue and a quaternary ammonium group are suitable for dyeing and printing polyacrylonitrile. Thus, 18.9 parts 1-(3-aminophenyl)-3-methyl-5-pyrazolone (I) and 120 parts toluene were heated to 100.degree., ClCH₂CH₂COCl 18 was added dropwise within 1/2 hr., the mixt. filtered after 2 hrs., the ppt. washed with petr. ether, and dried in vacua at 70.degree. to give a yellow powder (decomp. 210.degree.). This product (30 parts) was added to a mixt. of H₂O 175, Me₃N 80, and a highly sulfonated oil 0.5 parts. The mixt. was heated with stirring within 1 hr. to 70.degree., and stirred at this temp. for 2 hrs. After cooling, the soln. was filtered and the quaternary compd. pptd. with 200 parts Me₂CO. o-O₂NC₆H₄NH₂ (II) (13.8 parts) dissolved in 50 parts 31% HCl was diazotized and added to 39 parts of the above quaternary compd. in 300 parts H₂O. The coupling was completed by adding AcONa. The resulting compd. dyed polyacrylonitrile fibers from a weakly acid bath yellow tints of good fastness. Similarly, dyes were prepd. (amine diazotized, pyrazole deriv., acylating agent, other amine, and color on polyacrylonitrile given): 2,4-O₂N(Me)C₆H₃NH₂, I, ClCOCH₂Cl (III), pyridine (IV), reddish yellow; II, I, product from SOCl₂ + betaine-HCl, yellow; II, 1-(4-aminophenyl)-3-methyl-5-benzenesulfonyloxypyrazole, III, IV, yellow; 2,4-O₂N(MeO)C₆H₃NH₂, 1-(4-chloroacetamidophenyl)-3-methyl-5-pyrazolone, -, Me₂NH (then Me₂SO₄), orange.

IT **93868-82-7**, Acetanilide, 2-chloro-4'-(4-hydroxy-3-methylpyrazol-1-yl)-, benzenesulfonate (prepn. of)

RN 93868-82-7 CAPLUS

CN Acetanilide, 2-chloro-4'-(4-hydroxy-3-methylpyrazol-1-yl)-, benzenesulfonate (7CI) (CA INDEX NAME)



09/773,736

=> d his

(FILE 'HOME' ENTERED AT 17:24:09 ON 15 SEP 2002)

FILE 'REGISTRY' ENTERED AT 17:24:16 ON 15 SEP 2002

L1 SCREEN 1839
L2 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047 OR 20
L3 STRUCTURE UPLOADED
L4 QUE L3 AND L1 NOT L2
L5 19 S L4 SSS SAM
L6 SCREEN 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047 OR 20
L7 STRUCTURE UPLOADED
L8 QUE L7 NOT L6
L9 16 S L8 SSS SAM
L10 STRUCTURE UPLOADED
L11 0 S L10 SSS SAM
L12 SCREEN 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 20
L13 STRUCTURE UPLOADED
L14 QUE L13 NOT L12
L15 11 S L14 SSS SAM
L16 SCREEN 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 20
L17 STRUCTURE UPLOADED
L18 QUE L17 NOT L16
L19 5 S L18 SSS SAM
L20 SCREEN 2016 OR 2026 OR 1841 OR 2039 OR 2040 OR 2045 OR 20
L21 STRUCTURE UPLOADED
L22 QUE L21 NOT L20
L23 4 S L22 SSS SAM
L24 1205 S L22 SSS FUL
L25 STRUCTURE UPLOADED
L26 50 S L3 SSS SAM SUB=L24
L27 1205 S L3 SSS FUL SUB=L24
L28 8 S L25 SSS SAM SUB=L24
L29 170 S L25 SSS FUL SUB=L24
L30 1035 S L24 NOT L29

FILE 'CAPLUS' ENTERED AT 17:41:05 ON 15 SEP 2002

L31 136 S L30

FILE 'CAOLD' ENTERED AT 17:44:37 ON 15 SEP 2002

=> s 130


L32 15 L30

=> d 132 1-15 bib,hitstr

09/773,736

L32 ANSWER 1 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA64:3743e CAOLD
TI copolymeric dye intermediates for color photography
PA Du Pont de Nemours, E. I., & Co.
DT Patent
PATENT NO. KIND DATE


PI GB 995363
IT **4733-74-8**
RN 4733-74-8 CAOLD
CN Benzenesulfonamide, p-(5-hydroxy-3-methylpyrazol-1-yl)-N-[2-(vinylloxy)ethyl]-, benzoate (ester) (8CI) (CA INDEX NAME)




09/773,736

L32 ANSWER 2 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA63:11769g CAOLD
TI dyeing of cellulose-polyester mixts.
PA Sandoz Ltd.
DT Patent
IT **5014-76-6**
RN 5014-76-6 CAOLD
CN Pyrazole-3-carboxamide, N-(2-mercaptoethyl)-1-[p-[(2-mercaptoethyl)sulfamoyl]phenyl]-4-[[p-[(2-mercaptoethyl)sulfamoyl]phenyl]azo]-, tris(hydrogen sulfate), tripotassium salt (7CI, 8CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



● 3 K


09/773,736

L32 ANSWER 3 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA60:4653h CAOLD
TI action of butylsympatol on renal lesions caused by burns
AU Laurentaci, Gaetano; Nerini, V.
TI antidiabetic activity of 3,5-dimethylpyrazoles
AU Wright, John Brenton; Dulin, W. E.; Markillie, J. H.
IT 91952-28-2 91959-10-3 92439-93-5
RN 91952-28-2 CAOLD
CN Urea, [[p-(3,5-dimethylpyrazol-1-yl)phenyl]sulfonyl]- (7CI) (CA INDEX NAME)




same as #134

RN 91959-10-3 CAOLD
CN Benzamide, p-(3,5-dimethylpyrazol-1-yl)-N-methyl- (7CI) (CA INDEX NAME)



RN 92439-93-5 CAOLD
CN Benzamide, p-(3,5-dimethylpyrazol-1-yl)-N,N-dimethyl- (7CI) (CA INDEX NAME)



09/773,736

L32 ANSWER 4 OF 15 CAOLD COPYRIGHT 2002 ACS

AN CA60:1874a CAOLD

TI phthalocyaninesulfonamides (N-substituted)

PA Farbenfabriken Bayer A.-G.

DT Patent


PATENT NO.	KIND	DATE
-----	-----	-----

PI GB 844419

IT **93871-42-2 94312-26-2**


RN 93871-42-2 CAOLD

CN Pyrazol-5-ol, 1-[p-(ethylamino)phenyl]-3-methyl-, benzenesulfonate (7CI)
(CA INDEX NAME)



RN 94312-26-2 CAOLD


CN Pyrazol-5-ol, 3-methyl-1-[p-(propylamino)phenyl]-, benzenesulfonate (7CI)
(CA INDEX NAME)




09/773,736

L32 ANSWER 5 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA59:15419b CAOLD
TI phthalocyaninesulfonamides and -carboxamides
AU Bienert, Berthold; Breig, K.; Groll, M.; Gutjahr, H.
PA Farbenfabriken Bayer A.-G.
DT Patent
PATENT NO. KIND DATE

PI US 3047582 1962
DE 1150479
IT **93871-42-2 94312-26-2**
RN 93871-42-2 CAOLD
CN Pyrazol-5-ol, 1-[p-(ethylamino)phenyl]-3-methyl-, benzenesulfonate (7CI)
(CA INDEX NAME)




RN 94312-26-2 CAOLD
CN Pyrazol-5-ol, 3-methyl-1-[p-(propylamino)phenyl]-, benzenesulfonate (7CI)
(CA INDEX NAME)



09/773,736

L32 ANSWER 6 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA59:13989d CAOLD
TI sulfamoylbenzo-1,2,3,4-thiatiazine 1,1-dioxides-class with oral diuretic
activity
AU Lee Glyn E.; Wragg, W. R.
IT **91552-30-6**
RN 91552-30-6 CAOLD
CN m-Benzenedisulfonamide, 4-chloro-N,N'-dimethyl-6-pyrazol-1-yl- (7CI) (CA
INDEX NAME)



09/773,736

L32 ANSWER 7 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA59:778g CAOLD
TI copolymers from maleic acid derivs. and chromogenic monomers
AU Umberger, Jacob Q.
PA Du Pont de Nemours, E. I., & Co.
DT Patent


PATENT NO.	KIND	DATE
-----	-----	----

PI BE 618202
DE 1226880

IT **4733-74-8**

RN 4733-74-8 CAOLD

CN Benzenesulfonamide, p-(5-hydroxy-3-methylpyrazol-1-yl)-N-[2-(vinylloxy)ethyl]-, benzoate (ester) (8CI) (CA INDEX NAME)



09/773,736

L32 ANSWER 8 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA57:8698g CAOLD
TI dyes (monoazo), sol. quaternary ammonium salts of
PA CIBA Ltd.
DT Patent


PATENT NO.	KIND	DATE
-----	-----	----

PI GB 889471

IT **93868-82-7**


RN 93868-82-7 CAOLD

CN Acetanilide, 2-chloro-4'-(4-hydroxy-3-methylpyrazol-1-yl)-, benzenesulfonate (7CI) (CA INDEX NAME)



09/773,736

L32 ANSWER 10 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA53:11349g CAOLD
TI metalation of 1-phenyl and 1-methylpyrazole with n-butyllithium
AU Alley, Peggy W.; Shirley, D. A.
IT **99072-71-6**
RN 99072-71-6 CAOLD
CN Benzoic acid, o-pyrazol-1-yl-, hydrazide (6CI) (CA INDEX NAME)




7

09/773,736

L32 ANSWER 11 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA53:3958d CAOLD
TI photographic color images
AU Huenig, Siegfried
PA ADOX FOTOWERKE Dr. C. Schleussner G. m. b. H.
DT Patent
PATENT NO. KIND DATE

PI DE 12075
IT **106475-53-0**
RN 106475-53-0 CAOLD
CN Acetamide, N-[p-(5-hydroxy-3-methylpyrazol-1-yl)phenylsulfonyl]-, acetate
(6CI) (CA INDEX NAME)



09/773,736

L32 ANSWER 12 OF 15 CAOLD COPYRIGHT 2002 ACS

AN CA52:8574g CAOLD

TI bleaching agents, stilbene compds. as

PA Farbenfabriken Bayer Akt.-Ges.

DT Patent

PATENT NO.	KIND	DATE
-----	-----	----

PI GB 787429


DE 1055173

DE 1096321

IT **102659-85-8**


RN 102659-85-8 CAOLD

CN 2,2'-Stilbenedisulfonic acid, 4-(2-methoxyacetamido)-4'-(3-methylpyrazol-1-yl)- (6CI) (CA INDEX NAME)




09/773,736


L32 ANSWER 13 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA52:3781f CAOLD
TI syntheses of phenylpyrazolone derivs. - (VIII) absorption spectrum of
phenylpyrazolone azomethine derivs., (IX) phenylpyrazolone azomethine
derivs. on C.I.E. color chart
AU Itano, Kohei
IT 100975-19-7 106475-53-0 108477-91-4
RN 100975-19-7 CAOLD
CN Acetamide, N-[p-(3-acetamido-5-hydroxypyrazol-1-yl)phenylsulfonyl]-,
acetate (6CI) (CA INDEX NAME)



RN 106475-53-0 CAOLD
CN Acetamide, N-[p-(5-hydroxy-3-methylpyrazol-1-yl)phenylsulfonyl]-, acetate
(6CI) (CA INDEX NAME)




RN 108477-91-4 CAOLD
CN Acetamide, N-[p-(3-benzenesulfonamido-5-hydroxypyrazol-1-yl)phenylsulfonyl]-, acetate (6CI) (CA INDEX NAME)




09/773,736

L32 ANSWER 14 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA52:362e CAOLD
TI prepn. and properties of substituted benzo[c]pyrazolo[1,2-a]pyrazol-1,9-
diones
AU Veibel, Stig; Lillelund, H.
IT **132624-87-4**
RN 132624-87-4 CAOLD
CN Piperidine, 1-[o-(3-methyl-5-oxo-3-pyrazolin-2-yl)benzoyl]- (6CI) (CA
INDEX NAME)



09/773,736

L32 ANSWER 15 OF 15 CAOLD COPYRIGHT 2002 ACS
AN CA51:17891g CAOLD
TI prepn. of trinitrophenylpyrazoles
AU Finar, Ivor L.; Hurlock, R. J.
IT **99845-40-6 99983-04-7**
RN 99845-40-6 CAOLD
CN Acetanilide, 4'-(4-nitropyrazol-1-yl)- (6CI) (CA INDEX NAME)



RN 99983-04-7 CAOLD
CN Acetanilide, 2'-nitro-4'-(4-nitropyrazol-1-yl)- (6CI) (CA INDEX NAME)

